commit f39505656cdffd645c794966230a3637e55803f4 Author: Shvetsov Nikolai Date: Sun Apr 26 16:01:17 2026 +0300 skelet gotoviy diff --git a/.gitignore b/.gitignore new file mode 100644 index 0000000..e69de29 diff --git a/.ipynb_checkpoints/README-checkpoint.md b/.ipynb_checkpoints/README-checkpoint.md new file mode 100644 index 0000000..e69de29 diff --git a/.ipynb_checkpoints/week2_analysis-checkpoint.ipynb b/.ipynb_checkpoints/week2_analysis-checkpoint.ipynb new file mode 100644 index 0000000..da7b18d --- /dev/null +++ b/.ipynb_checkpoints/week2_analysis-checkpoint.ipynb @@ -0,0 +1,776 @@ +{ + "cells": [ + { + "cell_type": "markdown", + "id": "d25254ef-77e8-414a-a4c8-f367e48a4eff", + "metadata": {}, + "source": [ + "# Анализ данных FDA Drug Adverse Events\n", + "\n", + "В данной работе проводится анализ данных о побочных эффектах лекарственных препаратов. \n", + "Цель работы — загрузить датасет, изучить его структуру, провести базовый анализ и построить визуализации с использованием библиотек `pandas`, `numpy`, `matplotlib`, `seaborn` и `tqdm`." + ] + }, + { + "cell_type": "code", + "execution_count": 1, + "id": "f9f3cdba-7699-400d-941d-b6aa79357639", + "metadata": { + "jp-MarkdownHeadingCollapsed": true + }, + "outputs": [], + "source": [ + "import pandas as pd\n", + "import numpy as np\n", + "import matplotlib.pyplot as plt\n", + "import seaborn as sns\n", + "from tqdm import tqdm" + ] + }, + { + "cell_type": "code", + "execution_count": 2, + "id": "1665af01-f42a-48f3-aa29-2e9c8b823f96", + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
report_idcountryoccur_countryreport_typeseriousdeathlife_threateninghospitalizationdisablingreceive_date...reaction_pneumoniareaction_bleedingreaction_complexityyearmonthdayweekdayreport_type_riskage_drug_riskgender_drug_risk
026016170USUS12.000002025-11-10...0022025111000.0807360.6515840.000000
126017452NPNP11.010102025-11-10...0042025111000.0807368.8469390.000000
226017586USUS12.000002025-11-10...0032025111000.0807360.0000000.000000
326018910SGSG11.000002025-11-10...0022025111000.0807364.4285710.071429
426018949EUEU31.000002025-11-10...0022025111000.1785710.0000000.000000
\n", + "

5 rows × 40 columns

\n", + "
" + ], + "text/plain": [ + " report_id country occur_country report_type serious death \\\n", + "0 26016170 US US 1 2.0 0 \n", + "1 26017452 NP NP 1 1.0 1 \n", + "2 26017586 US US 1 2.0 0 \n", + "3 26018910 SG SG 1 1.0 0 \n", + "4 26018949 EU EU 3 1.0 0 \n", + "\n", + " life_threatening hospitalization disabling receive_date ... \\\n", + "0 0 0 0 2025-11-10 ... \n", + "1 0 1 0 2025-11-10 ... \n", + "2 0 0 0 2025-11-10 ... \n", + "3 0 0 0 2025-11-10 ... \n", + "4 0 0 0 2025-11-10 ... \n", + "\n", + " reaction_pneumonia reaction_bleeding reaction_complexity year month day \\\n", + "0 0 0 2 2025 11 10 \n", + "1 0 0 4 2025 11 10 \n", + "2 0 0 3 2025 11 10 \n", + "3 0 0 2 2025 11 10 \n", + "4 0 0 2 2025 11 10 \n", + "\n", + " weekday report_type_risk age_drug_risk gender_drug_risk \n", + "0 0 0.080736 0.651584 0.000000 \n", + "1 0 0.080736 8.846939 0.000000 \n", + "2 0 0.080736 0.000000 0.000000 \n", + "3 0 0.080736 4.428571 0.071429 \n", + "4 0 0.178571 0.000000 0.000000 \n", + "\n", + "[5 rows x 40 columns]" + ] + }, + "execution_count": 2, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df = pd.read_csv(\"data/gm_feature_engineered_fda.csv\")\n", + "\n", + "df.head()" + ] + }, + { + "cell_type": "code", + "execution_count": 3, + "id": "b2c52280-a63e-415f-9174-3ddeeb0e9092", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "Index(['report_id', 'country', 'occur_country', 'report_type', 'serious',\n", + " 'death', 'life_threatening', 'hospitalization', 'disabling',\n", + " 'receive_date', 'age', 'age_unit', 'gender', 'weight', 'drug',\n", + " 'reaction', 'is_serious', 'severity_score', 'severity_norm',\n", + " 'age_group', 'country_group', 'drug_risk', 'drug_freq',\n", + " 'high_risk_drug', 'reaction_length', 'reaction_pain',\n", + " 'reaction_infection', 'reaction_death', 'reaction_cancer',\n", + " 'reaction_failure', 'reaction_pneumonia', 'reaction_bleeding',\n", + " 'reaction_complexity', 'year', 'month', 'day', 'weekday',\n", + " 'report_type_risk', 'age_drug_risk', 'gender_drug_risk'],\n", + " dtype='str')" + ] + }, + "execution_count": 3, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.columns" + ] + }, + { + "cell_type": "markdown", + "id": "c7e87bc6-bbbb-45c1-a51c-f1483111eb56", + "metadata": {}, + "source": [ + "## 1. Первичный анализ данных\n", + "\n", + "На этом этапе рассматривается структура таблицы: количество строк и столбцов, типы данных, наличие пропусков, а также основные статистические характеристики числовых признаков." + ] + }, + { + "cell_type": "code", + "execution_count": 4, + "id": "a17b1b49-7d0d-4f70-a1c2-57dfc056a1d9", + "metadata": {}, + "outputs": [ + { + "name": "stdout", + "output_type": "stream", + "text": [ + "\n", + "RangeIndex: 1287 entries, 0 to 1286\n", + "Data columns (total 40 columns):\n", + " # Column Non-Null Count Dtype \n", + "--- ------ -------------- ----- \n", + " 0 report_id 1287 non-null int64 \n", + " 1 country 1287 non-null str \n", + " 2 occur_country 1287 non-null str \n", + " 3 report_type 1287 non-null int64 \n", + " 4 serious 1287 non-null float64\n", + " 5 death 1287 non-null int64 \n", + " 6 life_threatening 1287 non-null int64 \n", + " 7 hospitalization 1287 non-null int64 \n", + " 8 disabling 1287 non-null int64 \n", + " 9 receive_date 1287 non-null str \n", + " 10 age 1287 non-null float64\n", + " 11 age_unit 1287 non-null float64\n", + " 12 gender 1287 non-null str \n", + " 13 weight 1287 non-null float64\n", + " 14 drug 1287 non-null str \n", + " 15 reaction 1287 non-null str \n", + " 16 is_serious 1287 non-null int64 \n", + " 17 severity_score 1287 non-null int64 \n", + " 18 severity_norm 1287 non-null float64\n", + " 19 age_group 1286 non-null str \n", + " 20 country_group 1287 non-null str \n", + " 21 drug_risk 1287 non-null float64\n", + " 22 drug_freq 1287 non-null int64 \n", + " 23 high_risk_drug 1287 non-null int64 \n", + " 24 reaction_length 1287 non-null int64 \n", + " 25 reaction_pain 1287 non-null int64 \n", + " 26 reaction_infection 1287 non-null int64 \n", + " 27 reaction_death 1287 non-null int64 \n", + " 28 reaction_cancer 1287 non-null int64 \n", + " 29 reaction_failure 1287 non-null int64 \n", + " 30 reaction_pneumonia 1287 non-null int64 \n", + " 31 reaction_bleeding 1287 non-null int64 \n", + " 32 reaction_complexity 1287 non-null int64 \n", + " 33 year 1287 non-null int64 \n", + " 34 month 1287 non-null int64 \n", + " 35 day 1287 non-null int64 \n", + " 36 weekday 1287 non-null int64 \n", + " 37 report_type_risk 1287 non-null float64\n", + " 38 age_drug_risk 1287 non-null float64\n", + " 39 gender_drug_risk 1287 non-null float64\n", + "dtypes: float64(9), int64(23), str(8)\n", + "memory usage: 402.3 KB\n" + ] + }, + { + "data": { + "text/plain": [ + "report_id 0\n", + "country 0\n", + "occur_country 0\n", + "report_type 0\n", + "serious 0\n", + "death 0\n", + "life_threatening 0\n", + "hospitalization 0\n", + "disabling 0\n", + "receive_date 0\n", + "age 0\n", + "age_unit 0\n", + "gender 0\n", + "weight 0\n", + "drug 0\n", + "reaction 0\n", + "is_serious 0\n", + "severity_score 0\n", + "severity_norm 0\n", + "age_group 1\n", + "country_group 0\n", + "drug_risk 0\n", + "drug_freq 0\n", + "high_risk_drug 0\n", + "reaction_length 0\n", + "reaction_pain 0\n", + "reaction_infection 0\n", + "reaction_death 0\n", + "reaction_cancer 0\n", + "reaction_failure 0\n", + "reaction_pneumonia 0\n", + "reaction_bleeding 0\n", + "reaction_complexity 0\n", + "year 0\n", + "month 0\n", + "day 0\n", + "weekday 0\n", + "report_type_risk 0\n", + "age_drug_risk 0\n", + "gender_drug_risk 0\n", + "dtype: int64" + ] + }, + "execution_count": 4, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.info()\n", + "df.describe()\n", + "df.isnull().sum()" + ] + }, + { + "cell_type": "markdown", + "id": "676c57bf-d2c3-4cba-b333-bf9f2990135a", + "metadata": {}, + "source": [ + "## 2. Группировка и анализ признаков\n", + "\n", + "Для более подробного анализа используются группировки данных. \n", + "Это позволяет сравнить показатели по полу, странам и лекарственным препаратам." + ] + }, + { + "cell_type": "code", + "execution_count": 5, + "id": "124f939b-cc53-4b0d-a7b4-5101cbda0645", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "serious\n", + "1.0 808\n", + "2.0 479\n", + "Name: count, dtype: int64" + ] + }, + "execution_count": 5, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df[\"serious\"].value_counts()" + ] + }, + { + "cell_type": "code", + "execution_count": 6, + "id": "a1fb32cc-b1ff-4585-b7b1-661824bcea9d", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "death\n", + "0 1215\n", + "1 72\n", + "Name: count, dtype: int64" + ] + }, + "execution_count": 6, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df[\"death\"].value_counts()" + ] + }, + { + "cell_type": "code", + "execution_count": 7, + "id": "20a5a103-b2e5-416a-8f90-0e4fc05d8d8b", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "np.float64(53.92307692307692)" + ] + }, + "execution_count": 7, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df[\"age\"].mean()" + ] + }, + { + "cell_type": "code", + "execution_count": 8, + "id": "8965b8d8-db80-4d18-a86c-70446756e7c7", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "gender\n", + "Female 54.161939\n", + "Male 53.464853\n", + "Name: age, dtype: float64" + ] + }, + "execution_count": 8, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.groupby(\"gender\")[\"age\"].mean()" + ] + }, + { + "cell_type": "code", + "execution_count": 9, + "id": "7c4ae568-ebae-4675-90e0-6f6bea52e4a5", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "country\n", + "US 1252.0\n", + "EU 184.0\n", + "CA 110.0\n", + "JP 62.0\n", + "GB 55.0\n", + "CN 34.0\n", + "AU 20.0\n", + "BR 7.0\n", + "IN 6.0\n", + "PR 3.0\n", + "Name: serious, dtype: float64" + ] + }, + "execution_count": 9, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.groupby(\"country\")[\"serious\"].sum().sort_values(ascending=False).head(10)" + ] + }, + { + "cell_type": "code", + "execution_count": 10, + "id": "ab8f72ba-d2d4-4c50-a0a0-d233fc0ab9b9", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "drug\n", + "APREMILAST 14.0\n", + "ELRANATAMAB 12.0\n", + "SILDENAFIL 9.0\n", + "DOLUTEGRAVIR 8.0\n", + "DEFITELIO 8.0\n", + "MELPHALAN 8.0\n", + "GLIVEC 8.0\n", + "HEMLIBRA 8.0\n", + "YUTREPIA 8.0\n", + "TUKYSA 7.0\n", + "Name: severity_score, dtype: float64" + ] + }, + "execution_count": 10, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.groupby(\"drug\")[\"severity_score\"].mean().sort_values(ascending=False).head(10)" + ] + }, + { + "cell_type": "markdown", + "id": "f4994af1-aaa7-4c2b-90a7-70c16fca4b12", + "metadata": {}, + "source": [ + "## 3. Визуализация данных\n", + "\n", + "В этом разделе построены графики для наглядного анализа данных: распределение возраста пациентов, сравнение серьёзности случаев по полу и количество случаев по странам." + ] + }, + { + "cell_type": "code", + "execution_count": 11, + "id": "122f15cd-3374-4148-a201-9c105329e160", + "metadata": {}, + "outputs": [ + { + "data": { + "image/png": "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", + "text/plain": [ + "
" + ] + }, + "metadata": {}, + "output_type": "display_data" + } + ], + "source": [ + "df[\"age\"].hist()\n", + "plt.title(\"Распределение возраста пациентов\")\n", + "plt.xlabel(\"Возраст\")\n", + "plt.ylabel(\"Количество\")\n", + "plt.show()" + ] + }, + { + "cell_type": "code", + "execution_count": 12, + "id": "a313c60d-5e66-485b-8d4b-bf0ade4de2da", + "metadata": {}, + "outputs": [ + { + "data": { + "image/png": "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", + "text/plain": [ + "
" + ] + }, + "metadata": {}, + "output_type": "display_data" + } + ], + "source": [ + "sns.boxplot(x=\"gender\", y=\"severity_score\", data=df)\n", + "plt.title(\"Серьёзность случаев по полу\")\n", + "plt.show()" + ] + }, + { + "cell_type": "code", + "execution_count": 13, + "id": "be1b82e2-6630-4332-9292-1fba6c6bef27", + "metadata": {}, + "outputs": [ + { + "data": { + "image/png": "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", + "text/plain": [ + "
" + ] + }, + "metadata": {}, + "output_type": "display_data" + } + ], + "source": [ + "top_countries = df[\"country\"].value_counts().head(10)\n", + "\n", + "top_countries.plot(kind=\"bar\")\n", + "plt.title(\"Топ стран по количеству случаев\")\n", + "plt.show()" + ] + }, + { + "cell_type": "markdown", + "id": "2abe77de-739a-4768-8b64-4381480bd2e1", + "metadata": {}, + "source": [ + "## 4. Использование tqdm\n", + "\n", + "Библиотека `tqdm` используется для отображения прогресс-бара при обработке данных. \n", + "В данной работе она применена для демонстрации прохода по строкам датасета." + ] + }, + { + "cell_type": "code", + "execution_count": 14, + "id": "8aa34e5c-26c8-4b35-b920-f427700dd8bd", + "metadata": {}, + "outputs": [ + { + "name": "stderr", + "output_type": "stream", + "text": [ + "100%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████| 1287/1287 [00:00<00:00, 2301948.51it/s]\n" + ] + } + ], + "source": [ + "from tqdm import tqdm\n", + "\n", + "count = 0\n", + "for i in tqdm(range(len(df))):\n", + " count += 1" + ] + }, + { + "cell_type": "markdown", + "id": "9cb10000-fa7b-4809-9f95-017e28d20f49", + "metadata": {}, + "source": [ + "## 5. Создание нового признака\n", + "\n", + "Для дополнительного анализа был создан новый столбец `risk_flag`. \n", + "Он показывает, относится ли случай к группе повышенного риска на основе значения `severity_score`." + ] + }, + { + "cell_type": "code", + "execution_count": 15, + "id": "d675d16a-2e41-4051-94f4-37a01ff4bb2f", + "metadata": {}, + "outputs": [], + "source": [ + "df[\"risk_flag\"] = df[\"severity_score\"] > 7" + ] + }, + { + "cell_type": "code", + "execution_count": 16, + "id": "f8ac6ccd-fd69-4472-8840-aeeb2daa1e26", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "risk_flag\n", + "False 1258\n", + "True 29\n", + "Name: count, dtype: int64" + ] + }, + "execution_count": 16, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df[\"risk_flag\"].value_counts()" + ] + }, + { + "cell_type": "markdown", + "id": "f1d00383-7ac0-4548-bea7-b961c53e7506", + "metadata": {}, + "source": [ + "## Вывод\n", + "\n", + "В ходе работы был загружен и проанализирован датасет FDA Drug Adverse Events. \n", + "Были изучены основные признаки, выполнена проверка структуры данных и построены визуализации.\n", + "\n", + "В работе были использованы:\n", + "- `pandas` для загрузки и обработки данных;\n", + "- `numpy` для работы с числовыми значениями;\n", + "- `matplotlib` и `seaborn` для построения графиков;\n", + "- `tqdm` для отображения прогресса обработки.\n", + "\n", + "Полученные графики помогают наглядно оценить распределение возраста пациентов, различия по полу и страны с наибольшим количеством зарегистрированных случаев." + ] + } + ], + "metadata": { + "kernelspec": { + "display_name": "Python 3 (ipykernel)", + "language": "python", + "name": "python3" + }, + "language_info": { + "codemirror_mode": { + "name": "ipython", + "version": 3 + }, + "file_extension": ".py", + "mimetype": "text/x-python", + "name": "python", + "nbconvert_exporter": "python", + "pygments_lexer": "ipython3", + "version": "3.14.4" + } + }, + "nbformat": 4, + "nbformat_minor": 5 +} diff --git a/README.md b/README.md new file mode 100644 index 0000000..33c8345 --- /dev/null +++ b/README.md @@ -0,0 +1,51 @@ +# Анализ данных FDA Drug Adverse Events + +## Описание проекта + +В данном проекте выполнен анализ данных о побочных эффектах лекарственных препаратов на основе датасета FDA Drug Adverse Events. + +Работа выполнена в Jupyter Notebook в рамках задания по анализу и визуализации данных. + +## Цель работы + +Цель работы — освоить базовую работу с JupyterLab, библиотеками для анализа данных и визуализации, а также закрепить навыки ведения проекта с использованием Git. + +## Используемые библиотеки + +В проекте использовались следующие библиотеки: + +- pandas +- numpy +- matplotlib +- seaborn +- tqdm + +## Что было сделано + +В ходе работы были выполнены следующие действия: + +1. Загружен датасет из CSV-файла. +2. Проведён первичный анализ данных: + - просмотр первых строк таблицы; + - анализ структуры данных; + - получение статистического описания; + - проверка пропущенных значений. +3. Выполнена группировка данных по отдельным признакам. +4. Создан новый признак `risk_flag` для выделения случаев повышенного риска. +5. Построены графики: + - гистограмма распределения возраста; + - boxplot серьёзности случаев по полу; + - столбчатая диаграмма стран с наибольшим количеством случаев; + - тепловая карта корреляций. +6. Использована библиотека `tqdm` для отображения прогресса обработки данных. + +## Структура проекта + +```text +project_drugs/ +├── data/ +│ └── gm_feature_engineered_fda.csv +├── week2_analysis.ipynb +├── README.md +├── requirements.txt +└── .gitignore \ No newline at end of file diff --git a/data/gm_feature_engineered_fda.csv b/data/gm_feature_engineered_fda.csv new file mode 100644 index 0000000..002fcb6 --- /dev/null +++ b/data/gm_feature_engineered_fda.csv @@ -0,0 +1,1288 @@ +report_id,country,occur_country,report_type,serious,death,life_threatening,hospitalization,disabling,receive_date,age,age_unit,gender,weight,drug,reaction,is_serious,severity_score,severity_norm,age_group,country_group,drug_risk,drug_freq,high_risk_drug,reaction_length,reaction_pain,reaction_infection,reaction_death,reaction_cancer,reaction_failure,reaction_pneumonia,reaction_bleeding,reaction_complexity,year,month,day,weekday,report_type_risk,age_drug_risk,gender_drug_risk +26016170,US,US,1,2.0,0,0,0,0,2025-11-10,42.0,801.0,Male,75.0,DUPIXENT,abdominal pain,0,0,0.0,Adult,US,0.015513897866839042,221,0,14,1,0,0,0,0,0,0,2,2025,11,10,0,0.08073634859349145,0.6515837104072397,0.0 +26017452,NP,NP,1,1.0,1,0,1,0,2025-11-10,51.0,801.0,Male,75.0,METHOTREXATE,toxicity to various agents,1,8,0.5714285714285714,MidAge,Other,0.17346938775510204,7,1,26,0,0,0,0,0,0,0,4,2025,11,10,0,0.08073634859349145,8.846938775510203,0.0 +26017586,US,US,1,2.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,PEPCID COMPLETE,exposure during pregnancy,0,0,0.0,MidAge,US,0.0,1,0,25,0,0,0,0,0,0,0,3,2025,11,10,0,0.08073634859349145,0.0,0.0 +26018910,SG,SG,1,1.0,0,0,0,0,2025-11-10,62.0,801.0,Female,75.0,PACLITAXEL,drug ineffective,1,0,0.0,MidAge,Other,0.07142857142857142,3,0,16,0,0,0,0,0,0,0,2,2025,11,10,0,0.08073634859349145,4.428571428571428,0.07142857142857142 +26018949,EU,EU,3,1.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,DULOXETINE,drug interaction,1,0,0.0,MidAge,EU,0.0,2,0,16,0,0,0,0,0,0,0,2,2025,11,10,0,0.17857142857142855,0.0,0.0 +26019625,US,US,1,1.0,0,0,0,0,2025-11-10,67.0,801.0,Male,75.0,DOCETAXEL,osteoporosis,1,0,0.0,Senior,US,0.061224489795918366,7,0,12,0,0,0,0,0,0,0,1,2025,11,10,0,0.08073634859349145,4.1020408163265305,0.0 +26019988,US,US,1,2.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,POLYETHYLENE GLYCOL 3350,incorrect product administration duration,0,0,0.0,MidAge,US,0.0,4,0,41,0,0,0,0,0,0,0,4,2025,11,10,0,0.08073634859349145,0.0,0.0 +25942883,CA,CA,2,1.0,0,0,0,0,2025-10-21,46.0,801.0,Male,75.0,VEDOLIZUMAB,colitis ulcerative,1,0,0.0,Adult,CA,0.057692307692307696,26,0,18,0,0,0,0,0,0,0,2,2025,10,21,1,0.08936301793444651,2.653846153846154,0.0 +25942964,JP,JP,1,1.0,1,0,0,0,2025-10-21,78.0,801.0,Male,75.0,BEVACIZUMAB,vascular stent thrombosis,1,5,0.35714285714285715,Senior,JP,0.17857142857142858,2,1,25,0,0,0,0,0,0,0,3,2025,10,21,1,0.08073634859349145,13.928571428571429,0.0 +25943989,US,US,1,2.0,0,0,0,0,2025-10-21,57.0,801.0,Female,75.0,SKYRIZI,swelling of eyelid,0,0,0.0,MidAge,US,0.051587301587301584,36,0,18,0,0,0,0,0,0,0,3,2025,10,21,1,0.08073634859349145,2.9404761904761902,0.051587301587301584 +25944665,US,US,1,2.0,0,0,0,0,2025-10-21,68.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Senior,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,21,1,0.08073634859349145,1.0549450549450547,0.015513897866839042 +25945112,US,Unknown,1,1.0,0,0,1,0,2025-10-21,93.0,801.0,Male,75.0,ABIRATERONE ACETATE,blood potassium decreased,1,3,0.21428571428571427,Senior,US,0.21428571428571427,1,1,25,0,0,0,0,0,0,0,3,2025,10,21,1,0.08073634859349145,19.928571428571427,0.0 +25945394,US,US,2,1.0,0,0,0,0,2025-10-21,57.0,801.0,Female,83.46,SKYRIZI,loss of consciousness,1,0,0.0,MidAge,US,0.051587301587301584,36,0,21,0,0,0,0,0,0,0,3,2025,10,21,1,0.08936301793444651,2.9404761904761902,0.051587301587301584 +25945732,US,US,1,1.0,0,0,1,0,2025-10-21,16.0,801.0,Female,75.0,WEGOVY,asthma,1,3,0.21428571428571427,Child,US,0.14285714285714285,4,1,6,0,0,0,0,0,0,0,1,2025,10,21,1,0.08073634859349145,2.2857142857142856,0.14285714285714285 +25946070,US,US,1,2.0,0,0,0,0,2025-10-21,64.0,801.0,Female,96.16,NEULASTA,needle issue,0,0,0.0,MidAge,US,0.0,5,0,12,0,0,0,0,0,0,0,2,2025,10,21,1,0.08073634859349145,0.0,0.0 +25946757,US,US,1,2.0,0,0,0,0,2025-10-22,77.0,801.0,Female,98.866,REMODULIN,peripheral swelling,0,0,0.0,Senior,US,0.0,4,0,19,0,0,0,0,0,0,0,2,2025,10,22,2,0.08073634859349145,0.0,0.0 +26022111,US,US,1,2.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,DUPIXENT,rash macular,0,0,0.0,MidAge,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,2,2025,11,10,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26023703,CA,CA,1,1.0,0,0,0,0,2025-11-11,65.0,801.0,Female,75.0,LETROZOLE,drug intolerance,1,0,0.0,MidAge,CA,0.07142857142857142,3,0,16,0,0,0,0,0,0,0,2,2025,11,11,1,0.08073634859349145,4.642857142857142,0.07142857142857142 +26024027,US,US,1,1.0,0,0,0,0,2025-11-11,82.0,801.0,Male,75.0,DUPIXENT,cataract,1,0,0.0,Senior,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,11,11,1,0.08073634859349145,1.2721396250808015,0.0 +26073427,JP,JP,1,2.0,0,0,0,0,2025-11-21,4.0,800.0,Male,75.0,MINOCYCLINE,therapy partial responder,0,0,0.0,Child,JP,0.0,1,0,25,0,0,0,0,0,0,0,3,2025,11,21,4,0.08073634859349145,0.0,0.0 +26073603,CA,CA,1,1.0,0,1,0,0,2025-11-21,57.0,801.0,Male,75.0,DEXAMETHASONE,ventricular hypertrophy,1,4,0.2857142857142857,MidAge,CA,0.1857142857142857,5,1,23,0,0,0,0,0,0,0,2,2025,11,21,4,0.08073634859349145,10.585714285714284,0.0 +26074251,CA,CA,2,1.0,0,0,0,0,2025-11-21,57.0,801.0,Female,75.0,RITUXIMAB,blood pressure increased,1,0,0.0,MidAge,CA,0.12406015037593986,19,0,24,0,0,0,0,0,0,0,3,2025,11,21,4,0.08936301793444651,7.071428571428572,0.12406015037593986 +26075829,US,US,1,2.0,0,0,0,0,2025-11-21,27.0,801.0,Female,75.0,DUPIXENT,condition aggravated,0,0,0.0,Young,US,0.015513897866839042,221,0,20,0,0,0,0,0,0,0,2,2025,11,21,4,0.08073634859349145,0.4188752424046541,0.015513897866839042 +26076396,US,US,2,1.0,0,0,0,0,2025-11-21,71.0,801.0,Female,75.0,AXICABTAGENE CILOLEUCEL,squamous cell carcinoma of skin,1,0,0.0,Senior,US,0.0,1,0,31,0,0,0,0,0,0,0,5,2025,11,21,4,0.08936301793444651,0.0,0.0 +25946933,US,US,1,1.0,0,0,0,0,2025-10-22,68.0,801.0,Female,80.726,FIRDAPSE,carpal tunnel syndrome,1,0,0.0,Senior,US,0.0,3,0,22,0,0,0,0,0,0,0,3,2025,10,22,2,0.08073634859349145,0.0,0.0 +25947729,US,US,1,2.0,0,0,0,0,2025-10-22,57.0,801.0,Female,52.608,REMODULIN,device maintenance issue,0,0,0.0,MidAge,US,0.0,4,0,24,0,0,0,0,0,0,0,3,2025,10,22,2,0.08073634859349145,0.0,0.0 +25948863,US,US,1,2.0,0,0,0,0,2025-10-22,57.0,801.0,Male,75.0,DUPIXENT,illness,0,0,0.0,MidAge,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,1,2025,10,22,2,0.08073634859349145,0.8842921784098254,0.0 +25949525,US,US,1,1.0,0,0,0,0,2025-10-22,53.0,801.0,Male,75.0,TRULICITY,hepatobiliary cancer,1,0,0.0,MidAge,US,0.04285714285714286,5,0,20,0,0,0,1,0,0,0,2,2025,10,22,2,0.08073634859349145,2.2714285714285714,0.0 +25949592,EU,EU,2,1.0,0,0,1,0,2025-10-22,57.0,801.0,Female,75.0,METHOTREXATE SODIUM,chest pain,1,3,0.21428571428571427,MidAge,EU,0.125,4,1,10,1,0,0,0,0,0,0,2,2025,10,22,2,0.08936301793444651,7.125,0.125 +25950497,US,US,1,2.0,0,0,0,0,2025-10-23,57.0,801.0,Female,75.0,DUPIXENT,weight increased,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,10,23,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26024809,EU,EU,3,1.0,0,0,1,0,2025-11-11,57.0,801.0,Female,75.0,ACETAMINOPHEN,cholestasis,1,3,0.21428571428571427,MidAge,EU,0.10267857142857142,16,0,11,0,0,0,0,0,0,0,1,2025,11,11,1,0.17857142857142855,5.852678571428571,0.10267857142857142 +26025781,US,US,2,2.0,0,0,0,0,2025-11-11,72.0,801.0,Male,75.0,VONJO,off label use,0,0,0.0,Senior,US,0.0,3,0,13,0,0,0,0,0,0,0,3,2025,11,11,1,0.08936301793444651,0.0,0.0 +26025862,EU,EU,1,1.0,0,0,1,0,2025-11-11,57.0,801.0,Female,75.0,RIVAROXABAN,cerebellar ischaemia,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,2,1,20,0,0,0,0,0,0,0,2,2025,11,11,1,0.08073634859349145,12.214285714285714,0.21428571428571427 +26026281,US,US,1,2.0,0,0,0,0,2025-11-11,9.0,801.0,Female,75.0,DUPIXENT,breast mass,0,0,0.0,Child,US,0.015513897866839042,221,0,11,0,0,0,0,0,0,0,2,2025,11,11,1,0.08073634859349145,0.13962508080155137,0.015513897866839042 +26027334,CA,CA,1,1.0,0,0,0,0,2025-11-11,56.0,801.0,Female,75.0,VOLTAREN,blindness unilateral,1,0,0.0,MidAge,CA,0.0,1,0,20,0,0,0,0,0,0,0,2,2025,11,11,1,0.08073634859349145,0.0,0.0 +26027792,US,US,1,2.0,0,0,0,0,2025-11-11,57.0,801.0,Male,75.0,PLUVICTO,general physical health deterioration,0,0,0.0,MidAge,US,0.0,8,0,37,0,0,0,0,0,0,0,4,2025,11,11,1,0.08073634859349145,0.0,0.0 +26027806,US,US,2,1.0,0,0,0,0,2025-11-11,57.0,801.0,Female,75.0,NUPLAZID,hallucination,1,0,0.0,MidAge,US,0.09523809523809523,6,0,13,0,0,0,0,0,0,0,1,2025,11,11,1,0.08936301793444651,5.428571428571428,0.09523809523809523 +26079555,US,US,1,2.0,0,0,0,0,2025-11-23,64.0,801.0,Female,75.0,DUPIXENT,drug ineffective,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,11,23,6,0.08073634859349145,0.9928894634776987,0.015513897866839042 +26079812,CN,CN,1,1.0,0,0,0,0,2025-11-23,74.0,801.0,Male,76.0,TISLELIZUMAB,myelosuppression,1,0,0.0,Senior,CN,0.0,3,0,16,0,0,0,0,0,0,0,1,2025,11,23,6,0.08073634859349145,0.0,0.0 +26080164,KR,KR,1,1.0,0,0,0,0,2025-11-24,80.0,801.0,Female,75.0,ISONIAZID,thrombocytopenia,1,0,0.0,Senior,Other,0.0,1,0,16,0,0,0,0,0,0,0,1,2025,11,24,0,0.08073634859349145,0.0,0.0 +26028683,US,US,1,1.0,0,0,1,0,2025-11-11,57.0,801.0,Female,75.0,LENALIDOMIDE,infusion related hypersensitivity reaction,1,3,0.21428571428571427,MidAge,US,0.15413533834586465,19,1,42,0,0,0,0,0,0,0,4,2025,11,11,1,0.08073634859349145,8.785714285714285,0.15413533834586465 +26028764,US,US,1,1.0,0,0,0,0,2025-11-11,14.0,801.0,Male,75.0,DUPIXENT,neuropathy peripheral,1,0,0.0,Child,US,0.015513897866839042,221,0,21,0,0,0,0,0,0,0,2,2025,11,11,1,0.08073634859349145,0.21719457013574658,0.0 +26030831,GB,GB,1,1.0,0,0,0,0,2025-11-12,57.0,801.0,Female,75.0,CARBOPLATIN,contusion,1,0,0.0,MidAge,GB,0.12244897959183673,7,0,9,0,0,0,0,0,0,0,1,2025,11,12,2,0.08073634859349145,6.979591836734694,0.12244897959183673 +26032761,US,US,2,1.0,0,0,0,0,2025-11-12,58.0,801.0,Male,75.0,CREON,pancreatic carcinoma,1,0,0.0,MidAge,US,0.03296703296703297,13,0,20,0,0,0,0,0,0,0,2,2025,11,12,2,0.08936301793444651,1.9120879120879122,0.0 +26033409,US,US,1,2.0,0,0,0,0,2025-11-12,57.0,801.0,Female,75.0,CYCLOSPORINE,burning sensation,0,0,0.0,MidAge,US,0.0,5,0,17,0,0,0,0,0,0,0,2,2025,11,12,2,0.08073634859349145,0.0,0.0 +26081541,US,US,2,1.0,0,0,1,0,2025-11-24,80.0,801.0,Female,58.0,HUMAN IMMUNOGLOBULIN G,hip fracture,1,3,0.21428571428571427,Senior,US,0.10714285714285714,8,0,12,0,0,0,0,0,0,0,2,2025,11,24,0,0.08936301793444651,8.571428571428571,0.10714285714285714 +26082823,US,Unknown,1,1.0,0,1,0,1,2025-11-23,55.0,801.0,Male,96.75,LOSARTAN,therapy interrupted,1,6,0.42857142857142855,MidAge,US,0.2857142857142857,2,1,19,0,0,0,0,0,0,0,2,2025,11,23,6,0.08073634859349145,15.714285714285714,0.0 +25956114,US,US,1,2.0,0,0,0,0,2025-10-24,57.0,801.0,Female,75.0,SIROLIMUS,mouth ulceration,0,0,0.0,MidAge,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,10,24,4,0.08073634859349145,0.0,0.0 +25956734,US,US,1,2.0,0,0,0,0,2025-10-24,85.0,801.0,Female,75.0,AYVAKIT,peripheral swelling,0,0,0.0,Senior,US,0.0,2,0,19,0,0,0,0,0,0,0,2,2025,10,24,4,0.08073634859349145,0.0,0.0 +25957410,PR,PR,1,2.0,0,0,0,0,2025-10-24,69.0,801.0,Female,75.0,LENALIDOMIDE,asthenia,0,0,0.0,Senior,Other,0.15413533834586465,19,1,8,0,0,0,0,0,0,0,1,2025,10,24,4,0.08073634859349145,10.63533834586466,0.15413533834586465 +26037054,US,US,2,2.0,0,0,0,0,2025-11-12,57.0,801.0,Female,75.0,CORTICOTROPIN,arthralgia,0,0,0.0,MidAge,US,0.0,3,0,10,0,0,0,0,0,0,0,1,2025,11,12,2,0.08936301793444651,0.0,0.0 +26037579,US,US,2,1.0,0,0,1,0,2025-11-12,31.0,801.0,Female,75.0,SPRAVATO,hyperventilation,1,3,0.21428571428571427,Young,US,0.026785714285714284,8,0,16,0,0,0,0,0,0,0,1,2025,11,12,2,0.08936301793444651,0.8303571428571428,0.026785714285714284 +26037984,US,US,2,1.0,1,0,1,0,2025-11-12,80.0,801.0,Female,75.0,SKYRIZI,pneumonia aspiration,1,8,0.5714285714285714,Senior,US,0.051587301587301584,36,0,20,0,0,0,0,0,1,0,2,2025,11,12,2,0.08936301793444651,4.1269841269841265,0.051587301587301584 +26038660,US,US,1,2.0,0,0,0,0,2025-11-13,57.0,801.0,Female,75.0,TRELEGY ELLIPTA,nausea,0,0,0.0,MidAge,US,0.0,4,0,6,0,0,0,0,0,0,0,1,2025,11,13,3,0.08073634859349145,0.0,0.0 +26039780,US,US,1,2.0,0,0,0,0,2025-11-13,57.0,801.0,Female,75.0,ACETAMINOPHEN,toxicity to various agents,0,0,0.0,MidAge,US,0.10267857142857142,16,0,26,0,0,0,0,0,0,0,4,2025,11,13,3,0.08073634859349145,5.852678571428571,0.10267857142857142 +25960555,US,US,1,2.0,0,0,0,0,2025-10-27,69.0,801.0,Male,129.25,GEMTESA,glycosylated haemoglobin increased,0,0,0.0,Senior,US,0.0,1,0,34,0,0,0,0,0,0,0,3,2025,10,27,0,0.08073634859349145,0.0,0.0 +25960784,US,US,1,2.0,0,0,0,0,2025-10-27,57.0,801.0,Male,79.55,DUPIXENT,cough,0,0,0.0,MidAge,US,0.015513897866839042,221,0,5,0,0,0,0,0,0,0,1,2025,10,27,0,0.08073634859349145,0.8842921784098254,0.0 +25960865,US,US,1,2.0,0,0,0,0,2025-10-27,71.0,801.0,Male,75.0,ORGOVYX,pollakiuria,0,0,0.0,Senior,US,0.0,4,0,11,0,0,0,0,0,0,0,1,2025,10,27,0,0.08073634859349145,0.0,0.0 +25961851,US,IL,1,1.0,0,0,0,0,2025-10-27,67.0,801.0,Male,75.0,OPDIVO,hepatitis,1,0,0.0,Senior,US,0.08928571428571429,4,0,9,0,0,0,0,0,0,0,1,2025,10,27,0,0.08073634859349145,5.982142857142858,0.0 +25962337,MX,MX,1,1.0,0,0,0,0,2025-10-27,41.0,801.0,Male,76.0,OCREVUS,multiple sclerosis,1,0,0.0,Adult,Other,0.0,3,0,18,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,0.0,0.0 +25962418,EU,EU,1,1.0,1,0,0,0,2025-10-27,51.0,801.0,Male,75.0,BUPRENORPHINE,asphyxia,1,5,0.35714285714285715,MidAge,EU,0.2857142857142857,2,1,8,0,0,0,0,0,0,0,1,2025,10,27,0,0.08073634859349145,14.571428571428571,0.0 +26040942,US,Unknown,1,2.0,0,0,0,0,2025-11-12,57.0,801.0,Female,75.0,DUPIXENT,conjunctivitis,0,0,0.0,MidAge,US,0.015513897866839042,221,0,14,0,0,0,0,0,0,0,1,2025,11,12,2,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26041752,US,US,1,2.0,0,0,0,0,2025-11-13,57.0,801.0,Female,59.09,DUPIXENT,oropharyngeal discomfort,0,0,0.0,MidAge,US,0.015513897866839042,221,0,24,0,0,0,0,0,0,0,2,2025,11,13,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26041819,US,US,1,2.0,0,0,0,0,2025-11-13,64.0,801.0,Male,75.0,DUPIXENT,sensitive skin,0,0,0.0,MidAge,US,0.015513897866839042,221,0,14,0,0,0,0,0,0,0,2,2025,11,13,3,0.08073634859349145,0.9928894634776987,0.0 +26042023,CN,CN,1,1.0,0,0,1,0,2025-11-13,57.0,801.0,Female,75.0,TORIPALIMAB,myelosuppression,1,3,0.21428571428571427,MidAge,CN,0.21428571428571427,1,1,16,0,0,0,0,0,0,0,1,2025,11,13,3,0.08073634859349145,12.214285714285714,0.21428571428571427 +26086588,EU,EU,1,1.0,0,0,1,0,2025-11-25,63.0,801.0,Male,75.0,MIRTAZAPINE,hepatotoxicity,1,3,0.21428571428571427,MidAge,EU,0.19047619047619047,3,1,14,0,0,0,0,0,0,0,1,2025,11,25,1,0.08073634859349145,12.0,0.0 +26087035,EU,EU,1,1.0,0,0,0,0,2025-11-25,29.0,801.0,Female,75.0,ESOMEPRAZOLE,rash maculo-papular,1,0,0.0,Young,EU,0.0,1,0,19,0,0,0,0,0,0,0,2,2025,11,25,1,0.08073634859349145,0.0,0.0 +26087817,US,US,2,1.0,0,0,0,0,2025-11-25,57.0,801.0,Female,75.0,VENCLEXTA,pancytopenia,1,0,0.0,MidAge,US,0.18571428571428572,5,1,12,0,0,0,0,0,0,0,1,2025,11,25,1,0.08936301793444651,10.585714285714285,0.18571428571428572 +26088412,US,US,1,1.0,0,0,1,0,2025-11-25,80.0,801.0,Male,75.0,XGEVA,compression fracture,1,3,0.21428571428571427,Senior,US,0.10714285714285714,2,0,20,0,0,0,0,0,0,0,2,2025,11,25,1,0.08073634859349145,8.571428571428571,0.0 +25964429,CA,CA,2,1.0,0,0,0,0,2025-10-27,57.0,801.0,Female,75.0,BENRALIZUMAB,chest discomfort,1,0,0.0,MidAge,CA,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,10,27,0,0.08936301793444651,0.0,0.0 +25965077,GB,GB,1,1.0,0,0,0,0,2025-10-27,57.0,801.0,Female,57.0,CITALOPRAM,muscle twitching,1,0,0.0,MidAge,GB,0.42857142857142855,2,1,16,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,24.428571428571427,0.42857142857142855 +25965105,US,US,2,1.0,0,0,0,0,2025-10-27,35.0,801.0,Female,75.0,SPRAVATO,sedation,1,0,0.0,Young,US,0.026785714285714284,8,0,8,0,0,0,0,0,0,0,1,2025,10,27,0,0.08936301793444651,0.9375,0.026785714285714284 +25965415,US,US,1,2.0,0,0,0,0,2025-10-27,91.0,801.0,Female,75.0,DUPIXENT,injection site pain,0,0,0.0,Senior,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,10,27,0,0.08073634859349145,1.4117647058823528,0.015513897866839042 +25965482,US,US,1,2.0,0,0,0,0,2025-10-27,40.0,801.0,Male,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Adult,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,0.6205559146735616,0.0 +25966454,US,US,1,2.0,0,0,0,0,2025-10-28,74.0,801.0,Female,75.0,ORENCIA,pain,0,0,0.0,Senior,US,0.10204081632653061,14,0,4,1,0,0,0,0,0,0,1,2025,10,28,1,0.08073634859349145,7.551020408163265,0.10204081632653061 +26044249,US,US,1,2.0,0,0,0,0,2025-11-14,71.0,801.0,Male,75.0,TIGECYCLINE,diarrhoea,0,0,0.0,Senior,US,0.0,1,0,9,0,0,0,0,0,0,0,1,2025,11,14,4,0.08073634859349145,0.0,0.0 +26044397,GB,GB,1,1.0,0,0,0,0,2025-11-14,67.0,801.0,Male,75.0,FINASTERIDE,disorder of sex development,1,0,0.0,Senior,GB,0.0,2,0,27,0,0,0,0,0,0,0,4,2025,11,14,4,0.08073634859349145,0.0,0.0 +26045369,US,US,2,1.0,0,0,0,0,2025-11-14,78.0,801.0,Male,75.0,IXAZOMIB,compression fracture,1,0,0.0,Senior,US,0.0,2,0,20,0,0,0,0,0,0,0,2,2025,11,14,4,0.08936301793444651,0.0,0.0 +26045950,AU,AU,1,1.0,0,0,1,0,2025-11-14,65.0,801.0,Male,91.9,LENALIDOMIDE,pyrexia,1,3,0.21428571428571427,MidAge,AU,0.15413533834586465,19,1,7,0,0,0,0,0,0,0,1,2025,11,14,4,0.08073634859349145,10.018796992481203,0.0 +26089046,US,US,1,2.0,0,0,0,0,2025-11-25,71.0,801.0,Female,75.0,DUPIXENT,injury associated with device,0,0,0.0,Senior,US,0.015513897866839042,221,0,29,0,0,0,0,0,0,0,4,2025,11,25,1,0.08073634859349145,1.101486748545572,0.015513897866839042 +26089451,US,US,1,2.0,0,0,0,0,2025-11-25,70.0,801.0,Male,75.0,DUPIXENT,drug effect less than expected,0,0,0.0,Senior,US,0.015513897866839042,221,0,30,0,0,0,0,0,0,0,5,2025,11,25,1,0.08073634859349145,1.085972850678733,0.0 +26092152,US,US,1,1.0,0,1,1,0,2025-11-26,17.0,801.0,Male,75.0,IBUPROFEN,hypotension,1,7,0.5,Child,US,0.11607142857142858,8,0,11,0,0,0,0,0,0,0,1,2025,11,26,2,0.08073634859349145,1.9732142857142858,0.0 +26092624,CN,CN,1,2.0,0,0,0,0,2025-11-26,63.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,aspartate aminotransferase increased,0,0,0.0,MidAge,CN,0.10150375939849625,19,0,36,0,0,0,0,0,0,0,3,2025,11,26,2,0.08073634859349145,6.394736842105264,0.0 +26051768,US,US,2,1.0,0,0,0,0,2025-11-17,57.0,801.0,Female,75.0,RISPERIDONE,adverse drug reaction,1,0,0.0,MidAge,US,0.125,4,1,21,0,0,0,0,0,0,0,3,2025,11,17,0,0.08936301793444651,7.125,0.125 +26052620,EU,EU,2,1.0,0,0,0,0,2025-11-17,44.0,801.0,Male,75.0,SKYRIZI,chronic lymphocytic leukaemia,1,0,0.0,Adult,EU,0.051587301587301584,36,0,29,0,0,0,0,0,0,0,3,2025,11,17,0,0.08936301793444651,2.2698412698412698,0.0 +26053807,US,US,1,2.0,0,0,0,0,2025-11-17,53.0,801.0,Female,75.0,DUPIXENT,nasopharyngitis,0,0,0.0,MidAge,US,0.015513897866839042,221,0,15,0,0,0,0,0,0,0,1,2025,11,17,0,0.08073634859349145,0.8222365869424693,0.015513897866839042 +26053821,US,US,1,2.0,0,0,0,0,2025-11-17,38.0,801.0,Male,75.0,DUPIXENT,idiopathic urticaria,0,0,0.0,Adult,US,0.015513897866839042,221,0,20,0,0,0,0,0,0,0,2,2025,11,17,0,0.08073634859349145,0.5895281189398835,0.0 +26054011,EU,EU,1,1.0,0,0,0,0,2025-11-17,47.0,801.0,Female,75.0,AZATHIOPRINE,toxicity to various agents,1,0,0.0,Adult,EU,0.0,2,0,26,0,0,0,0,0,0,0,4,2025,11,17,0,0.08073634859349145,0.0,0.0 +25973973,US,Unknown,1,1.0,0,0,0,0,2025-10-28,37.0,801.0,Female,87.75,TALTZ,migraine,1,0,0.0,Adult,US,0.0,1,0,8,0,0,0,0,0,0,0,1,2025,10,28,1,0.08073634859349145,0.0,0.0 +25974378,US,Unknown,1,1.0,0,0,1,0,2025-10-29,79.0,801.0,Female,52.71,DARATUMUMAB\HYALURONIDASE-FIHJ,renal failure,1,3,0.21428571428571427,Senior,US,0.21428571428571427,2,1,13,0,0,0,0,1,0,0,2,2025,10,29,2,0.08073634859349145,16.928571428571427,0.21428571428571427 +25974459,EU,EU,1,1.0,0,0,1,0,2025-10-29,57.0,804.0,Female,1.88,METOPROLOL,bradycardia neonatal,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,1,1,20,0,0,0,0,0,0,0,2,2025,10,29,2,0.08073634859349145,12.214285714285714,0.21428571428571427 +25974554,US,US,2,1.0,0,0,0,0,2025-10-29,76.0,801.0,Female,75.0,CREON,hip arthroplasty,1,0,0.0,Senior,US,0.03296703296703297,13,0,16,0,0,0,0,0,0,0,2,2025,10,29,2,0.08936301793444651,2.5054945054945055,0.03296703296703297 +25975621,US,US,1,2.0,0,0,0,0,2025-10-29,30.0,801.0,Male,75.0,XELJANZ XR,therapeutic product effect incomplete,0,0,0.0,Young,US,0.0,9,0,37,0,0,0,0,0,0,0,4,2025,10,29,2,0.08073634859349145,0.0,0.0 +26056547,US,US,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,ISOTRETINOIN,adverse drug reaction,0,0,0.0,MidAge,US,0.023809523809523808,9,0,21,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,1.357142857142857,0.023809523809523808 +26056790,US,US,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,ISOTRETINOIN,alopecia,0,0,0.0,MidAge,US,0.023809523809523808,9,0,8,0,0,0,0,0,0,0,1,2025,11,18,1,0.08073634859349145,1.357142857142857,0.023809523809523808 +26056938,US,US,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,ISOTRETINOIN,adverse event,0,0,0.0,MidAge,US,0.023809523809523808,9,0,13,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,1.357142857142857,0.023809523809523808 +26057223,US,US,1,2.0,0,0,0,0,2025-11-18,17.0,801.0,Female,75.0,ISOTRETINOIN,oropharyngeal pain,0,0,0.0,Child,US,0.023809523809523808,9,0,18,1,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,0.40476190476190477,0.023809523809523808 +26057276,US,US,1,2.0,0,0,0,0,2025-11-18,16.0,801.0,Female,75.0,ISOTRETINOIN,intentional dose omission,0,0,0.0,Child,US,0.023809523809523808,9,0,25,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,0.38095238095238093,0.023809523809523808 +26059368,CN,CN,1,1.0,0,0,1,0,2025-11-18,73.0,801.0,Male,59.0,DICLOFENAC SODIUM,upper gastrointestinal haemorrhage,1,3,0.21428571428571427,Senior,CN,0.4047619047619048,3,1,34,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,29.54761904761905,0.0 +26059692,US,US,1,1.0,1,0,0,0,2025-11-18,57.0,801.0,Female,75.0,XEOMIN,death,1,5,0.35714285714285715,MidAge,US,0.08928571428571429,4,0,5,0,0,1,0,0,0,0,1,2025,11,18,1,0.08073634859349145,5.089285714285714,0.08928571428571429 +26093258,US,US,1,2.0,0,0,0,0,2025-11-26,49.0,801.0,Female,75.0,DUPIXENT,dyspnoea,0,0,0.0,Adult,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,11,26,2,0.08073634859349145,0.7601809954751131,0.015513897866839042 +26094244,US,US,2,1.0,0,0,0,0,2025-11-26,41.0,801.0,Male,75.0,XYWAV,impaired gastric emptying,1,0,0.0,Adult,US,0.04285714285714286,5,0,25,0,0,0,0,0,0,0,3,2025,11,26,2,0.08936301793444651,1.7571428571428571,0.0 +26094325,US,US,1,1.0,0,0,0,0,2025-11-26,65.0,801.0,Female,75.0,BENLYSTA,osteoarthritis,1,0,0.0,MidAge,US,0.0,1,0,14,0,0,0,0,0,0,0,1,2025,11,26,2,0.08073634859349145,0.0,0.0 +26094998,US,US,2,1.0,0,0,0,0,2025-11-26,57.0,801.0,Female,100.0,HUMAN IMMUNOGLOBULIN G,lower respiratory tract infection,1,0,0.0,MidAge,US,0.10714285714285714,8,0,33,0,1,0,0,0,0,0,4,2025,11,26,2,0.08936301793444651,6.107142857142857,0.10714285714285714 +26095702,US,US,1,2.0,0,0,0,0,2025-11-27,70.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Senior,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,1.085972850678733,0.015513897866839042 +26096699,US,US,1,1.0,0,0,0,0,2025-11-27,76.0,801.0,Female,99.787,ALBUTEROL SULFATE,wrong technique in product usage process,1,0,0.0,Senior,US,0.0,8,0,40,0,0,0,0,0,0,0,6,2025,11,27,3,0.08073634859349145,0.0,0.0 +26096903,EU,EU,1,1.0,0,0,0,0,2025-11-27,77.0,801.0,Male,88.0,DAPTOMYCIN,interstitial lung disease,1,0,0.0,Senior,EU,0.16666666666666666,3,1,25,0,0,0,0,0,0,0,3,2025,11,27,3,0.08073634859349145,12.833333333333332,0.0 +26059706,CA,CA,2,1.0,0,0,0,0,2025-11-18,31.0,801.0,Male,75.0,VEDOLIZUMAB,colitis ulcerative,1,0,0.0,Young,CA,0.057692307692307696,26,0,18,0,0,0,0,0,0,0,2,2025,11,18,1,0.08936301793444651,1.7884615384615385,0.0 +26059854,EU,EU,1,1.0,0,0,1,0,2025-11-18,59.0,801.0,Male,60.0,LOVENOX,deep vein thrombosis,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,1,1,20,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,12.642857142857142,0.0 +26060854,US,US,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,PLUVICTO,general physical health deterioration,0,0,0.0,MidAge,US,0.0,8,0,37,0,0,0,0,0,0,0,4,2025,11,18,1,0.08073634859349145,0.0,0.0 +26097227,US,US,1,2.0,0,0,0,0,2025-11-27,71.0,801.0,Male,75.0,ORGOVYX,pollakiuria,0,0,0.0,Senior,US,0.0,4,0,11,0,0,0,0,0,0,0,1,2025,11,27,3,0.08073634859349145,0.0,0.0 +26097766,EU,EU,1,1.0,0,0,0,0,2025-11-27,34.0,801.0,Female,75.0,SPINRAZA,caesarean section,1,0,0.0,Young,EU,0.0,1,0,17,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,0.0,0.0 +26097861,US,US,1,2.0,0,0,0,0,2025-11-27,35.0,801.0,Male,75.0,OXYCODONE HYDROCHLORIDE,drug diversion,0,0,0.0,Young,US,0.0,1,0,14,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,0.0,0.0 +26098037,US,US,1,2.0,0,0,0,0,2025-11-27,66.0,801.0,Male,75.0,RITUXIMAB,treatment failure,0,0,0.0,Senior,US,0.12406015037593986,19,0,17,0,0,0,0,1,0,0,2,2025,11,27,3,0.08073634859349145,8.18796992481203,0.0 +26098509,CA,CA,1,1.0,0,0,1,0,2025-11-27,96.0,801.0,Female,53.0,JANUMET,atrial fibrillation,1,3,0.21428571428571427,Senior,CA,0.21428571428571427,1,1,19,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,20.57142857142857,0.21428571428571427 +26098657,EU,EU,1,1.0,0,0,0,0,2025-11-27,8.0,801.0,Female,75.0,MYCOPHENOLATE MOFETIL,lymphadenitis,1,0,0.0,Child,EU,0.10150375939849625,19,0,13,0,0,0,0,0,0,0,1,2025,11,27,3,0.08073634859349145,0.81203007518797,0.10150375939849625 +26099858,EU,EU,1,1.0,0,0,0,0,2025-11-28,13.0,801.0,Female,75.0,QUETIAPINE FUMARATE,pericardial effusion,1,0,0.0,Child,EU,0.0,1,0,20,0,0,0,0,0,0,0,2,2025,11,28,4,0.08073634859349145,0.0,0.0 +26064337,US,US,1,2.0,0,0,0,0,2025-11-19,57.0,801.0,Female,75.0,DUPIXENT,condition aggravated,0,0,0.0,MidAge,US,0.015513897866839042,221,0,20,0,0,0,0,0,0,0,2,2025,11,19,2,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26065147,GB,GB,1,1.0,0,0,1,0,2025-11-19,57.0,801.0,Male,75.0,ELEXACAFTOR\IVACAFTOR\TEZACAFTOR,lower respiratory tract infection,1,3,0.21428571428571427,MidAge,GB,0.21428571428571427,2,1,33,0,1,0,0,0,0,0,4,2025,11,19,2,0.08073634859349145,12.214285714285714,0.0 +26066186,BR,BR,1,1.0,0,0,1,0,2025-11-19,57.0,801.0,Female,76.0,TYSABRI,seizure,1,3,0.21428571428571427,MidAge,BR,0.21428571428571427,1,1,7,0,0,0,0,0,0,0,1,2025,11,19,2,0.08073634859349145,12.214285714285714,0.21428571428571427 +25982210,US,Unknown,1,1.0,0,0,0,0,2025-10-31,76.0,801.0,Female,112.0,ZILBRYSQ,influenza like illness,1,0,0.0,Senior,US,0.10714285714285714,2,0,22,0,0,0,0,0,0,0,3,2025,10,31,4,0.08073634859349145,8.142857142857142,0.10714285714285714 +25982964,US,US,1,1.0,0,0,0,0,2025-10-31,57.0,801.0,Male,129.25,ORENITRAM,skin laceration,1,0,0.0,MidAge,US,0.0,2,0,15,0,0,0,0,0,0,0,2,2025,10,31,4,0.08073634859349145,0.0,0.0 +25983464,EU,EU,1,1.0,0,0,0,0,2025-10-31,72.0,801.0,Female,75.0,OLANZAPINE,urinary retention,1,0,0.0,Senior,EU,0.11904761904761905,6,0,17,0,0,0,0,0,0,0,2,2025,10,31,4,0.08073634859349145,8.571428571428571,0.11904761904761905 +25984489,EU,EU,1,1.0,1,0,0,0,2025-10-31,34.0,801.0,Male,75.0,FENTANYL,toxicity to various agents,1,5,0.35714285714285715,Young,EU,0.35714285714285715,1,1,26,0,0,0,0,0,0,0,4,2025,10,31,4,0.08073634859349145,12.142857142857142,0.0 +25984612,US,US,1,2.0,0,0,0,0,2025-10-31,66.0,801.0,Female,75.0,BIVIGAM,urticaria,0,0,0.0,Senior,US,0.0,1,0,9,0,0,0,0,0,0,0,1,2025,10,31,4,0.08073634859349145,0.0,0.0 +26104154,US,US,1,2.0,0,0,0,0,2025-11-29,57.0,801.0,Female,75.0,DUPIXENT,accidental exposure to product,0,0,0.0,MidAge,US,0.015513897866839042,221,0,30,0,0,0,0,0,0,0,4,2025,11,29,5,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26104774,JP,JP,1,2.0,0,0,0,0,2025-11-30,37.0,801.0,Female,49.0,MYCOPHENOLATE MOFETIL,therapy partial responder,0,0,0.0,Adult,JP,0.10150375939849625,19,0,25,0,0,0,0,0,0,0,3,2025,11,30,6,0.08073634859349145,3.755639097744361,0.10150375939849625 +26104989,US,US,1,2.0,0,0,0,0,2025-11-30,47.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,treatment failure,0,0,0.0,Adult,US,0.10150375939849625,19,0,17,0,0,0,0,1,0,0,2,2025,11,30,6,0.08073634859349145,4.7706766917293235,0.0 +26105126,US,US,1,2.0,0,0,0,0,2025-12-01,4.0,801.0,Male,75.0,DUPIXENT,dry skin,0,0,0.0,Child,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2025,12,1,0,0.08073634859349145,0.06205559146735617,0.0 +26067778,US,US,1,1.0,0,0,0,0,2025-11-20,57.0,801.0,Female,75.0,SKYRIZI,renal cancer stage iv,1,0,0.0,MidAge,US,0.051587301587301584,36,0,21,0,0,0,1,0,0,0,4,2025,11,20,3,0.08073634859349145,2.9404761904761902,0.051587301587301584 +26067859,CA,CA,2,1.0,0,0,0,0,2025-11-20,57.0,801.0,Female,75.0,VEDOLIZUMAB,oral herpes,1,0,0.0,MidAge,CA,0.057692307692307696,26,0,11,0,0,0,0,0,0,0,2,2025,11,20,3,0.08936301793444651,3.2884615384615388,0.057692307692307696 +26068197,US,US,2,1.0,0,0,0,0,2025-11-20,57.0,801.0,Male,75.0,DUPILUMAB,pleurisy,1,0,0.0,MidAge,US,0.04285714285714286,5,0,8,0,0,0,0,0,0,0,1,2025,11,20,3,0.08936301793444651,2.442857142857143,0.0 +26068993,CA,CA,1,1.0,1,1,1,1,2025-11-20,43.0,801.0,Female,96.0,DICLOFENAC SODIUM,type 2 diabetes mellitus,1,14,1.0,Adult,CA,0.4047619047619048,3,1,24,0,0,0,0,0,0,0,4,2025,11,20,3,0.08073634859349145,17.40476190476191,0.4047619047619048 +26069507,EU,EU,1,1.0,0,1,0,0,2025-11-20,65.0,801.0,Male,65.0,AMLODIPINE,intentional overdose,1,4,0.2857142857142857,MidAge,EU,0.16964285714285715,8,1,20,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,11.026785714285715,0.0 +26070088,CA,CA,1,1.0,0,0,1,0,2025-11-20,88.0,801.0,Male,75.0,SEMAGLUTIDE,balance disorder,1,3,0.21428571428571427,Senior,CA,0.14285714285714285,3,1,16,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,12.571428571428571,0.0 +26070426,US,US,1,2.0,0,0,0,0,2025-11-20,57.0,801.0,Female,75.0,XEOMIN,blister,0,0,0.0,MidAge,US,0.08928571428571429,4,0,7,0,0,0,0,0,0,0,1,2025,11,20,3,0.08073634859349145,5.089285714285714,0.08928571428571429 +25985260,US,US,1,2.0,0,0,0,0,2025-10-31,57.0,801.0,Female,75.0,XDEMVY,therapeutic product effect variable,0,0,0.0,MidAge,US,0.0,1,0,35,0,0,0,0,0,0,0,4,2025,10,31,4,0.08073634859349145,0.0,0.0 +25985880,EU,EU,1,1.0,0,0,1,0,2025-11-01,32.0,801.0,Male,75.0,PRAZEPAM,coma,1,3,0.21428571428571427,Young,EU,0.21428571428571427,1,1,4,0,0,0,0,0,0,0,1,2025,11,1,5,0.08073634859349145,6.857142857142857,0.0 +25987176,EU,EU,1,1.0,0,0,0,0,2025-11-03,57.0,801.0,Female,75.0,IBUPROFEN,meningitis aseptic,1,0,0.0,MidAge,EU,0.11607142857142858,8,0,18,0,0,0,0,0,0,0,2,2025,11,3,0,0.08073634859349145,6.616071428571429,0.11607142857142858 +25988472,US,US,2,1.0,1,0,0,0,2025-11-03,75.0,801.0,Male,75.0,NUPLAZID,death,1,5,0.35714285714285715,Senior,US,0.09523809523809523,6,0,5,0,0,1,0,0,0,0,1,2025,11,3,0,0.08936301793444651,7.142857142857142,0.0 +26105665,US,US,2,1.0,1,0,0,0,2025-12-01,93.0,801.0,Female,75.0,VABYSMO,death,1,5,0.35714285714285715,Senior,US,0.35714285714285715,1,1,5,0,0,1,0,0,0,0,1,2025,12,1,0,0.08936301793444651,33.214285714285715,0.35714285714285715 +26106570,US,US,1,2.0,0,0,0,0,2025-12-01,28.0,801.0,Male,75.0,DUPIXENT,nasal congestion,0,0,0.0,Young,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,12,1,0,0.08073634859349145,0.43438914027149317,0.0 +26072356,EU,EU,2,1.0,0,0,1,0,2025-11-20,8.0,800.0,Male,75.0,DARATUMUMAB,infection,1,3,0.21428571428571427,Child,EU,0.14285714285714285,3,1,9,0,1,0,0,0,0,0,1,2025,11,20,3,0.08936301793444651,1.1428571428571428,0.0 +26072518,US,US,1,2.0,0,0,0,0,2025-11-20,68.0,801.0,Female,75.0,DUPIXENT,psoriasis,0,0,0.0,Senior,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,11,20,3,0.08073634859349145,1.0549450549450547,0.015513897866839042 +26072923,US,US,1,2.0,0,0,0,0,2025-11-21,57.0,801.0,Female,75.0,TRIAMCINOLONE ACETONIDE,product closure issue,0,0,0.0,MidAge,US,0.19047619047619047,3,1,21,0,0,0,0,0,0,0,3,2025,11,21,4,0.08073634859349145,10.857142857142856,0.19047619047619047 +26073814,CA,CA,1,1.0,0,0,1,0,2025-11-21,59.0,801.0,Female,75.0,IBUPROFEN,arthralgia,1,3,0.21428571428571427,MidAge,CA,0.11607142857142858,8,0,10,0,0,0,0,0,0,0,1,2025,11,21,4,0.08073634859349145,6.848214285714286,0.11607142857142858 +26075043,US,US,1,2.0,0,0,0,0,2025-11-21,77.0,801.0,Female,75.0,TYLENOL,drug ineffective,0,0,0.0,Senior,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,11,21,4,0.08073634859349145,0.0,0.0 +25988634,US,US,2,2.0,0,0,0,0,2025-11-03,14.0,801.0,Male,75.0,OMNITROPE,injection site pain,0,0,0.0,Child,US,0.0,5,0,19,1,0,0,0,0,0,0,3,2025,11,3,0,0.08936301793444651,0.0,0.0 +25990620,EU,EU,2,1.0,0,0,1,0,2025-11-03,77.0,801.0,Male,168.0,POMALIDOMIDE,deep vein thrombosis,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,20,0,0,0,0,0,0,0,3,2025,11,3,0,0.08936301793444651,16.5,0.0 +25991469,US,US,1,2.0,0,0,0,0,2025-11-03,57.0,801.0,Female,75.0,DUPIXENT,accidental exposure to product,0,0,0.0,MidAge,US,0.015513897866839042,221,0,30,0,0,0,0,0,0,0,4,2025,11,3,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25991645,US,US,1,2.0,0,0,0,0,2025-11-03,19.0,801.0,Female,75.0,DUPIXENT,off label use,0,0,0.0,Young,US,0.015513897866839042,221,0,13,0,0,0,0,0,0,0,3,2025,11,3,0,0.08073634859349145,0.2947640594699418,0.015513897866839042 +26110377,US,US,1,2.0,0,0,0,0,2025-12-02,59.0,801.0,Female,56.961,REMODULIN,dyspnoea,0,0,0.0,MidAge,US,0.0,4,0,8,0,0,0,0,0,0,0,1,2025,12,2,1,0.08073634859349145,0.0,0.0 +26110391,JP,JP,1,1.0,0,0,1,0,2025-12-02,57.0,801.0,Female,75.0,METHOTREXATE,hepatic cancer metastatic,1,3,0.21428571428571427,MidAge,JP,0.17346938775510204,7,1,25,0,0,0,1,0,0,0,3,2025,12,2,1,0.08073634859349145,9.887755102040817,0.17346938775510204 +26076082,ZA,ZA,2,1.0,0,0,0,0,2025-11-21,71.0,801.0,Female,75.0,BUDESONIDE\FORMOTEROL,fall,1,0,0.0,Senior,ZA,0.10714285714285714,2,0,4,0,0,0,0,0,0,0,1,2025,11,21,4,0.08936301793444651,7.607142857142857,0.10714285714285714 +26077579,JP,JP,1,1.0,1,0,0,0,2025-11-21,70.0,801.0,Male,75.0,TREPROSTINIL,interstitial lung disease,1,5,0.35714285714285715,Senior,JP,0.2857142857142857,2,1,25,0,0,0,0,0,0,0,3,2025,11,21,4,0.08073634859349145,20.0,0.0 +26078107,US,US,1,2.0,0,0,0,0,2025-11-22,57.0,801.0,Female,75.0,LENALIDOMIDE,fatigue,0,0,0.0,MidAge,US,0.15413533834586465,19,1,7,0,0,0,0,0,0,0,1,2025,11,22,5,0.08073634859349145,8.785714285714285,0.15413533834586465 +26078174,US,US,1,2.0,0,0,0,0,2025-11-22,57.0,801.0,Female,80.726,REMODULIN,contusion,0,0,0.0,MidAge,US,0.0,4,0,9,0,0,0,0,0,0,0,1,2025,11,22,5,0.08073634859349145,0.0,0.0 +26114265,EU,EU,1,1.0,0,0,0,0,2025-12-02,53.0,801.0,Male,75.0,DOCETAXEL,prostate cancer metastatic,1,0,0.0,MidAge,EU,0.061224489795918366,7,0,26,0,0,0,1,0,0,0,3,2025,12,2,1,0.08073634859349145,3.2448979591836733,0.0 +26114751,US,US,1,2.0,0,0,0,0,2025-12-02,37.0,801.0,Female,75.0,NEULASTA,device adhesion issue,0,0,0.0,Adult,US,0.0,5,0,21,0,0,0,0,0,0,0,3,2025,12,2,1,0.08073634859349145,0.0,0.0 +26116452,US,US,1,2.0,0,0,0,0,2025-12-03,57.0,801.0,Male,75.0,DUPIXENT,sleep disorder due to a general medical condition,0,0,0.0,MidAge,US,0.015513897866839042,221,0,49,0,0,0,0,0,0,0,8,2025,12,3,2,0.08073634859349145,0.8842921784098254,0.0 +26117033,US,US,1,2.0,0,0,0,0,2025-12-03,64.0,801.0,Male,75.0,LENALIDOMIDE,product dose omission in error,0,0,0.0,MidAge,US,0.15413533834586465,19,1,30,0,0,0,0,0,0,0,5,2025,12,3,2,0.08073634859349145,9.864661654135338,0.0 +26080012,US,US,1,2.0,0,0,0,0,2025-11-24,57.0,801.0,Male,75.0,DUPIXENT,nasal congestion,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,11,24,0,0.08073634859349145,0.8842921784098254,0.0 +26080928,US,US,1,2.0,0,0,0,0,2025-11-24,57.0,801.0,Female,75.0,DUPIXENT,nasopharyngitis,0,0,0.0,MidAge,US,0.015513897866839042,221,0,15,0,0,0,0,0,0,0,1,2025,11,24,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26080942,US,US,1,2.0,0,0,0,0,2025-11-24,82.0,801.0,Male,72.7,POMALYST,fatigue,0,0,0.0,Senior,US,0.11428571428571428,5,0,7,0,0,0,0,0,0,0,1,2025,11,24,0,0.08073634859349145,9.371428571428572,0.0 +26081495,US,Unknown,2,2.0,0,0,0,0,2025-11-24,57.0,801.0,Female,75.0,ACETAMINOPHEN,toxicity to various agents,0,0,0.0,MidAge,US,0.10267857142857142,16,0,26,0,0,0,0,0,0,0,4,2025,11,24,0,0.08936301793444651,5.852678571428571,0.10267857142857142 +26081576,GB,GB,3,1.0,0,0,0,0,2025-11-24,36.0,801.0,Female,75.0,GABAPENTIN,diarrhoea,1,0,0.0,Adult,GB,0.061224489795918366,7,0,9,0,0,0,0,0,0,0,1,2025,11,24,0,0.17857142857142855,2.204081632653061,0.061224489795918366 +26083048,JP,JP,1,1.0,0,0,0,1,2025-11-24,88.0,801.0,Male,46.9,CUBICIN,suspected drug-induced liver injury,1,2,0.14285714285714285,Senior,JP,0.14285714285714285,1,1,35,0,0,0,0,0,0,0,4,2025,11,24,0,0.08073634859349145,12.571428571428571,0.0 +25992846,US,US,1,2.0,0,0,0,0,2025-11-03,56.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,11,3,0,0.08073634859349145,0.8687782805429863,0.015513897866839042 +25994642,CA,CA,2,1.0,0,0,1,0,2025-11-04,58.0,801.0,Male,75.0,DUPILUMAB,pneumonia,1,3,0.21428571428571427,MidAge,CA,0.04285714285714286,5,0,9,0,0,0,0,0,1,0,1,2025,11,4,1,0.08936301793444651,2.4857142857142858,0.0 +25995128,EU,EU,1,1.0,0,0,0,0,2025-11-04,39.0,801.0,Female,75.0,RITUXIMAB,epstein-barr virus infection,1,0,0.0,Adult,EU,0.12406015037593986,19,0,28,0,1,0,0,0,0,0,3,2025,11,4,1,0.08073634859349145,4.838345864661655,0.12406015037593986 +25995896,US,US,1,1.0,0,0,0,0,2025-11-04,73.0,801.0,Female,79.95,KEVZARA,atrial fibrillation,1,0,0.0,Senior,US,0.14285714285714285,4,1,19,0,0,0,0,0,0,0,2,2025,11,4,1,0.08073634859349145,10.428571428571429,0.14285714285714285 +26117600,US,Unknown,1,1.0,0,0,0,0,2025-12-03,74.0,801.0,Male,99.79,ATORVASTATIN CALCIUM,vitreous floaters,1,0,0.0,Senior,US,0.0,1,0,17,0,0,0,0,0,0,0,2,2025,12,3,2,0.08073634859349145,0.0,0.0 +26118801,US,US,2,1.0,0,0,1,0,2025-12-03,66.0,801.0,Female,75.0,SKYRIZI,vertigo,1,3,0.21428571428571427,Senior,US,0.051587301587301584,36,0,7,0,0,0,0,0,0,0,1,2025,12,3,2,0.08936301793444651,3.4047619047619047,0.051587301587301584 +26119273,US,US,1,1.0,0,0,1,0,2025-12-04,63.0,801.0,Female,75.0,ACETAMINOPHEN,upper gastrointestinal haemorrhage,1,3,0.21428571428571427,MidAge,US,0.10267857142857142,16,0,34,0,0,0,0,0,0,0,3,2025,12,4,3,0.08073634859349145,6.46875,0.10267857142857142 +26119583,US,US,2,1.0,0,0,0,0,2025-12-04,75.0,801.0,Male,75.0,CREON,pancreatectomy,1,0,0.0,Senior,US,0.03296703296703297,13,0,14,0,0,0,0,0,0,0,1,2025,12,4,3,0.08936301793444651,2.4725274725274726,0.0 +26119798,US,US,1,2.0,0,0,0,0,2025-12-04,69.0,801.0,Male,75.0,DUPIXENT,dry eye,0,0,0.0,Senior,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,2,2025,12,4,3,0.08073634859349145,1.070458952811894,0.0 +26121393,US,Unknown,1,1.0,1,0,0,0,2025-12-03,82.0,801.0,Male,75.0,QUTENZA,death,1,5,0.35714285714285715,Senior,US,0.35714285714285715,1,1,5,0,0,1,0,0,0,0,1,2025,12,3,2,0.08073634859349145,29.285714285714285,0.0 +25998921,CA,CA,2,1.0,0,0,1,0,2025-11-05,82.0,801.0,Female,75.0,VEDOLIZUMAB,alcohol withdrawal syndrome,1,3,0.21428571428571427,Senior,CA,0.057692307692307696,26,0,27,0,0,0,0,0,0,0,3,2025,11,5,2,0.08936301793444651,4.730769230769231,0.057692307692307696 +25999421,US,US,1,1.0,0,0,1,0,2025-11-05,57.0,801.0,Female,75.0,LENALIDOMIDE,adverse event,1,3,0.21428571428571427,MidAge,US,0.15413533834586465,19,1,13,0,0,0,0,0,0,0,2,2025,11,5,2,0.08073634859349145,8.785714285714285,0.15413533834586465 +25999502,JP,JP,1,1.0,1,0,1,0,2025-11-05,8.0,800.0,Male,51.5,TRIAMCINOLONE ACETONIDE,ascites,1,8,0.5714285714285714,Child,JP,0.19047619047619047,3,1,7,0,0,0,0,0,0,0,1,2025,11,5,2,0.08073634859349145,1.5238095238095237,0.0 +25999960,US,US,1,1.0,0,0,0,0,2025-11-05,68.0,801.0,Female,75.0,MELOXICAM,renal impairment,1,0,0.0,Senior,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,11,5,2,0.08073634859349145,0.0,0.0 +26088137,US,US,1,1.0,0,0,0,0,2025-11-25,73.0,801.0,Female,87.09,KEYTRUDA,hallucination,1,0,0.0,Senior,US,0.11904761904761905,3,0,13,0,0,0,0,0,0,0,1,2025,11,25,1,0.08073634859349145,8.690476190476192,0.11904761904761905 +26095980,EU,EU,1,1.0,0,0,0,0,2025-11-27,57.0,801.0,Female,75.0,OMEPRAZOLE,spinal fracture,1,0,0.0,MidAge,EU,0.07142857142857142,3,0,15,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,4.071428571428571,0.07142857142857142 +26097142,US,US,1,2.0,0,0,0,0,2025-11-27,57.0,801.0,Female,75.0,DUPIXENT,rash,0,0,0.0,MidAge,US,0.015513897866839042,221,0,4,0,0,0,0,0,0,0,1,2025,11,27,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26097519,GB,GB,1,1.0,0,0,0,0,2025-11-27,57.0,801.0,Female,75.0,EPIRUBICIN,neuropathy peripheral,1,0,0.0,MidAge,GB,0.10714285714285714,2,0,21,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,6.107142857142857,0.10714285714285714 +26097843,CA,CA,2,1.0,0,0,1,0,2025-11-27,57.0,801.0,Female,75.0,OMALIZUMAB,asthenia,1,3,0.21428571428571427,MidAge,CA,0.21428571428571427,1,1,8,0,0,0,0,0,0,0,1,2025,11,27,3,0.08936301793444651,12.214285714285714,0.21428571428571427 +26098734,EU,EU,1,1.0,0,0,1,0,2025-11-27,94.0,801.0,Female,56.0,LANSOPRAZOLE,subacute cutaneous lupus erythematosus,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,38,0,0,0,0,0,0,0,4,2025,11,27,3,0.08073634859349145,20.142857142857142,0.21428571428571427 +26099139,US,Unknown,1,1.0,0,0,1,0,2025-11-28,42.0,801.0,Female,76.385,MYALEPT,illness,1,3,0.21428571428571427,Adult,US,0.21428571428571427,1,1,7,0,0,0,0,0,0,0,1,2025,11,28,4,0.08073634859349145,9.0,0.21428571428571427 +26099410,AU,AU,1,1.0,0,0,0,0,2025-11-28,52.0,801.0,Female,75.0,METHOTREXATE,aplastic anaemia,1,0,0.0,MidAge,AU,0.17346938775510204,7,1,16,0,0,0,0,0,0,0,2,2025,11,28,4,0.08073634859349145,9.020408163265307,0.17346938775510204 +26099625,EU,EU,1,1.0,0,0,1,0,2025-11-28,54.0,801.0,Male,88.0,CLOZAPINE,respiratory distress,1,3,0.21428571428571427,MidAge,EU,0.23214285714285715,4,1,20,0,0,0,0,0,0,0,2,2025,11,28,4,0.08073634859349145,12.535714285714286,0.0 +26135149,US,US,1,2.0,0,0,0,0,2025-12-09,57.0,801.0,Female,75.0,ESTRADIOL,product dose omission in error,0,0,0.0,MidAge,US,0.0,8,0,30,0,0,0,0,0,0,0,5,2025,12,9,1,0.08073634859349145,0.0,0.0 +26135730,IN,IN,1,1.0,0,0,0,0,2025-12-09,68.0,801.0,Female,75.0,PALBOCICLIB,cataract,1,0,0.0,Senior,IN,0.0,1,0,8,0,0,0,0,0,0,0,1,2025,12,9,1,0.08073634859349145,0.0,0.0 +26135945,ID,ID,1,1.0,0,0,1,0,2025-12-09,45.0,801.0,Female,75.0,METHYLPREDNISOLONE,pulmonary tuberculosis,1,3,0.21428571428571427,Adult,Other,0.14285714285714285,3,1,22,0,0,0,0,0,0,0,2,2025,12,9,1,0.08073634859349145,6.428571428571428,0.14285714285714285 +26012842,US,US,1,1.0,0,0,0,0,2025-11-07,52.0,801.0,Female,75.0,ORENCIA,adverse event,1,0,0.0,MidAge,US,0.10204081632653061,14,0,13,0,0,0,0,0,0,0,2,2025,11,7,4,0.08073634859349145,5.3061224489795915,0.10204081632653061 +26014448,US,US,1,2.0,0,0,0,0,2025-11-08,57.0,801.0,Female,75.0,ALBUTEROL SULFATE,wrong technique in device usage process,0,0,0.0,MidAge,US,0.0,8,0,39,0,0,0,0,0,0,0,6,2025,11,8,5,0.08073634859349145,0.0,0.0 +26014758,US,US,1,2.0,0,0,0,0,2025-11-08,49.0,801.0,Female,75.0,ZEPBOUND,drug ineffective,0,0,0.0,Adult,US,0.0,2,0,16,0,0,0,0,0,0,0,2,2025,11,8,5,0.08073634859349145,0.0,0.0 +26015582,US,US,1,2.0,0,0,0,0,2025-11-09,57.0,801.0,Male,109.31,DUPIXENT,injection site pain,0,0,0.0,MidAge,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,11,9,6,0.08073634859349145,0.8842921784098254,0.0 +26099759,CH,CH,1,1.0,0,0,0,0,2025-11-28,59.0,801.0,Male,75.0,OLANZAPINE,arrhythmia,1,0,0.0,MidAge,Other,0.11904761904761905,6,0,10,0,0,0,0,0,0,0,1,2025,11,28,4,0.08073634859349145,7.023809523809525,0.0 +26100181,EU,EU,1,1.0,0,0,0,0,2025-11-28,60.0,801.0,Male,75.0,BORTEZOMIB,plasma cell myeloma,1,0,0.0,MidAge,EU,0.0,3,0,19,0,0,0,0,0,0,0,3,2025,11,28,4,0.08073634859349145,0.0,0.0 +26102301,EU,EU,1,1.0,0,0,1,0,2025-11-28,63.0,801.0,Male,75.0,ATORVASTATIN,clostridium difficile colitis,1,3,0.21428571428571427,MidAge,EU,0.10714285714285714,2,0,29,0,0,0,0,0,0,0,3,2025,11,28,4,0.08073634859349145,6.75,0.0 +26140266,EU,EU,1,1.0,0,0,0,0,2025-12-10,66.0,801.0,Female,75.0,DOXYCYCLINE,symptom recurrence,1,0,0.0,Senior,EU,0.19642857142857142,4,1,18,0,0,0,0,0,0,0,2,2025,12,10,2,0.08073634859349145,12.964285714285714,0.19642857142857142 +26140738,US,US,1,2.0,0,0,0,0,2025-12-10,15.0,801.0,Male,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Child,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,12,10,2,0.08073634859349145,0.23270846800258563,0.0 +26104918,US,US,1,1.0,0,0,0,0,2025-11-30,69.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,lung transplant rejection,1,0,0.0,Senior,US,0.10150375939849625,19,0,25,0,0,0,0,0,0,0,3,2025,11,30,6,0.08073634859349145,7.003759398496241,0.0 +26104932,US,US,1,2.0,0,0,0,0,2025-11-30,50.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,treatment failure,0,0,0.0,Adult,US,0.10150375939849625,19,0,17,0,0,0,0,1,0,0,2,2025,11,30,6,0.08073634859349145,5.075187969924812,0.0 +26105175,GB,GB,1,1.0,0,0,1,0,2025-12-01,57.0,801.0,Female,75.0,BISOPROLOL,brash syndrome,1,3,0.21428571428571427,MidAge,GB,0.21428571428571427,1,1,14,0,0,0,0,0,0,0,2,2025,12,1,0,0.08073634859349145,12.214285714285714,0.21428571428571427 +26107429,EU,EU,1,1.0,0,1,0,0,2025-12-01,57.0,801.0,Male,75.0,MIDAZOLAM,loss of consciousness,1,4,0.2857142857142857,MidAge,EU,0.2857142857142857,1,1,21,0,0,0,0,0,0,0,3,2025,12,1,0,0.08073634859349145,16.285714285714285,0.0 +26107658,US,Unknown,1,1.0,1,0,0,0,2025-11-26,100.0,801.0,Female,75.0,VELTASSA,death,1,5,0.35714285714285715,Senior,US,0.2619047619047619,3,1,5,0,0,1,0,0,0,0,1,2025,11,26,2,0.08073634859349145,26.190476190476193,0.2619047619047619 +26016688,US,US,1,2.0,0,0,0,0,2025-11-10,50.0,801.0,Female,75.0,ORENCIA,arthralgia,0,0,0.0,Adult,US,0.10204081632653061,14,0,10,0,0,0,0,0,0,0,1,2025,11,10,0,0.08073634859349145,5.1020408163265305,0.10204081632653061 +26017593,CA,CA,1,1.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,INFLIXIMAB,blood pressure systolic increased,1,0,0.0,MidAge,CA,0.07142857142857142,9,0,33,0,0,0,0,0,0,0,4,2025,11,10,0,0.08073634859349145,4.071428571428571,0.07142857142857142 +26018808,US,US,2,1.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,SKYRIZI,breast cyst,1,0,0.0,MidAge,US,0.051587301587301584,36,0,11,0,0,0,0,0,0,0,2,2025,11,10,0,0.08936301793444651,2.9404761904761902,0.051587301587301584 +26020294,US,US,1,2.0,0,0,0,0,2025-11-10,76.0,801.0,Male,90.703,POLYETHYLENE GLYCOL 3350,incorrect product administration duration,0,0,0.0,Senior,US,0.0,4,0,41,0,0,0,0,0,0,0,4,2025,11,10,0,0.08073634859349145,0.0,0.0 +26021051,US,US,1,2.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,ACETAMINOPHEN,toxicity to various agents,0,0,0.0,MidAge,US,0.10267857142857142,16,0,26,0,0,0,0,0,0,0,4,2025,11,10,0,0.08073634859349145,5.852678571428571,0.10267857142857142 +26141953,EU,EU,1,1.0,0,0,0,0,2025-12-10,51.0,801.0,Male,75.0,OZEMPIC,optic ischaemic neuropathy,1,0,0.0,MidAge,EU,0.0,1,0,26,0,0,0,0,0,0,0,3,2025,12,10,2,0.08073634859349145,0.0,0.0 +26142277,US,US,1,1.0,0,0,0,0,2025-12-10,57.0,801.0,Female,75.0,SEMAGLUTIDE,arteriosclerosis coronary artery,1,0,0.0,MidAge,US,0.14285714285714285,3,1,32,0,0,0,0,0,0,0,3,2025,12,10,2,0.08073634859349145,8.142857142857142,0.14285714285714285 +26143168,US,US,1,1.0,0,0,0,0,2025-12-11,60.0,801.0,Female,75.0,SPRAVATO,dizziness,1,0,0.0,MidAge,US,0.026785714285714284,8,0,9,0,0,0,0,0,0,0,1,2025,12,11,3,0.08073634859349145,1.607142857142857,0.026785714285714284 +26143506,JP,JP,1,1.0,0,0,0,0,2025-12-11,9.0,800.0,Male,75.0,CABOMETYX,immune-mediated hepatic disorder,1,0,0.0,Child,JP,0.10714285714285714,4,0,32,0,0,0,0,0,0,0,3,2025,12,11,3,0.08073634859349145,0.9642857142857142,0.0 +26145894,US,US,1,2.0,0,0,0,0,2025-12-11,2.0,801.0,Male,75.0,DUPIXENT,rash macular,0,0,0.0,Child,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,2,2025,12,11,3,0.08073634859349145,0.031027795733678084,0.0 +26145908,US,US,1,2.0,0,0,0,0,2025-12-11,74.0,801.0,Female,75.0,DUPIXENT,asthma,0,0,0.0,Senior,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,12,11,3,0.08073634859349145,1.1480284421460891,0.015513897866839042 +26145975,US,US,1,2.0,0,0,0,0,2025-12-11,17.0,801.0,Male,75.0,DUPIXENT,keratitis,0,0,0.0,Child,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,12,11,3,0.08073634859349145,0.2637362637362637,0.0 +26022548,EU,EU,1,1.0,0,0,0,0,2025-11-10,61.0,801.0,Male,75.0,VENLAFAXINE,drug withdrawal syndrome,1,0,0.0,MidAge,EU,0.25,2,1,24,0,0,0,0,0,0,0,3,2025,11,10,0,0.08073634859349145,15.25,0.0 +26022791,EU,EU,1,1.0,0,0,1,0,2025-11-10,44.0,801.0,Female,75.0,MOUNJARO,blood iron decreased,1,3,0.21428571428571427,Adult,EU,0.2142857142857143,4,1,20,0,0,0,0,0,0,0,3,2025,11,10,0,0.08073634859349145,9.428571428571429,0.2142857142857143 +26023143,JP,JP,1,1.0,0,0,0,0,2025-11-10,57.0,801.0,Male,75.0,MOMELOTINIB,renal impairment,1,0,0.0,MidAge,JP,0.0,3,0,16,0,0,0,0,0,0,0,2,2025,11,10,0,0.08073634859349145,0.0,0.0 +26023763,AU,AU,1,1.0,0,0,0,0,2025-11-11,86.0,801.0,Female,75.0,PREDNISOLONE SODIUM PHOSPHATE,staphylococcal bacteraemia,1,0,0.0,Senior,AU,0.0,2,0,26,0,0,0,0,0,0,0,2,2025,11,11,1,0.08073634859349145,0.0,0.0 +26024478,US,US,1,2.0,0,0,0,0,2025-11-11,57.0,801.0,Female,75.0,ACETAMINOPHEN,toxicity to various agents,0,0,0.0,MidAge,US,0.10267857142857142,16,0,26,0,0,0,0,0,0,0,4,2025,11,11,1,0.08073634859349145,5.852678571428571,0.10267857142857142 +26024788,US,US,1,2.0,0,0,0,0,2025-11-11,57.0,801.0,Female,75.0,TRULICITY,blood glucose abnormal,0,0,0.0,MidAge,US,0.04285714285714286,5,0,22,0,0,0,0,0,0,0,3,2025,11,11,1,0.08073634859349145,2.442857142857143,0.04285714285714286 +26025369,US,US,1,1.0,0,0,1,0,2025-11-11,51.0,801.0,Female,75.0,ACCRUFER,pneumonia,1,3,0.21428571428571427,MidAge,US,0.07142857142857142,3,0,9,0,0,0,0,0,1,0,1,2025,11,11,1,0.08073634859349145,3.642857142857143,0.07142857142857142 +26108172,US,US,1,1.0,0,0,1,0,2025-12-01,30.0,801.0,Female,90.0,TAZVERIK,hospitalisation,1,3,0.21428571428571427,Young,US,0.21428571428571427,1,1,15,0,0,0,0,0,0,0,1,2025,12,1,0,0.08073634859349145,6.428571428571428,0.21428571428571427 +26109630,US,US,1,2.0,0,0,0,0,2025-12-01,70.0,801.0,Female,75.0,CYTOMEL,hypersensitivity,0,0,0.0,Senior,US,0.0,1,0,16,0,0,0,0,0,0,0,1,2025,12,1,0,0.08073634859349145,0.0,0.0 +26109993,US,US,1,2.0,0,0,0,0,2025-12-01,57.0,801.0,Male,75.0,DUPIXENT,pruritus,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,12,1,0,0.08073634859349145,0.8842921784098254,0.0 +26110588,US,US,1,2.0,0,0,0,0,2025-12-02,57.0,801.0,Female,75.0,LITHIUM,mobility decreased,0,0,0.0,MidAge,US,0.0,1,0,18,0,0,0,0,0,0,0,2,2025,12,2,1,0.08073634859349145,0.0,0.0 +26111602,US,US,1,1.0,0,0,1,0,2025-12-02,55.0,801.0,Female,75.0,ETOPOSIDE,respiratory failure,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,2,1,19,0,0,0,0,1,0,0,2,2025,12,2,1,0.08073634859349145,11.785714285714285,0.21428571428571427 +26146947,US,US,1,1.0,0,1,0,0,2025-12-11,48.0,801.0,Male,75.0,DAPTOMYCIN,drug resistance,1,4,0.2857142857142857,Adult,US,0.16666666666666666,3,1,15,0,0,0,0,0,0,0,2,2025,12,11,3,0.08073634859349145,8.0,0.0 +26147218,GB,GB,1,1.0,0,1,1,1,2025-12-11,33.0,801.0,Male,83.0,MOUNJARO,palpitations,1,9,0.6428571428571429,Young,GB,0.2142857142857143,4,1,12,0,0,0,0,0,0,0,1,2025,12,11,3,0.08073634859349145,7.071428571428572,0.0 +26147757,CA,CA,1,1.0,1,0,0,0,2025-12-11,58.0,801.0,Female,75.0,FLUTICASONE PROPIONATE,thrombocytopenia,1,5,0.35714285714285715,MidAge,CA,0.35714285714285715,1,1,16,0,0,0,0,0,0,0,1,2025,12,11,3,0.08073634859349145,20.714285714285715,0.35714285714285715 +26027947,US,US,2,1.0,0,0,0,0,2025-11-11,87.0,801.0,Female,75.0,NUPLAZID,hallucination,1,0,0.0,Senior,US,0.09523809523809523,6,0,13,0,0,0,0,0,0,0,1,2025,11,11,1,0.08936301793444651,8.285714285714285,0.09523809523809523 +26028285,US,US,1,1.0,0,0,0,0,2025-11-11,0.0,801.0,Female,3.4,ABILIFY MAINTENA,tremor neonatal,1,0,0.0,,US,0.0,1,0,15,0,0,0,0,0,0,0,2,2025,11,11,1,0.08073634859349145,0.0,0.0 +26028919,US,US,1,2.0,0,0,0,0,2025-11-12,15.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Child,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,11,12,2,0.08073634859349145,0.23270846800258563,0.015513897866839042 +26030877,US,US,1,2.0,0,0,0,0,2025-11-12,57.0,801.0,Female,163.26,BESREMI,nausea,0,0,0.0,MidAge,US,0.0,1,0,6,0,0,0,0,0,0,0,1,2025,11,12,2,0.08073634859349145,0.0,0.0 +26112331,US,Unknown,1,1.0,0,0,1,0,2025-12-01,57.0,801.0,Female,75.0,AMBRISENTAN,sinus disorder,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,14,0,0,0,0,0,0,0,2,2025,12,1,0,0.08073634859349145,12.214285714285714,0.21428571428571427 +26112775,US,US,1,2.0,0,0,0,0,2025-12-02,57.0,801.0,Male,75.0,DUPIXENT,poor quality product administered,0,0,0.0,MidAge,US,0.015513897866839042,221,0,33,0,0,0,0,0,0,0,4,2025,12,2,1,0.08073634859349145,0.8842921784098254,0.0 +26113451,EU,EU,1,1.0,0,0,1,0,2025-12-02,53.0,801.0,Male,77.0,EVEROLIMUS,abdominal pain,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,1,1,14,1,0,0,0,0,0,0,2,2025,12,2,1,0.08073634859349145,11.357142857142856,0.0 +26114557,JP,JP,1,1.0,0,0,0,0,2025-12-02,57.0,801.0,Male,75.0,MOMELOTINIB,leukaemia,1,0,0.0,MidAge,JP,0.0,3,0,9,0,0,0,0,0,0,0,1,2025,12,2,1,0.08073634859349145,0.0,0.0 +26150391,US,US,1,2.0,0,0,0,0,2025-12-12,47.0,801.0,Male,75.0,DUPIXENT,hyperkeratosis,0,0,0.0,Adult,US,0.015513897866839042,221,0,14,0,0,0,0,0,0,0,1,2025,12,12,4,0.08073634859349145,0.729153199741435,0.0 +26150553,US,Unknown,1,2.0,0,0,0,0,2025-12-12,59.0,801.0,Female,84.354,JAKAFI,product dose omission issue,0,0,0.0,MidAge,US,0.0,3,0,27,0,0,0,0,0,0,0,4,2025,12,12,4,0.08073634859349145,0.0,0.0 +26034279,US,US,1,2.0,0,0,0,0,2025-11-12,57.0,801.0,Female,75.0,ACETAMINOPHEN,toxicity to various agents,0,0,0.0,MidAge,US,0.10267857142857142,16,0,26,0,0,0,0,0,0,0,4,2025,11,12,2,0.08073634859349145,5.852678571428571,0.10267857142857142 +26034589,US,US,1,1.0,0,0,0,0,2025-11-12,65.0,801.0,Female,75.0,DUPIXENT,thyroid cancer,1,0,0.0,MidAge,US,0.015513897866839042,221,0,14,0,0,0,1,0,0,0,2,2025,11,12,2,0.08073634859349145,1.0084033613445378,0.015513897866839042 +26036251,US,US,1,1.0,0,0,1,0,2025-11-12,57.0,801.0,Female,75.0,HYDROCORTISONE,adverse event,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,13,0,0,0,0,0,0,0,2,2025,11,12,2,0.08073634859349145,12.214285714285714,0.21428571428571427 +26117244,US,US,1,2.0,0,0,0,0,2025-12-03,77.0,801.0,Female,75.0,DUPIXENT,night sweats,0,0,0.0,Senior,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,2,2025,12,3,2,0.08073634859349145,1.1945701357466063,0.015513897866839042 +26119040,US,US,1,2.0,0,0,0,0,2025-12-04,33.0,801.0,Female,75.0,CLINDAMYCIN PHOSPHATE,drug ineffective,0,0,0.0,Young,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,12,4,3,0.08073634859349145,0.0,0.0 +26156223,US,US,1,2.0,0,0,0,0,2025-12-15,57.0,801.0,Female,75.0,ACOLTREMON,abnormal sensation in eye,0,0,0.0,MidAge,US,0.0,1,0,25,0,0,0,0,0,0,0,4,2025,12,15,0,0.08073634859349145,0.0,0.0 +26156667,CA,CA,1,1.0,0,0,0,0,2025-12-15,57.0,801.0,Female,75.0,DULOXETINE HYDROCHLORIDE,pulmonary malformation,1,0,0.0,MidAge,CA,0.0,1,0,22,0,0,0,0,0,0,0,2,2025,12,15,0,0.08073634859349145,0.0,0.0 +26157639,US,Unknown,1,2.0,0,0,0,0,2025-12-12,79.0,801.0,Male,75.0,LENALIDOMIDE,rash maculo-papular,0,0,0.0,Senior,US,0.15413533834586465,19,1,19,0,0,0,0,0,0,0,2,2025,12,12,4,0.08073634859349145,12.176691729323307,0.0 +26057650,CA,CA,3,1.0,1,1,1,1,2025-11-18,57.0,801.0,Female,96.0,APREMILAST,arthropathy,1,14,1.0,MidAge,CA,1.0,1,1,11,0,0,0,0,0,0,0,1,2025,11,18,1,0.17857142857142855,57.0,1.0 +26058231,US,US,1,2.0,0,0,0,0,2025-11-18,67.0,801.0,Male,81.6,CLONAZEPAM,drug ineffective,0,0,0.0,Senior,US,0.07142857142857142,3,0,16,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,4.785714285714286,0.0 +26059566,US,Unknown,1,1.0,0,0,1,0,2025-11-18,76.0,801.0,Male,220.0,DARATUMUMAB\HYALURONIDASE-FIHJ,speech disorder,1,3,0.21428571428571427,Senior,US,0.21428571428571427,2,1,15,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,16.285714285714285,0.0 +26060122,US,US,1,2.0,0,0,0,0,2025-11-18,52.0,801.0,Female,75.0,XELJANZ XR,conjunctivitis,0,0,0.0,MidAge,US,0.0,9,0,14,0,0,0,0,0,0,0,1,2025,11,18,1,0.08073634859349145,0.0,0.0 +26060661,US,US,1,2.0,0,0,0,0,2025-11-18,87.0,801.0,Male,75.0,DUPIXENT,incorrect dose administered,0,0,0.0,Senior,US,0.015513897866839042,221,0,27,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,1.3497091144149966,0.0 +26158139,CA,US,2,1.0,0,0,0,0,2025-12-15,63.0,801.0,Male,75.0,VEDOLIZUMAB,hypoaesthesia,1,0,0.0,MidAge,CA,0.057692307692307696,26,0,13,0,0,0,0,0,0,0,1,2025,12,15,0,0.08936301793444651,3.634615384615385,0.0 +26158706,US,US,1,2.0,0,0,0,0,2025-12-15,57.0,801.0,Female,103.0,DUPIXENT,feeling abnormal,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,12,15,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26159125,US,US,1,2.0,0,0,0,0,2025-12-16,57.0,801.0,Male,75.0,DUPIXENT,confusional state,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,12,16,1,0.08073634859349145,0.8842921784098254,0.0 +26160125,US,US,1,2.0,0,0,0,0,2025-12-16,57.0,801.0,Female,75.0,DOCIVYX,off label use,0,0,0.0,MidAge,US,0.0,1,0,13,0,0,0,0,0,0,0,3,2025,12,16,1,0.08073634859349145,0.0,0.0 +26160206,BR,BR,2,1.0,0,0,0,0,2025-12-16,57.0,801.0,Female,75.0,RISPERIDONE,suicide attempt,1,0,0.0,MidAge,BR,0.125,4,1,15,0,0,0,0,0,0,0,2,2025,12,16,1,0.08936301793444651,7.125,0.125 +26160907,CN,CN,1,1.0,0,0,0,0,2025-12-16,23.0,801.0,Female,70.0,DACTINOMYCIN,urticaria,1,0,0.0,Young,CN,0.0,1,0,9,0,0,0,0,0,0,0,1,2025,12,16,1,0.08073634859349145,0.0,0.0 +26120970,EU,EU,1,1.0,0,0,1,0,2025-12-04,24.0,801.0,Male,97.0,OLANZAPINE PAMOATE,pulmonary embolism,1,3,0.21428571428571427,Young,EU,0.21428571428571427,1,1,18,0,0,0,0,0,0,0,2,2025,12,4,3,0.08073634859349145,5.142857142857142,0.0 +26122132,CN,CN,1,1.0,0,0,1,0,2025-12-04,74.0,801.0,Male,60.0,EPIRUBICIN,chemical cystitis,1,3,0.21428571428571427,Senior,CN,0.10714285714285714,2,0,17,0,0,0,0,0,0,0,2,2025,12,4,3,0.08073634859349145,7.928571428571428,0.0 +26122819,US,US,1,2.0,0,0,0,0,2025-12-04,61.0,801.0,Female,89.36,REVLIMID,blister,0,0,0.0,MidAge,US,0.05357142857142857,4,0,7,0,0,0,0,0,0,0,1,2025,12,4,3,0.08073634859349145,3.267857142857143,0.05357142857142857 +26123548,EU,EU,1,1.0,0,1,1,0,2025-12-04,58.0,801.0,Female,75.0,ARIPIPRAZOLE,coma,1,7,0.5,MidAge,EU,0.5,1,1,4,0,0,0,0,0,0,0,1,2025,12,4,3,0.08073634859349145,29.0,0.5 +26123805,US,US,1,1.0,0,0,0,0,2025-12-05,57.0,801.0,Female,75.0,NOURIANZ,hallucination,1,0,0.0,MidAge,US,0.0,1,0,13,0,0,0,0,0,0,0,1,2025,12,5,4,0.08073634859349145,0.0,0.0 +26037452,US,US,1,2.0,0,0,0,0,2025-11-12,57.0,801.0,Male,75.0,MOUNJARO,injection site mass,0,0,0.0,MidAge,US,0.2142857142857143,4,1,19,0,0,0,0,0,0,0,3,2025,11,12,2,0.08073634859349145,12.214285714285715,0.0 +26038639,US,US,1,2.0,0,0,0,0,2025-11-13,57.0,801.0,Female,75.0,ACETAMINOPHEN,toxicity to various agents,0,0,0.0,MidAge,US,0.10267857142857142,16,0,26,0,0,0,0,0,0,0,4,2025,11,13,3,0.08073634859349145,5.852678571428571,0.10267857142857142 +26039720,US,US,1,2.0,0,0,0,0,2025-11-13,57.0,801.0,Female,75.0,ACETAMINOPHEN,toxicity to various agents,0,0,0.0,MidAge,US,0.10267857142857142,16,0,26,0,0,0,0,0,0,0,4,2025,11,13,3,0.08073634859349145,5.852678571428571,0.10267857142857142 +26040625,US,Unknown,1,2.0,0,0,0,0,2025-11-12,60.0,801.0,Male,75.0,LENALIDOMIDE,petechiae,0,0,0.0,MidAge,US,0.15413533834586465,19,1,9,0,0,0,0,0,0,0,1,2025,11,12,2,0.08073634859349145,9.248120300751879,0.0 +26040854,EU,EU,1,1.0,0,0,0,0,2025-11-13,47.0,801.0,Male,75.0,MORPHINE,drug dependence,1,0,0.0,Adult,EU,0.0,1,0,15,0,0,0,0,0,0,0,2,2025,11,13,3,0.08073634859349145,0.0,0.0 +26041192,US,US,1,2.0,0,0,0,0,2025-11-13,57.0,801.0,Female,75.0,ACETAMINOPHEN,toxicity to various agents,0,0,0.0,MidAge,US,0.10267857142857142,16,0,26,0,0,0,0,0,0,0,4,2025,11,13,3,0.08073634859349145,5.852678571428571,0.10267857142857142 +26041273,US,US,1,2.0,0,0,0,0,2025-11-13,69.0,801.0,Male,75.0,CLARITIN,illness,0,0,0.0,Senior,US,0.0,1,0,7,0,0,0,0,0,0,0,1,2025,11,13,3,0.08073634859349145,0.0,0.0 +26064144,GB,GB,1,1.0,0,0,0,0,2025-11-19,54.0,801.0,Female,88.0,ROSUVASTATIN,joint swelling,1,0,0.0,MidAge,GB,0.0,2,0,14,0,0,0,0,0,0,0,2,2025,11,19,2,0.08073634859349145,0.0,0.0 +26064926,GB,GB,1,1.0,0,0,0,0,2025-11-19,33.0,801.0,Female,75.0,VARENICLINE TARTRATE,muscle spasms,1,0,0.0,Young,GB,0.0,1,0,13,0,0,0,0,0,0,0,2,2025,11,19,2,0.08073634859349145,0.0,0.0 +26064993,EU,EU,3,1.0,0,0,0,0,2025-11-19,57.0,801.0,Female,75.0,PITAVASTATIN CALCIUM,mobility decreased,1,0,0.0,MidAge,EU,0.0,1,0,18,0,0,0,0,0,0,0,2,2025,11,19,2,0.17857142857142855,0.0,0.0 +26124897,US,US,1,2.0,0,0,0,0,2025-12-05,57.0,801.0,Male,75.0,DUPIXENT,eye swelling,0,0,0.0,MidAge,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,2,2025,12,5,4,0.08073634859349145,0.8842921784098254,0.0 +26125344,EU,EU,1,1.0,0,0,1,0,2025-12-05,63.0,801.0,Male,75.0,CAPECITABINE,infusion site infection,1,3,0.21428571428571427,MidAge,EU,0.10714285714285714,2,0,23,0,1,0,0,0,0,0,3,2025,12,5,4,0.08073634859349145,6.75,0.0 +26125425,US,US,1,2.0,0,0,0,0,2025-12-05,68.0,801.0,Female,50.91,DUPIXENT,injection site pain,0,0,0.0,Senior,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,12,5,4,0.08073634859349145,1.0549450549450547,0.015513897866839042 +26126369,US,US,1,2.0,0,0,0,0,2025-12-05,32.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,12,5,4,0.08073634859349145,0.49644473173884934,0.015513897866839042 +26127436,US,US,1,2.0,0,0,0,0,2025-12-05,57.0,801.0,Male,75.0,SKYRIZI,injection site papule,0,0,0.0,MidAge,US,0.051587301587301584,36,0,21,0,0,0,0,0,0,0,3,2025,12,5,4,0.08073634859349145,2.9404761904761902,0.0 +26128031,US,US,1,2.0,0,0,0,0,2025-12-06,35.0,801.0,Female,75.0,DUPIXENT,asthma,0,0,0.0,Young,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,12,6,5,0.08073634859349145,0.5429864253393665,0.015513897866839042 +26162284,EU,EU,1,1.0,1,0,0,0,2025-12-16,75.0,801.0,Male,89.5,VALSARTAN,cardiogenic shock,1,5,0.35714285714285715,Senior,EU,0.35714285714285715,1,1,17,0,0,0,0,0,0,0,2,2025,12,16,1,0.08073634859349145,26.785714285714285,0.0 +26164147,US,US,1,2.0,0,0,0,0,2025-12-16,28.0,801.0,Female,75.0,DUPIXENT,maternal exposure during pregnancy,0,0,0.0,Young,US,0.015513897866839042,221,0,34,0,0,0,0,0,0,0,4,2025,12,16,1,0.08073634859349145,0.43438914027149317,0.015513897866839042 +26164633,US,US,1,2.0,0,0,0,0,2025-12-16,85.0,801.0,Male,75.0,DUPIXENT,accidental exposure to product,0,0,0.0,Senior,US,0.015513897866839042,221,0,30,0,0,0,0,0,0,0,4,2025,12,16,1,0.08073634859349145,1.3186813186813187,0.0 +26165658,EU,EU,1,1.0,0,0,1,0,2025-12-16,57.0,801.0,Male,75.0,ALPRAZOLAM,drug use disorder,1,3,0.21428571428571427,MidAge,EU,0.14285714285714285,3,1,17,0,0,0,0,0,0,0,3,2025,12,16,1,0.08073634859349145,8.142857142857142,0.0 +26165834,GB,GB,1,1.0,0,0,0,0,2025-12-16,56.0,801.0,Female,68.0,IBUPROFEN,angioedema,1,0,0.0,MidAge,GB,0.11607142857142858,8,0,10,0,0,0,0,0,0,0,1,2025,12,16,1,0.08073634859349145,6.5,0.11607142857142858 +26065655,US,US,1,1.0,0,0,1,1,2025-11-19,32.0,801.0,Female,75.0,SUMATRIPTAN,susac^s syndrome,1,5,0.35714285714285715,Young,US,0.35714285714285715,1,1,16,0,0,0,0,0,0,0,2,2025,11,19,2,0.08073634859349145,11.428571428571429,0.35714285714285715 +26066331,US,US,1,2.0,0,0,0,0,2025-11-19,59.0,801.0,Female,95.0,LINZESS,discomfort,0,0,0.0,MidAge,US,0.0,1,0,10,0,0,0,0,0,0,0,1,2025,11,19,2,0.08073634859349145,0.0,0.0 +26067451,CA,CA,2,1.0,0,0,1,0,2025-11-20,43.0,801.0,Female,85.0,BELIMUMAB,loss of consciousness,1,3,0.21428571428571427,Adult,CA,0.21428571428571427,1,1,21,0,0,0,0,0,0,0,3,2025,11,20,3,0.08936301793444651,9.214285714285714,0.21428571428571427 +26067585,US,US,1,1.0,0,0,1,0,2025-11-20,9.0,801.0,Female,75.0,DUPIXENT,suicidal ideation,1,3,0.21428571428571427,Child,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,0.13962508080155137,0.015513897866839042 +26069057,PH,PH,1,1.0,0,1,1,0,2025-11-20,48.0,801.0,Female,92.0,XIGDUO XR,septic shock,1,7,0.5,Adult,Other,0.5,1,1,12,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,24.0,0.5 +26128341,US,US,1,2.0,0,0,0,0,2025-12-07,66.0,801.0,Female,75.0,DUPIXENT,dry skin,0,0,0.0,Senior,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2025,12,7,6,0.08073634859349145,1.0239172592113768,0.015513897866839042 +26128475,US,US,2,1.0,0,0,0,0,2025-12-07,62.0,801.0,Female,75.0,CREON,pancreatic carcinoma,1,0,0.0,MidAge,US,0.03296703296703297,13,0,20,0,0,0,0,0,0,0,2,2025,12,7,6,0.08936301793444651,2.043956043956044,0.03296703296703297 +26131514,EU,EU,1,1.0,0,0,0,0,2025-12-08,72.0,801.0,Female,75.0,OXALIPLATIN,anaphylactic reaction,1,0,0.0,Senior,EU,0.08571428571428572,5,0,21,0,0,0,0,0,0,0,2,2025,12,8,0,0.08073634859349145,6.171428571428572,0.08571428571428572 +26131581,US,US,1,2.0,0,0,0,0,2025-12-08,57.0,801.0,Male,85.36,DUPIXENT,neurodermatitis,0,0,0.0,MidAge,US,0.015513897866839042,221,0,15,0,0,0,0,0,0,0,1,2025,12,8,0,0.08073634859349145,0.8842921784098254,0.0 +26069772,GB,GB,1,1.0,0,0,0,0,2025-11-20,57.0,801.0,Female,75.0,RISPERIDONE,tearfulness,1,0,0.0,MidAge,GB,0.125,4,1,11,0,0,0,0,0,0,0,1,2025,11,20,3,0.08073634859349145,7.125,0.125 +26071649,CH,CH,1,1.0,0,0,1,0,2025-11-20,75.0,801.0,Male,91.0,ZOLPIDEM TARTRATE,chest pain,1,3,0.21428571428571427,Senior,Other,0.21428571428571427,1,1,10,1,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,16.07142857142857,0.0 +26071825,US,US,2,1.0,0,0,0,0,2025-11-20,62.0,801.0,Male,75.0,SKYRIZI,skin cancer,1,0,0.0,MidAge,US,0.051587301587301584,36,0,11,0,0,0,1,0,0,0,2,2025,11,20,3,0.08936301793444651,3.198412698412698,0.0 +26072635,US,US,1,2.0,0,0,0,0,2025-11-20,63.0,801.0,Female,83.007,VYALEV,catheter site cellulitis,0,0,0.0,MidAge,US,0.0,1,0,24,0,0,0,0,0,0,0,3,2025,11,20,3,0.08073634859349145,0.0,0.0 +26166091,US,US,1,2.0,0,0,0,0,2025-12-16,57.0,801.0,Female,75.0,SKYRIZI,feeling abnormal,0,0,0.0,MidAge,US,0.051587301587301584,36,0,16,0,0,0,0,0,0,0,2,2025,12,16,1,0.08073634859349145,2.9404761904761902,0.051587301587301584 +26166387,US,US,1,2.0,0,0,0,0,2025-12-17,55.0,801.0,Female,75.0,DUPIXENT,sinusitis,0,0,0.0,MidAge,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,12,17,2,0.08073634859349145,0.8532643826761473,0.015513897866839042 +26166873,EU,EU,1,1.0,0,0,1,0,2025-12-17,74.0,801.0,Female,75.0,OBINUTUZUMAB,septic shock,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,12,0,0,0,0,0,0,0,2,2025,12,17,2,0.08073634859349145,15.857142857142856,0.21428571428571427 +26168426,US,US,1,1.0,0,0,0,0,2025-12-17,57.0,801.0,Female,75.0,XOLAIR,underdose,1,0,0.0,MidAge,US,0.14285714285714285,4,1,9,0,0,0,0,0,0,0,1,2025,12,17,2,0.08073634859349145,8.142857142857142,0.14285714285714285 +26168440,CA,CA,2,1.0,0,0,1,0,2025-12-17,57.0,801.0,Female,75.0,TEZEPELUMAB,musculoskeletal discomfort,1,3,0.21428571428571427,MidAge,CA,0.10714285714285714,2,0,26,0,0,0,0,0,0,0,2,2025,12,17,2,0.08936301793444651,6.107142857142857,0.10714285714285714 +26169007,EU,EU,1,1.0,0,0,0,0,2025-12-17,73.0,801.0,Male,56.0,OXALIPLATIN,hyperkalaemia,1,0,0.0,Senior,EU,0.08571428571428572,5,0,13,0,0,0,0,0,0,0,1,2025,12,17,2,0.08073634859349145,6.257142857142857,0.0 +26169951,US,US,2,1.0,0,0,0,0,2025-12-17,57.0,801.0,Female,75.0,BRINSUPRI,angina pectoris,1,0,0.0,MidAge,US,0.0,1,0,15,0,0,0,0,0,0,0,2,2025,12,17,2,0.08936301793444651,0.0,0.0 +26134740,US,US,1,1.0,0,0,0,0,2025-12-09,17.0,801.0,Male,75.0,DUPIXENT,loss of consciousness,1,0,0.0,Child,US,0.015513897866839042,221,0,21,0,0,0,0,0,0,0,3,2025,12,9,1,0.08073634859349145,0.2637362637362637,0.0 +26135455,US,US,1,2.0,0,0,0,0,2025-12-09,57.0,801.0,Female,75.0,ESTRADIOL,product adhesion issue,0,0,0.0,MidAge,US,0.0,8,0,22,0,0,0,0,0,0,0,3,2025,12,9,1,0.08073634859349145,0.0,0.0 +26135927,BR,BR,1,1.0,0,0,0,0,2025-12-09,57.0,801.0,Male,75.0,CABOMETYX,intestinal obstruction,1,0,0.0,MidAge,BR,0.10714285714285714,4,0,22,0,0,0,0,0,0,0,2,2025,12,9,1,0.08073634859349145,6.107142857142857,0.0 +26136184,US,US,1,2.0,0,0,0,0,2025-12-09,57.0,801.0,Male,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,12,9,1,0.08073634859349145,0.8842921784098254,0.0 +26136346,US,US,1,2.0,0,0,0,0,2025-12-09,57.0,801.0,Female,75.0,PLUVICTO,general physical health deterioration,0,0,0.0,MidAge,US,0.0,8,0,37,0,0,0,0,0,0,0,4,2025,12,9,1,0.08073634859349145,0.0,0.0 +26074646,US,Unknown,1,1.0,0,0,0,1,2025-11-20,86.0,801.0,Female,45.36,DESVENLAFAXINE SUCCINATE,vision blurred,1,2,0.14285714285714285,Senior,US,0.14285714285714285,1,1,14,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,12.285714285714285,0.14285714285714285 +26076185,AU,AU,1,1.0,0,0,0,1,2025-11-21,57.0,801.0,Female,75.0,WEGOVY,blindness,1,2,0.14285714285714285,MidAge,AU,0.14285714285714285,4,1,9,0,0,0,0,0,0,0,1,2025,11,21,4,0.08073634859349145,8.142857142857142,0.14285714285714285 +26076752,EU,EU,1,1.0,1,0,1,1,2025-11-21,64.0,801.0,Male,75.0,LENALIDOMIDE,plasma cell myeloma,1,10,0.7142857142857143,MidAge,EU,0.15413533834586465,19,1,19,0,0,0,0,0,0,0,3,2025,11,21,4,0.08073634859349145,9.864661654135338,0.0 +26137413,US,US,1,2.0,0,0,0,0,2025-12-09,57.0,801.0,Female,75.0,COMBIGAN,product temperature excursion issue,0,0,0.0,MidAge,US,0.0,1,0,35,0,0,0,0,0,0,0,4,2025,12,9,1,0.08073634859349145,0.0,0.0 +26138290,US,US,1,2.0,0,0,0,0,2025-12-10,70.0,801.0,Female,55.338,FINASTERIDE,off label use,0,0,0.0,Senior,US,0.0,2,0,13,0,0,0,0,0,0,0,3,2025,12,10,2,0.08073634859349145,0.0,0.0 +26140248,US,US,2,1.0,0,0,0,0,2025-12-10,29.0,801.0,Male,75.0,PREDNISONE,drug ineffective,1,0,0.0,Young,US,0.1607142857142857,8,1,16,0,0,0,0,0,0,0,2,2025,12,10,2,0.08936301793444651,4.660714285714286,0.0 +26140600,US,US,1,2.0,0,0,0,0,2025-12-10,66.0,801.0,Female,75.0,DUPIXENT,product use in unapproved indication,0,0,0.0,Senior,US,0.015513897866839042,221,0,36,0,0,0,0,0,0,0,5,2025,12,10,2,0.08073634859349145,1.0239172592113768,0.015513897866839042 +26077953,US,US,1,2.0,0,0,0,0,2025-11-22,65.0,801.0,Male,90.7,ONAPGO,balance disorder,0,0,0.0,MidAge,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,11,22,5,0.08073634859349145,0.0,0.0 +26079830,US,US,1,2.0,0,0,0,0,2025-11-23,49.0,801.0,Female,75.0,SKYRIZI,covid-19,0,0,0.0,Adult,US,0.051587301587301584,36,0,8,0,0,0,0,0,0,0,1,2025,11,23,6,0.08073634859349145,2.5277777777777777,0.051587301587301584 +26080182,US,US,1,2.0,0,0,0,0,2025-11-24,57.0,801.0,Male,75.0,DUPIXENT,anxiety,0,0,0.0,MidAge,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,1,2025,11,24,0,0.08073634859349145,0.8842921784098254,0.0 +26171208,US,US,1,2.0,0,0,0,0,2025-12-17,57.0,801.0,Female,83.4,VIZAMYL,back pain,0,0,0.0,MidAge,US,0.0,1,0,9,1,0,0,0,0,0,0,2,2025,12,17,2,0.08073634859349145,0.0,0.0 +26171370,CA,CA,1,1.0,0,1,1,1,2025-12-17,43.0,801.0,Female,70.0,ORENCIA,drug ineffective,1,9,0.6428571428571429,Adult,CA,0.10204081632653061,14,0,16,0,0,0,0,0,0,0,2,2025,12,17,2,0.08073634859349145,4.387755102040816,0.10204081632653061 +26172652,CN,CN,1,1.0,0,0,0,0,2025-12-18,86.0,801.0,Male,43.0,ENOXAPARIN SODIUM,mucosal haemorrhage,1,0,0.0,Senior,CN,0.0,2,0,19,0,0,0,0,0,0,0,2,2025,12,18,3,0.08073634859349145,0.0,0.0 +26185746,US,Unknown,1,2.0,0,0,0,0,2025-12-19,67.0,801.0,Male,121.5,VANCOMYCIN,arthralgia,0,0,0.0,Senior,US,0.0,1,0,10,0,0,0,0,0,0,0,1,2025,12,19,4,0.08073634859349145,0.0,0.0 +26216688,CA,CA,2,1.0,0,0,0,0,2025-12-31,57.0,801.0,Female,75.0,OCREVUS,infusion related reaction,1,0,0.0,MidAge,CA,0.0,3,0,25,0,0,0,0,0,0,0,3,2025,12,31,2,0.08936301793444651,0.0,0.0 +26150409,US,Unknown,1,1.0,0,0,0,0,2025-12-12,72.0,801.0,Male,75.0,BORTEZOMIB,hepatitis acute,1,0,0.0,Senior,US,0.0,3,0,15,0,0,0,0,0,0,0,2,2025,12,12,4,0.08073634859349145,0.0,0.0 +26150557,US,US,1,1.0,0,0,1,0,2025-12-12,28.0,801.0,Female,75.0,DOXYCYCLINE,acute generalised exanthematous pustulosis,1,3,0.21428571428571427,Young,US,0.19642857142857142,4,1,42,0,0,0,0,0,0,0,4,2025,12,12,4,0.08073634859349145,5.5,0.19642857142857142 +26150881,US,Unknown,2,1.0,0,0,1,0,2025-12-12,57.0,801.0,Female,75.0,ACETAMINOPHEN,overdose,1,3,0.21428571428571427,MidAge,US,0.10267857142857142,16,0,8,0,0,0,0,0,0,0,1,2025,12,12,4,0.08936301793444651,5.852678571428571,0.10267857142857142 +26151286,US,US,1,1.0,0,0,0,0,2025-12-12,25.0,801.0,Female,75.0,PREDNISONE,renal failure,1,0,0.0,Young,US,0.1607142857142857,8,1,13,0,0,0,0,1,0,0,2,2025,12,12,4,0.08073634859349145,4.017857142857142,0.1607142857142857 +26153297,US,US,1,2.0,0,0,0,0,2025-12-14,57.0,801.0,Female,75.0,VALIUM,drug hypersensitivity,0,0,0.0,MidAge,US,0.0,1,0,21,0,0,0,0,0,0,0,2,2025,12,14,6,0.08073634859349145,0.0,0.0 +26198702,GB,GB,1,1.0,0,0,1,0,2025-12-25,36.0,801.0,Male,75.0,PREGABALIN,priapism,1,3,0.21428571428571427,Adult,GB,0.10714285714285714,6,0,8,0,0,0,0,0,0,0,1,2025,12,25,3,0.08073634859349145,3.8571428571428568,0.0 +26205143,US,US,1,2.0,0,0,0,0,2025-12-28,43.0,801.0,Female,75.0,DUPIXENT,hiatus hernia,0,0,0.0,Adult,US,0.015513897866839042,221,0,13,0,0,0,0,0,0,0,2,2025,12,28,6,0.08073634859349145,0.6670976082740788,0.015513897866839042 +26205615,CN,CN,1,1.0,0,0,0,0,2025-12-28,73.0,801.0,Male,87.5,TISLELIZUMAB,myelosuppression,1,0,0.0,Senior,CN,0.0,3,0,16,0,0,0,0,0,0,0,1,2025,12,28,6,0.08073634859349145,0.0,0.0 +26205682,US,US,1,2.0,0,0,0,0,2025-12-29,57.0,801.0,Female,61.36,DUPIXENT,drug ineffective,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,12,29,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26155794,CN,CN,1,2.0,0,0,0,0,2025-12-15,57.0,801.0,Female,75.0,TACROLIMUS,upper respiratory tract infection,0,0,0.0,MidAge,CN,0.09183673469387754,7,0,33,0,1,0,0,0,0,0,4,2025,12,15,0,0.08073634859349145,5.23469387755102,0.09183673469387754 +26157266,US,US,1,1.0,1,0,0,0,2025-12-15,57.0,801.0,Male,75.0,PREDNISONE,death,1,5,0.35714285714285715,MidAge,US,0.1607142857142857,8,1,5,0,0,1,0,0,0,0,1,2025,12,15,0,0.08073634859349145,9.160714285714285,0.0 +26158076,US,US,1,1.0,0,0,0,0,2025-12-15,18.0,801.0,Female,75.0,ADVIL,nausea,1,0,0.0,Child,US,0.0,1,0,6,0,0,0,0,0,0,0,1,2025,12,15,0,0.08073634859349145,0.0,0.0 +26158791,US,US,1,2.0,0,0,0,0,2025-12-15,57.0,801.0,Male,75.0,PLUVICTO,drug effect less than expected,0,0,0.0,MidAge,US,0.0,8,0,30,0,0,0,0,0,0,0,5,2025,12,15,0,0.08073634859349145,0.0,0.0 +26159048,US,US,1,1.0,0,0,1,0,2025-12-16,77.0,801.0,Female,59.42,POMALYST,pneumonia,1,3,0.21428571428571427,Senior,US,0.11428571428571428,5,0,9,0,0,0,0,0,1,0,1,2025,12,16,1,0.08073634859349145,8.799999999999999,0.11428571428571428 +26160992,CA,CA,1,1.0,0,0,0,1,2025-12-16,71.0,801.0,Female,75.0,DEXAMETHASONE,cough,1,2,0.14285714285714285,Senior,CA,0.1857142857142857,5,1,5,0,0,0,0,0,0,0,1,2025,12,16,1,0.08073634859349145,13.185714285714285,0.1857142857142857 +26042999,US,US,1,2.0,0,0,0,0,2025-11-13,28.0,801.0,Female,75.0,CORTICOTROPIN,drug ineffective,0,0,0.0,Young,US,0.0,3,0,16,0,0,0,0,0,0,0,2,2025,11,13,3,0.08073634859349145,0.0,0.0 +26043608,CA,CA,1,1.0,0,0,0,0,2025-11-13,41.0,801.0,Male,75.0,TETRABENAZINE,tardive dyskinesia,1,0,0.0,Adult,CA,0.0,1,0,18,0,0,0,0,0,0,0,2,2025,11,13,3,0.08073634859349145,0.0,0.0 +26044580,US,US,2,2.0,0,0,0,0,2025-11-14,70.0,801.0,Female,46.719,SKYRIZI,insomnia,0,0,0.0,Senior,US,0.051587301587301584,36,0,8,0,0,0,0,0,0,0,1,2025,11,14,4,0.08936301793444651,3.6111111111111107,0.051587301587301584 +26045147,RU,RU,1,1.0,0,0,0,0,2025-11-14,57.0,801.0,Female,75.0,NUVARING,pregnancy with contraceptive device,1,0,0.0,MidAge,Other,0.0,1,0,35,0,0,0,0,0,0,0,4,2025,11,14,4,0.08073634859349145,0.0,0.0 +26207059,CA,Unknown,1,1.0,1,1,1,1,2025-12-29,40.0,801.0,Female,96.0,CIMZIA,abdominal discomfort,1,14,1.0,Adult,CA,0.5,2,1,20,0,0,0,0,0,0,0,2,2025,12,29,0,0.08073634859349145,20.0,0.5 +26207369,GB,GB,1,1.0,0,0,0,0,2025-12-29,65.0,801.0,Female,63.0,METRONIDAZOLE,faeces discoloured,1,0,0.0,MidAge,GB,0.14285714285714285,2,1,18,0,0,0,0,0,0,0,2,2025,12,29,0,0.08073634859349145,9.285714285714285,0.14285714285714285 +26207950,US,US,1,1.0,0,0,0,0,2025-12-29,57.0,801.0,Female,75.0,ORENCIA,omphalitis,1,0,0.0,MidAge,US,0.10204081632653061,14,0,10,0,0,0,0,0,0,0,1,2025,12,29,0,0.08073634859349145,5.816326530612245,0.10204081632653061 +26208140,US,Unknown,1,1.0,1,0,1,0,2025-12-29,60.0,801.0,Male,75.0,DOXYCYCLINE,aspergillus infection,1,8,0.5714285714285714,MidAge,US,0.19642857142857142,4,1,21,0,1,0,0,0,0,0,2,2025,12,29,0,0.08073634859349145,11.785714285714285,0.0 +26208612,US,US,1,2.0,0,0,0,0,2025-12-29,57.0,801.0,Female,75.0,TIOCONAZOLE,drug ineffective,0,0,0.0,MidAge,US,0.0,2,0,16,0,0,0,0,0,0,0,2,2025,12,29,0,0.08073634859349145,0.0,0.0 +26208665,US,US,1,2.0,0,0,0,0,2025-12-29,57.0,801.0,Female,75.0,TIOCONAZOLE,application site papules,0,0,0.0,MidAge,US,0.0,2,0,24,0,0,0,0,0,0,0,3,2025,12,29,0,0.08073634859349145,0.0,0.0 +26208975,US,Unknown,1,1.0,0,0,0,0,2025-12-26,67.0,801.0,Female,75.0,COSENTYX,condition aggravated,1,0,0.0,Senior,US,0.05714285714285714,10,0,20,0,0,0,0,0,0,0,2,2025,12,26,4,0.08073634859349145,3.8285714285714283,0.05714285714285714 +26209556,US,US,1,1.0,0,1,1,0,2025-12-29,4.0,802.0,Male,75.0,NITROGLYCERIN,drug ineffective,1,7,0.5,Child,US,0.5,1,1,16,0,0,0,0,0,0,0,2,2025,12,29,0,0.08073634859349145,2.0,0.0 +26209732,CN,CN,1,1.0,0,0,1,0,2025-12-29,29.0,801.0,Male,76.0,CYTARABINE,myelosuppression,1,3,0.21428571428571427,Young,CN,0.21428571428571427,1,1,16,0,0,0,0,0,0,0,1,2025,12,29,0,0.08073634859349145,6.2142857142857135,0.0 +26210260,US,US,2,1.0,0,0,0,0,2025-12-29,67.0,801.0,Male,75.0,CILTACABTAGENE AUTOLEUCEL,rectal cancer,1,0,0.0,Senior,US,0.17857142857142858,2,1,13,0,0,0,1,0,0,0,2,2025,12,29,0,0.08936301793444651,11.964285714285715,0.0 +18629916,US,US,1,1.0,0,0,0,0,2020-12-17,58.0,801.0,Female,71.61,XELJANZ XR,knee arthroplasty,1,0,0.0,MidAge,US,0.0,9,0,17,0,0,0,0,0,0,0,2,2020,12,17,3,0.08073634859349145,0.0,0.0 +18711888,JP,JP,1,1.0,0,1,1,0,2021-01-07,79.0,801.0,Male,59.0,METHYLPREDNISOLONE SODIUM SUCCINATE,immunosuppression,1,7,0.5,Senior,JP,0.5,1,1,17,0,0,0,0,0,0,0,1,2021,1,7,3,0.08073634859349145,39.5,0.0 +19072609,CA,CA,1,1.0,0,0,0,0,2021-03-30,10.0,802.0,Female,75.0,VALPROIC ACID,drug resistance,1,0,0.0,Child,CA,0.0,1,0,15,0,0,0,0,0,0,0,2,2021,3,30,1,0.08073634859349145,0.0,0.0 +19084798,US,US,2,1.0,0,0,0,0,2021-04-01,69.0,801.0,Male,75.0,VEDOLIZUMAB,seizure,1,0,0.0,Senior,US,0.057692307692307696,26,0,7,0,0,0,0,0,0,0,1,2021,4,1,3,0.08936301793444651,3.980769230769231,0.0 +19266523,US,US,1,1.0,0,0,1,0,2021-05-18,34.0,801.0,Male,75.0,NOVOLOG MIX 70/30,device failure,1,3,0.21428571428571427,Young,US,0.21428571428571427,1,1,14,0,0,0,0,1,0,0,2,2021,5,18,1,0.08073634859349145,7.285714285714286,0.0 +19565561,EU,EU,1,1.0,1,0,0,0,2021-07-14,70.0,801.0,Female,75.0,YERVOY,bone marrow failure,1,5,0.35714285714285715,Senior,EU,0.35714285714285715,4,1,19,0,0,0,0,1,0,0,3,2021,7,14,2,0.08073634859349145,25.0,0.35714285714285715 +19716626,CO,CO,2,1.0,0,0,1,0,2021-08-18,21.0,801.0,Female,47.0,VEDOLIZUMAB,intestinal stenosis,1,3,0.21428571428571427,Young,Other,0.057692307692307696,26,0,19,0,0,0,0,0,0,0,2,2021,8,18,2,0.08936301793444651,1.2115384615384617,0.057692307692307696 +19806455,JP,JP,1,1.0,0,0,1,0,2021-09-09,12.0,802.0,Male,8.3,SABRIL,retinal degeneration,1,3,0.21428571428571427,Child,JP,0.21428571428571427,1,1,20,0,0,0,0,0,0,0,2,2021,9,9,3,0.08073634859349145,2.571428571428571,0.0 +19929547,CA,CA,1,1.0,0,0,1,0,2021-10-07,58.0,801.0,Female,75.0,REVATIO,hospitalisation,1,3,0.21428571428571427,MidAge,CA,0.21428571428571427,1,1,15,0,0,0,0,0,0,0,1,2021,10,7,3,0.08073634859349145,12.428571428571427,0.21428571428571427 +20054843,CA,CA,2,1.0,0,0,0,0,2021-11-10,57.0,801.0,Female,52.0,REMICADE,colitis ulcerative,1,0,0.0,MidAge,CA,0.0,3,0,18,0,0,0,0,0,0,0,2,2021,11,10,2,0.08936301793444651,0.0,0.0 +20057826,US,US,2,1.0,0,0,1,0,2021-11-11,15.0,801.0,Female,99.79,LANADELUMAB,loss of consciousness,1,3,0.21428571428571427,Child,US,0.12857142857142856,5,1,21,0,0,0,0,0,0,0,3,2021,11,11,3,0.08936301793444651,1.9285714285714284,0.12857142857142856 +20108870,EU,EU,2,1.0,0,0,1,0,2021-11-24,6.0,801.0,Male,75.0,TEDUGLUTIDE,gastrointestinal anastomotic stenosis,1,3,0.21428571428571427,Child,EU,0.14285714285714285,3,1,37,0,0,0,0,0,0,0,3,2021,11,24,2,0.08936301793444651,0.8571428571428571,0.0 +20311546,US,US,1,2.0,0,0,0,0,2022-01-08,56.0,801.0,Female,75.0,OTEZLA,therapy non-responder,0,0,0.0,MidAge,US,0.0,4,0,21,0,0,0,0,0,0,0,2,2022,1,8,5,0.08073634859349145,0.0,0.0 +20701332,US,US,2,1.0,0,0,1,0,2022-04-12,57.0,801.0,Female,61.0,HUMAN IMMUNOGLOBULIN G,white blood cell count increased,1,3,0.21428571428571427,MidAge,US,0.10714285714285714,8,0,32,0,0,0,0,0,0,0,5,2022,4,12,1,0.08936301793444651,6.107142857142857,0.10714285714285714 +20715870,JP,JP,2,1.0,1,0,1,0,2022-04-15,76.0,801.0,Male,75.0,LEUPROLIDE ACETATE,pneumonia,1,8,0.5714285714285714,Senior,JP,0.38095238095238093,3,1,9,0,0,0,0,0,1,0,1,2022,4,15,4,0.08936301793444651,28.95238095238095,0.0 +26212271,US,US,1,2.0,0,0,0,0,2025-12-30,34.0,801.0,Female,75.0,DUPIXENT,pruritus,0,0,0.0,Young,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,12,30,1,0.08073634859349145,0.5274725274725274,0.015513897866839042 +26212419,US,US,1,2.0,0,0,0,0,2025-12-30,67.0,801.0,Male,77.11,DUPIXENT,accidental exposure to product,0,0,0.0,Senior,US,0.015513897866839042,221,0,30,0,0,0,0,0,0,0,4,2025,12,30,1,0.08073634859349145,1.0394311570782158,0.0 +26212972,US,US,1,1.0,0,0,1,0,2025-12-30,53.0,801.0,Female,75.0,CEFADROXIL,drug ineffective,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,16,0,0,0,0,0,0,0,2,2025,12,30,1,0.08073634859349145,11.357142857142856,0.21428571428571427 +26213687,US,US,1,1.0,0,1,0,0,2025-12-30,67.0,801.0,Female,75.0,METHOTREXATE SODIUM,histoplasmosis disseminated,1,4,0.2857142857142857,Senior,US,0.125,4,1,27,0,0,0,0,0,0,0,2,2025,12,30,1,0.08073634859349145,8.375,0.125 +26214053,US,US,1,2.0,0,0,0,0,2025-12-30,57.0,801.0,Male,75.0,SKYRIZI,product storage error,0,0,0.0,MidAge,US,0.051587301587301584,36,0,21,0,0,0,0,0,0,0,3,2025,12,30,1,0.08073634859349145,2.9404761904761902,0.0 +26215335,US,US,1,2.0,0,0,0,0,2025-12-30,73.0,801.0,Male,75.0,DUPIXENT,rash pruritic,0,0,0.0,Senior,US,0.015513897866839042,221,0,13,0,0,0,0,0,0,0,2,2025,12,30,1,0.08073634859349145,1.1325145442792501,0.0 +21035577,US,US,2,1.0,0,0,0,0,2022-07-01,57.0,801.0,Female,75.0,XYWAV,surgery,1,0,0.0,MidAge,US,0.04285714285714286,5,0,7,0,0,0,0,0,0,0,1,2022,7,1,4,0.08936301793444651,2.442857142857143,0.04285714285714286 +21079021,US,US,1,1.0,0,0,0,0,2022-07-13,57.0,801.0,Female,75.0,ELMIRON,pigmentary maculopathy,1,0,0.0,MidAge,US,0.0,1,0,22,0,0,0,0,0,0,0,2,2022,7,13,2,0.08073634859349145,0.0,0.0 +21134601,EU,EU,1,1.0,0,1,0,0,2022-07-27,3.0,801.0,Female,75.0,LEVETIRACETAM,apnoea,1,4,0.2857142857142857,Child,EU,0.05714285714285714,5,0,6,0,0,0,0,0,0,0,1,2022,7,27,2,0.08073634859349145,0.17142857142857143,0.05714285714285714 +21237605,JP,JP,2,1.0,0,0,0,0,2022-08-22,74.0,801.0,Male,75.0,ATEZOLIZUMAB,ascites,1,0,0.0,Senior,JP,0.0,1,0,7,0,0,0,0,0,0,0,1,2022,8,22,0,0.08936301793444651,0.0,0.0 +26216860,US,US,1,1.0,0,0,0,0,2025-12-31,57.0,801.0,Female,75.0,SPRAVATO,product administration error,1,0,0.0,MidAge,US,0.026785714285714284,8,0,28,0,0,0,0,0,0,0,3,2025,12,31,2,0.08073634859349145,1.5267857142857142,0.026785714285714284 +26164299,US,US,1,2.0,0,0,0,0,2025-12-16,64.0,801.0,Female,75.0,DUPIXENT,sleep disorder due to a general medical condition,0,0,0.0,MidAge,US,0.015513897866839042,221,0,49,0,0,0,0,0,0,0,8,2025,12,16,1,0.08073634859349145,0.9928894634776987,0.015513897866839042 +26164475,US,US,1,2.0,0,0,0,0,2025-12-16,57.0,801.0,Female,81.82,DUPIXENT,incorrect dose administered,0,0,0.0,MidAge,US,0.015513897866839042,221,0,27,0,0,0,0,0,0,0,3,2025,12,16,1,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26165003,US,US,1,2.0,0,0,0,0,2025-12-16,57.0,801.0,Female,75.0,NURTEC ODT,nausea,0,0,0.0,MidAge,US,0.0,2,0,6,0,0,0,0,0,0,0,1,2025,12,16,1,0.08073634859349145,0.0,0.0 +26165285,GB,GB,1,1.0,0,0,1,0,2025-12-16,57.0,801.0,Male,75.0,CLOZARIL,white blood cell count increased,1,3,0.21428571428571427,MidAge,GB,0.10714285714285714,4,0,32,0,0,0,0,0,0,0,5,2025,12,16,1,0.08073634859349145,6.107142857142857,0.0 +26165528,US,US,1,1.0,0,0,1,0,2025-12-16,63.0,801.0,Female,75.0,DUPIXENT,blood glucose decreased,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,23,0,0,0,0,0,0,0,3,2025,12,16,1,0.08073634859349145,0.9773755656108597,0.015513897866839042 +26165986,US,US,1,2.0,0,0,0,0,2025-12-16,68.0,801.0,Female,56.699,PAROXETINE,discomfort,0,0,0.0,Senior,US,0.0,2,0,10,0,0,0,0,0,0,0,1,2025,12,16,1,0.08073634859349145,0.0,0.0 +26166271,US,US,1,2.0,0,0,0,0,2025-12-16,57.0,801.0,Female,75.0,DUPIXENT,eyelid margin crusting,0,0,0.0,MidAge,US,0.015513897866839042,221,0,22,0,0,0,0,0,0,0,3,2025,12,16,1,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26168039,US,US,1,2.0,0,0,0,0,2025-12-17,57.0,801.0,Female,75.0,EXPAREL,labelled drug-drug interaction medication error,0,0,0.0,MidAge,US,0.0,1,0,47,0,0,0,0,0,0,0,5,2025,12,17,2,0.08073634859349145,0.0,0.0 +26168349,CN,CN,1,1.0,0,0,0,0,2025-12-17,38.0,801.0,Female,75.0,METHYLPREDNISOLONE,therapy partial responder,1,0,0.0,Adult,CN,0.14285714285714285,3,1,25,0,0,0,0,0,0,0,3,2025,12,17,2,0.08073634859349145,5.428571428571428,0.14285714285714285 +26168497,US,US,1,1.0,0,0,1,0,2025-12-17,57.0,801.0,Female,75.0,LAMOTRIGINE,nausea,1,3,0.21428571428571427,MidAge,US,0.10714285714285714,2,0,6,0,0,0,0,0,0,0,1,2025,12,17,2,0.08073634859349145,6.107142857142857,0.10714285714285714 +21326800,EU,EU,1,1.0,1,1,1,0,2022-09-13,32.0,801.0,Male,75.0,CITALOPRAM,acute hepatic failure,1,12,0.8571428571428571,Young,EU,0.42857142857142855,2,1,21,0,0,0,0,1,0,0,3,2022,9,13,1,0.08073634859349145,13.714285714285714,0.0 +21477418,DZ,DZ,2,1.0,0,0,0,0,2022-10-19,34.0,801.0,Female,75.0,REBIF,abortion spontaneous,1,0,0.0,Young,Other,0.0,1,0,20,0,0,0,0,0,0,0,2,2022,10,19,2,0.08936301793444651,0.0,0.0 +21482588,US,US,2,1.0,0,0,1,0,2022-10-20,46.0,801.0,Female,75.0,LANADELUMAB,covid-19,1,3,0.21428571428571427,Adult,US,0.12857142857142856,5,1,8,0,0,0,0,0,0,0,1,2022,10,20,3,0.08936301793444651,5.914285714285714,0.12857142857142856 +21627444,US,US,2,1.0,0,0,0,0,2022-11-22,58.0,801.0,Female,79.0,LANADELUMAB,vascular device infection,1,0,0.0,MidAge,US,0.12857142857142856,5,1,25,0,1,0,0,0,0,0,3,2022,11,22,1,0.08936301793444651,7.457142857142856,0.12857142857142856 +22523709,EU,EU,1,1.0,0,0,0,0,2023-06-06,32.0,801.0,Female,75.0,DUPILUMAB,myopericarditis,1,0,0.0,Young,EU,0.04285714285714286,5,0,15,0,0,0,0,0,0,0,1,2023,6,6,1,0.08073634859349145,1.3714285714285714,0.04285714285714286 +22760014,CA,CA,2,1.0,0,0,0,0,2023-07-28,57.0,801.0,Female,75.0,RITUXIMAB,productive cough,1,0,0.0,MidAge,CA,0.12406015037593986,19,0,16,0,0,0,0,0,0,0,2,2023,7,28,4,0.08936301793444651,7.071428571428572,0.12406015037593986 +26169335,EU,EU,1,1.0,0,0,0,0,2025-12-17,20.0,801.0,Male,75.0,CLOZAPINE,visual impairment,1,0,0.0,Young,EU,0.23214285714285715,4,1,17,0,0,0,0,0,0,0,2,2025,12,17,2,0.08073634859349145,4.642857142857143,0.0 +26170201,CA,CA,1,1.0,0,0,1,0,2025-12-17,57.0,801.0,Female,75.0,ORENCIA,arthritis,1,3,0.21428571428571427,MidAge,CA,0.10204081632653061,14,0,9,0,0,0,0,0,0,0,1,2025,12,17,2,0.08073634859349145,5.816326530612245,0.10204081632653061 +26170955,US,US,1,2.0,0,0,0,0,2025-12-17,66.0,801.0,Male,75.0,DUPIXENT,inappropriate schedule of product administration,0,0,0.0,Senior,US,0.015513897866839042,221,0,48,0,0,0,0,0,0,0,5,2025,12,17,2,0.08073634859349145,1.0239172592113768,0.0 +26171307,US,US,1,1.0,0,1,1,0,2025-12-17,75.0,801.0,Female,75.0,CARBOPLATIN,hyperglycaemia,1,7,0.5,Senior,US,0.12244897959183673,7,0,14,0,0,0,0,0,0,0,1,2025,12,17,2,0.08073634859349145,9.183673469387754,0.12244897959183673 +26171684,US,US,1,1.0,0,0,0,0,2025-12-17,57.0,801.0,Female,75.0,HUMALOG,thyroid cancer,1,0,0.0,MidAge,US,0.05357142857142857,4,0,14,0,0,0,1,0,0,0,2,2025,12,17,2,0.08073634859349145,3.0535714285714284,0.05357142857142857 +26171899,AU,AU,1,1.0,0,0,0,0,2025-12-17,57.0,801.0,Female,75.0,PREDNISOLONE SODIUM PHOSPHATE,adrenocortical insufficiency acute,1,0,0.0,MidAge,AU,0.0,2,0,34,0,0,0,0,0,0,0,3,2025,12,17,2,0.08073634859349145,0.0,0.0 +26172360,EU,EU,1,1.0,0,0,1,0,2025-12-18,55.0,801.0,Male,75.0,PEMETREXED,immune-mediated encephalitis,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,3,1,28,0,0,0,0,0,0,0,2,2025,12,18,3,0.08073634859349145,11.785714285714285,0.0 +26172427,JP,JP,1,1.0,0,0,0,0,2025-12-18,85.0,801.0,Male,75.0,MOMELOTINIB,interstitial lung disease,1,0,0.0,Senior,JP,0.0,3,0,25,0,0,0,0,0,0,0,3,2025,12,18,3,0.08073634859349145,0.0,0.0 +22864705,CA,CA,1,1.0,0,0,0,0,2023-08-25,58.0,801.0,Female,75.0,ABACAVIR SULFATE\LAMIVUDINE,asthma,1,0,0.0,MidAge,CA,0.0,1,0,6,0,0,0,0,0,0,0,1,2023,8,25,4,0.08073634859349145,0.0,0.0 +22869618,CA,CA,1,1.0,0,1,1,0,2023-08-26,26.0,801.0,Female,75.0,ONDANSETRON,febrile neutropenia,1,7,0.5,Young,CA,0.5,1,1,19,0,0,0,0,0,0,0,2,2023,8,26,5,0.08073634859349145,13.0,0.5 +22915601,CA,CA,2,1.0,0,0,0,0,2023-09-07,70.0,801.0,Female,75.0,VEDOLIZUMAB,haematochezia,1,0,0.0,Senior,CA,0.057692307692307696,26,0,13,0,0,0,0,0,0,0,1,2023,9,7,3,0.08936301793444651,4.038461538461538,0.057692307692307696 +22927008,EU,EU,1,1.0,0,0,1,0,2023-09-11,61.0,801.0,Male,85.0,GLIMEPIRIDE,necrotising oesophagitis,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,1,1,24,0,0,0,0,0,0,0,2,2023,9,11,0,0.08073634859349145,13.071428571428571,0.0 +23021253,US,US,2,1.0,0,0,1,0,2023-10-03,56.0,801.0,Female,112.0,ICATIBANT,atrial fibrillation,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,19,0,0,0,0,0,0,0,2,2023,10,3,1,0.08936301793444651,12.0,0.21428571428571427 +23067004,US,US,1,1.0,0,0,1,0,2023-10-16,63.0,801.0,Male,79.0,DUPIXENT,vertigo,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,1,2023,10,16,0,0.08073634859349145,0.9773755656108597,0.0 +23133086,CA,CA,2,1.0,0,0,0,0,2023-11-01,68.0,801.0,Male,75.0,VEDOLIZUMAB,colitis ulcerative,1,0,0.0,Senior,CA,0.057692307692307696,26,0,18,0,0,0,0,0,0,0,2,2023,11,1,2,0.08936301793444651,3.9230769230769234,0.0 +23248120,US,US,2,1.0,0,0,0,0,2023-11-30,61.0,801.0,Female,72.575,RINVOQ,femur fracture,1,0,0.0,MidAge,US,0.0,3,0,14,0,0,0,0,0,0,0,2,2023,11,30,3,0.08936301793444651,0.0,0.0 +23251346,US,US,1,1.0,0,0,0,0,2023-12-01,57.0,801.0,Male,75.0,ILUVIEN,glaucoma,1,0,0.0,MidAge,US,0.0,3,0,8,0,0,0,0,0,0,0,1,2023,12,1,4,0.08073634859349145,0.0,0.0 +23279263,US,US,1,2.0,0,0,0,0,2023-12-09,37.0,801.0,Female,75.0,DUPIXENT,dry skin,0,0,0.0,Adult,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2023,12,9,5,0.08073634859349145,0.5740142210730446,0.015513897866839042 +15255440,GB,GB,1,1.0,0,0,1,1,2018-08-08,60.0,801.0,Female,97.0,HUMIRA,platelet count increased,1,5,0.35714285714285715,MidAge,GB,0.17857142857142858,2,1,24,0,0,0,0,0,0,0,3,2018,8,8,2,0.08073634859349145,10.714285714285715,0.17857142857142858 +16386549,CA,CA,2,1.0,0,0,0,0,2019-06-04,44.0,801.0,Female,75.0,VEDOLIZUMAB,crohn^s disease,1,0,0.0,Adult,CA,0.057692307692307696,26,0,15,0,0,0,0,0,0,0,2,2019,6,4,1,0.08936301793444651,2.5384615384615388,0.057692307692307696 +16643132,US,US,1,1.0,0,0,0,0,2019-07-29,80.0,801.0,Female,75.0,XELJANZ XR,hip arthroplasty,1,0,0.0,Senior,US,0.0,9,0,16,0,0,0,0,0,0,0,2,2019,7,29,0,0.08073634859349145,0.0,0.0 +17472287,CA,Unknown,1,1.0,0,0,0,0,2020-02-28,39.0,801.0,Female,75.0,LEFLUNOMIDE,rheumatoid arthritis,1,0,0.0,Adult,CA,0.0,1,0,20,0,0,0,0,0,0,0,2,2020,2,28,4,0.08073634859349145,0.0,0.0 +18323100,US,US,1,1.0,1,0,0,0,2020-09-28,57.0,801.0,Female,75.0,OXYCONTIN,death,1,5,0.35714285714285715,MidAge,US,0.35714285714285715,1,1,5,0,0,1,0,0,0,0,1,2020,9,28,0,0.08073634859349145,20.357142857142858,0.35714285714285715 +18330267,JP,JP,1,2.0,0,0,0,0,2020-09-30,57.0,801.0,Male,75.0,OPSUMIT,haemoptysis,0,0,0.0,MidAge,JP,0.10714285714285714,2,0,11,0,0,0,0,0,0,0,1,2020,9,30,2,0.08073634859349145,6.107142857142857,0.0 +18354634,BR,BR,2,1.0,0,0,0,0,2020-10-07,57.0,801.0,Female,75.0,VEDOLIZUMAB,thermal burn,1,0,0.0,MidAge,BR,0.057692307692307696,26,0,12,0,0,0,0,0,0,0,2,2020,10,7,2,0.08936301793444651,3.2884615384615388,0.057692307692307696 +18599765,US,US,1,2.0,0,0,0,0,2020-12-10,56.0,801.0,Male,75.0,XELJANZ XR,drug effect less than expected,0,0,0.0,MidAge,US,0.0,9,0,30,0,0,0,0,0,0,0,5,2020,12,10,3,0.08073634859349145,0.0,0.0 +18669615,TH,TH,1,1.0,0,0,1,0,2020-12-28,63.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,burkholderia pseudomallei infection,1,3,0.21428571428571427,MidAge,Other,0.10150375939849625,19,0,35,0,1,0,0,0,0,0,3,2020,12,28,0,0.08073634859349145,6.394736842105264,0.0 +26173413,TW,TW,1,1.0,0,0,0,0,2025-12-18,27.0,801.0,Female,75.0,TECENTRIQ,off label use,1,0,0.0,Young,Other,0.14285714285714285,3,1,13,0,0,0,0,0,0,0,3,2025,12,18,3,0.08073634859349145,3.8571428571428568,0.14285714285714285 +26173561,US,US,1,2.0,0,0,0,0,2025-12-18,57.0,801.0,Female,64.989,DUPIXENT,injection site pain,0,0,0.0,MidAge,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,12,18,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26173642,US,US,1,1.0,0,0,0,0,2025-12-18,57.0,801.0,Female,75.0,SPRAVATO,heart rate decreased,1,0,0.0,MidAge,US,0.026785714285714284,8,0,20,0,0,0,0,0,0,0,3,2025,12,18,3,0.08073634859349145,1.5267857142857142,0.026785714285714284 +26173938,US,US,1,2.0,0,0,0,0,2025-12-18,23.0,801.0,Male,75.0,DUPIXENT,injection site pruritus,0,0,0.0,Young,US,0.015513897866839042,221,0,23,0,0,0,0,0,0,0,3,2025,12,18,3,0.08073634859349145,0.35681965093729795,0.0 +26175343,GB,GB,1,1.0,0,0,1,0,2025-12-18,57.0,801.0,Male,75.0,ELEXACAFTOR\IVACAFTOR\TEZACAFTOR,hospitalisation,1,3,0.21428571428571427,MidAge,GB,0.21428571428571427,2,1,15,0,0,0,0,0,0,0,1,2025,12,18,3,0.08073634859349145,12.214285714285714,0.0 +26175600,CA,CA,1,1.0,0,0,0,0,2025-12-18,43.0,801.0,Female,96.0,ORENCIA,abdominal pain upper,1,0,0.0,Adult,CA,0.10204081632653061,14,0,20,1,0,0,0,0,0,0,3,2025,12,18,3,0.08073634859349145,4.387755102040816,0.10204081632653061 +26175653,CA,CA,1,1.0,1,0,0,0,2025-12-18,43.0,801.0,Female,96.0,ORENCIA,death,1,5,0.35714285714285715,Adult,CA,0.10204081632653061,14,0,5,0,0,1,0,0,0,0,1,2025,12,18,3,0.08073634859349145,4.387755102040816,0.10204081632653061 +26176005,CN,CN,1,1.0,0,0,0,0,2025-12-18,34.0,801.0,Female,75.0,CYCLOSPORINE,graft versus host disease,1,0,0.0,Young,CN,0.0,5,0,25,0,0,0,0,0,0,0,4,2025,12,18,3,0.08073634859349145,0.0,0.0 +26176678,US,US,1,2.0,0,0,0,0,2025-12-18,57.0,801.0,Female,75.0,JOENJA,infection,0,0,0.0,MidAge,US,0.0,3,0,9,0,1,0,0,0,0,0,1,2025,12,18,3,0.08073634859349145,0.0,0.0 +23590937,CA,CA,1,1.0,0,0,1,0,2024-03-04,68.0,801.0,Female,75.0,RITUXIMAB,drug ineffective,1,3,0.21428571428571427,Senior,CA,0.12406015037593986,19,0,16,0,0,0,0,0,0,0,2,2024,3,4,0,0.08073634859349145,8.43609022556391,0.12406015037593986 +23597417,EU,EU,1,1.0,1,0,0,0,2024-03-05,57.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,septic shock,1,5,0.35714285714285715,MidAge,EU,0.10150375939849625,19,0,12,0,0,0,0,0,0,0,2,2024,3,5,1,0.08073634859349145,5.7857142857142865,0.0 +23629574,JP,JP,1,1.0,1,0,0,0,2024-03-14,57.0,801.0,Female,75.0,YERVOY,death,1,5,0.35714285714285715,MidAge,JP,0.35714285714285715,4,1,5,0,0,1,0,0,0,0,1,2024,3,14,3,0.08073634859349145,20.357142857142858,0.35714285714285715 +23634057,EU,EU,1,1.0,0,0,1,0,2024-03-14,70.0,801.0,Female,63.0,PREDNISONE,confusional state,1,3,0.21428571428571427,Senior,EU,0.1607142857142857,8,1,17,0,0,0,0,0,0,0,2,2024,3,14,3,0.08073634859349145,11.249999999999998,0.1607142857142857 +23653159,CA,CA,2,1.0,0,0,1,0,2024-03-20,57.0,801.0,Female,75.0,ADALIMUMAB-AATY,fatigue,1,3,0.21428571428571427,MidAge,CA,0.21428571428571427,1,1,7,0,0,0,0,0,0,0,1,2024,3,20,2,0.08936301793444651,12.214285714285714,0.21428571428571427 +23713613,CA,CA,1,1.0,0,0,0,0,2024-04-05,52.0,801.0,Male,75.0,ESCITALOPRAM,neoplasm skin,1,0,0.0,MidAge,CA,0.25,2,1,13,0,0,0,0,0,0,0,2,2024,4,5,4,0.08073634859349145,13.0,0.0 +23715529,US,US,2,1.0,0,0,1,0,2024-04-07,39.0,801.0,Female,88.45,SKYRIZI,nephrolithiasis,1,3,0.21428571428571427,Adult,US,0.051587301587301584,36,0,15,0,0,0,0,0,0,0,1,2024,4,7,6,0.08936301793444651,2.011904761904762,0.051587301587301584 +23784594,US,US,1,2.0,0,0,0,0,2024-04-25,20.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2024,4,25,3,0.08073634859349145,0.3102779573367808,0.015513897866839042 +23831144,CA,CA,3,1.0,0,0,0,0,2024-05-08,57.0,801.0,Female,75.0,GABAPENTIN,asthma,1,0,0.0,MidAge,CA,0.061224489795918366,7,0,6,0,0,0,0,0,0,0,1,2024,5,8,2,0.17857142857142855,3.489795918367347,0.061224489795918366 +24007724,CA,CA,2,1.0,0,0,1,0,2024-06-25,31.0,801.0,Male,75.0,HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN,urinary bladder rupture,1,3,0.21428571428571427,Young,CA,0.07142857142857142,3,0,23,0,0,0,0,0,0,0,3,2024,6,25,1,0.08936301793444651,2.214285714285714,0.0 +24096472,US,US,1,1.0,1,0,1,0,2024-07-16,76.0,801.0,Female,75.0,KEVZARA,death,1,8,0.5714285714285714,Senior,US,0.14285714285714285,4,1,5,0,0,1,0,0,0,0,1,2024,7,16,1,0.08073634859349145,10.857142857142856,0.14285714285714285 +26178326,GB,GB,1,1.0,0,0,0,0,2025-12-19,69.0,801.0,Female,113.0,ALENDRONIC ACID,pain in jaw,1,0,0.0,Senior,GB,0.0,1,0,11,1,0,0,0,0,0,0,3,2025,12,19,4,0.08073634859349145,0.0,0.0 +26178946,EU,EU,1,1.0,1,0,1,0,2025-12-19,57.0,801.0,Female,75.0,MELPHALAN,acute respiratory distress syndrome,1,8,0.5714285714285714,MidAge,EU,0.5714285714285714,1,1,35,0,0,0,0,0,0,0,4,2025,12,19,4,0.08073634859349145,32.57142857142857,0.5714285714285714 +26179527,US,US,1,1.0,0,0,0,0,2025-12-19,32.0,801.0,Female,75.0,TACROLIMUS,drug ineffective for unapproved indication,1,0,0.0,Young,US,0.09183673469387754,7,0,42,0,0,0,0,0,0,0,5,2025,12,19,4,0.08073634859349145,2.9387755102040813,0.09183673469387754 +26179851,US,US,1,2.0,0,0,0,0,2025-12-19,57.0,801.0,Female,38.77,DUPIXENT,injection site irritation,0,0,0.0,MidAge,US,0.015513897866839042,221,0,25,0,0,0,0,0,0,0,3,2025,12,19,4,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26181108,EU,EU,1,1.0,0,0,1,0,2025-12-21,57.0,801.0,Male,75.0,ALPRAZOLAM,drug use disorder,1,3,0.21428571428571427,MidAge,EU,0.14285714285714285,3,1,17,0,0,0,0,0,0,0,3,2025,12,21,6,0.08073634859349145,8.142857142857142,0.0 +26181122,US,US,1,2.0,0,0,0,0,2025-12-21,75.0,801.0,Female,75.0,SUTAB,nausea,0,0,0.0,Senior,US,0.0,2,0,6,0,0,0,0,0,0,0,1,2025,12,21,6,0.08073634859349145,0.0,0.0 +26183281,GB,GB,1,1.0,0,0,1,1,2025-12-21,18.0,801.0,Female,50.0,NAPROXEN,platelet dysfunction,1,5,0.35714285714285715,Child,GB,0.2857142857142857,2,1,20,0,0,0,0,0,0,0,2,2025,12,21,6,0.08073634859349145,5.142857142857142,0.2857142857142857 +26183591,JP,JP,1,1.0,0,0,1,0,2025-12-21,47.0,801.0,Female,75.0,LENALIDOMIDE,condition aggravated,1,3,0.21428571428571427,Adult,JP,0.15413533834586465,19,1,20,0,0,0,0,0,0,0,2,2025,12,21,6,0.08073634859349145,7.244360902255639,0.15413533834586465 +26048306,GB,GB,1,1.0,0,1,0,0,2025-11-14,21.0,801.0,Female,75.0,METRONIDAZOLE,haemolytic uraemic syndrome,1,4,0.2857142857142857,Young,GB,0.14285714285714285,2,1,27,0,0,0,0,0,0,0,3,2025,11,14,4,0.08073634859349145,3.0,0.14285714285714285 +26049965,JP,JP,1,1.0,0,0,0,0,2025-11-15,5.0,802.0,Female,3.9,SUGAMMADEX SODIUM,anaphylactic reaction,1,0,0.0,Child,JP,0.0,1,0,21,0,0,0,0,0,0,0,2,2025,11,15,5,0.08073634859349145,0.0,0.0 +26050264,US,US,1,2.0,0,0,0,0,2025-11-16,54.0,801.0,Female,75.0,TRULICITY,accidental overdose,0,0,0.0,MidAge,US,0.04285714285714286,5,0,19,0,0,0,0,0,0,0,2,2025,11,16,6,0.08073634859349145,2.3142857142857145,0.04285714285714286 +26051384,US,US,2,2.0,0,0,0,0,2025-11-17,64.0,801.0,Female,75.0,OTEZLA,therapy interrupted,0,0,0.0,MidAge,US,0.0,4,0,19,0,0,0,0,0,0,0,2,2025,11,17,0,0.08936301793444651,0.0,0.0 +26051465,EU,EU,1,1.0,0,0,1,0,2025-11-17,73.0,801.0,Female,75.0,OXALIPLATIN,neurotoxicity,1,3,0.21428571428571427,Senior,EU,0.08571428571428572,5,0,13,0,0,0,0,0,0,0,1,2025,11,17,0,0.08073634859349145,6.257142857142857,0.08571428571428572 +26051599,US,US,1,2.0,0,0,0,0,2025-11-17,46.0,801.0,Male,75.0,DUPIXENT,nasal polyps,0,0,0.0,Adult,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,2,2025,11,17,0,0.08073634859349145,0.7136393018745959,0.0 +26052141,GB,GB,3,1.0,0,0,0,0,2025-11-17,49.0,801.0,Female,70.0,LEVETIRACETAM,dyspnoea,1,0,0.0,Adult,GB,0.05714285714285714,5,0,8,0,0,0,0,0,0,0,1,2025,11,17,0,0.17857142857142855,2.8,0.05714285714285714 +26052437,US,US,1,1.0,0,1,1,0,2025-11-17,14.0,801.0,Male,75.0,AMLODIPINE,hypotension,1,7,0.5,Child,US,0.16964285714285715,8,1,11,0,0,0,0,0,0,0,1,2025,11,17,0,0.08073634859349145,2.375,0.0 +26052532,EU,EU,1,1.0,0,0,1,0,2025-11-17,74.0,801.0,Male,82.0,PACLITAXEL,erythema,1,3,0.21428571428571427,Senior,EU,0.07142857142857142,3,0,8,0,0,0,0,0,0,0,1,2025,11,17,0,0.08073634859349145,5.285714285714286,0.0 +26052585,GB,GB,1,1.0,0,0,0,1,2025-11-17,77.0,801.0,Male,75.0,AMLODIPINE,loose tooth,1,2,0.14285714285714285,Senior,GB,0.16964285714285715,8,1,11,0,0,0,0,0,0,0,2,2025,11,17,0,0.08073634859349145,13.0625,0.0 +26052909,US,US,1,1.0,0,1,1,0,2025-11-17,71.0,801.0,Male,75.0,RISPERIDONE,rhabdomyolysis,1,7,0.5,Senior,US,0.125,4,1,14,0,0,0,0,0,0,0,1,2025,11,17,0,0.08073634859349145,8.875,0.0 +24160409,CA,CA,2,1.0,0,0,1,0,2024-08-01,57.0,801.0,Female,75.0,RITUXIMAB-ABBS,rheumatoid arthritis,1,3,0.21428571428571427,MidAge,CA,0.10714285714285714,2,0,20,0,0,0,0,0,0,0,2,2024,8,1,3,0.08936301793444651,6.107142857142857,0.10714285714285714 +24165026,JP,JP,2,1.0,1,0,1,0,2024-08-02,57.0,801.0,Male,74.2,HEMLIBRA,haemorrhage subcutaneous,1,8,0.5714285714285714,MidAge,JP,0.5714285714285714,1,1,24,0,0,0,0,0,0,0,2,2024,8,2,4,0.08936301793444651,32.57142857142857,0.0 +24194792,US,US,1,1.0,0,0,0,0,2024-08-09,26.0,801.0,Female,75.0,XELJANZ,product dose omission in error,1,0,0.0,Young,US,0.0,3,0,30,0,0,0,0,0,0,0,5,2024,8,9,4,0.08073634859349145,0.0,0.0 +24196736,CA,CA,1,1.0,0,0,0,0,2024-08-10,57.0,801.0,Female,75.0,INFLIXIMAB,large intestinal stenosis,1,0,0.0,MidAge,CA,0.07142857142857142,9,0,25,0,0,0,0,0,0,0,3,2024,8,10,5,0.08073634859349145,4.071428571428571,0.07142857142857142 +24272890,CA,CA,2,1.0,0,0,1,0,2024-09-02,88.0,801.0,Male,75.0,SARILUMAB,pneumonia aspiration,1,3,0.21428571428571427,Senior,CA,0.21428571428571427,1,1,20,0,0,0,0,0,1,0,2,2024,9,2,0,0.08936301793444651,18.857142857142858,0.0 +24403786,US,US,1,2.0,0,0,0,0,2024-10-07,57.0,801.0,Female,75.0,CEQUA,expired product administered,0,0,0.0,MidAge,US,0.0,1,0,28,0,0,0,0,0,0,0,3,2024,10,7,0,0.08073634859349145,0.0,0.0 +24416841,EU,EU,2,1.0,0,1,1,0,2024-10-09,57.0,801.0,Female,75.0,VORASIDENIB,acute myocardial infarction,1,7,0.5,MidAge,EU,0.5,1,1,27,0,0,0,0,0,0,0,3,2024,10,9,2,0.08936301793444651,28.5,0.5 +24468262,EU,EU,1,1.0,0,0,1,0,2024-10-18,77.0,801.0,Female,75.0,METFORMIN,lactic acidosis,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,2,1,15,0,0,0,0,0,0,0,2,2024,10,18,4,0.08073634859349145,16.5,0.21428571428571427 +24580933,US,US,2,2.0,0,0,0,0,2024-11-05,34.0,801.0,Male,65.76,ADCETRIS,weight decreased,0,0,0.0,Young,US,0.0,2,0,16,0,0,0,0,0,0,0,2,2024,11,5,1,0.08936301793444651,0.0,0.0 +24592435,US,US,1,1.0,0,1,0,0,2024-11-08,57.0,801.0,Female,75.0,PADCEV,stevens-johnson syndrome,1,4,0.2857142857142857,MidAge,US,0.2857142857142857,1,1,24,0,0,0,0,0,0,0,2,2024,11,8,4,0.08073634859349145,16.285714285714285,0.2857142857142857 +24593717,US,US,2,1.0,0,0,0,0,2024-11-08,81.0,801.0,Male,99.773,VYNDAMAX,neuropathy peripheral,1,0,0.0,Senior,US,0.0,1,0,21,0,0,0,0,0,0,0,2,2024,11,8,4,0.08936301793444651,0.0,0.0 +24653886,US,US,1,2.0,0,0,0,0,2024-11-22,57.0,801.0,Female,75.0,TRESIBA,cataract,0,0,0.0,MidAge,US,0.0,1,0,8,0,0,0,0,0,0,0,1,2024,11,22,4,0.08073634859349145,0.0,0.0 +24680200,US,US,1,1.0,0,1,1,0,2024-11-29,69.0,801.0,Female,149.0,LUMASON,anaphylactic shock,1,7,0.5,Senior,US,0.25,2,1,18,0,0,0,0,0,0,0,2,2024,11,29,4,0.08073634859349145,17.25,0.25 +24710857,JP,JP,1,1.0,0,0,1,0,2024-12-09,7.0,800.0,Male,75.0,TECENTRIQ,type 1 diabetes mellitus,1,3,0.21428571428571427,Child,JP,0.14285714285714285,3,1,24,0,0,0,0,0,0,0,4,2024,12,9,0,0.08073634859349145,1.0,0.0 +24724775,US,US,1,2.0,0,0,0,0,2024-12-12,50.0,801.0,Male,75.0,DUPIXENT,pruritus,0,0,0.0,Adult,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2024,12,12,3,0.08073634859349145,0.7756948933419521,0.0 +24741785,CA,CA,1,1.0,0,0,0,0,2024-12-17,57.0,801.0,Female,75.0,DICLOFENAC SODIUM,glossodynia,1,0,0.0,MidAge,CA,0.4047619047619048,3,1,11,0,0,0,0,0,0,0,1,2024,12,17,1,0.08073634859349145,23.071428571428577,0.4047619047619048 +24750723,JP,JP,1,1.0,0,0,0,0,2024-12-18,80.0,801.0,Male,62.7,NUCALA,compression fracture,1,0,0.0,Senior,JP,0.0,2,0,20,0,0,0,0,0,0,0,2,2024,12,18,2,0.08073634859349145,0.0,0.0 +24757647,US,Unknown,1,2.0,0,0,0,0,2024-12-20,64.0,801.0,Female,75.0,BIMZELX,abdominal pain upper,0,0,0.0,MidAge,US,0.0,22,0,20,1,0,0,0,0,0,0,3,2024,12,20,4,0.08073634859349145,0.0,0.0 +24757661,US,Unknown,1,2.0,0,0,0,0,2024-12-20,34.0,801.0,Female,136.0,BIMZELX,arthralgia,0,0,0.0,Young,US,0.0,22,0,10,0,0,0,0,0,0,0,1,2024,12,20,4,0.08073634859349145,0.0,0.0 +24757890,US,Unknown,1,2.0,0,0,0,0,2024-12-20,72.0,801.0,Female,63.492,BIMZELX,eating disorder,0,0,0.0,Senior,US,0.0,22,0,15,0,0,0,0,0,0,0,2,2024,12,20,4,0.08073634859349145,0.0,0.0 +24758147,US,Unknown,1,2.0,0,0,0,0,2024-12-20,55.0,801.0,Female,75.0,BIMZELX,pain in extremity,0,0,0.0,MidAge,US,0.0,22,0,17,1,0,0,0,0,0,0,3,2024,12,20,4,0.08073634859349145,0.0,0.0 +24758228,US,Unknown,1,2.0,0,0,0,0,2024-12-20,82.0,801.0,Female,75.0,BIMZELX,psoriasis,0,0,0.0,Senior,US,0.0,22,0,9,0,0,0,0,0,0,0,1,2024,12,20,4,0.08073634859349145,0.0,0.0 +24758295,US,Unknown,1,2.0,0,0,0,0,2024-12-20,45.0,801.0,Female,75.0,BIMZELX,condition aggravated,0,0,0.0,Adult,US,0.0,22,0,20,0,0,0,0,0,0,0,2,2024,12,20,4,0.08073634859349145,0.0,0.0 +24781880,CA,Unknown,2,1.0,0,0,0,0,2024-12-27,57.0,801.0,Female,75.0,CERTOLIZUMAB PEGOL,pneumonia,1,0,0.0,MidAge,CA,0.04285714285714286,5,0,9,0,0,0,0,0,1,0,1,2024,12,27,4,0.08936301793444651,2.442857142857143,0.04285714285714286 +24790547,US,US,1,2.0,0,0,0,0,2024-12-30,69.0,801.0,Male,75.0,DUPIXENT,dyspnoea,0,0,0.0,Senior,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2024,12,30,0,0.08073634859349145,1.070458952811894,0.0 +24808934,EU,EU,1,1.0,0,1,1,0,2025-01-06,80.0,801.0,Female,75.0,ESCITALOPRAM,anaphylactic reaction,1,7,0.5,Senior,EU,0.25,2,1,21,0,0,0,0,0,0,0,2,2025,1,6,0,0.08073634859349145,20.0,0.25 +24821098,US,US,1,2.0,0,0,0,0,2025-01-08,14.0,801.0,Male,64.857,FABRAZYME,weight decreased,0,0,0.0,Child,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,1,8,2,0.08073634859349145,0.0,0.0 +24850205,GB,GB,2,1.0,0,0,0,0,2025-01-16,65.0,801.0,Male,75.0,VEDOLIZUMAB,lower respiratory tract infection,1,0,0.0,MidAge,GB,0.057692307692307696,26,0,33,0,1,0,0,0,0,0,4,2025,1,16,3,0.08936301793444651,3.75,0.0 +24867025,CA,CA,2,1.0,0,0,1,0,2025-01-21,69.0,801.0,Female,75.0,VELTASSA,hospitalisation,1,3,0.21428571428571427,Senior,CA,0.2619047619047619,3,1,15,0,0,0,0,0,0,0,1,2025,1,21,1,0.08936301793444651,18.071428571428573,0.2619047619047619 +24879228,US,US,1,2.0,0,0,0,0,2025-01-23,65.0,801.0,Female,75.0,DUPIXENT,asthma,0,0,0.0,MidAge,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,1,23,3,0.08073634859349145,1.0084033613445378,0.015513897866839042 +24880376,EU,EU,2,1.0,0,0,0,0,2025-01-23,58.0,801.0,Male,75.0,FOSCARBIDOPA\FOSLEVODOPA,suicidal ideation,1,0,0.0,MidAge,EU,0.0,1,0,17,0,0,0,0,0,0,0,2,2025,1,23,3,0.08936301793444651,0.0,0.0 +24891163,US,US,1,2.0,0,0,0,0,2025-01-27,27.0,801.0,Female,75.0,DUPIXENT,sleep disorder due to a general medical condition,0,0,0.0,Young,US,0.015513897866839042,221,0,49,0,0,0,0,0,0,0,8,2025,1,27,0,0.08073634859349145,0.4188752424046541,0.015513897866839042 +24953586,CA,CA,1,1.0,1,0,0,0,2025-02-11,97.0,801.0,Female,97.0,RITUXIMAB,abdominal discomfort,1,5,0.35714285714285715,Senior,CA,0.12406015037593986,19,0,20,0,0,0,0,0,0,0,2,2025,2,11,1,0.08073634859349145,12.033834586466167,0.12406015037593986 +24971610,US,US,2,1.0,0,0,1,0,2025-02-14,57.0,801.0,Female,75.0,MAVENCLAD,bladder mass,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,12,0,0,0,0,0,0,0,2,2025,2,14,4,0.08936301793444651,12.214285714285714,0.21428571428571427 +24983394,EU,EU,2,1.0,0,0,1,0,2025-02-19,75.0,801.0,Male,70.0,CARBIDOPA\LEVODOPA,influenza,1,3,0.21428571428571427,Senior,EU,0.3333333333333333,3,1,9,0,0,0,0,0,0,0,1,2025,2,19,2,0.08936301793444651,25.0,0.0 +26185292,US,US,1,1.0,0,0,1,0,2025-12-22,35.0,801.0,Female,75.0,AMPICILLIN AND SULBACTAM,septic cardiomyopathy,1,3,0.21428571428571427,Young,US,0.21428571428571427,1,1,21,0,0,0,0,0,0,0,2,2025,12,22,0,0.08073634859349145,7.5,0.21428571428571427 +26187627,CA,CA,2,1.0,0,0,0,0,2025-12-22,66.0,801.0,Female,75.0,ROSUVASTATIN,throat cancer,1,0,0.0,Senior,CA,0.0,2,0,13,0,0,0,1,0,0,0,2,2025,12,22,0,0.08936301793444651,0.0,0.0 +26187775,US,US,1,1.0,0,0,0,0,2025-12-22,70.0,801.0,Female,75.0,WEGOVY,skin neoplasm excision,1,0,0.0,Senior,US,0.14285714285714285,4,1,22,0,0,0,0,0,0,0,3,2025,12,22,0,0.08073634859349145,10.0,0.14285714285714285 +26188141,EU,EU,1,1.0,0,0,0,0,2025-12-22,45.0,801.0,Male,75.0,ADALIMUMAB,enterocolitis,1,0,0.0,Adult,EU,0.07142857142857142,3,0,13,0,0,0,0,0,0,0,1,2025,12,22,0,0.08073634859349145,3.214285714285714,0.0 +26188747,US,US,1,1.0,0,0,1,0,2025-12-22,57.0,801.0,Female,75.0,RITUXIMAB,infection,1,3,0.21428571428571427,MidAge,US,0.12406015037593986,19,0,9,0,1,0,0,0,0,0,1,2025,12,22,0,0.08073634859349145,7.071428571428572,0.12406015037593986 +21662498,US,US,2,1.0,0,0,0,0,2022-11-30,63.0,801.0,Male,149.69,BOSULIF,suicidal ideation,1,0,0.0,MidAge,US,0.0,1,0,17,0,0,0,0,0,0,0,2,2022,11,30,2,0.08936301793444651,0.0,0.0 +21719011,CA,CA,2,1.0,0,0,0,0,2022-12-13,40.0,801.0,Female,75.0,HUMAN IMMUNOGLOBULIN G,haemorrhage,1,0,0.0,Adult,CA,0.10714285714285714,8,0,11,0,0,0,0,0,0,0,1,2022,12,13,1,0.08936301793444651,4.285714285714286,0.10714285714285714 +21723304,JP,JP,1,1.0,0,0,1,1,2022-12-13,75.0,801.0,Female,75.0,YERVOY,coagulation factor deficiency,1,5,0.35714285714285715,Senior,JP,0.35714285714285715,4,1,29,0,0,0,0,0,0,0,3,2022,12,13,1,0.08073634859349145,26.785714285714285,0.35714285714285715 +22056267,US,US,1,1.0,1,0,1,0,2023-03-02,67.0,801.0,Female,75.0,PRIVIGEN,death,1,8,0.5714285714285714,Senior,US,0.39285714285714285,2,1,5,0,0,1,0,0,0,0,1,2023,3,2,3,0.08073634859349145,26.32142857142857,0.39285714285714285 +22314833,US,US,1,1.0,0,0,0,0,2023-05-12,57.0,801.0,Female,75.0,TRIKAFTA,hunger,1,0,0.0,MidAge,US,0.0,1,0,6,0,0,0,0,0,0,0,1,2023,5,12,4,0.08073634859349145,0.0,0.0 +22667236,CA,CA,2,1.0,0,0,0,0,2023-07-04,57.0,801.0,Female,75.0,RITUXIMAB-ABBS,covid-19,1,0,0.0,MidAge,CA,0.10714285714285714,2,0,8,0,0,0,0,0,0,0,1,2023,7,4,1,0.08936301793444651,6.107142857142857,0.10714285714285714 +22757375,US,US,2,2.0,0,0,0,0,2023-07-27,70.0,801.0,Female,75.0,XELJANZ XR,movement disorder,0,0,0.0,Senior,US,0.0,9,0,17,0,0,0,0,0,0,0,2,2023,7,27,3,0.08936301793444651,0.0,0.0 +22812740,EU,EU,1,1.0,0,0,0,0,2023-08-11,55.0,801.0,Female,52.0,CIPROFLOXACIN,hallucination,1,0,0.0,MidAge,EU,0.07142857142857142,3,0,13,0,0,0,0,0,0,0,1,2023,8,11,4,0.08073634859349145,3.9285714285714284,0.07142857142857142 +26054705,CO,CO,2,1.0,0,0,1,0,2025-11-17,35.0,801.0,Male,62.0,INVEGA SUSTENNA,rhabdomyolysis,1,3,0.21428571428571427,Young,Other,0.21428571428571427,1,1,14,0,0,0,0,0,0,0,1,2025,11,17,0,0.08936301793444651,7.5,0.0 +26056244,US,US,2,1.0,0,0,0,0,2025-11-18,43.0,801.0,Male,75.0,SPRAVATO,hypertension,1,0,0.0,Adult,US,0.026785714285714284,8,0,12,0,0,0,0,0,0,0,1,2025,11,18,1,0.08936301793444651,1.1517857142857142,0.0 +26056769,US,US,1,1.0,0,0,1,0,2025-11-18,17.0,801.0,Female,52.154,ISOTRETINOIN,suicide attempt,1,3,0.21428571428571427,Child,US,0.023809523809523808,9,0,15,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,0.40476190476190477,0.023809523809523808 +26191705,EU,EU,1,1.0,0,0,1,0,2025-12-23,79.0,801.0,Female,75.0,DAPTOMYCIN,leukopenia,1,3,0.21428571428571427,Senior,EU,0.16666666666666666,3,1,10,0,0,0,0,0,0,0,1,2025,12,23,1,0.08073634859349145,13.166666666666666,0.16666666666666666 +26192258,US,US,1,2.0,0,0,0,0,2025-12-23,85.0,801.0,Female,75.0,DUPIXENT,dermatitis,0,0,0.0,Senior,US,0.015513897866839042,221,0,10,0,0,0,0,0,0,0,1,2025,12,23,1,0.08073634859349145,1.3186813186813187,0.015513897866839042 +26192568,US,US,1,2.0,0,0,0,0,2025-12-23,34.0,801.0,Female,75.0,DUPIXENT,allergy to animal,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,3,2025,12,23,1,0.08073634859349145,0.5274725274725274,0.015513897866839042 +26057889,EU,EU,1,1.0,0,0,1,0,2025-11-18,33.0,801.0,Female,75.0,PREDNISONE,salpingitis,1,3,0.21428571428571427,Young,EU,0.1607142857142857,8,1,11,0,0,0,0,0,0,0,1,2025,11,18,1,0.08073634859349145,5.303571428571428,0.1607142857142857 +26058646,EU,EU,2,1.0,0,0,0,0,2025-11-18,68.0,801.0,Male,75.0,OXALIPLATIN,type ii hypersensitivity,1,0,0.0,Senior,EU,0.08571428571428572,5,0,24,0,0,0,0,0,0,0,3,2025,11,18,1,0.08936301793444651,5.828571428571428,0.0 +26058699,GB,GB,1,1.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,CISPLATIN,lower limb fracture,1,0,0.0,MidAge,GB,0.10714285714285714,2,0,19,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,6.107142857142857,0.10714285714285714 +26058727,US,US,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,SYNTHROID,muscular weakness,0,0,0.0,MidAge,US,0.17857142857142858,2,1,17,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,10.178571428571429,0.17857142857142858 +26058875,EU,EU,1,1.0,0,0,1,0,2025-11-18,58.0,801.0,Female,75.0,LEVOFLOXACIN,gastrointestinal disorder,1,3,0.21428571428571427,MidAge,EU,0.25,4,1,25,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,14.5,0.25 +26059146,US,US,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,BELBUCA,product solubility abnormal,0,0,0.0,MidAge,US,0.0,1,0,27,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,0.0,0.0 +26060780,CN,CN,1,1.0,0,0,0,0,2025-11-18,11.0,801.0,Male,75.0,CYCLOSPORINE,skin graft rejection,1,0,0.0,Child,CN,0.0,5,0,20,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,0.0,0.0 +25016202,US,US,2,1.0,0,0,0,0,2025-02-27,25.0,801.0,Male,75.0,SKYRIZI,ileectomy,1,0,0.0,Young,US,0.051587301587301584,36,0,9,0,0,0,0,0,0,0,1,2025,2,27,3,0.08936301793444651,1.2896825396825395,0.0 +25044362,JP,JP,1,1.0,0,0,0,0,2025-03-06,6.0,800.0,Male,75.0,LUTATHERA,peptic ulcer,1,0,0.0,Child,JP,0.0,1,0,12,0,0,0,0,0,0,0,2,2025,3,6,3,0.08073634859349145,0.0,0.0 +25052071,US,US,1,2.0,0,0,0,0,2025-03-07,57.0,801.0,Female,75.0,OPZELURA,intentional product use issue,0,0,0.0,MidAge,US,0.0,2,0,29,0,0,0,0,0,0,0,4,2025,3,7,4,0.08073634859349145,0.0,0.0 +25056431,US,US,2,1.0,0,0,1,0,2025-03-10,40.0,801.0,Female,75.0,XYWAV,hospitalisation,1,3,0.21428571428571427,Adult,US,0.04285714285714286,5,0,15,0,0,0,0,0,0,0,1,2025,3,10,0,0.08936301793444651,1.7142857142857144,0.04285714285714286 +25098428,US,US,1,2.0,0,0,0,0,2025-03-20,73.0,801.0,Female,59.42,POMALYST,eye irritation,0,0,0.0,Senior,US,0.11428571428571428,5,0,14,0,0,0,0,0,0,0,2,2025,3,20,3,0.08073634859349145,8.342857142857143,0.11428571428571428 +25112740,US,Unknown,1,2.0,0,0,0,0,2025-03-24,57.0,801.0,Female,75.0,BIMZELX,fatigue,0,0,0.0,MidAge,US,0.0,22,0,7,0,0,0,0,0,0,0,1,2025,3,24,0,0.08073634859349145,0.0,0.0 +25119921,US,US,1,1.0,0,0,1,0,2025-03-25,77.0,801.0,Female,75.0,DUPIXENT,hospitalisation,1,3,0.21428571428571427,Senior,US,0.015513897866839042,221,0,15,0,0,0,0,0,0,0,1,2025,3,25,1,0.08073634859349145,1.1945701357466063,0.015513897866839042 +26061833,US,US,2,1.0,0,0,0,0,2025-11-18,51.0,801.0,Female,109.0,SKYRIZI,cholecystectomy,1,0,0.0,MidAge,US,0.051587301587301584,36,0,15,0,0,0,0,0,0,0,1,2025,11,18,1,0.08936301793444651,2.630952380952381,0.051587301587301584 +26061886,US,US,2,1.0,0,0,1,0,2025-11-19,64.0,801.0,Male,83.0,SKYRIZI,knee operation,1,3,0.21428571428571427,MidAge,US,0.051587301587301584,36,0,14,0,0,0,0,0,0,0,2,2025,11,19,2,0.08936301793444651,3.3015873015873014,0.0 +26061967,US,US,1,2.0,0,0,0,0,2025-11-19,27.0,801.0,Female,75.0,DUPIXENT,eczema,0,0,0.0,Young,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,11,19,2,0.08073634859349145,0.4188752424046541,0.015513897866839042 +26064425,US,US,1,2.0,0,0,0,0,2025-11-19,20.0,801.0,Female,75.0,DUPIXENT,influenza,0,0,0.0,Young,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,11,19,2,0.08073634859349145,0.3102779573367808,0.015513897866839042 +26065059,EU,EU,1,1.0,0,1,1,0,2025-11-19,63.0,801.0,Male,75.0,PREDNISOLONE,drug ineffective,1,7,0.5,MidAge,EU,0.35714285714285715,2,1,16,0,0,0,0,0,0,0,2,2025,11,19,2,0.08073634859349145,22.5,0.0 +26194311,US,US,1,1.0,0,0,0,0,2025-12-24,62.0,801.0,Female,75.0,TEMOZOLOMIDE,neoplasm progression,1,0,0.0,MidAge,US,0.0,1,0,20,0,0,0,0,0,0,0,2,2025,12,24,2,0.08073634859349145,0.0,0.0 +26195875,US,US,3,1.0,1,0,1,0,2025-12-24,57.0,801.0,Female,75.0,CLOZAPINE,toxicity to various agents,1,8,0.5714285714285714,MidAge,US,0.23214285714285715,4,1,26,0,0,0,0,0,0,0,4,2025,12,24,2,0.17857142857142855,13.232142857142858,0.23214285714285715 +26196766,US,US,1,2.0,0,0,0,0,2025-12-24,57.0,801.0,Female,75.0,OMEPRAZOLE,product storage error,0,0,0.0,MidAge,US,0.07142857142857142,3,0,21,0,0,0,0,0,0,0,3,2025,12,24,2,0.08073634859349145,4.071428571428571,0.07142857142857142 +26197185,JP,JP,1,1.0,0,0,0,0,2025-12-24,57.0,801.0,Male,75.0,VONOPRAZAN FUMARATE,gastric haemorrhage,1,0,0.0,MidAge,JP,0.0,1,0,19,0,0,0,0,0,0,0,2,2025,12,24,2,0.08073634859349145,0.0,0.0 +26197590,US,US,1,2.0,0,0,0,0,2025-12-24,69.0,801.0,Male,75.0,DUPIXENT,incorrect dose administered,0,0,0.0,Senior,US,0.015513897866839042,221,0,27,0,0,0,0,0,0,0,3,2025,12,24,2,0.08073634859349145,1.070458952811894,0.0 +26066179,NZ,NZ,1,1.0,0,0,0,0,2025-11-19,32.0,801.0,Female,75.0,CLOZARIL,faecaloma,1,0,0.0,Young,Other,0.10714285714285714,4,0,9,0,0,0,0,0,0,0,1,2025,11,19,2,0.08073634859349145,3.4285714285714284,0.10714285714285714 +26067246,US,US,1,2.0,0,0,0,0,2025-11-20,22.0,801.0,Male,75.0,DUPIXENT,pruritus,0,0,0.0,Young,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,11,20,3,0.08073634859349145,0.3413057530704589,0.0 +26067299,US,US,1,1.0,0,0,0,0,2025-11-20,9.0,801.0,Female,75.0,COSENTYX,crohn^s disease,1,0,0.0,Child,US,0.05714285714285714,10,0,15,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,0.5142857142857142,0.05714285714285714 +26067718,US,US,2,1.0,0,0,0,0,2025-11-20,35.0,801.0,Male,75.0,CREON,pulmonary embolism,1,0,0.0,Young,US,0.03296703296703297,13,0,18,0,0,0,0,0,0,0,2,2025,11,20,3,0.08936301793444651,1.153846153846154,0.0 +26069514,AU,AU,1,1.0,0,0,0,0,2025-11-20,16.0,801.0,Male,75.0,ISOTRETINOIN,granuloma skin,1,0,0.0,Child,AU,0.023809523809523808,9,0,14,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,0.38095238095238093,0.0 +22985228,CA,CA,2,1.0,0,0,0,0,2023-09-26,28.0,801.0,Female,75.0,VEDOLIZUMAB,crohn^s disease,1,0,0.0,Young,CA,0.057692307692307696,26,0,15,0,0,0,0,0,0,0,2,2023,9,26,1,0.08936301793444651,1.6153846153846154,0.057692307692307696 +23013810,US,US,1,1.0,0,1,1,0,2023-10-01,28.0,801.0,Male,75.0,OLANZAPINE,gastric hypomotility,1,7,0.5,Young,US,0.11904761904761905,6,0,20,0,0,0,0,0,0,0,2,2023,10,1,6,0.08073634859349145,3.3333333333333335,0.0 +23086087,US,US,2,1.0,0,0,0,0,2023-10-19,57.0,801.0,Female,75.0,XYWAV,suicidal ideation,1,0,0.0,MidAge,US,0.04285714285714286,5,0,17,0,0,0,0,0,0,0,2,2023,10,19,3,0.08936301793444651,2.442857142857143,0.04285714285714286 +23156733,EU,EU,1,1.0,0,0,0,0,2023-11-07,57.0,801.0,Female,75.0,LAMOTRIGINE,epilepsy,1,0,0.0,MidAge,EU,0.10714285714285714,2,0,8,0,0,0,0,0,0,0,1,2023,11,7,1,0.08073634859349145,6.107142857142857,0.10714285714285714 +23202001,US,US,1,2.0,0,0,0,0,2023-11-20,59.0,801.0,Male,75.0,DUPIXENT,dry skin,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2023,11,20,0,0.08073634859349145,0.9153199741435035,0.0 +23226999,US,US,2,1.0,0,0,0,0,2023-11-24,57.0,801.0,Female,91.0,HUMAN IMMUNOGLOBULIN G,pneumonia,1,0,0.0,MidAge,US,0.10714285714285714,8,0,9,0,0,0,0,0,1,0,1,2023,11,24,4,0.08936301793444651,6.107142857142857,0.10714285714285714 +23258011,CA,CA,2,1.0,0,0,0,0,2023-12-04,68.0,801.0,Male,75.0,DUPILUMAB,dermatitis exfoliative generalised,1,0,0.0,Senior,CA,0.04285714285714286,5,0,34,0,0,0,0,0,0,0,3,2023,12,4,0,0.08936301793444651,2.914285714285714,0.0 +23353482,US,US,1,2.0,0,0,0,0,2023-12-31,57.0,801.0,Female,75.0,DARZALEX FASPRO,product complaint,0,0,0.0,MidAge,US,0.0,1,0,17,0,0,0,0,0,0,0,2,2023,12,31,6,0.08073634859349145,0.0,0.0 +23411869,US,US,1,1.0,0,0,0,0,2024-01-17,57.0,801.0,Female,75.0,XCOPRI,loss of consciousness,1,0,0.0,MidAge,US,0.0,1,0,21,0,0,0,0,0,0,0,3,2024,1,17,2,0.08073634859349145,0.0,0.0 +23483149,US,US,1,2.0,0,0,0,0,2024-02-05,72.0,801.0,Female,51.71,IBRANCE,hypoacusis,0,0,0.0,Senior,US,0.07142857142857142,3,0,10,0,0,0,0,0,0,0,1,2024,2,5,0,0.08073634859349145,5.142857142857142,0.07142857142857142 +23560046,CA,CA,2,1.0,0,0,0,0,2024-02-23,57.0,801.0,Female,75.0,KESIMPTA,colitis,1,0,0.0,MidAge,CA,0.0,2,0,7,0,0,0,0,0,0,0,1,2024,2,23,4,0.08936301793444651,0.0,0.0 +23647903,US,US,1,1.0,0,0,1,0,2024-03-19,79.0,801.0,Female,75.0,DUPIXENT,hip fracture,1,3,0.21428571428571427,Senior,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,2,2024,3,19,1,0.08073634859349145,1.2255979314802843,0.015513897866839042 +23661525,US,US,1,1.0,0,0,0,0,2024-03-22,64.0,801.0,Male,75.0,XTANDI,malignant neoplasm progression,1,0,0.0,MidAge,US,0.0,1,0,30,0,0,0,0,0,0,0,3,2024,3,22,4,0.08073634859349145,0.0,0.0 +23672594,CA,CA,1,1.0,0,0,1,0,2024-03-26,78.0,801.0,Female,93.0,ACETAMINOPHEN,abdominal pain upper,1,3,0.21428571428571427,Senior,CA,0.10267857142857142,16,0,20,1,0,0,0,0,0,0,3,2024,3,26,1,0.08073634859349145,8.008928571428571,0.10267857142857142 +25151916,US,US,1,1.0,0,0,1,0,2025-04-02,57.0,801.0,Male,75.0,ACETAMINOPHEN,overdose,1,3,0.21428571428571427,MidAge,US,0.10267857142857142,16,0,8,0,0,0,0,0,0,0,1,2025,4,2,2,0.08073634859349145,5.852678571428571,0.0 +25161731,US,US,2,1.0,0,0,0,0,2025-04-04,17.0,801.0,Female,54.43,COSENTYX,leukoplakia oral,1,0,0.0,Child,US,0.05714285714285714,10,0,16,0,0,0,0,0,0,0,2,2025,4,4,4,0.08936301793444651,0.9714285714285714,0.05714285714285714 +25174177,US,US,1,2.0,0,0,0,0,2025-04-08,68.0,801.0,Male,75.0,DUPIXENT,dyspnoea,0,0,0.0,Senior,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,4,8,1,0.08073634859349145,1.0549450549450547,0.0 +25179118,US,US,1,2.0,0,0,0,0,2025-04-09,23.0,801.0,Female,75.0,DUPIXENT,rash erythematous,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,4,9,2,0.08073634859349145,0.35681965093729795,0.015513897866839042 +25184693,US,US,1,2.0,0,0,0,0,2025-04-10,57.0,801.0,Male,75.0,DUPIXENT,abdominal pain,0,0,0.0,MidAge,US,0.015513897866839042,221,0,14,1,0,0,0,0,0,0,2,2025,4,10,3,0.08073634859349145,0.8842921784098254,0.0 +25206524,US,US,1,1.0,0,0,0,0,2025-04-17,56.0,801.0,Male,75.0,REVLIMID,gait disturbance,1,0,0.0,MidAge,US,0.05357142857142857,4,0,16,0,0,0,0,0,0,0,2,2025,4,17,3,0.08073634859349145,3.0,0.0 +25221495,US,US,1,1.0,0,0,1,0,2025-04-21,54.0,801.0,Female,50.794,DUPIXENT,pneumonia,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,9,0,0,0,0,0,1,0,1,2025,4,21,0,0.08073634859349145,0.8377504848093082,0.015513897866839042 +26198104,CN,CN,1,1.0,0,0,0,0,2025-12-24,30.0,801.0,Female,56.0,TOBRAMYCIN,conjunctival oedema,1,0,0.0,Young,CN,0.0,1,0,19,0,0,0,0,0,0,0,2,2025,12,24,2,0.08073634859349145,0.0,0.0 +26198858,US,US,1,2.0,0,0,0,0,2025-12-25,57.0,801.0,Female,75.0,BUPROPION HYDROCHLORIDE,product odour abnormal,0,0,0.0,MidAge,US,0.0,1,0,22,0,0,0,0,0,0,0,3,2025,12,25,3,0.08073634859349145,0.0,0.0 +26199048,US,US,1,1.0,0,0,1,0,2025-12-25,31.0,801.0,Female,75.0,MYCOPHENOLATE MOFETIL,toxicity to various agents,1,3,0.21428571428571427,Young,US,0.10150375939849625,19,0,26,0,0,0,0,0,0,0,4,2025,12,25,3,0.08073634859349145,3.1466165413533838,0.10150375939849625 +26199224,GB,GB,1,1.0,0,0,1,0,2025-12-25,57.0,801.0,Male,75.0,GABAPENTIN,gastritis,1,3,0.21428571428571427,MidAge,GB,0.061224489795918366,7,0,9,0,0,0,0,0,0,0,1,2025,12,25,3,0.08073634859349145,3.489795918367347,0.0 +26199305,US,US,1,1.0,0,0,1,0,2025-12-25,81.0,801.0,Male,79.55,DUPIXENT,respiration abnormal,1,3,0.21428571428571427,Senior,US,0.015513897866839042,221,0,20,0,0,0,0,0,0,0,2,2025,12,25,3,0.08073634859349145,1.2566257272139625,0.0 +26199587,US,US,1,2.0,0,0,0,0,2025-12-25,54.0,801.0,Female,75.0,DUPIXENT,headache,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,12,25,3,0.08073634859349145,0.8377504848093082,0.015513897866839042 +26200009,CN,CN,1,1.0,0,0,0,0,2025-12-25,55.0,801.0,Female,75.0,XGEVA,white blood cell count decreased,1,0,0.0,MidAge,CN,0.10714285714285714,2,0,32,0,0,0,0,0,0,0,5,2025,12,25,3,0.08073634859349145,5.892857142857142,0.10714285714285714 +26201048,EU,EU,1,1.0,0,0,0,0,2025-12-26,57.0,801.0,Female,75.0,ADALIMUMAB,enterocolitis,1,0,0.0,MidAge,EU,0.07142857142857142,3,0,13,0,0,0,0,0,0,0,1,2025,12,26,4,0.08073634859349145,4.071428571428571,0.07142857142857142 +26201358,US,US,1,1.0,0,0,1,0,2025-12-26,57.0,801.0,Female,75.0,RITUXIMAB,upper respiratory tract infection,1,3,0.21428571428571427,MidAge,US,0.12406015037593986,19,0,33,0,1,0,0,0,0,0,4,2025,12,26,4,0.08073634859349145,7.071428571428572,0.12406015037593986 +23936034,US,Unknown,2,1.0,0,0,0,0,2024-06-04,12.0,801.0,Female,114.0,FENFLURAMINE,seizure,1,0,0.0,Child,US,0.0,1,0,7,0,0,0,0,0,0,0,1,2024,6,4,1,0.08936301793444651,0.0,0.0 +24010568,CA,CA,2,1.0,0,0,0,0,2024-06-25,49.0,801.0,Female,75.0,RITUXIMAB,bronchitis,1,0,0.0,Adult,CA,0.12406015037593986,19,0,10,0,0,0,0,0,0,0,1,2024,6,25,1,0.08936301793444651,6.078947368421053,0.12406015037593986 +24090663,JP,JP,2,1.0,0,0,0,0,2024-07-15,4.0,801.0,Female,16.4,FENFLURAMINE HYDROCHLORIDE,epilepsy,1,0,0.0,Child,JP,0.0,1,0,8,0,0,0,0,0,0,0,1,2024,7,15,0,0.08936301793444651,0.0,0.0 +24173931,US,US,1,1.0,0,0,1,0,2024-08-05,57.0,801.0,Male,75.0,IDELVION,wrist surgery,1,3,0.21428571428571427,MidAge,US,0.10714285714285714,2,0,13,0,0,0,0,0,0,0,2,2024,8,5,0,0.08073634859349145,6.107142857142857,0.0 +24201351,US,US,1,2.0,0,0,0,0,2024-08-12,67.0,801.0,Male,75.0,KEVZARA,gait disturbance,0,0,0.0,Senior,US,0.14285714285714285,4,1,16,0,0,0,0,0,0,0,2,2024,8,12,0,0.08073634859349145,9.571428571428571,0.0 +24249490,US,US,1,2.0,0,0,0,0,2024-08-26,71.0,801.0,Male,75.0,DUPIXENT,rash macular,0,0,0.0,Senior,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,2,2024,8,26,0,0.08073634859349145,1.101486748545572,0.0 +25249130,US,US,1,1.0,0,0,0,0,2025-04-29,57.0,801.0,Female,63.492,PARAGARD T 380A,surgery,1,0,0.0,MidAge,US,0.0,4,0,7,0,0,0,0,0,0,0,1,2025,4,29,1,0.08073634859349145,0.0,0.0 +25254839,US,US,3,2.0,0,0,0,0,2025-04-30,57.0,801.0,Male,75.0,FILSPARI,influenza,0,0,0.0,MidAge,US,0.0,4,0,9,0,0,0,0,0,0,0,1,2025,4,30,2,0.17857142857142855,0.0,0.0 +25261914,US,US,1,1.0,0,0,0,0,2025-05-02,28.0,801.0,Male,75.0,VIREAD,osteonecrosis,1,0,0.0,Young,US,0.0,1,0,13,0,0,0,0,0,0,0,1,2025,5,2,4,0.08073634859349145,0.0,0.0 +25265288,US,US,2,1.0,0,0,0,0,2025-05-02,57.0,801.0,Female,75.0,XYWAV,surgery,1,0,0.0,MidAge,US,0.04285714285714286,5,0,7,0,0,0,0,0,0,0,1,2025,5,2,4,0.08936301793444651,2.442857142857143,0.04285714285714286 +25265545,AU,AU,2,1.0,0,0,0,1,2025-05-02,66.0,801.0,Female,75.0,LENVIMA,palmar-plantar erythrodysaesthesia syndrome,1,2,0.14285714285714285,Senior,AU,0.07142857142857142,2,0,43,0,0,0,0,0,0,0,3,2025,5,2,4,0.08936301793444651,4.714285714285714,0.07142857142857142 +25286267,CA,CA,2,1.0,0,0,0,0,2025-05-09,29.0,801.0,Female,75.0,SKYRIZI,obstruction,1,0,0.0,Young,CA,0.051587301587301584,36,0,11,0,0,0,0,0,0,0,1,2025,5,9,4,0.08936301793444651,1.496031746031746,0.051587301587301584 +25303791,US,US,1,1.0,0,0,0,0,2025-05-13,43.0,801.0,Male,75.0,OCREVUS,headache,1,0,0.0,Adult,US,0.0,3,0,8,0,0,0,0,0,0,0,1,2025,5,13,1,0.08073634859349145,0.0,0.0 +25306101,EU,EU,1,1.0,0,0,1,0,2025-05-13,17.0,801.0,Female,57.0,PRIVIGEN,"hallucination, visual",1,3,0.21428571428571427,Child,EU,0.39285714285714285,2,1,21,0,0,0,0,0,0,0,2,2025,5,13,1,0.08073634859349145,6.678571428571429,0.39285714285714285 +26205112,US,US,1,1.0,0,0,0,0,2025-12-28,57.0,801.0,Female,75.0,ESTRADIOL,circumstance or information capable of leading to medication error,1,0,0.0,MidAge,US,0.0,8,0,66,0,0,0,0,0,0,0,9,2025,12,28,6,0.08073634859349145,0.0,0.0 +26205165,CA,CA,2,1.0,0,0,0,0,2025-12-28,46.0,801.0,Female,75.0,REMICADE,breast conserving surgery,1,0,0.0,Adult,CA,0.0,3,0,25,0,0,0,0,0,0,0,3,2025,12,28,6,0.08936301793444651,0.0,0.0 +25385478,JP,JP,1,1.0,1,0,0,0,2025-06-02,70.0,801.0,Male,75.0,KEYTRUDA,myocarditis,1,5,0.35714285714285715,Senior,JP,0.11904761904761905,3,0,11,0,0,0,0,0,0,0,1,2025,6,2,0,0.08073634859349145,8.333333333333334,0.0 +25389056,US,US,1,2.0,0,0,0,0,2025-06-03,57.0,801.0,Female,75.0,LEVALBUTEROL TARTRATE,product ineffective,0,0,0.0,MidAge,US,0.0,1,0,19,0,0,0,0,0,0,0,2,2025,6,3,1,0.08073634859349145,0.0,0.0 +25407295,US,US,2,1.0,1,0,0,0,2025-06-06,69.0,801.0,Male,75.0,CILTACABTAGENE AUTOLEUCEL,neoplasm malignant,1,5,0.35714285714285715,Senior,US,0.17857142857142858,2,1,18,0,0,0,0,0,0,0,2,2025,6,6,4,0.08936301793444651,12.321428571428571,0.0 +25423495,US,Unknown,1,1.0,0,0,0,0,2025-06-11,51.0,801.0,Female,75.0,CIMZIA,rheumatoid arthritis,1,0,0.0,MidAge,US,0.5,2,1,20,0,0,0,0,0,0,0,2,2025,6,11,2,0.08073634859349145,25.5,0.5 +25424319,US,US,1,2.0,0,0,0,0,2025-06-11,22.0,801.0,Female,75.0,DUPIXENT,mental status changes,0,0,0.0,Young,US,0.015513897866839042,221,0,21,0,0,0,0,0,0,0,3,2025,6,11,2,0.08073634859349145,0.3413057530704589,0.015513897866839042 +25427330,JP,JP,1,1.0,0,0,1,0,2025-06-12,65.0,801.0,Female,75.0,TECENTRIQ,pneumothorax,1,3,0.21428571428571427,MidAge,JP,0.14285714285714285,3,1,12,0,0,0,0,0,0,0,1,2025,6,12,3,0.08073634859349145,9.285714285714285,0.14285714285714285 +25431623,US,US,2,1.0,0,0,0,0,2025-06-13,57.0,801.0,Female,75.0,NUPLAZID,glaucoma,1,0,0.0,MidAge,US,0.09523809523809523,6,0,8,0,0,0,0,0,0,0,1,2025,6,13,4,0.08936301793444651,5.428571428571428,0.09523809523809523 +25437737,US,US,1,1.0,0,0,0,0,2025-06-16,35.0,801.0,Female,75.0,MYCOPHENOLATE MOFETIL,abortion spontaneous,1,0,0.0,Young,US,0.10150375939849625,19,0,20,0,0,0,0,0,0,0,2,2025,6,16,0,0.08073634859349145,3.5526315789473686,0.10150375939849625 +25440977,US,Unknown,1,2.0,0,0,0,0,2025-06-16,57.0,801.0,Female,75.0,BIMZELX,product leakage,0,0,0.0,MidAge,US,0.0,22,0,15,0,0,0,0,0,0,0,2,2025,6,16,0,0.08073634859349145,0.0,0.0 +25444016,US,Unknown,1,1.0,0,0,0,0,2025-06-17,57.0,801.0,Female,75.0,BIMZELX,pruritus,1,0,0.0,MidAge,US,0.0,22,0,8,0,0,0,0,0,0,0,1,2025,6,17,1,0.08073634859349145,0.0,0.0 +25444164,US,Unknown,1,2.0,0,0,0,0,2025-06-17,45.0,801.0,Female,75.0,BIMZELX,hidradenitis,0,0,0.0,Adult,US,0.0,22,0,12,0,0,0,0,0,0,0,1,2025,6,17,1,0.08073634859349145,0.0,0.0 +19001201,CA,CA,1,1.0,1,0,0,0,2021-03-12,34.0,801.0,Female,81.0,DUAC,maternal exposure during pregnancy,1,5,0.35714285714285715,Young,CA,0.35714285714285715,1,1,34,0,0,0,0,0,0,0,4,2021,3,12,4,0.08073634859349145,12.142857142857142,0.35714285714285715 +19042011,CA,CA,2,1.0,0,0,0,0,2021-03-22,74.0,801.0,Female,75.0,VEDOLIZUMAB,crohn^s disease,1,0,0.0,Senior,CA,0.057692307692307696,26,0,15,0,0,0,0,0,0,0,2,2021,3,22,0,0.08936301793444651,4.269230769230769,0.057692307692307696 +19330477,JP,JP,2,1.0,1,0,1,0,2021-05-28,60.0,801.0,Male,75.0,LEUPROLIDE ACETATE,hepatic cirrhosis,1,8,0.5714285714285714,MidAge,JP,0.38095238095238093,3,1,17,0,0,0,0,0,0,0,2,2021,5,28,4,0.08936301793444651,22.857142857142854,0.0 +19760478,EU,EU,1,1.0,1,0,0,0,2021-08-30,62.0,801.0,Male,75.0,IRINOTECAN,tumour lysis syndrome,1,5,0.35714285714285715,MidAge,EU,0.35714285714285715,1,1,21,0,0,0,0,0,0,0,3,2021,8,30,0,0.08073634859349145,22.142857142857142,0.0 +19903309,EU,EU,1,1.0,1,0,1,0,2021-10-01,57.0,801.0,Female,75.0,RITUXIMAB,multiple organ dysfunction syndrome,1,8,0.5714285714285714,MidAge,EU,0.12406015037593986,19,0,35,0,0,0,0,0,0,0,4,2021,10,1,4,0.08073634859349145,7.071428571428572,0.12406015037593986 +20372475,EU,EU,3,1.0,1,0,1,0,2022-01-25,57.0,801.0,Female,75.0,LEVOFLOXACIN,condition aggravated,1,8,0.5714285714285714,MidAge,EU,0.25,4,1,20,0,0,0,0,0,0,0,2,2022,1,25,1,0.17857142857142855,14.25,0.25 +20595588,AU,AU,1,1.0,0,0,1,0,2022-03-15,37.0,801.0,Male,75.0,CLOZARIL,hospitalisation,1,3,0.21428571428571427,Adult,AU,0.10714285714285714,4,0,15,0,0,0,0,0,0,0,1,2022,3,15,1,0.08073634859349145,3.964285714285714,0.0 +20687713,CA,CA,1,1.0,0,0,0,0,2022-04-08,57.0,801.0,Female,75.0,INFLIXIMAB,blood pressure systolic increased,1,0,0.0,MidAge,CA,0.07142857142857142,9,0,33,0,0,0,0,0,0,0,4,2022,4,8,4,0.08073634859349145,4.071428571428571,0.07142857142857142 +20934992,US,US,1,2.0,0,0,0,0,2022-06-08,57.0,801.0,Female,75.0,ACTEMRA,arthralgia,0,0,0.0,MidAge,US,0.17857142857142858,6,1,10,0,0,0,0,0,0,0,1,2022,6,8,2,0.08073634859349145,10.178571428571429,0.17857142857142858 +20957443,AU,AU,2,1.0,0,0,0,0,2022-06-14,55.0,801.0,Female,75.0,TEDUGLUTIDE,renal impairment,1,0,0.0,MidAge,AU,0.14285714285714285,3,1,16,0,0,0,0,0,0,0,2,2022,6,14,1,0.08936301793444651,7.857142857142857,0.14285714285714285 +21290596,EU,EU,1,1.0,0,0,1,0,2022-09-03,72.0,801.0,Female,75.0,LEVOFLOXACIN,acinetobacter infection,1,3,0.21428571428571427,Senior,EU,0.25,4,1,23,0,1,0,0,0,0,0,2,2022,9,3,5,0.08073634859349145,18.0,0.25 +26092923,EU,EU,1,1.0,0,0,1,0,2025-11-26,72.0,801.0,Female,75.0,TRASTUZUMAB,pneumonia,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,9,0,0,0,0,0,1,0,1,2025,11,26,2,0.08073634859349145,15.428571428571427,0.21428571428571427 +25624102,US,US,1,2.0,0,0,0,0,2025-07-30,59.0,801.0,Female,75.0,DUPIXENT,asthma,0,0,0.0,MidAge,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,7,30,2,0.08073634859349145,0.9153199741435035,0.015513897866839042 +25628487,JP,JP,1,1.0,1,0,1,0,2025-07-31,73.0,801.0,Male,75.0,DEFITELIO,sepsis,1,8,0.5714285714285714,Senior,JP,0.5714285714285714,1,1,6,0,0,0,0,0,0,0,1,2025,7,31,3,0.08073634859349145,41.714285714285715,0.0 +26093652,US,US,1,1.0,0,0,1,0,2025-11-26,57.0,801.0,Female,75.0,CABOMETYX,encephalopathy,1,3,0.21428571428571427,MidAge,US,0.10714285714285714,4,0,14,0,0,0,0,0,0,0,1,2025,11,26,2,0.08073634859349145,6.107142857142857,0.10714285714285714 +25869196,US,US,1,1.0,0,0,0,0,2025-10-01,69.0,801.0,Male,75.0,GABAPENTIN,adrenal insufficiency,1,0,0.0,Senior,US,0.061224489795918366,7,0,21,0,0,0,0,0,0,0,2,2025,10,1,2,0.08073634859349145,4.224489795918367,0.0 +25869400,CN,CN,2,1.0,0,0,1,0,2025-10-01,73.0,801.0,Female,50.0,BRENTUXIMAB VEDOTIN,agranulocytosis,1,3,0.21428571428571427,Senior,CN,0.21428571428571427,1,1,15,0,0,0,0,0,0,0,1,2025,10,1,2,0.08936301793444651,15.642857142857142,0.21428571428571427 +25869587,CN,CN,1,1.0,0,0,0,0,2025-10-01,48.0,801.0,Female,42.4,EPIRUBICIN HYDROCHLORIDE,alanine aminotransferase increased,1,0,0.0,Adult,CN,0.0,1,0,34,0,0,0,0,0,0,0,3,2025,10,1,2,0.08073634859349145,0.0,0.0 +25870453,US,US,1,2.0,0,0,0,0,2025-10-01,14.0,801.0,Female,75.0,DUPIXENT,white blood cell count increased,0,0,0.0,Child,US,0.015513897866839042,221,0,32,0,0,0,0,0,0,0,5,2025,10,1,2,0.08073634859349145,0.21719457013574658,0.015513897866839042 +25870534,US,US,1,2.0,0,0,0,0,2025-10-01,57.0,801.0,Male,99.09,DUPIXENT,dry eye,0,0,0.0,MidAge,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,2,2025,10,1,2,0.08073634859349145,0.8842921784098254,0.0 +25872020,US,US,1,2.0,0,0,0,0,2025-10-02,33.0,801.0,Female,75.0,EBGLYSS,food allergy,0,0,0.0,Young,US,0.0,1,0,12,0,0,0,0,0,0,0,2,2025,10,2,3,0.08073634859349145,0.0,0.0 +25872059,AR,AR,1,1.0,0,0,1,1,2025-10-02,85.0,801.0,Male,75.0,XOLAIR,lower limb fracture,1,5,0.35714285714285715,Senior,Other,0.14285714285714285,4,1,19,0,0,0,0,0,0,0,3,2025,10,2,3,0.08073634859349145,12.142857142857142,0.0 +25873207,JP,JP,1,1.0,0,0,0,0,2025-10-02,64.0,801.0,Female,75.0,DOCETAXEL,scleroderma,1,0,0.0,MidAge,JP,0.061224489795918366,7,0,11,0,0,0,0,0,0,0,1,2025,10,2,3,0.08073634859349145,3.9183673469387754,0.061224489795918366 +25873355,EU,EU,1,1.0,0,0,0,0,2025-10-02,81.0,801.0,Male,75.0,PREGABALIN,hepatic cytolysis,1,0,0.0,Senior,EU,0.10714285714285714,6,0,17,0,0,0,0,0,0,0,2,2025,10,2,3,0.08073634859349145,8.678571428571429,0.0 +25873436,US,US,1,1.0,0,0,0,0,2025-10-02,57.0,801.0,Female,75.0,CRESTOR,atrial fibrillation,1,0,0.0,MidAge,US,0.0,1,0,19,0,0,0,0,0,0,0,2,2025,10,2,3,0.08073634859349145,0.0,0.0 +25873517,US,US,1,1.0,0,0,1,0,2025-10-02,59.0,801.0,Female,75.0,ENBREL,femur fracture,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,14,0,0,0,0,0,0,0,2,2025,10,2,3,0.08073634859349145,12.642857142857142,0.21428571428571427 +25874475,US,Unknown,1,1.0,0,0,0,0,2025-10-02,51.0,801.0,Female,75.0,CALQUENCE,myalgia,1,0,0.0,MidAge,US,0.0,1,0,7,0,0,0,0,0,0,0,1,2025,10,2,3,0.08073634859349145,0.0,0.0 +25874637,US,US,1,1.0,0,0,1,0,2025-10-02,46.0,801.0,Female,98.0,GAMUNEX-C,dysphagia,1,3,0.21428571428571427,Adult,US,0.21428571428571427,1,1,9,0,0,0,0,0,0,0,1,2025,10,2,3,0.08073634859349145,9.857142857142856,0.21428571428571427 +25875461,US,US,1,2.0,0,0,0,0,2025-10-03,2.0,801.0,Male,75.0,DUPIXENT,hypersensitivity,0,0,0.0,Child,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,1,2025,10,3,4,0.08073634859349145,0.031027795733678084,0.0 +25875609,US,US,1,2.0,0,0,0,0,2025-10-03,63.0,801.0,Female,75.0,DUPIXENT,accidental exposure to product,0,0,0.0,MidAge,US,0.015513897866839042,221,0,30,0,0,0,0,0,0,0,4,2025,10,3,4,0.08073634859349145,0.9773755656108597,0.015513897866839042 +25876095,US,US,2,1.0,0,0,0,0,2025-10-03,57.0,801.0,Female,75.0,CREON,hospice care,1,0,0.0,MidAge,US,0.03296703296703297,13,0,12,0,0,0,0,0,0,0,2,2025,10,3,4,0.08936301793444651,1.879120879120879,0.03296703296703297 +25876204,CA,CA,2,1.0,0,0,0,0,2025-10-03,57.0,801.0,Male,75.0,SKYRIZI,lung neoplasm malignant,1,0,0.0,MidAge,CA,0.051587301587301584,36,0,23,0,0,0,0,0,0,0,3,2025,10,3,4,0.08936301793444651,2.9404761904761902,0.0 +25877296,GB,GB,1,1.0,0,0,0,0,2025-10-03,67.0,801.0,Female,64.0,APIXABAN,diarrhoea,1,0,0.0,Senior,GB,0.07142857142857142,3,0,9,0,0,0,0,0,0,0,1,2025,10,3,4,0.08073634859349145,4.785714285714286,0.07142857142857142 +25676749,GB,GB,1,1.0,0,0,0,0,2025-08-13,76.0,801.0,Female,75.0,RITUXIMAB,renal impairment,1,0,0.0,Senior,GB,0.12406015037593986,19,0,16,0,0,0,0,0,0,0,2,2025,8,13,2,0.08073634859349145,9.428571428571429,0.12406015037593986 +25677397,US,US,1,1.0,0,0,0,0,2025-08-13,13.0,801.0,Female,75.0,DUPIXENT,loss of consciousness,1,0,0.0,Child,US,0.015513897866839042,221,0,21,0,0,0,0,0,0,0,3,2025,8,13,2,0.08073634859349145,0.20168067226890754,0.015513897866839042 +25677478,US,US,1,1.0,0,0,0,0,2025-08-13,87.0,801.0,Male,75.0,LENALIDOMIDE,anxiety,1,0,0.0,Senior,US,0.15413533834586465,19,1,7,0,0,0,0,0,0,0,1,2025,8,13,2,0.08073634859349145,13.409774436090224,0.0 +25689695,US,US,1,2.0,0,0,0,0,2025-08-18,77.0,801.0,Female,72.562,ALBUTEROL SULFATE,wrong technique in product usage process,0,0,0.0,Senior,US,0.0,8,0,40,0,0,0,0,0,0,0,6,2025,8,18,0,0.08073634859349145,0.0,0.0 +25698066,US,US,1,1.0,0,0,1,0,2025-08-19,72.0,801.0,Female,75.0,INCLISIRAN,stevens-johnson syndrome,1,3,0.21428571428571427,Senior,US,0.21428571428571427,1,1,24,0,0,0,0,0,0,0,2,2025,8,19,1,0.08073634859349145,15.428571428571427,0.21428571428571427 +25698242,US,US,1,2.0,0,0,0,0,2025-08-19,76.0,801.0,Female,75.0,AIMOVIG,injection site bruising,0,0,0.0,Senior,US,0.0,1,0,23,0,0,0,0,0,0,0,3,2025,8,19,1,0.08073634859349145,0.0,0.0 +25700943,US,US,1,2.0,0,0,0,0,2025-08-19,10.0,801.0,Female,75.0,DUPIXENT,skin abrasion,0,0,0.0,Child,US,0.015513897866839042,221,0,13,0,0,0,0,0,0,0,2,2025,8,19,1,0.08073634859349145,0.1551389786683904,0.015513897866839042 +25701577,US,US,1,1.0,0,0,0,0,2025-08-19,64.0,801.0,Female,75.0,BASAGLAR,cerebrovascular accident,1,0,0.0,MidAge,US,0.0,2,0,24,0,0,0,0,0,0,0,2,2025,8,19,1,0.08073634859349145,0.0,0.0 +25703616,US,US,3,2.0,0,0,0,0,2025-08-20,57.0,801.0,Female,75.0,AVMAPKI FAKZYNJA CO-PACK,product dose omission issue,0,0,0.0,MidAge,US,0.0,2,0,27,0,0,0,0,0,0,0,4,2025,8,20,2,0.17857142857142855,0.0,0.0 +25703630,US,US,1,2.0,0,0,0,0,2025-08-20,57.0,801.0,Female,75.0,AVMAPKI FAKZYNJA CO-PACK,ear discomfort,0,0,0.0,MidAge,US,0.0,2,0,14,0,0,0,0,0,0,0,2,2025,8,20,2,0.08073634859349145,0.0,0.0 +25704493,US,US,1,2.0,0,0,0,0,2025-08-20,47.0,801.0,Male,75.0,COSENTYX,device malfunction,0,0,0.0,Adult,US,0.05714285714285714,10,0,18,0,0,0,0,0,0,0,2,2025,8,20,2,0.08073634859349145,2.6857142857142855,0.0 +25709582,US,US,1,2.0,0,0,0,0,2025-08-21,57.0,801.0,Female,75.0,PLUVICTO,general physical health deterioration,0,0,0.0,MidAge,US,0.0,8,0,37,0,0,0,0,0,0,0,4,2025,8,21,3,0.08073634859349145,0.0,0.0 +25710339,US,US,1,2.0,0,0,0,0,2025-08-21,57.0,801.0,Female,75.0,MIRENA,condition aggravated,0,0,0.0,MidAge,US,0.0,1,0,20,0,0,0,0,0,0,0,2,2025,8,21,3,0.08073634859349145,0.0,0.0 +25712364,US,US,1,2.0,0,0,0,0,2025-08-21,10.0,801.0,Female,30.84,GENOTROPIN,product reconstitution quality issue,0,0,0.0,Child,US,0.0,1,0,36,0,0,0,0,0,0,0,4,2025,8,21,3,0.08073634859349145,0.0,0.0 +22935544,CA,CA,1,1.0,0,0,0,0,2023-09-12,45.0,801.0,Male,75.0,ABRILADA,lumbar vertebral fracture,1,0,0.0,Adult,CA,0.0,1,0,25,0,0,0,0,0,0,0,3,2023,9,12,1,0.08073634859349145,0.0,0.0 +23140921,US,US,2,1.0,0,0,0,0,2023-11-03,25.0,801.0,Female,68.0,HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN,autism spectrum disorder,1,0,0.0,Young,US,0.07142857142857142,3,0,24,0,0,0,0,0,0,0,3,2023,11,3,4,0.08936301793444651,1.7857142857142856,0.07142857142857142 +23187306,US,US,1,1.0,0,0,1,0,2023-11-15,84.0,801.0,Female,75.0,DUPIXENT,dehydration,1,3,0.21428571428571427,Senior,US,0.015513897866839042,221,0,11,0,0,0,0,0,0,0,1,2023,11,15,2,0.08073634859349145,1.3031674208144794,0.015513897866839042 +23187979,US,US,1,2.0,0,0,0,0,2023-11-15,78.0,801.0,Female,75.0,XELJANZ XR,respiratory disorder,0,0,0.0,Senior,US,0.0,9,0,20,0,0,0,0,0,0,0,2,2023,11,15,2,0.08073634859349145,0.0,0.0 +23241361,IN,IN,1,1.0,0,0,0,0,2023-11-29,75.0,801.0,Female,60.2,LORLATINIB,cardiac failure congestive,1,0,0.0,Senior,IN,0.0,1,0,26,0,0,0,0,1,0,0,3,2023,11,29,2,0.08073634859349145,0.0,0.0 +23252606,EU,EU,2,1.0,0,0,0,0,2023-12-01,39.0,801.0,Female,75.0,HIZENTRA,pericarditis,1,0,0.0,Adult,EU,0.0,1,0,12,0,0,0,0,0,0,0,1,2023,12,1,4,0.08936301793444651,0.0,0.0 +23306538,US,US,1,1.0,0,0,0,0,2023-12-18,70.0,801.0,Male,75.0,BORTEZOMIB,autonomic neuropathy,1,0,0.0,Senior,US,0.0,3,0,20,0,0,0,0,0,0,0,2,2023,12,18,0,0.08073634859349145,0.0,0.0 +23340329,US,US,1,2.0,0,0,0,0,2023-12-27,31.0,801.0,Female,61.678,DUPIXENT,rash,0,0,0.0,Young,US,0.015513897866839042,221,0,4,0,0,0,0,0,0,0,1,2023,12,27,2,0.08073634859349145,0.4809308338720103,0.015513897866839042 +23360202,CA,CA,1,1.0,0,0,1,0,2024-01-03,45.0,801.0,Female,95.0,ASPIRIN,full blood count abnormal,1,3,0.21428571428571427,Adult,CA,0.21428571428571427,1,1,25,0,0,0,0,0,0,0,4,2024,1,3,2,0.08073634859349145,9.642857142857142,0.21428571428571427 +23497508,US,US,1,2.0,0,0,0,0,2024-02-08,13.0,801.0,Male,56.0,DUPIXENT,off label use,0,0,0.0,Child,US,0.015513897866839042,221,0,13,0,0,0,0,0,0,0,3,2024,2,8,3,0.08073634859349145,0.20168067226890754,0.0 +23638800,IN,IN,1,1.0,0,0,0,0,2024-03-15,59.0,801.0,Female,75.0,DACOMITINIB,skin disorder,1,0,0.0,MidAge,IN,0.0,1,0,13,0,0,0,0,0,0,0,2,2024,3,15,4,0.08073634859349145,0.0,0.0 +23699494,JP,JP,1,1.0,1,0,0,0,2024-04-02,57.0,801.0,Male,75.0,YERVOY,acute myocardial infarction,1,5,0.35714285714285715,MidAge,JP,0.35714285714285715,4,1,27,0,0,0,0,0,0,0,3,2024,4,2,1,0.08073634859349145,20.357142857142858,0.0 +26098808,EU,EU,1,1.0,0,0,0,0,2025-11-27,28.0,801.0,Female,75.0,MYCOPHENOLATE MOFETIL,transplant rejection,1,0,0.0,Young,EU,0.10150375939849625,19,0,20,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,2.842105263157895,0.10150375939849625 +26098970,GB,GB,1,1.0,0,0,0,0,2025-11-27,70.0,801.0,Male,99.0,AMITRIPTYLINE,depression,1,0,0.0,Senior,GB,0.0,1,0,10,0,0,0,0,0,0,0,1,2025,11,27,3,0.08073634859349145,0.0,0.0 +26099322,US,US,1,1.0,0,0,1,0,2025-11-28,77.0,801.0,Female,75.0,DUPIXENT,sciatica,1,3,0.21428571428571427,Senior,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,11,28,4,0.08073634859349145,1.1945701357466063,0.015513897866839042 +26099780,AE,AE,1,1.0,0,0,0,0,2025-11-28,30.0,801.0,Male,75.0,OLANZAPINE,thrombocytopenia,1,0,0.0,Young,Other,0.11904761904761905,6,0,16,0,0,0,0,0,0,0,1,2025,11,28,4,0.08073634859349145,3.5714285714285716,0.0 +26100121,US,US,1,2.0,0,0,0,0,2025-11-28,68.0,801.0,Male,86.7,ZYTIGA,aspartate aminotransferase increased,0,0,0.0,Senior,US,0.0,1,0,36,0,0,0,0,0,0,0,3,2025,11,28,4,0.08073634859349145,0.0,0.0 +26100389,US,US,1,1.0,0,1,1,0,2025-11-28,60.0,801.0,Female,38.0,LIDOCAINE,generalised tonic-clonic seizure,1,7,0.5,MidAge,US,0.5,1,1,32,0,0,0,0,0,0,0,3,2025,11,28,4,0.08073634859349145,30.0,0.5 +25878349,US,US,1,2.0,0,0,0,0,2025-10-03,25.0,801.0,Male,75.0,EPCLUSA,inappropriate schedule of product administration,0,0,0.0,Young,US,0.0,1,0,48,0,0,0,0,0,0,0,5,2025,10,3,4,0.08073634859349145,0.0,0.0 +25879335,US,US,2,2.0,0,0,0,0,2025-10-03,57.0,801.0,Female,75.0,SKYRIZI,unevaluable event,0,0,0.0,MidAge,US,0.051587301587301584,36,0,17,0,0,0,0,0,0,0,2,2025,10,3,4,0.08936301793444651,2.9404761904761902,0.051587301587301584 +25879483,US,US,1,2.0,0,0,0,0,2025-10-03,57.0,801.0,Female,75.0,ORENCIA,loss of therapeutic response,0,0,0.0,MidAge,US,0.10204081632653061,14,0,28,0,0,0,0,0,0,0,4,2025,10,3,4,0.08073634859349145,5.816326530612245,0.10204081632653061 +26114902,EU,EU,1,1.0,0,0,1,0,2025-12-03,72.0,801.0,Female,94.0,AMLODIPINE,cough,1,3,0.21428571428571427,Senior,EU,0.16964285714285715,8,1,5,0,0,0,0,0,0,0,1,2025,12,3,2,0.08073634859349145,12.214285714285715,0.16964285714285715 +26115941,EU,EU,1,1.0,1,0,0,0,2025-12-03,70.0,801.0,Male,73.0,OPDIVO,immune-mediated myocarditis,1,5,0.35714285714285715,Senior,EU,0.08928571428571429,4,0,27,0,0,0,0,0,0,0,2,2025,12,3,2,0.08073634859349145,6.25,0.0 +25806715,US,US,1,2.0,0,0,0,0,2025-09-16,92.0,801.0,Male,73.923,TYVASO DPI,haemoglobin increased,0,0,0.0,Senior,US,0.0,4,0,21,0,0,0,0,0,0,0,2,2025,9,16,1,0.08073634859349145,0.0,0.0 +25810145,US,US,1,2.0,0,0,0,0,2025-09-17,29.0,801.0,Male,75.0,DUPIXENT,dry skin,0,0,0.0,Young,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2025,9,17,2,0.08073634859349145,0.4499030381383322,0.0 +25811832,US,US,1,2.0,0,0,0,0,2025-09-17,43.0,801.0,Female,75.0,TOLVAPTAN,nausea,0,0,0.0,Adult,US,0.0,1,0,6,0,0,0,0,0,0,0,1,2025,9,17,2,0.08073634859349145,0.0,0.0 +25812547,US,US,1,2.0,0,0,0,0,2025-09-17,41.0,801.0,Male,75.0,TRUVADA,tooth loss,0,0,0.0,Adult,US,0.0,1,0,10,0,0,0,0,0,0,0,2,2025,9,17,2,0.08073634859349145,0.0,0.0 +25897870,US,US,1,2.0,0,0,0,0,2025-10-08,56.0,801.0,Male,75.0,XELJANZ,back pain,0,0,0.0,MidAge,US,0.0,3,0,9,1,0,0,0,0,0,0,2,2025,10,8,2,0.08073634859349145,0.0,0.0 +25898451,EU,EU,1,1.0,0,0,0,0,2025-10-09,76.0,801.0,Female,70.0,CARBOPLATIN,diarrhoea,1,0,0.0,Senior,EU,0.12244897959183673,7,0,9,0,0,0,0,0,0,0,1,2025,10,9,3,0.08073634859349145,9.306122448979592,0.12244897959183673 +25900222,AU,Unknown,1,1.0,1,0,0,0,2025-10-09,52.0,801.0,Female,75.0,MIRTAZAPINE,completed suicide,1,5,0.35714285714285715,MidAge,AU,0.19047619047619047,3,1,17,0,0,0,0,0,0,0,2,2025,10,9,3,0.08073634859349145,9.904761904761905,0.19047619047619047 +25900437,EU,EU,1,1.0,0,0,1,0,2025-10-09,73.0,801.0,Female,75.0,ETOPOSIDE,condition aggravated,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,2,1,20,0,0,0,0,0,0,0,2,2025,10,9,3,0.08073634859349145,15.642857142857142,0.21428571428571427 +25901409,US,Unknown,1,1.0,0,0,1,0,2025-10-09,75.0,801.0,Female,66.68,ZILBRYSQ,pneumonia fungal,1,3,0.21428571428571427,Senior,US,0.10714285714285714,2,0,16,0,0,0,0,0,1,0,2,2025,10,9,3,0.08073634859349145,8.035714285714285,0.10714285714285714 +26119910,US,US,1,2.0,0,0,0,0,2025-12-04,7.0,801.0,Female,49.8,DUPIXENT,eczema,0,0,0.0,Child,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,12,4,3,0.08073634859349145,0.10859728506787329,0.015513897866839042 +26120086,US,US,2,1.0,0,0,0,0,2025-12-04,72.0,801.0,Female,75.0,SKYRIZI,skin cancer,1,0,0.0,Senior,US,0.051587301587301584,36,0,11,0,0,0,1,0,0,0,2,2025,12,4,3,0.08936301793444651,3.714285714285714,0.051587301587301584 +26120572,US,US,1,2.0,0,0,0,0,2025-12-04,44.0,801.0,Male,75.0,LEVETIRACETAM,drug ineffective for unapproved indication,0,0,0.0,Adult,US,0.05714285714285714,5,0,42,0,0,0,0,0,0,0,5,2025,12,4,3,0.08073634859349145,2.5142857142857142,0.0 +26121692,EU,EU,1,1.0,0,0,0,0,2025-12-04,50.0,801.0,Female,80.0,CLINDAMYCIN,suicide attempt,1,0,0.0,Adult,EU,0.0,1,0,15,0,0,0,0,0,0,0,2,2025,12,4,3,0.08073634859349145,0.0,0.0 +25819351,US,US,1,2.0,0,0,0,0,2025-09-18,60.0,801.0,Female,75.0,DUPIXENT,osteoporosis,0,0,0.0,MidAge,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,1,2025,9,18,3,0.08073634859349145,0.9308338720103425,0.015513897866839042 +25821848,US,US,2,2.0,0,0,0,0,2025-09-19,57.0,801.0,Female,75.0,DAYBUE,insomnia,0,0,0.0,MidAge,US,0.0,1,0,8,0,0,0,0,0,0,0,1,2025,9,19,4,0.08936301793444651,0.0,0.0 +25827222,EU,EU,1,1.0,0,0,0,0,2025-09-20,57.0,801.0,Female,75.0,CYCLOSPORINE,inappropriate antidiuretic hormone secretion,1,0,0.0,MidAge,EU,0.0,5,0,44,0,0,0,0,0,0,0,4,2025,9,20,5,0.08073634859349145,0.0,0.0 +25828032,US,US,1,1.0,0,0,0,0,2025-09-21,78.0,801.0,Female,75.0,ORENCIA,product storage error,1,0,0.0,Senior,US,0.10204081632653061,14,0,21,0,0,0,0,0,0,0,3,2025,9,21,6,0.08073634859349145,7.959183673469388,0.10204081632653061 +25831797,EU,EU,2,1.0,0,0,1,0,2025-09-22,43.0,801.0,Male,75.0,COSENTYX,crohn^s disease,1,3,0.21428571428571427,Adult,EU,0.05714285714285714,10,0,15,0,0,0,0,0,0,0,2,2025,9,22,0,0.08936301793444651,2.457142857142857,0.0 +25833498,NG,NG,1,1.0,1,0,1,0,2025-09-22,35.0,801.0,Male,75.0,GLIVEC,death,1,8,0.5714285714285714,Young,Other,0.5714285714285714,1,1,5,0,0,1,0,0,0,0,1,2025,9,22,0,0.08073634859349145,20.0,0.0 +24232935,CA,CA,1,1.0,0,0,0,0,2024-08-21,36.0,801.0,Female,75.0,DICLOFENAC POTASSIUM,ankylosing spondylitis,1,0,0.0,Adult,CA,0.0,1,0,22,0,0,0,0,0,0,0,2,2024,8,21,2,0.08073634859349145,0.0,0.0 +24238348,US,US,3,2.0,0,0,0,0,2024-08-22,57.0,801.0,Male,75.0,FILSPARI,blepharospasm,0,0,0.0,MidAge,US,0.0,4,0,13,0,0,0,0,0,0,0,1,2024,8,22,3,0.17857142857142855,0.0,0.0 +24239253,US,US,3,2.0,0,0,0,0,2024-08-22,45.0,801.0,Female,75.0,FILSPARI,dizziness,0,0,0.0,Adult,US,0.0,4,0,9,0,0,0,0,0,0,0,1,2024,8,22,3,0.17857142857142855,0.0,0.0 +24249540,US,US,1,2.0,0,0,0,0,2024-08-26,57.0,801.0,Male,113.38,DUPIXENT,dry skin,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2024,8,26,0,0.08073634859349145,0.8842921784098254,0.0 +24319982,US,US,2,2.0,0,0,0,0,2024-09-14,44.0,801.0,Female,75.0,VEDOLIZUMAB,product dose omission issue,0,0,0.0,Adult,US,0.057692307692307696,26,0,27,0,0,0,0,0,0,0,4,2024,9,14,5,0.08936301793444651,2.5384615384615388,0.057692307692307696 +24375157,EU,EU,1,1.0,0,0,0,0,2024-09-28,36.0,801.0,Male,75.0,PRAVASTATIN SODIUM,dizziness,1,0,0.0,Adult,EU,0.0,1,0,9,0,0,0,0,0,0,0,1,2024,9,28,5,0.08073634859349145,0.0,0.0 +24393988,US,US,2,1.0,0,0,0,0,2024-10-03,70.0,801.0,Female,75.0,CREON,hip fracture,1,0,0.0,Senior,US,0.03296703296703297,13,0,12,0,0,0,0,0,0,0,2,2024,10,3,3,0.08936301793444651,2.307692307692308,0.03296703296703297 +24427511,US,US,1,2.0,0,0,0,0,2024-10-11,2.0,801.0,Male,75.0,DUPIXENT,rhinorrhoea,0,0,0.0,Child,US,0.015513897866839042,221,0,11,0,0,0,0,0,0,0,1,2024,10,11,4,0.08073634859349145,0.031027795733678084,0.0 +24432991,US,US,1,2.0,0,0,0,0,2024-10-14,57.0,801.0,Female,46.712,DUPIXENT,drug intolerance,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2024,10,14,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +24448233,CA,Unknown,2,1.0,0,0,0,0,2024-10-16,57.0,801.0,Female,75.0,CERTOLIZUMAB PEGOL,ankylosing spondylitis,1,0,0.0,MidAge,CA,0.04285714285714286,5,0,22,0,0,0,0,0,0,0,2,2024,10,16,2,0.08936301793444651,2.442857142857143,0.04285714285714286 +24461531,US,US,1,1.0,0,0,0,0,2024-10-18,37.0,801.0,Female,86.168,BIMZELX,psoriasis,1,0,0.0,Adult,US,0.0,22,0,9,0,0,0,0,0,0,0,1,2024,10,18,4,0.08073634859349145,0.0,0.0 +24528490,US,US,2,1.0,0,0,0,0,2024-10-21,30.0,801.0,Female,118.37,NURTEC ODT,maternal exposure during pregnancy,1,0,0.0,Young,US,0.0,2,0,34,0,0,0,0,0,0,0,4,2024,10,21,0,0.08936301793444651,0.0,0.0 +24547969,CA,CA,2,1.0,0,0,1,0,2024-10-25,57.0,801.0,Female,75.0,VEDOLIZUMAB,anal abscess,1,3,0.21428571428571427,MidAge,CA,0.057692307692307696,26,0,12,0,0,0,0,0,0,0,2,2024,10,25,4,0.08936301793444651,3.2884615384615388,0.057692307692307696 +26122664,US,US,1,1.0,1,0,0,0,2025-12-04,58.0,801.0,Female,75.0,POMALYST,death,1,5,0.35714285714285715,MidAge,US,0.11428571428571428,5,0,5,0,0,1,0,0,0,0,1,2025,12,4,3,0.08073634859349145,6.628571428571428,0.11428571428571428 +26124756,AU,AU,1,1.0,0,0,0,0,2025-12-05,63.0,801.0,Male,75.0,DARATUMUMAB,thrombocytopenia,1,0,0.0,MidAge,AU,0.14285714285714285,3,1,16,0,0,0,0,0,0,0,1,2025,12,5,4,0.08073634859349145,9.0,0.0 +25902448,ZA,ZA,2,1.0,0,0,1,0,2025-10-09,53.0,801.0,Male,75.0,BUDESONIDE\FORMOTEROL,cardiac disorder,1,3,0.21428571428571427,MidAge,ZA,0.10714285714285714,2,0,16,0,0,0,0,0,0,0,2,2025,10,9,3,0.08936301793444651,5.678571428571428,0.0 +25902839,US,US,2,1.0,0,0,0,0,2025-10-09,82.0,801.0,Male,62.0,VENCLEXTA,acute myeloid leukaemia,1,0,0.0,Senior,US,0.18571428571428572,5,1,23,0,0,0,0,0,0,0,3,2025,10,9,3,0.08936301793444651,15.22857142857143,0.0 +25903878,JP,JP,1,1.0,0,0,1,0,2025-10-10,78.0,801.0,Male,75.0,TREPROSTINIL,dyspnoea,1,3,0.21428571428571427,Senior,JP,0.2857142857142857,2,1,8,0,0,0,0,0,0,0,1,2025,10,10,4,0.08073634859349145,22.285714285714285,0.0 +25904325,US,US,1,1.0,0,0,0,0,2025-10-10,68.0,801.0,Female,74.83,ALBUTEROL SULFATE,wrong technique in product usage process,1,0,0.0,Senior,US,0.0,8,0,40,0,0,0,0,0,0,0,6,2025,10,10,4,0.08073634859349145,0.0,0.0 +26127348,US,US,1,1.0,0,0,1,0,2025-12-05,60.0,801.0,Female,75.0,DUPIXENT,staphylococcal infection,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,24,0,1,0,0,0,0,0,2,2025,12,5,4,0.08073634859349145,0.9308338720103425,0.015513897866839042 +26127968,JP,JP,1,1.0,0,0,0,0,2025-12-06,4.0,801.0,Female,75.0,LEVETIRACETAM,drug ineffective,1,0,0.0,Child,JP,0.05714285714285714,5,0,16,0,0,0,0,0,0,0,2,2025,12,6,5,0.08073634859349145,0.22857142857142856,0.05714285714285714 +26128105,US,US,1,2.0,0,0,0,0,2025-12-07,56.0,801.0,Female,75.0,DUPIXENT,vomiting,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,12,7,6,0.08073634859349145,0.8687782805429863,0.015513897866839042 +26128172,US,US,1,2.0,0,0,0,0,2025-12-07,21.0,801.0,Male,75.0,DUPIXENT,pruritus,0,0,0.0,Young,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,12,7,6,0.08073634859349145,0.32579185520361986,0.0 +26128806,US,US,1,1.0,0,0,0,0,2025-12-08,19.0,801.0,Female,75.0,ISOTRETINOIN,abortion spontaneous,1,0,0.0,Young,US,0.023809523809523808,9,0,20,0,0,0,0,0,0,0,2,2025,12,8,0,0.08073634859349145,0.45238095238095233,0.023809523809523808 +26129616,AU,AU,1,1.0,0,0,0,0,2025-12-08,57.0,801.0,Female,75.0,CABERGOLINE,blood prolactin increased,1,0,0.0,MidAge,AU,0.0,1,0,25,0,0,0,0,0,0,0,3,2025,12,8,0,0.08073634859349145,0.0,0.0 +26130588,US,Unknown,1,1.0,0,0,1,0,2025-12-05,57.0,801.0,Female,75.0,VELTASSA,therapy interrupted,1,3,0.21428571428571427,MidAge,US,0.2619047619047619,3,1,19,0,0,0,0,0,0,0,2,2025,12,5,4,0.08073634859349145,14.928571428571429,0.2619047619047619 +25909872,US,US,1,2.0,0,0,0,0,2025-10-12,57.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,12,6,0.08073634859349145,0.8842921784098254,0.015513897866839042 +24608222,US,US,1,1.0,0,0,1,0,2024-11-12,65.0,801.0,Female,75.0,IBRANCE,lower limb fracture,1,3,0.21428571428571427,MidAge,US,0.07142857142857142,3,0,19,0,0,0,0,0,0,0,3,2024,11,12,1,0.08073634859349145,4.642857142857142,0.07142857142857142 +24615040,JP,JP,2,1.0,0,0,0,0,2024-11-13,74.0,801.0,Male,57.9,OPDIVO,immune-mediated enterocolitis,1,0,0.0,Senior,JP,0.08928571428571429,4,0,29,0,0,0,0,0,0,0,2,2024,11,13,2,0.08936301793444651,6.607142857142858,0.0 +24617185,US,US,1,1.0,0,0,0,0,2024-11-14,29.0,801.0,Female,79.365,PARAGARD T 380A,reproductive complication associated with device,1,0,0.0,Young,US,0.0,4,0,48,0,0,0,0,0,0,0,5,2024,11,14,3,0.08073634859349145,0.0,0.0 +24620277,US,US,1,2.0,0,0,0,0,2024-11-14,57.0,801.0,Female,75.0,CONTRAVE,headache,0,0,0.0,MidAge,US,0.0,1,0,8,0,0,0,0,0,0,0,1,2024,11,14,3,0.08073634859349145,0.0,0.0 +24630201,EU,EU,1,1.0,0,0,0,0,2024-11-18,55.0,801.0,Female,75.0,DASATINIB,cytomegalovirus colitis,1,0,0.0,MidAge,EU,0.0,2,0,23,0,0,0,0,0,0,0,2,2024,11,18,0,0.08073634859349145,0.0,0.0 +24650881,JP,JP,2,1.0,1,0,0,0,2024-11-22,47.0,801.0,Male,58.3,MARIBAVIR,infection,1,5,0.35714285714285715,Adult,JP,0.35714285714285715,1,1,9,0,1,0,0,0,0,0,1,2024,11,22,4,0.08936301793444651,16.785714285714285,0.0 +24665528,US,US,1,1.0,0,0,0,0,2024-11-26,59.0,801.0,Female,75.0,VONJO,nephrolithiasis,1,0,0.0,MidAge,US,0.0,3,0,15,0,0,0,0,0,0,0,1,2024,11,26,1,0.08073634859349145,0.0,0.0 +24674829,CA,CA,2,1.0,0,0,1,0,2024-11-28,64.0,801.0,Male,75.0,VEDOLIZUMAB,chronic obstructive pulmonary disease,1,3,0.21428571428571427,MidAge,CA,0.057692307692307696,26,0,37,0,0,0,0,0,0,0,4,2024,11,28,3,0.08936301793444651,3.6923076923076925,0.0 +24677745,US,US,2,1.0,0,0,1,0,2024-11-29,58.0,801.0,Female,75.0,SKYRIZI,streptococcal infection,1,3,0.21428571428571427,MidAge,US,0.051587301587301584,36,0,23,0,1,0,0,0,0,0,2,2024,11,29,4,0.08936301793444651,2.992063492063492,0.051587301587301584 +24686521,GB,GB,1,1.0,1,1,0,0,2024-12-02,57.0,801.0,Female,75.0,SILDENAFIL,death,1,9,0.6428571428571429,MidAge,GB,0.6428571428571429,1,1,5,0,0,1,0,0,0,0,1,2024,12,2,0,0.08073634859349145,36.642857142857146,0.6428571428571429 +24723686,US,US,1,2.0,0,0,0,0,2024-12-11,12.0,801.0,Male,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Child,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2024,12,11,2,0.08073634859349145,0.1861667744020685,0.0 +24757720,US,Unknown,1,2.0,0,0,0,0,2024-12-20,44.0,801.0,Female,126.98,BIMZELX,dry skin,0,0,0.0,Adult,US,0.0,22,0,8,0,0,0,0,0,0,0,2,2024,12,20,4,0.08073634859349145,0.0,0.0 +24757801,US,Unknown,1,2.0,0,0,0,0,2024-12-20,57.0,801.0,Female,79.365,BIMZELX,joint swelling,0,0,0.0,MidAge,US,0.0,22,0,14,0,0,0,0,0,0,0,2,2024,12,20,4,0.08073634859349145,0.0,0.0 +24757854,US,Unknown,1,2.0,0,0,0,0,2024-12-20,31.0,801.0,Female,75.0,BIMZELX,psoriasis,0,0,0.0,Young,US,0.0,22,0,9,0,0,0,0,0,0,0,1,2024,12,20,4,0.08073634859349145,0.0,0.0 +24758125,US,US,1,2.0,0,0,0,0,2024-12-20,43.0,801.0,Female,75.0,BIMZELX,fatigue,0,0,0.0,Adult,US,0.0,22,0,7,0,0,0,0,0,0,0,1,2024,12,20,4,0.08073634859349145,0.0,0.0 +26131493,US,US,2,1.0,1,0,0,0,2025-12-08,79.0,801.0,Male,75.0,VENCLEXTA,death,1,5,0.35714285714285715,Senior,US,0.18571428571428572,5,1,5,0,0,1,0,0,0,0,1,2025,12,8,0,0.08936301793444651,14.671428571428573,0.0 +26132412,EU,EU,1,1.0,0,0,0,0,2025-12-08,49.0,801.0,Male,75.0,AMLODIPINE BESYLATE,depressed mood,1,0,0.0,Adult,EU,0.0,1,0,14,0,0,0,0,0,0,0,2,2025,12,8,0,0.08073634859349145,0.0,0.0 +26133060,US,Unknown,2,1.0,0,0,0,0,2025-12-09,67.0,801.0,Female,75.0,LENALIDOMIDE,b-cell type acute leukaemia,1,0,0.0,Senior,US,0.15413533834586465,19,1,27,0,0,0,0,0,0,0,4,2025,12,9,1,0.08936301793444651,10.327067669172932,0.15413533834586465 +26134409,EU,EU,1,1.0,0,0,1,0,2025-12-09,29.0,801.0,Female,75.0,PREDNISOLONE,blood corticotrophin decreased,1,3,0.21428571428571427,Young,EU,0.35714285714285715,2,1,30,0,0,0,0,0,0,0,3,2025,12,9,1,0.08073634859349145,10.357142857142858,0.35714285714285715 +25840168,US,US,1,1.0,0,0,0,0,2025-09-24,57.0,801.0,Female,75.0,NUCALA,underdose,1,0,0.0,MidAge,US,0.0,2,0,9,0,0,0,0,0,0,0,1,2025,9,24,2,0.08073634859349145,0.0,0.0 +25843408,US,US,1,2.0,0,0,0,0,2025-09-24,59.0,801.0,Female,75.0,DUPIXENT,fatigue,0,0,0.0,MidAge,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,1,2025,9,24,2,0.08073634859349145,0.9153199741435035,0.015513897866839042 +25845028,EU,EU,1,1.0,0,0,1,0,2025-09-25,57.0,801.0,Female,75.0,METOPROLOL SUCCINATE,upper respiratory tract infection,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,1,1,33,0,1,0,0,0,0,0,4,2025,9,25,3,0.08073634859349145,12.214285714285714,0.21428571428571427 +25851737,IN,IN,2,1.0,0,0,1,0,2025-09-26,65.0,801.0,Female,75.0,PERJETA,off label use,1,3,0.21428571428571427,MidAge,IN,0.21428571428571427,2,1,13,0,0,0,0,0,0,0,3,2025,9,26,4,0.08936301793444651,13.928571428571427,0.21428571428571427 +25852075,EU,EU,1,1.0,0,0,1,0,2025-09-26,57.0,801.0,Female,75.0,DIAZEPAM,drug ineffective,1,3,0.21428571428571427,MidAge,EU,0.2619047619047619,3,1,16,0,0,0,0,0,0,0,2,2025,9,26,4,0.08073634859349145,14.928571428571429,0.2619047619047619 +25853519,US,US,1,2.0,0,0,0,0,2025-09-26,57.0,801.0,Female,75.0,JOENJA,ear infection,0,0,0.0,MidAge,US,0.0,3,0,13,0,1,0,0,0,0,0,2,2025,9,26,4,0.08073634859349145,0.0,0.0 +25854787,US,US,1,2.0,0,0,0,0,2025-09-27,75.0,801.0,Female,62.142,CREON,paraesthesia,0,0,0.0,Senior,US,0.03296703296703297,13,0,12,0,0,0,0,0,0,0,1,2025,9,27,5,0.08073634859349145,2.4725274725274726,0.03296703296703297 +26134733,EU,EU,1,1.0,0,0,1,0,2025-12-09,63.0,801.0,Male,75.0,CYCLOPHOSPHAMIDE,sars-cov-2 test positive,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,2,1,24,0,0,0,0,0,0,0,3,2025,12,9,1,0.08073634859349145,13.5,0.0 +26135381,US,US,1,2.0,0,0,0,0,2025-12-09,57.0,801.0,Female,68.027,ESTRADIOL,product ineffective,0,0,0.0,MidAge,US,0.0,8,0,19,0,0,0,0,0,0,0,2,2025,12,9,1,0.08073634859349145,0.0,0.0 +26136610,US,US,1,2.0,0,0,0,0,2025-12-09,57.0,801.0,Female,75.0,RYBREVANT,adverse event,0,0,0.0,MidAge,US,0.05357142857142857,4,0,13,0,0,0,0,0,0,0,2,2025,12,9,1,0.08073634859349145,3.0535714285714284,0.05357142857142857 +26138311,US,Unknown,2,1.0,1,0,0,0,2025-12-10,57.0,801.0,Female,75.0,LENALIDOMIDE,death,1,5,0.35714285714285715,MidAge,US,0.15413533834586465,19,1,5,0,0,1,0,0,0,0,1,2025,12,10,2,0.08936301793444651,8.785714285714285,0.15413533834586465 +25917123,CA,CA,1,1.0,0,0,1,0,2025-10-14,57.0,801.0,Female,75.0,INFLIXIMAB,faecal vomiting,1,3,0.21428571428571427,MidAge,CA,0.07142857142857142,9,0,15,0,0,0,0,0,0,0,2,2025,10,14,1,0.08073634859349145,4.071428571428571,0.07142857142857142 +25918539,EU,EU,1,1.0,0,0,1,0,2025-10-14,17.0,801.0,Female,75.0,PREGABALIN,drug use disorder,1,3,0.21428571428571427,Child,EU,0.10714285714285714,6,0,17,0,0,0,0,0,0,0,3,2025,10,14,1,0.08073634859349145,1.8214285714285714,0.10714285714285714 +25862591,EU,EU,1,1.0,0,0,1,0,2025-09-30,78.0,801.0,Male,170.0,RITONAVIR,confusional state,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,17,0,0,0,0,0,0,0,2,2025,9,30,1,0.08073634859349145,16.71428571428571,0.0 +25866937,US,US,1,2.0,0,0,0,0,2025-10-01,72.0,801.0,Female,64.853,TYVASO,dyspnoea,0,0,0.0,Senior,US,0.0,2,0,8,0,0,0,0,0,0,0,1,2025,10,1,2,0.08073634859349145,0.0,0.0 +25867895,US,US,1,1.0,0,0,0,1,2025-10-01,58.0,801.0,Female,75.0,CARBOPLATIN,deafness,1,2,0.14285714285714285,MidAge,US,0.12244897959183673,7,0,8,0,0,0,0,0,0,0,1,2025,10,1,2,0.08073634859349145,7.1020408163265305,0.12244897959183673 +25868180,US,US,2,1.0,0,0,1,0,2025-10-01,72.0,801.0,Male,75.0,SKYRIZI,balance disorder,1,3,0.21428571428571427,Senior,US,0.051587301587301584,36,0,16,0,0,0,0,0,0,0,2,2025,10,1,2,0.08936301793444651,3.714285714285714,0.0 +25868490,US,US,1,2.0,0,0,0,0,2025-10-01,57.0,801.0,Female,75.0,SYMBICORT,cough,0,0,0.0,MidAge,US,0.0,2,0,5,0,0,0,0,0,0,0,1,2025,10,1,2,0.08073634859349145,0.0,0.0 +25918634,US,Unknown,1,2.0,0,0,0,0,2025-10-10,57.0,801.0,Female,75.0,ZYPREXA,treatment failure,0,0,0.0,MidAge,US,0.0,1,0,17,0,0,0,0,1,0,0,2,2025,10,10,4,0.08073634859349145,0.0,0.0 +25918810,US,US,1,2.0,0,0,0,0,2025-10-14,57.0,801.0,Female,75.0,ESTRADIOL,device adhesion issue,0,0,0.0,MidAge,US,0.0,8,0,21,0,0,0,0,0,0,0,3,2025,10,14,1,0.08073634859349145,0.0,0.0 +25919701,ZA,ZA,2,1.0,0,0,1,0,2025-10-14,54.0,801.0,Male,75.0,INSULIN GLARGINE,gangrene,1,3,0.21428571428571427,MidAge,ZA,0.21428571428571427,1,1,8,0,0,0,0,0,0,0,1,2025,10,14,1,0.08936301793444651,11.571428571428571,0.0 +25920310,CA,CA,1,1.0,0,0,0,0,2025-10-14,8.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,post transplant lymphoproliferative disorder,1,0,0.0,Child,CA,0.10150375939849625,19,0,44,0,0,0,0,0,0,0,4,2025,10,14,1,0.08073634859349145,0.81203007518797,0.0 +25921335,US,US,1,2.0,0,0,0,0,2025-10-14,62.0,801.0,Female,98.41,KEVZARA,inflammation,0,0,0.0,MidAge,US,0.14285714285714285,4,1,12,0,0,0,0,0,0,0,1,2025,10,14,1,0.08073634859349145,8.857142857142856,0.14285714285714285 +25921779,US,US,1,2.0,0,0,0,0,2025-10-14,57.0,801.0,Male,80.907,TYVASO DPI,inappropriate schedule of product administration,0,0,0.0,MidAge,US,0.0,4,0,48,0,0,0,0,0,0,0,5,2025,10,14,1,0.08073634859349145,0.0,0.0 +25922536,US,US,1,2.0,0,0,0,0,2025-10-15,57.0,801.0,Female,75.0,IQIRVO,nausea,0,0,0.0,MidAge,US,0.0,2,0,6,0,0,0,0,0,0,0,1,2025,10,15,2,0.08073634859349145,0.0,0.0 +25922927,US,US,1,2.0,0,0,0,0,2025-10-15,18.0,801.0,Male,75.0,DUPIXENT,rash erythematous,0,0,0.0,Child,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,15,2,0.08073634859349145,0.27925016160310273,0.0 +25869772,US,US,1,2.0,0,0,0,0,2025-10-01,57.0,801.0,Female,75.0,XEOMIN,drug ineffective,0,0,0.0,MidAge,US,0.08928571428571429,4,0,16,0,0,0,0,0,0,0,2,2025,10,1,2,0.08073634859349145,5.089285714285714,0.08928571428571429 +25871191,EU,EU,1,1.0,0,1,1,0,2025-10-01,71.0,801.0,Female,75.0,MYCOPHENOLATE MOFETIL,meningitis listeria,1,7,0.5,Senior,EU,0.10150375939849625,19,0,19,0,0,0,0,0,0,0,2,2025,10,1,2,0.08073634859349145,7.206766917293233,0.10150375939849625 +25872244,US,US,1,2.0,0,0,0,0,2025-10-02,57.0,801.0,Female,75.0,DUPIXENT,injection site pain,0,0,0.0,MidAge,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,10,2,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25874565,IN,IN,1,1.0,0,0,0,0,2025-10-02,21.0,801.0,Male,75.0,ACETAMINOPHEN,acute generalised exanthematous pustulosis,1,0,0.0,Young,IN,0.10267857142857142,16,0,42,0,0,0,0,0,0,0,4,2025,10,2,3,0.08073634859349145,2.15625,0.0 +25875012,US,US,1,1.0,0,0,0,0,2025-10-02,79.0,801.0,Female,75.3,REVLIMID,rash,1,0,0.0,Senior,US,0.05357142857142857,4,0,4,0,0,0,0,0,0,0,1,2025,10,2,3,0.08073634859349145,4.232142857142857,0.05357142857142857 +25875713,US,US,1,2.0,0,0,0,0,2025-10-03,83.0,801.0,Female,75.0,DUPIXENT,dyspnoea,0,0,0.0,Senior,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,10,3,4,0.08073634859349145,1.2876535229476405,0.015513897866839042 +25876361,US,US,2,1.0,0,0,1,0,2025-10-03,68.0,801.0,Female,75.0,TREMFYA,spinal stenosis,1,3,0.21428571428571427,Senior,US,0.10714285714285714,2,0,15,0,0,0,0,0,0,0,2,2025,10,3,4,0.08936301793444651,7.285714285714286,0.10714285714285714 +25876914,US,US,1,2.0,0,0,0,0,2025-10-03,57.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,3,4,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25876981,CN,CN,1,1.0,0,0,1,0,2025-10-03,57.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,white blood cell count decreased,1,3,0.21428571428571427,MidAge,CN,0.10150375939849625,19,0,32,0,0,0,0,0,0,0,5,2025,10,3,4,0.08073634859349145,5.7857142857142865,0.0 +25877076,US,US,1,2.0,0,0,0,0,2025-10-03,24.0,801.0,Male,75.0,DUPIXENT,eczema,0,0,0.0,Young,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,10,3,4,0.08073634859349145,0.372333548804137,0.0 +25877238,VE,VE,2,1.0,0,0,0,0,2025-10-03,57.0,801.0,Female,75.0,ENOXAPARIN SODIUM,pulmonary embolism,1,0,0.0,MidAge,Other,0.0,2,0,18,0,0,0,0,0,0,0,2,2025,10,3,4,0.08936301793444651,0.0,0.0 +25927597,US,US,1,2.0,0,0,0,0,2025-10-16,57.0,801.0,Female,75.0,JEMPERLI,chest discomfort,0,0,0.0,MidAge,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,10,16,3,0.08073634859349145,0.0,0.0 +25927759,US,US,1,1.0,0,0,1,0,2025-10-16,63.0,801.0,Female,75.0,TACROLIMUS,hypogammaglobulinaemia,1,3,0.21428571428571427,MidAge,US,0.09183673469387754,7,0,22,0,0,0,0,0,0,0,1,2025,10,16,3,0.08073634859349145,5.785714285714285,0.09183673469387754 +25929636,US,Unknown,1,1.0,0,0,1,0,2025-10-15,47.0,801.0,Male,75.0,TACROLIMUS,transplant rejection,1,3,0.21428571428571427,Adult,US,0.09183673469387754,7,0,20,0,0,0,0,0,0,0,2,2025,10,15,2,0.08073634859349145,4.316326530612244,0.0 +25878400,US,US,1,2.0,0,0,0,0,2025-10-03,29.0,801.0,Female,75.0,ZEPBOUND,tooth fracture,0,0,0.0,Young,US,0.0,2,0,14,0,0,0,0,0,0,0,2,2025,10,3,4,0.08073634859349145,0.0,0.0 +25878439,US,US,1,2.0,0,0,0,0,2025-10-03,61.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,3,4,0.08073634859349145,0.9463477698771816,0.015513897866839042 +25878897,EU,EU,1,1.0,0,0,1,0,2025-10-03,57.0,801.0,Female,75.0,OMEPRAZOLE,cerebellar syndrome,1,3,0.21428571428571427,MidAge,EU,0.07142857142857142,3,0,19,0,0,0,0,0,0,0,2,2025,10,3,4,0.08073634859349145,4.071428571428571,0.07142857142857142 +25879816,US,US,1,2.0,0,0,0,0,2025-10-03,3.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Child,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,3,4,0.08073634859349145,0.046541693600517124,0.015513897866839042 +25880182,US,US,1,2.0,0,0,0,0,2025-10-04,57.0,801.0,Male,75.0,OTEZLA,therapeutic product effect incomplete,0,0,0.0,MidAge,US,0.0,4,0,37,0,0,0,0,0,0,0,4,2025,10,4,5,0.08073634859349145,0.0,0.0 +26155011,US,US,1,2.0,0,0,0,0,2025-12-15,57.0,801.0,Male,75.0,KISUNLA,muscle spasms,0,0,0.0,MidAge,US,0.0,1,0,13,0,0,0,0,0,0,0,2,2025,12,15,0,0.08073634859349145,0.0,0.0 +26155402,AU,AU,1,2.0,0,0,0,0,2025-12-15,32.0,801.0,Female,75.0,AZATHIOPRINE,parvovirus b19 infection,0,0,0.0,Young,AU,0.0,2,0,24,0,1,0,0,0,0,0,3,2025,12,15,0,0.08073634859349145,0.0,0.0 +25893209,EU,EU,1,1.0,0,0,0,0,2025-10-08,55.0,801.0,Female,49.0,LETROZOLE,migraine,1,0,0.0,MidAge,EU,0.07142857142857142,3,0,8,0,0,0,0,0,0,0,1,2025,10,8,2,0.08073634859349145,3.9285714285714284,0.07142857142857142 +25893276,US,US,1,2.0,0,0,0,0,2025-10-08,42.0,801.0,Female,75.0,DUPIXENT,tremor,0,0,0.0,Adult,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,10,8,2,0.08073634859349145,0.6515837104072397,0.015513897866839042 +25271098,US,US,2,1.0,0,0,0,0,2025-05-06,57.0,801.0,Male,75.0,EPIDIOLEX,bipolar disorder,1,0,0.0,MidAge,US,0.14285714285714285,3,1,16,0,0,0,0,0,0,0,2,2025,5,6,1,0.08936301793444651,8.142857142857142,0.0 +25273933,US,US,1,1.0,0,0,0,0,2025-05-06,57.0,801.0,Male,75.0,VONJO,foreign body in throat,1,0,0.0,MidAge,US,0.0,3,0,22,0,0,0,0,0,0,0,4,2025,5,6,1,0.08073634859349145,0.0,0.0 +25283181,EU,EU,1,1.0,0,1,1,0,2025-05-08,23.0,801.0,Male,75.0,LACOSAMIDE,blood creatine phosphokinase increased,1,7,0.5,Young,EU,0.16666666666666666,3,1,38,0,0,0,0,0,0,0,4,2025,5,8,3,0.08073634859349145,3.833333333333333,0.0 +25291524,US,US,1,1.0,0,0,1,0,2025-05-10,52.0,801.0,Female,94.8,DUPIXENT,sepsis,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,5,10,5,0.08073634859349145,0.8067226890756302,0.015513897866839042 +25293979,US,US,1,2.0,0,0,0,0,2025-05-10,62.0,801.0,Male,75.0,DUPIXENT,cough,0,0,0.0,MidAge,US,0.015513897866839042,221,0,5,0,0,0,0,0,0,0,1,2025,5,10,5,0.08073634859349145,0.9618616677440206,0.0 +25299878,US,US,1,1.0,0,0,1,0,2025-05-12,77.0,801.0,Female,75.0,ORENCIA,hospitalisation,1,3,0.21428571428571427,Senior,US,0.10204081632653061,14,0,15,0,0,0,0,0,0,0,1,2025,5,12,0,0.08073634859349145,7.857142857142858,0.10204081632653061 +25307872,CA,CA,2,1.0,0,0,1,0,2025-05-13,58.0,801.0,Male,75.0,VEDOLIZUMAB,intestinal stenosis,1,3,0.21428571428571427,MidAge,CA,0.057692307692307696,26,0,19,0,0,0,0,0,0,0,2,2025,5,13,1,0.08936301793444651,3.3461538461538463,0.0 +25321265,US,US,2,1.0,0,0,0,0,2025-05-15,52.0,801.0,Male,75.0,SKYRIZI,bladder cancer recurrent,1,0,0.0,MidAge,US,0.051587301587301584,36,0,24,0,0,0,1,0,0,0,3,2025,5,15,3,0.08936301793444651,2.6825396825396823,0.0 +25326530,US,US,1,2.0,0,0,0,0,2025-05-16,16.0,801.0,Male,75.0,DUPIXENT,incorrect dose administered,0,0,0.0,Child,US,0.015513897866839042,221,0,27,0,0,0,0,0,0,0,3,2025,5,16,4,0.08073634859349145,0.24822236586942467,0.0 +25344026,US,US,1,2.0,0,0,0,0,2025-05-21,29.0,801.0,Male,75.0,DUPIXENT,nasal congestion,0,0,0.0,Young,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,5,21,2,0.08073634859349145,0.4499030381383322,0.0 +25355257,US,US,1,2.0,0,0,0,0,2025-05-24,57.0,801.0,Female,75.0,RUCONEST,weight decreased,0,0,0.0,MidAge,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,5,24,5,0.08073634859349145,0.0,0.0 +25367865,EU,EU,1,1.0,0,0,0,0,2025-05-28,38.0,801.0,Female,75.0,DULOXETINE,drug abuse,1,0,0.0,Adult,EU,0.0,2,0,10,0,0,0,0,0,0,0,2,2025,5,28,2,0.08073634859349145,0.0,0.0 +25382110,US,US,1,2.0,0,0,0,0,2025-05-31,57.0,801.0,Female,75.0,ZYMFENTRA,vein rupture,0,0,0.0,MidAge,US,0.0,1,0,12,0,0,0,0,0,0,0,2,2025,5,31,5,0.08073634859349145,0.0,0.0 +25446449,US,Unknown,1,2.0,0,0,0,0,2025-06-17,57.0,801.0,Female,75.0,BIMZELX,acne cystic,0,0,0.0,MidAge,US,0.0,22,0,11,0,0,0,0,0,0,0,2,2025,6,17,1,0.08073634859349145,0.0,0.0 +25446692,US,Unknown,1,2.0,0,0,0,0,2025-06-17,54.0,801.0,Female,75.0,BIMZELX,migraine,0,0,0.0,MidAge,US,0.0,22,0,8,0,0,0,0,0,0,0,1,2025,6,17,1,0.08073634859349145,0.0,0.0 +25446759,US,Unknown,1,2.0,0,0,0,0,2025-06-17,57.0,801.0,Female,75.0,BIMZELX,candida infection,0,0,0.0,MidAge,US,0.0,22,0,17,0,1,0,0,0,0,0,2,2025,6,17,1,0.08073634859349145,0.0,0.0 +25449460,US,US,1,1.0,0,0,0,0,2025-06-18,42.0,801.0,Female,74.83,PARAGARD T 380A,surgery,1,0,0.0,Adult,US,0.0,4,0,7,0,0,0,0,0,0,0,1,2025,6,18,2,0.08073634859349145,0.0,0.0 +25449851,US,Unknown,1,2.0,0,0,0,0,2025-06-18,41.0,801.0,Female,75.0,BIMZELX,injection site pain,0,0,0.0,Adult,US,0.0,22,0,19,1,0,0,0,0,0,0,3,2025,6,18,2,0.08073634859349145,0.0,0.0 +25465350,CA,CA,2,1.0,0,0,0,0,2025-06-22,53.0,801.0,Male,75.0,REMICADE,prostatomegaly,1,0,0.0,MidAge,CA,0.0,3,0,14,0,0,0,0,0,0,0,1,2025,6,22,6,0.08936301793444651,0.0,0.0 +25485019,EU,EU,1,1.0,0,0,0,0,2025-06-26,13.0,801.0,Female,68.0,SERTRALINE,multiple acyl-coenzyme a dehydrogenase deficiency,1,0,0.0,Child,EU,0.0,1,0,49,0,0,0,0,0,0,0,5,2025,6,26,3,0.08073634859349145,0.0,0.0 +25491566,US,US,2,1.0,0,0,0,0,2025-06-29,77.0,801.0,Female,75.0,SKYRIZI,mastectomy,1,0,0.0,Senior,US,0.051587301587301584,36,0,10,0,0,0,0,0,0,0,1,2025,6,29,6,0.08936301793444651,3.972222222222222,0.051587301587301584 +25501814,US,US,2,1.0,0,0,0,0,2025-07-02,57.0,801.0,Male,75.0,RINVOQ,back pain,1,0,0.0,MidAge,US,0.0,3,0,9,1,0,0,0,0,0,0,2,2025,7,2,2,0.08936301793444651,0.0,0.0 +25509724,JP,JP,2,1.0,1,0,0,0,2025-07-03,57.0,801.0,Female,75.0,EFGARTIGIMOD ALFA,sudden death,1,5,0.35714285714285715,MidAge,JP,0.35714285714285715,1,1,12,0,0,1,0,0,0,0,2,2025,7,3,3,0.08936301793444651,20.357142857142858,0.35714285714285715 +26172708,US,US,1,1.0,0,0,0,0,2025-12-18,49.0,801.0,Male,75.0,ORENCIA,erythema,1,0,0.0,Adult,US,0.10204081632653061,14,0,8,0,0,0,0,0,0,0,1,2025,12,18,3,0.08073634859349145,5.0,0.0 +26173909,CN,CN,1,1.0,0,0,1,0,2025-12-18,49.0,801.0,Female,75.0,PERJETA,myelosuppression,1,3,0.21428571428571427,Adult,CN,0.21428571428571427,2,1,16,0,0,0,0,0,0,0,1,2025,12,18,3,0.08073634859349145,10.5,0.21428571428571427 +26174032,CA,CA,2,1.0,0,0,0,0,2025-12-18,80.0,801.0,Female,75.0,VEDOLIZUMAB,haematochezia,1,0,0.0,Senior,CA,0.057692307692307696,26,0,13,0,0,0,0,0,0,0,1,2025,12,18,3,0.08936301793444651,4.615384615384616,0.057692307692307696 +26174423,US,US,1,2.0,0,0,0,0,2025-12-18,57.0,801.0,Male,75.0,DUPIXENT,drug ineffective,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,12,18,3,0.08073634859349145,0.8842921784098254,0.0 +26174476,US,US,1,2.0,0,0,0,0,2025-12-18,52.0,801.0,Male,75.0,VASCEPA,hypertension,0,0,0.0,MidAge,US,0.0,2,0,12,0,0,0,0,0,0,0,1,2025,12,18,3,0.08073634859349145,0.0,0.0 +25907331,JP,JP,1,1.0,0,0,1,0,2025-10-10,84.0,801.0,Female,49.9,TAVNEOS,drug-induced liver injury,1,3,0.21428571428571427,Senior,JP,0.21428571428571427,1,1,25,0,0,0,0,0,0,0,3,2025,10,10,4,0.08073634859349145,18.0,0.21428571428571427 +25907803,GB,GB,1,1.0,0,0,1,0,2025-10-10,65.0,801.0,Female,99.0,DOCETAXEL,cardiotoxicity,1,3,0.21428571428571427,MidAge,GB,0.061224489795918366,7,0,14,0,0,0,0,0,0,0,1,2025,10,10,4,0.08073634859349145,3.9795918367346936,0.061224489795918366 +25908895,US,US,1,2.0,0,0,0,0,2025-10-11,71.0,801.0,Female,75.0,HUMALOG,blood glucose increased,0,0,0.0,Senior,US,0.05357142857142857,4,0,23,0,0,0,0,0,0,0,3,2025,10,11,5,0.08073634859349145,3.8035714285714284,0.05357142857142857 +25910557,US,US,1,2.0,0,0,0,0,2025-10-13,47.0,801.0,Female,75.0,DUPIXENT,psoriasis,0,0,0.0,Adult,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,10,13,0,0.08073634859349145,0.729153199741435,0.015513897866839042 +25956595,GB,GB,1,1.0,0,0,0,0,2025-10-24,74.0,801.0,Male,99.0,BISOPROLOL FUMARATE,wheezing,1,0,0.0,Senior,GB,0.0,1,0,8,0,0,0,0,0,0,0,1,2025,10,24,4,0.08073634859349145,0.0,0.0 +25957123,GB,GB,1,1.0,0,0,0,0,2025-10-24,57.0,801.0,Male,75.0,CLOZARIL,eosinophilia,1,0,0.0,MidAge,GB,0.10714285714285714,4,0,12,0,0,0,0,0,0,0,1,2025,10,24,4,0.08073634859349145,6.107142857142857,0.0 +25958243,EU,EU,1,1.0,0,0,0,0,2025-10-24,95.0,801.0,Male,75.0,MIRTAZAPINE,wrong product administered,1,0,0.0,Senior,EU,0.19047619047619047,3,1,26,0,0,0,0,0,0,0,3,2025,10,24,4,0.08073634859349145,18.095238095238095,0.0 +25958715,JP,JP,1,1.0,0,0,1,0,2025-10-24,71.0,801.0,Male,75.0,GAZYVA,pneumonia,1,3,0.21428571428571427,Senior,JP,0.21428571428571427,1,1,9,0,0,0,0,0,1,0,1,2025,10,24,4,0.08073634859349145,15.214285714285714,0.0 +25531675,CA,CA,2,1.0,0,0,1,0,2025-07-09,88.0,801.0,Male,75.0,VEDOLIZUMAB,diarrhoea,1,3,0.21428571428571427,Senior,CA,0.057692307692307696,26,0,9,0,0,0,0,0,0,0,1,2025,7,9,2,0.08936301793444651,5.0769230769230775,0.0 +25544406,CA,CA,2,1.0,0,0,1,0,2025-07-11,65.0,801.0,Male,75.0,ADALIMUMAB,device issue,1,3,0.21428571428571427,MidAge,CA,0.07142857142857142,3,0,12,0,0,0,0,0,0,0,2,2025,7,11,4,0.08936301793444651,4.642857142857142,0.0 +25555961,US,US,1,2.0,0,0,0,0,2025-07-15,53.0,801.0,Female,75.0,DUPIXENT,asthma,0,0,0.0,MidAge,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,7,15,1,0.08073634859349145,0.8222365869424693,0.015513897866839042 +25567759,US,US,2,1.0,0,0,0,0,2025-07-16,58.0,801.0,Female,75.0,VEDOLIZUMAB,colitis ulcerative,1,0,0.0,MidAge,US,0.057692307692307696,26,0,18,0,0,0,0,0,0,0,2,2025,7,16,2,0.08936301793444651,3.3461538461538463,0.057692307692307696 +25574038,JP,JP,1,1.0,0,0,0,0,2025-07-17,57.0,801.0,Male,75.0,LENVIMA,hepatic function abnormal,1,0,0.0,MidAge,JP,0.07142857142857142,2,0,25,0,0,0,0,0,0,0,3,2025,7,17,3,0.08073634859349145,4.071428571428571,0.0 +25581638,CN,CN,1,1.0,0,1,0,0,2025-07-19,61.0,801.0,Female,75.0,DEXAMETHASONE,neutropenia,1,4,0.2857142857142857,MidAge,CN,0.1857142857142857,5,1,11,0,0,0,0,0,0,0,1,2025,7,19,5,0.08073634859349145,11.328571428571427,0.1857142857142857 +26175705,US,US,1,2.0,0,0,0,0,2025-12-18,57.0,801.0,Male,86.36,DUPIXENT,enterobiasis,0,0,0.0,MidAge,US,0.015513897866839042,221,0,12,0,0,0,0,0,0,0,1,2025,12,18,3,0.08073634859349145,0.8842921784098254,0.0 +26176744,US,US,1,2.0,0,0,0,0,2025-12-18,57.0,801.0,Male,75.0,SKYRIZI,nephrolithiasis,0,0,0.0,MidAge,US,0.051587301587301584,36,0,15,0,0,0,0,0,0,0,1,2025,12,18,3,0.08073634859349145,2.9404761904761902,0.0 +26176959,US,US,1,2.0,0,0,0,0,2025-12-18,57.0,801.0,Female,75.0,PLUVICTO,general physical health deterioration,0,0,0.0,MidAge,US,0.0,8,0,37,0,0,0,0,0,0,0,4,2025,12,18,3,0.08073634859349145,0.0,0.0 +26177297,US,US,1,2.0,0,0,0,0,2025-12-19,57.0,801.0,Female,75.0,FLUOXETINE,depression,0,0,0.0,MidAge,US,0.0,1,0,10,0,0,0,0,0,0,0,1,2025,12,19,4,0.08073634859349145,0.0,0.0 +26177783,US,US,1,1.0,0,0,0,0,2025-12-19,57.0,801.0,Male,75.0,RISPERDAL,galactorrhoea,1,0,0.0,MidAge,US,0.0,1,0,13,0,0,0,0,0,0,0,1,2025,12,19,4,0.08073634859349145,0.0,0.0 +26178621,US,US,1,2.0,0,0,0,0,2025-12-19,57.0,801.0,Female,75.0,DUPIXENT,pain in extremity,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,1,0,0,0,0,0,0,3,2025,12,19,4,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26178836,US,US,1,2.0,0,0,0,0,2025-12-19,57.0,801.0,Female,75.0,SELINEXOR,pneumonia,0,0,0.0,MidAge,US,0.0,1,0,9,0,0,0,0,0,1,0,1,2025,12,19,4,0.08073634859349145,0.0,0.0 +26178850,EU,EU,1,1.0,0,1,1,0,2025-12-19,42.0,801.0,Female,53.0,VENLAFAXINE,cardio-respiratory arrest,1,7,0.5,Adult,EU,0.25,2,1,25,0,0,0,0,0,0,0,2,2025,12,19,4,0.08073634859349145,10.5,0.25 +25911691,US,US,2,1.0,0,0,0,0,2025-10-13,57.0,801.0,Female,75.0,SKYRIZI,cataract,1,0,0.0,MidAge,US,0.051587301587301584,36,0,8,0,0,0,0,0,0,0,1,2025,10,13,0,0.08936301793444651,2.9404761904761902,0.051587301587301584 +25911705,US,US,1,2.0,0,0,0,0,2025-10-13,21.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,13,0,0.08073634859349145,0.32579185520361986,0.015513897866839042 +25912205,US,US,1,2.0,0,0,0,0,2025-10-13,43.0,801.0,Female,75.0,DUPIXENT,extra dose administered,0,0,0.0,Adult,US,0.015513897866839042,221,0,23,0,0,0,0,0,0,0,3,2025,10,13,0,0.08073634859349145,0.6670976082740788,0.015513897866839042 +25913244,US,US,1,2.0,0,0,0,0,2025-10-13,41.0,801.0,Female,75.0,XOLAIR,product storage error,0,0,0.0,Adult,US,0.14285714285714285,4,1,21,0,0,0,0,0,0,0,3,2025,10,13,0,0.08073634859349145,5.857142857142857,0.14285714285714285 +25959888,US,US,1,2.0,0,0,0,0,2025-10-26,15.0,801.0,Male,75.0,DUPIXENT,dysphagia,0,0,0.0,Child,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,10,26,6,0.08073634859349145,0.23270846800258563,0.0 +25959983,US,US,1,2.0,0,0,0,0,2025-10-26,57.0,801.0,Male,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,26,6,0.08073634859349145,0.8842921784098254,0.0 +25960039,US,US,1,2.0,0,0,0,0,2025-10-26,57.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,10,26,6,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25963265,US,US,1,1.0,0,0,1,0,2025-10-27,53.0,801.0,Male,75.0,HUMALOG,renal failure,1,3,0.21428571428571427,MidAge,US,0.05357142857142857,4,0,13,0,0,0,0,1,0,0,2,2025,10,27,0,0.08073634859349145,2.839285714285714,0.0 +25963980,CA,CA,1,1.0,0,0,0,0,2025-10-27,53.0,801.0,Female,75.0,GABAPENTIN,treatment failure,1,0,0.0,MidAge,CA,0.061224489795918366,7,0,17,0,0,0,0,1,0,0,2,2025,10,27,0,0.08073634859349145,3.2448979591836733,0.061224489795918366 +26180336,CA,CA,2,1.0,0,0,0,0,2025-12-19,78.0,801.0,Male,58.05,METHOTREXATE SODIUM,bronchiectasis,1,0,0.0,Senior,CA,0.125,4,1,14,0,0,0,0,0,0,0,1,2025,12,19,4,0.08936301793444651,9.75,0.0 +26180794,EU,EU,1,1.0,0,0,1,0,2025-12-21,84.0,801.0,Female,75.0,WELLBUTRIN XL,vertigo,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,7,0,0,0,0,0,0,0,1,2025,12,21,6,0.08073634859349145,18.0,0.21428571428571427 +26180808,EU,EU,1,1.0,0,0,0,0,2025-12-21,72.0,801.0,Male,75.0,LENALIDOMIDE,diabetes mellitus,1,0,0.0,Senior,EU,0.15413533834586465,19,1,17,0,0,0,0,0,0,0,2,2025,12,21,6,0.08073634859349145,11.097744360902254,0.0 +26181241,US,US,1,2.0,0,0,0,0,2025-12-21,57.0,801.0,Female,75.0,PLUVICTO,general physical health deterioration,0,0,0.0,MidAge,US,0.0,8,0,37,0,0,0,0,0,0,0,4,2025,12,21,6,0.08073634859349145,0.0,0.0 +26181403,US,US,1,2.0,0,0,0,0,2025-12-21,57.0,801.0,Male,75.0,SUTAB,pain,0,0,0.0,MidAge,US,0.0,2,0,4,1,0,0,0,0,0,0,1,2025,12,21,6,0.08073634859349145,0.0,0.0 +26182886,GB,GB,1,1.0,0,0,0,0,2025-12-21,30.0,801.0,Female,55.0,DYSPORT,laryngospasm,1,0,0.0,Young,GB,0.0,1,0,12,0,0,0,0,0,0,0,1,2025,12,21,6,0.08073634859349145,0.0,0.0 +25915903,EU,EU,1,1.0,0,0,0,0,2025-10-13,85.0,801.0,Male,82.0,DARZALEX,pleurisy,1,0,0.0,Senior,EU,0.0,2,0,8,0,0,0,0,0,0,0,1,2025,10,13,0,0.08073634859349145,0.0,0.0 +25916375,US,US,1,2.0,0,0,0,0,2025-10-14,59.0,801.0,Female,75.0,COPAXONE,treatment failure,0,0,0.0,MidAge,US,0.0,2,0,17,0,0,0,0,1,0,0,2,2025,10,14,1,0.08073634859349145,0.0,0.0 +25918023,CA,CA,1,1.0,0,0,0,0,2025-10-14,57.0,801.0,Female,75.0,INFLIXIMAB,basal cell carcinoma,1,0,0.0,MidAge,CA,0.07142857142857142,9,0,20,0,0,0,0,0,0,0,3,2025,10,14,1,0.08073634859349145,4.071428571428571,0.07142857142857142 +25918076,US,US,1,2.0,0,0,0,0,2025-10-14,57.0,801.0,Female,75.0,ALBUTEROL SULFATE,wrong technique in product usage process,0,0,0.0,MidAge,US,0.0,8,0,40,0,0,0,0,0,0,0,6,2025,10,14,1,0.08073634859349145,0.0,0.0 +25595556,EG,EG,2,1.0,0,0,1,0,2025-07-23,65.0,801.0,Female,48.0,LONSURF,decreased immune responsiveness,1,3,0.21428571428571427,MidAge,Other,0.21428571428571427,1,1,31,0,0,0,0,0,0,0,3,2025,7,23,2,0.08936301793444651,13.928571428571427,0.21428571428571427 +25596366,GB,GB,1,1.0,0,0,0,0,2025-07-23,19.0,802.0,Female,75.0,CYCLOSPORINE,adenovirus infection,1,0,0.0,Young,GB,0.0,5,0,20,0,1,0,0,0,0,0,2,2025,7,23,2,0.08073634859349145,0.0,0.0 +25600148,US,US,1,1.0,0,0,0,0,2025-07-24,57.0,801.0,Female,41.723,FIRDAPSE,cholecystectomy,1,0,0.0,MidAge,US,0.0,3,0,15,0,0,0,0,0,0,0,1,2025,7,24,3,0.08073634859349145,0.0,0.0 +25604575,US,US,1,2.0,0,0,0,0,2025-07-25,57.0,801.0,Female,75.0,VYLOY,face oedema,0,0,0.0,MidAge,US,0.0,1,0,11,0,0,0,0,0,0,0,2,2025,7,25,4,0.08073634859349145,0.0,0.0 +25626607,US,US,1,2.0,0,0,0,0,2025-07-31,56.0,801.0,Female,75.0,HYRIMOZ,injection site haemorrhage,0,0,0.0,MidAge,US,0.0,1,0,26,0,0,0,0,0,0,0,3,2025,7,31,3,0.08073634859349145,0.0,0.0 +25628847,US,US,1,1.0,0,0,1,0,2025-07-31,73.0,801.0,Male,111.11,TRULICITY,intestinal obstruction,1,3,0.21428571428571427,Senior,US,0.04285714285714286,5,0,22,0,0,0,0,0,0,0,2,2025,7,31,3,0.08073634859349145,3.1285714285714286,0.0 +25633182,EU,EU,1,1.0,0,0,1,0,2025-08-01,38.0,801.0,Female,75.0,MAGNESIUM SULFATE,respiratory failure,1,3,0.21428571428571427,Adult,EU,0.21428571428571427,1,1,19,0,0,0,0,1,0,0,2,2025,8,1,4,0.08073634859349145,8.142857142857142,0.21428571428571427 +25645804,US,US,1,1.0,0,0,0,0,2025-08-05,34.0,801.0,Female,158.73,PARAGARD T 380A,surgery,1,0,0.0,Young,US,0.0,4,0,7,0,0,0,0,0,0,0,1,2025,8,5,1,0.08073634859349145,0.0,0.0 +25648315,JP,JP,1,1.0,0,0,1,0,2025-08-06,57.0,801.0,Female,75.0,NEMOLIZUMAB,vomiting,1,3,0.21428571428571427,MidAge,JP,0.21428571428571427,1,1,8,0,0,0,0,0,0,0,1,2025,8,6,2,0.08073634859349145,12.214285714285714,0.21428571428571427 +26183467,US,US,1,1.0,0,0,0,0,2025-12-21,57.0,801.0,Female,78.005,ORENITRAM,renal function test abnormal,1,0,0.0,MidAge,US,0.0,2,0,28,0,0,0,0,0,0,0,4,2025,12,21,6,0.08073634859349145,0.0,0.0 +26183953,EU,EU,3,1.0,0,0,1,0,2025-12-22,57.0,801.0,Female,75.0,DIAZEPAM,drug use disorder,1,3,0.21428571428571427,MidAge,EU,0.2619047619047619,3,1,17,0,0,0,0,0,0,0,3,2025,12,22,0,0.17857142857142855,14.928571428571429,0.2619047619047619 +26185911,US,US,1,1.0,0,0,0,0,2025-12-22,54.0,801.0,Male,105.69,POMALYST,abdominal pain,1,0,0.0,MidAge,US,0.11428571428571428,5,0,14,1,0,0,0,0,0,0,2,2025,12,22,0,0.08073634859349145,6.171428571428571,0.0 +26186640,US,Unknown,1,1.0,0,0,1,0,2025-12-19,84.0,801.0,Male,102.0,APIXABAN,gastrointestinal haemorrhage,1,3,0.21428571428571427,Senior,US,0.07142857142857142,3,0,28,0,0,0,0,0,0,0,2,2025,12,19,4,0.08073634859349145,6.0,0.0 +26186679,US,US,1,2.0,0,0,0,0,2025-12-22,69.0,801.0,Female,75.0,DUPIXENT,sinusitis,0,0,0.0,Senior,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,12,22,0,0.08073634859349145,1.070458952811894,0.015513897866839042 +26186802,SG,SG,1,1.0,0,0,1,0,2025-12-22,38.0,801.0,Female,106.5,FLUDARABINE,covid-19 pneumonia,1,3,0.21428571428571427,Adult,Other,0.21428571428571427,1,1,18,0,0,0,0,0,1,0,2,2025,12,22,0,0.08073634859349145,8.142857142857142,0.21428571428571427 +25964804,EU,EU,1,1.0,0,0,0,0,2025-10-27,57.0,801.0,Female,75.0,NUBEQA,myocardial ischaemia,1,0,0.0,MidAge,EU,0.0,1,0,20,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,0.0,0.0 +25965195,US,US,1,2.0,0,0,0,0,2025-10-27,57.0,801.0,Female,75.0,DUPIXENT,product storage error,0,0,0.0,MidAge,US,0.015513897866839042,221,0,21,0,0,0,0,0,0,0,3,2025,10,27,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25967692,EU,EU,1,1.0,0,0,1,0,2025-10-28,46.0,801.0,Male,75.0,OXALIPLATIN,acute kidney injury,1,3,0.21428571428571427,Adult,EU,0.08571428571428572,5,0,19,0,0,0,0,0,0,0,3,2025,10,28,1,0.08073634859349145,3.942857142857143,0.0 +25651340,JP,JP,1,1.0,0,0,0,0,2025-08-06,57.0,801.0,Female,75.0,OPDIVO,adrenal insufficiency,1,0,0.0,MidAge,JP,0.08928571428571429,4,0,21,0,0,0,0,0,0,0,2,2025,8,6,2,0.08073634859349145,5.089285714285714,0.08928571428571429 +25652460,JP,JP,1,1.0,0,0,0,0,2025-08-07,69.0,801.0,Male,75.0,LIVTENCITY,cerebral infarction,1,0,0.0,Senior,JP,0.0,1,0,19,0,0,0,0,0,0,0,2,2025,8,7,3,0.08073634859349145,0.0,0.0 +25652985,US,US,2,1.0,0,0,0,0,2025-08-07,64.0,801.0,Female,75.0,SKYRIZI,rotator cuff repair,1,0,0.0,MidAge,US,0.051587301587301584,36,0,19,0,0,0,0,0,0,0,3,2025,8,7,3,0.08936301793444651,3.3015873015873014,0.051587301587301584 +25668537,US,US,1,1.0,0,0,1,0,2025-08-12,57.0,801.0,Female,39.692,REVUFORJ,fungal infection,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,16,0,1,0,0,0,0,0,2,2025,8,12,1,0.08073634859349145,12.214285714285714,0.21428571428571427 +25676651,US,US,1,2.0,0,0,0,0,2025-08-13,57.0,801.0,Female,75.0,ESTRADIOL,device adhesion issue,0,0,0.0,MidAge,US,0.0,8,0,21,0,0,0,0,0,0,0,3,2025,8,13,2,0.08073634859349145,0.0,0.0 +25678042,US,US,1,2.0,0,0,0,0,2025-08-13,23.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,8,13,2,0.08073634859349145,0.35681965093729795,0.015513897866839042 +25679067,JP,JP,1,1.0,0,1,1,0,2025-08-14,41.0,801.0,Male,75.0,DAPRODUSTAT,platelet count decreased,1,7,0.5,Adult,JP,0.5,1,1,24,0,0,0,0,0,0,0,3,2025,8,14,3,0.08073634859349145,20.5,0.0 +25679500,US,US,2,1.0,0,0,1,0,2025-08-14,73.0,801.0,Female,75.0,NUPLAZID,rectal ulcer haemorrhage,1,3,0.21428571428571427,Senior,US,0.09523809523809523,6,0,24,0,0,0,0,0,0,0,3,2025,8,14,3,0.08936301793444651,6.952380952380952,0.09523809523809523 +25689192,EU,EU,2,1.0,0,0,1,0,2025-08-18,72.0,801.0,Female,55.0,ENHERTU,hyperpyrexia,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,12,0,0,0,0,0,0,0,1,2025,8,18,0,0.08936301793444651,15.428571428571427,0.21428571428571427 +25923760,US,US,1,2.0,0,0,0,0,2025-10-15,57.0,801.0,Male,75.0,COLUMVI,product administration error,0,0,0.0,MidAge,US,0.0,1,0,28,0,0,0,0,0,0,0,3,2025,10,15,2,0.08073634859349145,0.0,0.0 +25923841,US,US,1,2.0,0,0,0,0,2025-10-15,34.0,801.0,Female,75.0,ACCRUFER,maternal exposure during pregnancy,0,0,0.0,Young,US,0.07142857142857142,3,0,34,0,0,0,0,0,0,0,4,2025,10,15,2,0.08073634859349145,2.4285714285714284,0.07142857142857142 +25925137,US,US,1,2.0,0,0,0,0,2025-10-15,57.0,801.0,Female,75.0,IQIRVO,product dose omission issue,0,0,0.0,MidAge,US,0.0,2,0,27,0,0,0,0,0,0,0,4,2025,10,15,2,0.08073634859349145,0.0,0.0 +25925676,US,US,1,2.0,0,0,0,0,2025-10-15,51.0,801.0,Female,75.0,DUPIXENT,dry skin,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2025,10,15,2,0.08073634859349145,0.7912087912087912,0.015513897866839042 +25926123,EU,EU,1,1.0,0,0,0,0,2025-10-15,58.0,801.0,Female,65.0,VALACYCLOVIR HYDROCHLORIDE,neuropathy peripheral,1,0,0.0,MidAge,EU,0.0,1,0,21,0,0,0,0,0,0,0,2,2025,10,15,2,0.08073634859349145,0.0,0.0 +25969016,EU,EU,1,1.0,0,0,0,0,2025-10-28,57.0,801.0,Female,75.0,ALPRAZOLAM,hallucination,1,0,0.0,MidAge,EU,0.14285714285714285,3,1,13,0,0,0,0,0,0,0,1,2025,10,28,1,0.08073634859349145,8.142857142857142,0.14285714285714285 +25970326,US,US,2,1.0,0,0,0,0,2025-10-28,76.0,801.0,Female,75.0,CREON,medical procedure,1,0,0.0,Senior,US,0.03296703296703297,13,0,17,0,0,0,0,0,0,0,2,2025,10,28,1,0.08936301793444651,2.5054945054945055,0.03296703296703297 +25970474,US,US,1,2.0,0,0,0,0,2025-10-28,57.0,801.0,Male,54.431,HUMIRA,drug ineffective,0,0,0.0,MidAge,US,0.17857142857142858,2,1,16,0,0,0,0,0,0,0,2,2025,10,28,1,0.08073634859349145,10.178571428571429,0.0 +25970960,US,US,1,2.0,0,0,0,0,2025-10-28,67.0,801.0,Male,75.0,METHOTREXATE SODIUM,drug ineffective,0,0,0.0,Senior,US,0.125,4,1,16,0,0,0,0,0,0,0,2,2025,10,28,1,0.08073634859349145,8.375,0.0 +25928444,IN,IN,3,1.0,0,0,1,0,2025-10-16,29.0,801.0,Male,75.0,CYCLOPHOSPHAMIDE,therapeutic response unexpected,1,3,0.21428571428571427,Young,IN,0.21428571428571427,2,1,31,0,0,0,0,0,0,0,3,2025,10,16,3,0.17857142857142855,6.2142857142857135,0.0 +25928754,US,US,1,1.0,0,0,0,0,2025-10-16,84.0,801.0,Male,75.0,ACCRUFER,choking,1,0,0.0,Senior,US,0.07142857142857142,3,0,7,0,0,0,0,0,0,0,1,2025,10,16,3,0.08073634859349145,6.0,0.0 +25930793,EU,EU,2,1.0,1,0,0,0,2025-10-16,79.0,801.0,Female,75.0,CARBIDOPA,death,1,5,0.35714285714285715,Senior,EU,0.35714285714285715,1,1,5,0,0,1,0,0,0,0,1,2025,10,16,3,0.08936301793444651,28.214285714285715,0.35714285714285715 +25931941,US,US,1,2.0,0,0,0,0,2025-10-16,58.0,801.0,Female,75.0,VUEWAY,rash,0,0,0.0,MidAge,US,0.0,1,0,4,0,0,0,0,0,0,0,1,2025,10,16,3,0.08073634859349145,0.0,0.0 +26192324,US,US,1,2.0,0,0,0,0,2025-12-23,82.0,801.0,Male,75.0,DUPIXENT,injection site pain,0,0,0.0,Senior,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,12,23,1,0.08073634859349145,1.2721396250808015,0.0 +26195307,US,US,1,1.0,0,0,1,0,2025-12-24,65.0,801.0,Female,75.0,TACROLIMUS,west nile viral infection,1,3,0.21428571428571427,MidAge,US,0.09183673469387754,7,0,25,0,1,0,0,0,0,0,4,2025,12,24,2,0.08073634859349145,5.969387755102041,0.09183673469387754 +26195589,TW,TW,1,1.0,0,0,1,0,2025-12-24,23.0,801.0,Male,75.0,CELECOXIB,toxicity to various agents,1,3,0.21428571428571427,Young,Other,0.21428571428571427,1,1,26,0,0,0,0,0,0,0,4,2025,12,24,2,0.08073634859349145,4.928571428571428,0.0 +25981881,EU,EU,1,1.0,0,0,0,0,2025-10-31,57.0,801.0,Female,75.0,RITUXIMAB,disease progression,1,0,0.0,MidAge,EU,0.12406015037593986,19,0,19,0,0,0,0,0,0,0,2,2025,10,31,4,0.08073634859349145,7.071428571428572,0.12406015037593986 +25982800,AU,AU,1,1.0,0,0,0,0,2025-10-31,75.0,801.0,Male,75.0,CARBOPLATIN,diffuse large b-cell lymphoma,1,0,0.0,Senior,AU,0.12244897959183673,7,0,29,0,0,0,0,0,0,0,4,2025,10,31,4,0.08073634859349145,9.183673469387754,0.0 +25983920,US,Unknown,1,2.0,0,0,0,0,2025-10-31,57.0,801.0,Female,75.0,WINREVAIR,adverse event,0,0,0.0,MidAge,US,0.2619047619047619,3,1,13,0,0,0,0,0,0,0,2,2025,10,31,4,0.08073634859349145,14.928571428571429,0.2619047619047619 +25984325,RU,RU,1,1.0,1,0,0,0,2025-10-31,62.0,801.0,Male,75.0,POLATUZUMAB VEDOTIN,neutropenia,1,5,0.35714285714285715,MidAge,Other,0.35714285714285715,1,1,11,0,0,0,0,0,0,0,1,2025,10,31,4,0.08073634859349145,22.142857142857142,0.0 +25761553,US,US,1,1.0,0,0,0,0,2025-09-04,57.0,801.0,Female,75.0,SUBOXONE,suicidal ideation,1,0,0.0,MidAge,US,0.0,1,0,17,0,0,0,0,0,0,0,2,2025,9,4,3,0.08073634859349145,0.0,0.0 +25769854,JP,JP,1,1.0,0,0,0,0,2025-09-07,7.0,800.0,Female,75.0,KEYTRUDA,malignant neoplasm progression,1,0,0.0,Child,JP,0.11904761904761905,3,0,30,0,0,0,0,0,0,0,3,2025,9,7,6,0.08073634859349145,0.8333333333333334,0.11904761904761905 +25773675,US,US,1,2.0,0,0,0,0,2025-09-08,57.0,801.0,Female,75.0,ESTRADIOL,circumstance or information capable of leading to device use error,0,0,0.0,MidAge,US,0.0,8,0,66,0,0,0,0,0,0,0,10,2025,9,8,0,0.08073634859349145,0.0,0.0 +25942376,US,US,2,1.0,0,0,0,0,2025-10-21,42.0,801.0,Male,75.0,SPRAVATO,respiratory depression,1,0,0.0,Adult,US,0.026785714285714284,8,0,22,0,0,0,0,0,0,0,2,2025,10,21,1,0.08936301793444651,1.125,0.0 +25942714,CN,CN,2,1.0,0,0,0,0,2025-10-21,57.0,801.0,Female,75.0,RITUXIMAB,infusion related reaction,1,0,0.0,MidAge,CN,0.12406015037593986,19,0,25,0,0,0,0,0,0,0,3,2025,10,21,1,0.08936301793444651,7.071428571428572,0.12406015037593986 +25942943,EU,EU,1,1.0,0,0,1,0,2025-10-21,74.0,801.0,Male,72.0,RISEDRONATE SODIUM,small intestinal ulcer haemorrhage,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,34,0,0,0,0,0,0,0,4,2025,10,21,1,0.08073634859349145,15.857142857142856,0.0 +25944859,US,US,1,2.0,0,0,0,0,2025-10-21,57.0,801.0,Female,75.0,VOQUEZNA,alopecia,0,0,0.0,MidAge,US,0.0,2,0,8,0,0,0,0,0,0,0,1,2025,10,21,1,0.08073634859349145,0.0,0.0 +25945010,US,US,1,2.0,0,0,0,0,2025-10-21,59.0,801.0,Female,75.0,VOQUEZNA,neuralgia,0,0,0.0,MidAge,US,0.0,2,0,9,0,0,0,0,0,0,0,1,2025,10,21,1,0.08073634859349145,0.0,0.0 +26202072,US,US,1,2.0,0,0,0,0,2025-12-26,20.0,801.0,Male,75.0,DUPIXENT,respiratory tract infection,0,0,0.0,Young,US,0.015513897866839042,221,0,27,0,1,0,0,0,0,0,3,2025,12,26,4,0.08073634859349145,0.3102779573367808,0.0 +26202153,US,US,1,2.0,0,0,0,0,2025-12-26,20.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,12,26,4,0.08073634859349145,0.3102779573367808,0.015513897866839042 +25985621,EU,EU,1,1.0,1,0,0,0,2025-10-31,32.0,801.0,Male,75.0,DIAZEPAM,high risk sexual behaviour,1,5,0.35714285714285715,Young,EU,0.2619047619047619,3,1,26,0,0,0,0,0,0,0,4,2025,10,31,4,0.08073634859349145,8.380952380952381,0.0 +25987012,US,US,1,2.0,0,0,0,0,2025-11-03,87.0,801.0,Female,75.0,HUMALOG,visual impairment,0,0,0.0,Senior,US,0.05357142857142857,4,0,17,0,0,0,0,0,0,0,2,2025,11,3,0,0.08073634859349145,4.660714285714286,0.05357142857142857 +25987766,EU,EU,1,1.0,0,0,0,0,2025-11-03,27.0,801.0,Female,75.0,IBUPROFEN,laryngeal oedema,1,0,0.0,Young,EU,0.11607142857142858,8,0,16,0,0,0,0,0,0,0,2,2025,11,3,0,0.08073634859349145,3.1339285714285716,0.11607142857142858 +25988523,EU,EU,2,1.0,0,0,1,0,2025-11-03,6.0,800.0,Female,75.0,RITUXIMAB,rheumatoid arthritis,1,3,0.21428571428571427,Child,EU,0.12406015037593986,19,0,20,0,0,0,0,0,0,0,2,2025,11,3,0,0.08936301793444651,0.7443609022556391,0.12406015037593986 +25778993,US,US,1,2.0,0,0,0,0,2025-09-09,45.0,801.0,Female,75.0,ORENCIA,arthralgia,0,0,0.0,Adult,US,0.10204081632653061,14,0,10,0,0,0,0,0,0,0,1,2025,9,9,1,0.08073634859349145,4.591836734693878,0.10204081632653061 +25786015,US,US,2,1.0,0,0,0,0,2025-09-10,57.0,801.0,Female,75.0,KESIMPTA,multiple sclerosis,1,0,0.0,MidAge,US,0.0,2,0,18,0,0,0,0,0,0,0,2,2025,9,10,2,0.08936301793444651,0.0,0.0 +25789146,EU,EU,1,1.0,0,0,1,0,2025-09-11,47.0,801.0,Female,75.0,FULVESTRANT,electrolyte imbalance,1,3,0.21428571428571427,Adult,EU,0.21428571428571427,1,1,21,0,0,0,0,0,0,0,2,2025,9,11,3,0.08073634859349145,10.071428571428571,0.21428571428571427 +25793992,US,US,1,2.0,0,0,0,0,2025-09-12,62.0,801.0,Female,146.51,ACTEMRA,back pain,0,0,0.0,MidAge,US,0.17857142857142858,6,1,9,1,0,0,0,0,0,0,2,2025,9,12,4,0.08073634859349145,11.071428571428571,0.17857142857142858 +25803310,US,US,1,1.0,0,0,0,0,2025-09-15,31.0,801.0,Female,73.016,HAEGARDA,maternal exposure during pregnancy,1,0,0.0,Young,US,0.0,1,0,34,0,0,0,0,0,0,0,4,2025,9,15,0,0.08073634859349145,0.0,0.0 +25803983,EU,EU,1,1.0,0,0,1,0,2025-09-15,60.0,801.0,Female,86.0,RITUXIMAB,leukocytosis,1,3,0.21428571428571427,MidAge,EU,0.12406015037593986,19,0,12,0,0,0,0,0,0,0,1,2025,9,15,0,0.08073634859349145,7.443609022556392,0.12406015037593986 +25807008,US,US,2,2.0,0,0,0,0,2025-09-16,57.0,801.0,Male,75.0,OMNITROPE,circumstance or information capable of leading to medication error,0,0,0.0,MidAge,US,0.0,5,0,66,0,0,0,0,0,0,0,9,2025,9,16,1,0.08936301793444651,0.0,0.0 +26206513,GB,GB,1,1.0,0,0,1,0,2025-12-29,42.0,801.0,Male,75.0,NAPROXEN,acute kidney injury,1,3,0.21428571428571427,Adult,GB,0.2857142857142857,2,1,19,0,0,0,0,0,0,0,3,2025,12,29,0,0.08073634859349145,12.0,0.0 +26206661,US,US,1,2.0,0,0,0,0,2025-12-29,40.0,801.0,Female,75.0,DUPIXENT,condition aggravated,0,0,0.0,Adult,US,0.015513897866839042,221,0,20,0,0,0,0,0,0,0,2,2025,12,29,0,0.08073634859349145,0.6205559146735616,0.015513897866839042 +25989009,US,US,1,2.0,0,0,0,0,2025-11-03,49.0,801.0,Female,136.05,ALBUTEROL SULFATE,dyspnoea,0,0,0.0,Adult,US,0.0,8,0,8,0,0,0,0,0,0,0,1,2025,11,3,0,0.08073634859349145,0.0,0.0 +25989467,EU,EU,1,1.0,0,0,1,0,2025-11-03,69.0,801.0,Female,68.0,LETROZOLE,dental operation,1,3,0.21428571428571427,Senior,EU,0.07142857142857142,3,0,16,0,0,0,0,0,0,0,2,2025,11,3,0,0.08073634859349145,4.928571428571428,0.07142857142857142 +25989562,CN,CN,1,1.0,0,0,1,0,2025-11-03,57.0,801.0,Female,75.0,METHIMAZOLE,antithyroid arthritis syndrome,1,3,0.21428571428571427,MidAge,CN,0.21428571428571427,1,1,30,0,0,0,0,0,0,0,3,2025,11,3,0,0.08073634859349145,12.214285714285714,0.21428571428571427 +25990104,EU,EU,1,1.0,0,0,1,0,2025-11-03,57.0,801.0,Female,75.0,BUPRENORPHINE,urinary retention,1,3,0.21428571428571427,MidAge,EU,0.2857142857142857,2,1,17,0,0,0,0,0,0,0,2,2025,11,3,0,0.08073634859349145,16.285714285714285,0.2857142857142857 +25991277,US,US,1,2.0,0,0,0,0,2025-11-03,57.0,801.0,Female,75.0,DUPIXENT,inappropriate schedule of product administration,0,0,0.0,MidAge,US,0.015513897866839042,221,0,48,0,0,0,0,0,0,0,5,2025,11,3,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25991992,US,US,1,2.0,0,0,0,0,2025-11-03,80.0,801.0,Female,75.0,SOLIQUA 100/33,pruritus,0,0,0.0,Senior,US,0.0,1,0,8,0,0,0,0,0,0,0,1,2025,11,3,0,0.08073634859349145,0.0,0.0 +25992492,US,US,1,2.0,0,0,0,0,2025-11-03,57.0,801.0,Female,75.0,DOXYLAMINE SUCCINATE,fatigue,0,0,0.0,MidAge,US,0.0,1,0,7,0,0,0,0,0,0,0,1,2025,11,3,0,0.08073634859349145,0.0,0.0 +25950490,US,US,2,1.0,1,0,0,0,2025-10-23,69.0,801.0,Female,75.0,SYNTHROID,renal failure,1,5,0.35714285714285715,Senior,US,0.17857142857142858,2,1,13,0,0,0,0,1,0,0,2,2025,10,23,3,0.08936301793444651,12.321428571428571,0.17857142857142858 +25950557,GB,GB,2,1.0,0,0,1,0,2025-10-23,78.0,801.0,Female,75.0,CARBIDOPA\LEVODOPA,faecaloma,1,3,0.21428571428571427,Senior,GB,0.3333333333333333,3,1,9,0,0,0,0,0,0,0,1,2025,10,23,3,0.08936301793444651,26.0,0.3333333333333333 +25950571,EU,EU,1,1.0,0,0,1,0,2025-10-23,78.0,801.0,Female,68.2,RYBREVANT,mucosal inflammation,1,3,0.21428571428571427,Senior,EU,0.05357142857142857,4,0,20,0,0,0,0,0,0,0,2,2025,10,23,3,0.08073634859349145,4.178571428571428,0.05357142857142857 +25950638,US,US,1,2.0,0,0,0,0,2025-10-23,57.0,801.0,Female,75.0,DUPIXENT,dry skin,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2025,10,23,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25950962,JP,JP,1,1.0,0,0,1,0,2025-10-23,57.0,801.0,Female,75.0,METHYLPHENIDATE HYDROCHLORIDE,hospitalisation,1,3,0.21428571428571427,MidAge,JP,0.10714285714285714,2,0,15,0,0,0,0,0,0,0,1,2025,10,23,3,0.08073634859349145,6.107142857142857,0.10714285714285714 +25951529,GB,GB,1,1.0,0,1,0,0,2025-10-23,57.0,801.0,Female,75.0,DIMETHYL FUMARATE,leukaemia,1,4,0.2857142857142857,MidAge,GB,0.2857142857142857,1,1,9,0,0,0,0,0,0,0,1,2025,10,23,3,0.08073634859349145,16.285714285714285,0.2857142857142857 +25952043,CA,CA,2,1.0,0,0,1,0,2025-10-23,53.0,801.0,Male,75.0,SKYRIZI,acute myocardial infarction,1,3,0.21428571428571427,MidAge,CA,0.051587301587301584,36,0,27,0,0,0,0,0,0,0,3,2025,10,23,3,0.08936301793444651,2.734126984126984,0.0 +26209725,EU,EU,1,1.0,0,0,0,0,2025-12-29,90.0,801.0,Female,77.0,ALDACTONE,neutropenia,1,0,0.0,Senior,EU,0.0,1,0,11,0,0,0,0,0,0,0,1,2025,12,29,0,0.08073634859349145,0.0,0.0 +26212493,US,US,1,1.0,0,0,0,0,2025-12-30,71.0,801.0,Female,80.726,FIRDAPSE,chondropathy,1,0,0.0,Senior,US,0.0,3,0,12,0,0,0,0,0,0,0,1,2025,12,30,1,0.08073634859349145,0.0,0.0 +25809572,US,US,1,2.0,0,0,0,0,2025-09-16,62.0,801.0,Male,75.0,DUPIXENT,no adverse event,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,3,2025,9,16,1,0.08073634859349145,0.9618616677440206,0.0 +25813326,BA,BA,1,1.0,0,1,1,0,2025-09-17,50.0,801.0,Male,88.0,FRAGMIN,drug ineffective,1,7,0.5,Adult,Other,0.5,1,1,16,0,0,0,0,0,0,0,2,2025,9,17,2,0.08073634859349145,25.0,0.0 +25815027,EU,EU,1,1.0,0,0,0,0,2025-09-18,58.0,801.0,Female,75.0,DOCETAXEL,infusion related reaction,1,0,0.0,MidAge,EU,0.061224489795918366,7,0,25,0,0,0,0,0,0,0,3,2025,9,18,3,0.08073634859349145,3.5510204081632653,0.061224489795918366 +25820588,US,US,2,1.0,0,0,1,0,2025-09-19,57.0,801.0,Female,63.946,ISTURISA,cardiac failure,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,15,0,0,0,0,1,0,0,2,2025,9,19,4,0.08936301793444651,12.214285714285714,0.21428571428571427 +25824948,US,US,1,1.0,0,0,0,0,2025-09-19,68.0,801.0,Female,75.0,XELJANZ XR,neuropathy peripheral,1,0,0.0,Senior,US,0.0,9,0,21,0,0,0,0,0,0,0,2,2025,9,19,4,0.08073634859349145,0.0,0.0 +25827473,CA,Unknown,2,1.0,0,0,0,0,2025-09-20,57.0,801.0,Female,75.0,CERTOLIZUMAB PEGOL,ankylosing spondylitis,1,0,0.0,MidAge,CA,0.04285714285714286,5,0,22,0,0,0,0,0,0,0,2,2025,9,20,5,0.08936301793444651,2.442857142857143,0.04285714285714286 +25827554,EU,EU,1,1.0,0,0,0,0,2025-09-20,57.0,801.0,Female,75.0,PROCYSBI,endocarditis,1,0,0.0,MidAge,EU,0.0,1,0,12,0,0,0,0,0,0,0,1,2025,9,20,5,0.08073634859349145,0.0,0.0 +25829336,US,US,1,2.0,0,0,0,0,2025-09-22,57.0,801.0,Female,75.0,TIOTROPIUM BROMIDE,drug ineffective,0,0,0.0,MidAge,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,9,22,0,0.08073634859349145,0.0,0.0 +25837612,US,US,1,2.0,0,0,0,0,2025-09-23,10.0,801.0,Female,75.0,OMNITROPE,circumstance or information capable of leading to medication error,0,0,0.0,Child,US,0.0,5,0,66,0,0,0,0,0,0,0,9,2025,9,23,1,0.08073634859349145,0.0,0.0 +25993464,US,US,1,1.0,0,0,0,0,2025-11-04,57.0,801.0,Female,92.517,SYMBICORT,hypothyroidism,1,0,0.0,MidAge,US,0.0,2,0,14,0,0,0,0,0,0,0,1,2025,11,4,1,0.08073634859349145,0.0,0.0 +25996218,US,US,1,1.0,0,0,1,0,2025-11-04,67.0,801.0,Female,75.0,CARBOPLATIN,emphysematous cystitis,1,3,0.21428571428571427,Senior,US,0.12244897959183673,7,0,22,0,0,0,0,0,0,0,2,2025,11,4,1,0.08073634859349145,8.204081632653061,0.12244897959183673 +25953945,EU,EU,1,1.0,0,0,1,0,2025-10-23,69.0,801.0,Female,45.0,PEMETREXED,dermatitis bullous,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,3,1,18,0,0,0,0,0,0,0,2,2025,10,23,3,0.08073634859349145,14.785714285714285,0.21428571428571427 +25955389,EU,EU,1,1.0,0,0,0,0,2025-10-24,39.0,801.0,Male,75.0,PAROXETINE,drug abuse,1,0,0.0,Adult,EU,0.0,2,0,10,0,0,0,0,0,0,0,2,2025,10,24,4,0.08073634859349145,0.0,0.0 +25955970,US,US,1,2.0,0,0,0,0,2025-10-24,57.0,801.0,Female,75.0,ALBUTEROL SULFATE,wrong technique in product usage process,0,0,0.0,MidAge,US,0.0,8,0,40,0,0,0,0,0,0,0,6,2025,10,24,4,0.08073634859349145,0.0,0.0 +25956632,CA,CA,1,1.0,0,0,1,0,2025-10-24,74.0,801.0,Male,102.0,AZACITIDINE,colitis,1,3,0.21428571428571427,Senior,CA,0.21428571428571427,1,1,7,0,0,0,0,0,0,0,1,2025,10,24,4,0.08073634859349145,15.857142857142856,0.0 +25958252,US,US,1,2.0,0,0,0,0,2025-10-24,64.0,801.0,Male,96.0,VYEPTI,chest discomfort,0,0,0.0,MidAge,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,10,24,4,0.08073634859349145,0.0,0.0 +25958467,US,US,1,2.0,0,0,0,0,2025-10-24,67.0,801.0,Female,54.422,NICOTINE POLACRILEX,expired product administered,0,0,0.0,Senior,US,0.0,1,0,28,0,0,0,0,0,0,0,3,2025,10,24,4,0.08073634859349145,0.0,0.0 +25959668,US,US,1,1.0,0,0,0,0,2025-10-26,75.0,801.0,Male,75.0,DUPIXENT,loss of consciousness,1,0,0.0,Senior,US,0.015513897866839042,221,0,21,0,0,0,0,0,0,0,3,2025,10,26,6,0.08073634859349145,1.1635423400129281,0.0 +25960062,US,US,1,2.0,0,0,0,0,2025-10-26,18.0,801.0,Female,75.0,DUPIXENT,incorrect dose administered,0,0,0.0,Child,US,0.015513897866839042,221,0,27,0,0,0,0,0,0,0,3,2025,10,26,6,0.08073634859349145,0.27925016160310273,0.015513897866839042 +25960453,US,US,1,2.0,0,0,0,0,2025-10-27,10.0,801.0,Male,75.0,OMNITROPE,circumstance or information capable of leading to medication error,0,0,0.0,Child,US,0.0,5,0,66,0,0,0,0,0,0,0,9,2025,10,27,0,0.08073634859349145,0.0,0.0 +25960763,CN,CN,1,1.0,1,0,0,0,2025-10-27,86.0,801.0,Male,69.0,SEVOFLURANE,anaphylactic shock,1,5,0.35714285714285715,Senior,CN,0.35714285714285715,1,1,18,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,30.714285714285715,0.0 +25961115,US,US,1,2.0,0,0,0,0,2025-10-27,71.0,801.0,Male,75.0,BASAGLAR,nephrolithiasis,0,0,0.0,Senior,US,0.0,2,0,15,0,0,0,0,0,0,0,1,2025,10,27,0,0.08073634859349145,0.0,0.0 +25961964,EU,EU,1,1.0,0,0,1,0,2025-10-27,67.0,801.0,Male,75.0,IBUPROFEN,acute kidney injury,1,3,0.21428571428571427,Senior,EU,0.11607142857142858,8,0,19,0,0,0,0,0,0,0,3,2025,10,27,0,0.08073634859349145,7.776785714285714,0.0 +25850248,GB,GB,1,1.0,0,0,1,0,2025-09-26,57.0,801.0,Female,75.0,PREGABALIN,post-traumatic stress disorder,1,3,0.21428571428571427,MidAge,GB,0.10714285714285714,6,0,30,0,0,0,0,0,0,0,3,2025,9,26,4,0.08073634859349145,6.107142857142857,0.10714285714285714 +25851139,US,US,1,1.0,0,0,0,0,2025-09-26,57.0,801.0,Female,75.0,RYBREVANT,infusion related reaction,1,0,0.0,MidAge,US,0.05357142857142857,4,0,25,0,0,0,0,0,0,0,3,2025,9,26,4,0.08073634859349145,3.0535714285714284,0.05357142857142857 +25851935,US,US,1,2.0,0,0,0,0,2025-09-26,57.0,801.0,Female,58.503,LEVOTHYROXINE SODIUM,thyroid disorder,0,0,0.0,MidAge,US,0.0,3,0,16,0,0,0,0,0,0,0,2,2025,9,26,4,0.08073634859349145,0.0,0.0 +25852798,EU,EU,1,1.0,0,0,0,0,2025-09-26,57.0,801.0,Male,75.0,ADCETRIS,malignant neoplasm progression,1,0,0.0,MidAge,EU,0.0,2,0,30,0,0,0,0,0,0,0,3,2025,9,26,4,0.08073634859349145,0.0,0.0 +25853407,CN,CN,1,1.0,0,0,0,0,2025-09-26,57.0,801.0,Female,75.0,RYBREVANT,myelosuppression,1,0,0.0,MidAge,CN,0.05357142857142857,4,0,16,0,0,0,0,0,0,0,1,2025,9,26,4,0.08073634859349145,3.0535714285714284,0.05357142857142857 +25998539,US,US,1,2.0,0,0,0,0,2025-11-05,53.0,801.0,Male,75.0,ORGOVYX,abdominal discomfort,0,0,0.0,MidAge,US,0.0,4,0,20,0,0,0,0,0,0,0,2,2025,11,5,2,0.08073634859349145,0.0,0.0 +25999282,US,US,1,1.0,0,0,1,0,2025-11-05,57.0,801.0,Female,68.31,DUPIXENT,haemoptysis,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,11,0,0,0,0,0,0,0,1,2025,11,5,2,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25999497,EU,EU,1,1.0,0,0,1,0,2025-11-05,71.0,801.0,Female,46.0,LORMETAZEPAM,poisoning deliberate,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,20,0,0,0,0,0,0,0,2,2025,11,5,2,0.08073634859349145,15.214285714285714,0.21428571428571427 +26000095,AU,AU,1,1.0,0,0,1,0,2025-11-05,56.0,801.0,Male,116.9,VINCRISTINE,rib fracture,1,3,0.21428571428571427,MidAge,AU,0.21428571428571427,1,1,12,0,0,0,0,0,0,0,2,2025,11,5,2,0.08073634859349145,12.0,0.0 +26000567,US,Unknown,1,1.0,0,0,1,0,2025-11-04,57.0,801.0,Male,97.2,WINREVAIR,catheter site haemorrhage,1,3,0.21428571428571427,MidAge,US,0.2619047619047619,3,1,25,0,0,0,0,0,0,0,3,2025,11,4,1,0.08073634859349145,14.928571428571429,0.0 +25962288,AU,AU,1,1.0,1,0,0,0,2025-10-27,57.0,801.0,Male,75.0,ALCOHOL (ALCOHOL),intentional overdose,1,5,0.35714285714285715,MidAge,AU,0.35714285714285715,1,1,20,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,20.357142857142858,0.0 +25962383,EU,EU,1,1.0,0,0,1,0,2025-10-27,71.0,801.0,Male,75.0,ADRENALIN,condition aggravated,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,20,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,15.214285714285714,0.0 +25964503,US,US,1,1.0,0,0,1,0,2025-10-27,13.0,801.0,Female,75.0,METHOTREXATE,neurotoxicity,1,3,0.21428571428571427,Child,US,0.17346938775510204,7,1,13,0,0,0,0,0,0,0,1,2025,10,27,0,0.08073634859349145,2.2551020408163267,0.17346938775510204 +25964880,US,US,1,1.0,0,0,1,0,2025-10-27,57.0,801.0,Female,75.0,WEGOVY,intestinal obstruction,1,3,0.21428571428571427,MidAge,US,0.14285714285714285,4,1,22,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,8.142857142857142,0.14285714285714285 +25965232,US,US,1,2.0,0,0,0,0,2025-10-27,57.0,801.0,Female,75.0,DUPIXENT,pruritus,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,10,27,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25965528,US,US,1,2.0,0,0,0,0,2025-10-27,15.0,801.0,Male,75.0,DUPIXENT,fear of injection,0,0,0.0,Child,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,3,2025,10,27,0,0.08073634859349145,0.23270846800258563,0.0 +25965609,US,US,1,2.0,0,0,0,0,2025-10-27,51.0,801.0,Male,75.0,DUPIXENT,eosinophilic oesophagitis,0,0,0.0,MidAge,US,0.015513897866839042,221,0,25,0,0,0,0,0,0,0,2,2025,10,27,0,0.08073634859349145,0.7912087912087912,0.0 +25965919,US,US,1,2.0,0,0,0,0,2025-10-27,57.0,801.0,Female,79.55,DUPIXENT,product use in unapproved indication,0,0,0.0,MidAge,US,0.015513897866839042,221,0,36,0,0,0,0,0,0,0,5,2025,10,27,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26003335,EU,EU,1,1.0,0,0,1,0,2025-11-06,52.0,801.0,Female,75.0,CLONAZEPAM,drug abuse,1,3,0.21428571428571427,MidAge,EU,0.07142857142857142,3,0,10,0,0,0,0,0,0,0,2,2025,11,6,3,0.08073634859349145,3.714285714285714,0.07142857142857142 +26003564,US,US,1,2.0,0,0,0,0,2025-11-06,1.0,801.0,Female,75.0,DUPIXENT,maternal exposure during breast feeding,0,0,0.0,Child,US,0.015513897866839042,221,0,39,0,0,0,0,0,0,0,5,2025,11,6,3,0.08073634859349145,0.015513897866839042,0.015513897866839042 +26003807,US,US,1,2.0,0,0,0,0,2025-11-06,57.0,801.0,Female,60.45,DUPIXENT,pruritus,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,11,6,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26004198,US,US,1,2.0,0,0,0,0,2025-11-06,57.0,801.0,Female,79.37,DUPIXENT,maternal exposure during pregnancy,0,0,0.0,MidAge,US,0.015513897866839042,221,0,34,0,0,0,0,0,0,0,4,2025,11,6,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26004279,US,US,1,2.0,0,0,0,0,2025-11-06,57.0,801.0,Male,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,MidAge,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,11,6,3,0.08073634859349145,0.8842921784098254,0.0 +25861426,US,US,2,1.0,0,0,0,0,2025-09-29,57.0,801.0,Female,79.0,HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN,mycobacterium avium complex infection,1,0,0.0,MidAge,US,0.07142857142857142,3,0,37,0,1,0,0,0,0,0,4,2025,9,29,0,0.08936301793444651,4.071428571428571,0.07142857142857142 +25861479,CA,CA,2,1.0,0,0,0,0,2025-09-30,57.0,801.0,Female,75.0,SIMPONI,rheumatoid arthritis,1,0,0.0,MidAge,CA,0.0,2,0,20,0,0,0,0,0,0,0,2,2025,9,30,1,0.08936301793444651,0.0,0.0 +25861574,VN,VN,2,1.0,0,0,0,0,2025-09-30,55.0,801.0,Male,75.0,DARZALEX,leukopenia,1,0,0.0,MidAge,Other,0.0,2,0,10,0,0,0,0,0,0,0,1,2025,9,30,1,0.08936301793444651,0.0,0.0 +25867473,US,US,2,1.0,0,0,1,0,2025-10-01,72.0,801.0,Male,75.0,CREON,sepsis,1,3,0.21428571428571427,Senior,US,0.03296703296703297,13,0,6,0,0,0,0,0,0,0,1,2025,10,1,2,0.08936301793444651,2.3736263736263736,0.0 +25868498,PR,PR,2,1.0,0,0,1,0,2025-10-01,74.0,801.0,Female,75.0,VENCLEXTA,white blood cell count decreased,1,3,0.21428571428571427,Senior,Other,0.18571428571428572,5,1,32,0,0,0,0,0,0,0,5,2025,10,1,2,0.08936301793444651,13.742857142857144,0.18571428571428572 +25868889,US,US,1,1.0,0,0,0,0,2025-10-01,62.0,801.0,Male,75.0,HYDRALAZINE HYDROCHLORIDE,glomerulonephritis,1,0,0.0,MidAge,US,0.0,1,0,18,0,0,0,0,0,0,0,1,2025,10,1,2,0.08073634859349145,0.0,0.0 +25868917,CA,CA,1,1.0,1,0,1,1,2025-10-01,40.0,801.0,Female,75.0,ACTEMRA,contraindicated product administered,1,10,0.7142857142857143,Adult,CA,0.17857142857142858,6,1,36,0,0,0,0,0,0,0,3,2025,10,1,2,0.08073634859349145,7.142857142857143,0.17857142857142858 +25967296,US,US,2,1.0,0,0,0,0,2025-10-28,57.0,801.0,Female,75.0,SKYRIZI,nephrolithiasis,1,0,0.0,MidAge,US,0.051587301587301584,36,0,15,0,0,0,0,0,0,0,1,2025,10,28,1,0.08936301793444651,2.9404761904761902,0.051587301587301584 +25969078,EU,EU,1,1.0,0,0,0,0,2025-10-28,57.0,801.0,Male,75.0,DOCETAXEL,hepatotoxicity,1,0,0.0,MidAge,EU,0.061224489795918366,7,0,14,0,0,0,0,0,0,0,1,2025,10,28,1,0.08073634859349145,3.489795918367347,0.0 +25969173,CA,CA,3,1.0,0,0,0,0,2025-10-28,48.0,801.0,Male,75.0,MYCOPHENOLATE MOFETIL,lymphadenopathy,1,0,0.0,Adult,CA,0.10150375939849625,19,0,15,0,0,0,0,0,0,0,1,2025,10,28,1,0.17857142857142855,4.87218045112782,0.0 +25969430,JP,JP,1,1.0,0,0,1,0,2025-10-28,78.0,801.0,Male,75.0,METHYLPREDNISOLONE,cerebral infarction,1,3,0.21428571428571427,Senior,JP,0.14285714285714285,3,1,19,0,0,0,0,0,0,0,2,2025,10,28,1,0.08073634859349145,11.142857142857142,0.0 +26005494,EU,EU,1,1.0,1,0,1,0,2025-11-06,48.0,801.0,Male,75.0,DOLUTEGRAVIR,pancytopenia,1,8,0.5714285714285714,Adult,EU,0.5714285714285714,1,1,12,0,0,0,0,0,0,0,1,2025,11,6,3,0.08073634859349145,27.428571428571427,0.0 +26006075,US,US,1,2.0,0,0,0,0,2025-11-06,20.0,801.0,Male,75.0,ADDERALL XR,restlessness,0,0,0.0,Young,US,0.0,2,0,12,0,0,0,0,0,0,0,1,2025,11,6,3,0.08073634859349145,0.0,0.0 +26007195,US,US,2,2.0,0,0,0,0,2025-11-06,70.0,801.0,Female,75.0,ZENATANE,product use issue,0,0,0.0,Senior,US,0.0,1,0,17,0,0,0,0,0,0,0,3,2025,11,6,3,0.08936301793444651,0.0,0.0 +26007924,US,Unknown,1,1.0,0,0,0,0,2025-11-05,73.0,801.0,Male,72.03,INSULIN LISPRO,device malfunction,1,0,0.0,Senior,US,0.0,1,0,18,0,0,0,0,0,0,0,2,2025,11,5,2,0.08073634859349145,0.0,0.0 +26008505,US,US,1,2.0,0,0,0,0,2025-11-06,41.0,801.0,Female,75.0,DUPIXENT,eosinophilic oesophagitis,0,0,0.0,Adult,US,0.015513897866839042,221,0,25,0,0,0,0,0,0,0,2,2025,11,6,3,0.08073634859349145,0.6360698125404007,0.015513897866839042 +26008572,CA,CA,1,1.0,0,0,0,0,2025-11-06,57.0,801.0,Female,75.0,VASCEPA,choking,1,0,0.0,MidAge,CA,0.0,2,0,7,0,0,0,0,0,0,0,1,2025,11,6,3,0.08073634859349145,0.0,0.0 +25871308,EU,EU,1,1.0,0,0,1,0,2025-10-01,73.0,801.0,Female,64.0,GEMCITABINE,lung disorder,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,13,0,0,0,0,0,0,0,2,2025,10,1,2,0.08073634859349145,15.642857142857142,0.21428571428571427 +25871403,US,US,1,2.0,0,0,0,0,2025-10-01,85.0,801.0,Female,81.633,DUPIXENT,foreign body sensation in eyes,0,0,0.0,Senior,US,0.015513897866839042,221,0,30,0,0,0,0,0,0,0,5,2025,10,1,2,0.08073634859349145,1.3186813186813187,0.015513897866839042 +25872576,US,US,1,2.0,0,0,0,0,2025-10-02,45.0,801.0,Female,75.0,DUPIXENT,off label use,0,0,0.0,Adult,US,0.015513897866839042,221,0,13,0,0,0,0,0,0,0,3,2025,10,2,3,0.08073634859349145,0.6981254040077569,0.015513897866839042 +25970469,EU,EU,2,1.0,0,0,1,0,2025-10-28,57.0,801.0,Female,75.0,METHOTREXATE,knee arthroplasty,1,3,0.21428571428571427,MidAge,EU,0.17346938775510204,7,1,17,0,0,0,0,0,0,0,2,2025,10,28,1,0.08936301793444651,9.887755102040817,0.17346938775510204 +25971455,CA,CA,1,1.0,0,0,0,0,2025-10-28,52.0,801.0,Female,75.0,TADALAFIL,condition aggravated,1,0,0.0,MidAge,CA,0.0,2,0,20,0,0,0,0,0,0,0,2,2025,10,28,1,0.08073634859349145,0.0,0.0 +25972265,EU,EU,1,1.0,0,0,0,0,2025-10-29,81.0,801.0,Female,75.0,CIPROFLOXACIN,mobility decreased,1,0,0.0,Senior,EU,0.07142857142857142,3,0,18,0,0,0,0,0,0,0,2,2025,10,29,2,0.08073634859349145,5.785714285714286,0.07142857142857142 +25973695,US,US,1,2.0,0,0,0,0,2025-10-29,57.0,801.0,Female,75.0,PROGESTERONE,headache,0,0,0.0,MidAge,US,0.0,1,0,8,0,0,0,0,0,0,0,1,2025,10,29,2,0.08073634859349145,0.0,0.0 +26010153,JP,JP,1,1.0,0,0,0,0,2025-11-07,57.0,801.0,Female,75.0,DENOSUMAB,carcinoembryonic antigen increased,1,0,0.0,MidAge,JP,0.0,1,0,34,0,0,0,0,0,0,0,3,2025,11,7,4,0.08073634859349145,0.0,0.0 +26010759,GB,GB,1,1.0,0,0,0,0,2025-11-07,68.0,801.0,Female,80.0,ATORVASTATIN,gastrointestinal disorder,1,0,0.0,Senior,GB,0.10714285714285714,2,0,25,0,0,0,0,0,0,0,2,2025,11,7,4,0.08073634859349145,7.285714285714286,0.10714285714285714 +26011435,US,US,1,2.0,0,0,0,0,2025-11-07,57.0,801.0,Female,75.0,ALBUTEROL SULFATE,circumstance or information capable of leading to medication error,0,0,0.0,MidAge,US,0.0,8,0,66,0,0,0,0,0,0,0,9,2025,11,7,4,0.08073634859349145,0.0,0.0 +26012164,CA,CA,1,1.0,1,0,0,0,2025-11-07,43.0,801.0,Female,68.0,ACTEMRA,condition aggravated,1,5,0.35714285714285715,Adult,CA,0.17857142857142858,6,1,20,0,0,0,0,0,0,0,2,2025,11,7,4,0.08073634859349145,7.678571428571429,0.17857142857142858 +25874196,BR,BR,2,1.0,0,0,0,0,2025-10-02,56.0,801.0,Female,69.0,VEDOLIZUMAB,colitis ulcerative,1,0,0.0,MidAge,BR,0.057692307692307696,26,0,18,0,0,0,0,0,0,0,2,2025,10,2,3,0.08936301793444651,3.230769230769231,0.057692307692307696 +25874925,GB,GB,1,1.0,0,0,0,0,2025-10-02,57.0,801.0,Male,75.0,VENETOCLAX,cytopenia,1,0,0.0,MidAge,GB,0.0,1,0,9,0,0,0,0,0,0,0,1,2025,10,2,3,0.08073634859349145,0.0,0.0 +25877531,CN,CN,1,1.0,0,0,0,0,2025-10-03,87.0,801.0,Female,57.0,TISLELIZUMAB,myelosuppression,1,0,0.0,Senior,CN,0.0,3,0,16,0,0,0,0,0,0,0,1,2025,10,3,4,0.08073634859349145,0.0,0.0 +25878570,US,US,1,1.0,0,0,1,0,2025-10-03,70.0,801.0,Male,75.0,LENALIDOMIDE,cardiac disorder,1,3,0.21428571428571427,Senior,US,0.15413533834586465,19,1,16,0,0,0,0,0,0,0,2,2025,10,3,4,0.08073634859349145,10.789473684210526,0.0 +25879151,EU,EU,1,1.0,0,0,1,0,2025-10-03,55.0,801.0,Male,72.0,CIPROFLOXACIN,dysbiosis,1,3,0.21428571428571427,MidAge,EU,0.07142857142857142,3,0,9,0,0,0,0,0,0,0,1,2025,10,3,4,0.08073634859349145,3.9285714285714284,0.0 +25881042,US,US,1,2.0,0,0,0,0,2025-10-04,57.0,801.0,Male,75.0,DUPIXENT,hypersensitivity,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,1,2025,10,4,5,0.08073634859349145,0.8842921784098254,0.0 +25975653,US,Unknown,1,1.0,0,0,1,0,2025-10-29,87.0,801.0,Female,75.0,LENALIDOMIDE,intentional dose omission,1,3,0.21428571428571427,Senior,US,0.15413533834586465,19,1,25,0,0,0,0,0,0,0,3,2025,10,29,2,0.08073634859349145,13.409774436090224,0.15413533834586465 +25976153,CA,CA,1,1.0,1,0,0,0,2025-10-29,43.0,801.0,Female,68.0,COSENTYX,confusional state,1,5,0.35714285714285715,Adult,CA,0.05714285714285714,10,0,17,0,0,0,0,0,0,0,2,2025,10,29,2,0.08073634859349145,2.457142857142857,0.05714285714285714 +25976382,GB,GB,1,1.0,0,0,0,0,2025-10-29,57.0,801.0,Female,75.0,COSENTYX,osteonecrosis,1,0,0.0,MidAge,GB,0.05714285714285714,10,0,13,0,0,0,0,0,0,0,1,2025,10,29,2,0.08073634859349145,3.257142857142857,0.05714285714285714 +25976463,US,US,1,2.0,0,0,0,0,2025-10-29,57.0,801.0,Male,75.0,TRELEGY ELLIPTA,visual impairment,0,0,0.0,MidAge,US,0.0,4,0,17,0,0,0,0,0,0,0,2,2025,10,29,2,0.08073634859349145,0.0,0.0 +14520544,US,US,2,1.0,0,0,1,0,2018-02-12,78.0,801.0,Female,75.0,VEDOLIZUMAB,hip fracture,1,3,0.21428571428571427,Senior,US,0.057692307692307696,26,0,12,0,0,0,0,0,0,0,2,2018,2,12,0,0.08936301793444651,4.5,0.057692307692307696 +15082980,US,US,1,2.0,0,0,0,0,2018-06-28,41.0,801.0,Female,75.0,SUBLOCADE,dysgeusia,0,0,0.0,Adult,US,0.0,1,0,9,0,0,0,0,0,0,0,1,2018,6,28,3,0.08073634859349145,0.0,0.0 +17707771,US,US,2,1.0,0,0,1,0,2020-04-24,26.0,801.0,Female,56.0,HUMAN IMMUNOGLOBULIN G,covid-19 pneumonia,1,3,0.21428571428571427,Young,US,0.10714285714285714,8,0,18,0,0,0,0,0,1,0,2,2020,4,24,4,0.08936301793444651,2.7857142857142856,0.10714285714285714 +17806834,CA,CA,1,1.0,0,0,0,0,2020-05-20,53.0,801.0,Female,53.0,ACTEMRA,abdominal pain,1,0,0.0,MidAge,CA,0.17857142857142858,6,1,14,1,0,0,0,0,0,0,2,2020,5,20,2,0.08073634859349145,9.464285714285715,0.17857142857142858 +17966309,US,US,2,1.0,0,0,1,0,2020-06-30,64.0,801.0,Male,76.0,HUMAN IMMUNOGLOBULIN G,diverticulitis,1,3,0.21428571428571427,MidAge,US,0.10714285714285714,8,0,14,0,0,0,0,0,0,0,1,2020,6,30,1,0.08936301793444651,6.857142857142857,0.0 +18512710,US,US,2,1.0,0,0,0,0,2020-11-17,67.0,801.0,Female,75.0,HUMAN IMMUNOGLOBULIN G,suspected covid-19,1,0,0.0,Senior,US,0.10714285714285714,8,0,18,0,0,0,0,0,0,0,2,2020,11,17,1,0.08936301793444651,7.178571428571428,0.10714285714285714 +25883268,US,US,1,2.0,0,0,0,0,2025-10-06,23.0,801.0,Male,75.0,IBUPROFEN,drug ineffective,0,0,0.0,Young,US,0.11607142857142858,8,0,16,0,0,0,0,0,0,0,2,2025,10,6,0,0.08073634859349145,2.669642857142857,0.0 +25883673,US,US,1,2.0,0,0,0,0,2025-10-06,57.0,801.0,Female,75.0,PLUVICTO,general physical health deterioration,0,0,0.0,MidAge,US,0.0,8,0,37,0,0,0,0,0,0,0,4,2025,10,6,0,0.08073634859349145,0.0,0.0 +25979055,EU,EU,1,1.0,0,0,0,0,2025-10-30,79.0,801.0,Female,70.0,CAPECITABINE,chest pain,1,0,0.0,Senior,EU,0.10714285714285714,2,0,10,1,0,0,0,0,0,0,2,2025,10,30,3,0.08073634859349145,8.464285714285714,0.10714285714285714 +25981270,US,US,1,2.0,0,0,0,0,2025-10-30,57.0,801.0,Female,75.0,NEMLUVIO,device malfunction,0,0,0.0,MidAge,US,0.0,1,0,18,0,0,0,0,0,0,0,2,2025,10,30,3,0.08073634859349145,0.0,0.0 +25982471,US,US,1,1.0,0,0,0,0,2025-10-31,57.0,801.0,Male,75.0,TRELEGY ELLIPTA,product dose omission issue,1,0,0.0,MidAge,US,0.0,4,0,27,0,0,0,0,0,0,0,4,2025,10,31,4,0.08073634859349145,0.0,0.0 +25982929,EU,EU,1,1.0,0,0,0,0,2025-10-31,43.0,801.0,Female,75.0,ASCIMINIB,blast crisis in myelogenous leukaemia,1,0,0.0,Adult,EU,0.0,1,0,37,0,0,0,0,0,0,0,5,2025,10,31,4,0.08073634859349145,0.0,0.0 +26040958,US,US,1,1.0,0,0,1,0,2025-11-13,57.0,801.0,Female,75.0,DUPIXENT,road traffic accident,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,21,0,0,0,0,0,0,0,3,2025,11,13,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26041849,US,US,1,2.0,0,0,0,0,2025-11-13,30.0,801.0,Male,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,11,13,3,0.08073634859349145,0.46541693600517126,0.0 +20225402,CA,CA,1,1.0,0,0,0,0,2021-12-24,50.0,801.0,Female,75.0,AMLODIPINE,extrapyramidal disorder,1,0,0.0,Adult,CA,0.16964285714285715,8,1,23,0,0,0,0,0,0,0,2,2021,12,24,4,0.08073634859349145,8.482142857142858,0.16964285714285715 +20582718,US,US,1,2.0,0,0,0,0,2022-03-11,65.0,801.0,Female,63.0,PREMARIN,oropharyngeal discomfort,0,0,0.0,MidAge,US,0.0,1,0,24,0,0,0,0,0,0,0,2,2022,3,11,4,0.08073634859349145,0.0,0.0 +20689596,EU,EU,1,1.0,1,0,0,0,2022-04-08,7.0,801.0,Female,75.0,KYMRIAH,condition aggravated,1,5,0.35714285714285715,Child,EU,0.35714285714285715,1,1,20,0,0,0,0,0,0,0,2,2022,4,8,4,0.08073634859349145,2.5,0.35714285714285715 +20711941,US,US,1,2.0,0,0,0,0,2022-04-14,57.0,801.0,Female,75.0,CRYSVITA,blood phosphorus decreased,0,0,0.0,MidAge,US,0.0,1,0,26,0,0,0,0,0,0,0,3,2022,4,14,3,0.08073634859349145,0.0,0.0 +20795424,IL,IL,1,1.0,0,0,0,0,2022-05-06,42.0,801.0,Male,75.0,ELELYSO,hip arthroplasty,1,0,0.0,Adult,Other,0.0,1,0,16,0,0,0,0,0,0,0,2,2022,5,6,4,0.08073634859349145,0.0,0.0 +20865961,US,US,2,1.0,0,0,1,0,2022-05-24,55.0,801.0,Female,38.0,EPIDIOLEX,cystitis,1,3,0.21428571428571427,MidAge,US,0.14285714285714285,3,1,8,0,0,0,0,0,0,0,1,2022,5,24,1,0.08936301793444651,7.857142857142857,0.14285714285714285 +21022604,GB,Unknown,2,1.0,0,0,1,0,2022-06-29,57.0,801.0,Female,75.0,CERTOLIZUMAB PEGOL,otitis externa,1,3,0.21428571428571427,MidAge,GB,0.04285714285714286,5,0,14,0,0,0,0,0,0,0,2,2022,6,29,2,0.08936301793444651,2.442857142857143,0.04285714285714286 +25987236,GB,GB,1,1.0,0,0,0,0,2025-11-03,43.0,801.0,Female,84.0,IBUPROFEN,rash,1,0,0.0,Adult,GB,0.11607142857142858,8,0,4,0,0,0,0,0,0,0,1,2025,11,3,0,0.08073634859349145,4.991071428571429,0.11607142857142858 +25987627,GB,GB,1,1.0,0,0,0,0,2025-11-03,57.0,801.0,Male,75.0,RAMIPRIL,muscle spasms,1,0,0.0,MidAge,GB,0.0,1,0,13,0,0,0,0,0,0,0,2,2025,11,3,0,0.08073634859349145,0.0,0.0 +25988518,EU,EU,3,1.0,1,0,0,0,2025-11-03,57.0,801.0,Female,75.0,ACETAMINOPHEN,drug use disorder,1,5,0.35714285714285715,MidAge,EU,0.10267857142857142,16,0,17,0,0,0,0,0,0,0,3,2025,11,3,0,0.17857142857142855,5.852678571428571,0.10267857142857142 +25988666,EU,EU,1,1.0,0,0,0,0,2025-11-03,64.0,801.0,Female,75.0,MEROPENEM,linear iga disease,1,0,0.0,MidAge,EU,0.0,1,0,18,0,0,0,0,0,0,0,3,2025,11,3,0,0.08073634859349145,0.0,0.0 +25989180,EU,EU,1,1.0,0,0,1,0,2025-11-03,39.0,801.0,Female,75.0,METFORMIN,maternal exposure during breast feeding,1,3,0.21428571428571427,Adult,EU,0.21428571428571427,2,1,39,0,0,0,0,0,0,0,5,2025,11,3,0,0.08073634859349145,8.357142857142856,0.21428571428571427 +25989247,CR,CR,2,1.0,0,0,0,1,2025-11-03,57.0,801.0,Male,75.0,EXFORGE HCT,pollakiuria,1,2,0.14285714285714285,MidAge,Other,0.14285714285714285,1,1,11,0,0,0,0,0,0,0,1,2025,11,3,0,0.08936301793444651,8.142857142857142,0.0 +25989328,EU,EU,1,1.0,0,0,0,0,2025-11-03,57.0,801.0,Female,75.0,INFLIXIMAB,colitis ulcerative,1,0,0.0,MidAge,EU,0.07142857142857142,9,0,18,0,0,0,0,0,0,0,2,2025,11,3,0,0.08073634859349145,4.071428571428571,0.07142857142857142 +25989786,US,US,1,1.0,0,0,0,0,2025-11-03,58.0,801.0,Male,75.0,PREDNISONE,cystoid macular oedema,1,0,0.0,MidAge,US,0.1607142857142857,8,1,22,0,0,0,0,0,0,0,3,2025,11,3,0,0.08073634859349145,9.321428571428571,0.0 +25995026,JP,JP,1,1.0,0,0,1,0,2025-11-04,17.0,801.0,Female,75.0,VENLAFAXINE HYDROCHLORIDE,altered state of consciousness,1,3,0.21428571428571427,Child,JP,0.21428571428571427,1,1,30,0,0,0,0,0,0,0,4,2025,11,4,1,0.08073634859349145,3.642857142857143,0.21428571428571427 +25915682,US,US,1,2.0,0,0,0,0,2025-10-13,57.0,801.0,Female,75.0,JOENJA,chronic sinusitis,0,0,0.0,MidAge,US,0.0,3,0,17,0,0,0,0,0,0,0,2,2025,10,13,0,0.08073634859349145,0.0,0.0 +25915844,US,US,1,2.0,0,0,0,0,2025-10-13,65.0,801.0,Female,75.0,DATROWAY,off label use,0,0,0.0,MidAge,US,0.0,2,0,13,0,0,0,0,0,0,0,3,2025,10,13,0,0.08073634859349145,0.0,0.0 +25916249,US,US,1,2.0,0,0,0,0,2025-10-14,54.0,801.0,Male,75.0,COSENTYX,wrong technique in device usage process,0,0,0.0,MidAge,US,0.05714285714285714,10,0,39,0,0,0,0,0,0,0,6,2025,10,14,1,0.08073634859349145,3.0857142857142854,0.0 +25917383,CA,CA,1,1.0,0,0,0,0,2025-10-14,57.0,801.0,Female,75.0,INFLIXIMAB,infusion site extravasation,1,0,0.0,MidAge,CA,0.07142857142857142,9,0,27,0,0,0,0,0,0,0,3,2025,10,14,1,0.08073634859349145,4.071428571428571,0.07142857142857142 +21465146,CA,CA,1,1.0,0,0,1,0,2022-10-17,37.0,801.0,Female,75.0,VICTOZA,blood potassium decreased,1,3,0.21428571428571427,Adult,CA,0.21428571428571427,1,1,25,0,0,0,0,0,0,0,3,2022,10,17,0,0.08073634859349145,7.928571428571428,0.21428571428571427 +21759553,EU,EU,1,1.0,0,0,0,0,2022-12-21,52.0,801.0,Female,66.0,LEVOFLOXACIN,pain in extremity,1,0,0.0,MidAge,EU,0.25,4,1,17,1,0,0,0,0,0,0,3,2022,12,21,2,0.08073634859349145,13.0,0.25 +21770192,EU,EU,2,1.0,0,0,0,0,2022-12-23,66.0,801.0,Male,88.0,ENCORAFENIB,insomnia,1,0,0.0,Senior,EU,0.0,1,0,8,0,0,0,0,0,0,0,1,2022,12,23,4,0.08936301793444651,0.0,0.0 +21784487,US,US,1,1.0,0,0,0,0,2022-12-27,74.0,801.0,Male,95.25,BRAFTOVI,haematemesis,1,0,0.0,Senior,US,0.0,1,0,12,0,0,0,0,0,0,0,1,2022,12,27,1,0.08073634859349145,0.0,0.0 +21919609,AU,AU,2,1.0,0,0,1,0,2023-01-27,51.0,801.0,Female,75.0,TEDUGLUTIDE,duodenal polyp,1,3,0.21428571428571427,MidAge,AU,0.14285714285714285,3,1,14,0,0,0,0,0,0,0,2,2023,1,27,4,0.08936301793444651,7.285714285714286,0.14285714285714285 +21995654,US,US,1,2.0,0,0,0,0,2023-02-15,35.0,801.0,Male,75.0,DUPIXENT,pain in extremity,0,0,0.0,Young,US,0.015513897866839042,221,0,17,1,0,0,0,0,0,0,3,2023,2,15,2,0.08073634859349145,0.5429864253393665,0.0 +22238358,CA,CA,2,1.0,0,0,0,0,2023-04-21,57.0,801.0,Female,75.0,RITUXIMAB,pulmonary embolism,1,0,0.0,MidAge,CA,0.12406015037593986,19,0,18,0,0,0,0,0,0,0,2,2023,4,21,4,0.08936301793444651,7.071428571428572,0.12406015037593986 +25920112,US,Unknown,1,1.0,0,0,0,0,2025-10-14,45.0,801.0,Female,75.0,MYCOPHENOLIC ACID,dizziness,1,0,0.0,Adult,US,0.0,1,0,9,0,0,0,0,0,0,0,1,2025,10,14,1,0.08073634859349145,0.0,0.0 +25920408,US,US,1,1.0,1,0,1,0,2025-10-14,57.0,801.0,Female,75.0,YUTREPIA,pulmonary fibrosis,1,8,0.5714285714285714,MidAge,US,0.5714285714285714,1,1,18,0,0,0,0,0,0,0,2,2025,10,14,1,0.08073634859349145,32.57142857142857,0.5714285714285714 +25921056,EU,EU,1,1.0,0,1,1,0,2025-10-14,59.0,801.0,Female,75.0,TUKYSA,cardiac failure,1,7,0.5,MidAge,EU,0.5,1,1,15,0,0,0,0,1,0,0,2,2025,10,14,1,0.08073634859349145,29.5,0.5 +25921285,US,US,1,2.0,0,0,0,0,2025-10-14,57.0,801.0,Female,75.0,DUPIXENT,wheezing,0,0,0.0,MidAge,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,10,14,1,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25921542,US,US,1,2.0,0,0,0,0,2025-10-14,21.0,801.0,Female,75.0,DUPIXENT,injection site irritation,0,0,0.0,Young,US,0.015513897866839042,221,0,25,0,0,0,0,0,0,0,3,2025,10,14,1,0.08073634859349145,0.32579185520361986,0.015513897866839042 +25922891,US,US,1,2.0,0,0,0,0,2025-10-15,57.0,801.0,Male,75.0,DUPIXENT,loss of personal independence in daily activities,0,0,0.0,MidAge,US,0.015513897866839042,221,0,49,0,0,0,0,0,0,0,7,2025,10,15,2,0.08073634859349145,0.8842921784098254,0.0 +25923148,US,US,2,1.0,0,0,0,0,2025-10-15,57.0,801.0,Female,75.0,CREON,cerebrovascular accident,1,0,0.0,MidAge,US,0.03296703296703297,13,0,24,0,0,0,0,0,0,0,2,2025,10,15,2,0.08936301793444651,1.879120879120879,0.03296703296703297 +25926550,EU,EU,1,1.0,0,0,0,0,2025-10-15,64.0,801.0,Male,75.0,AMLODIPINE,erythema,1,0,0.0,MidAge,EU,0.16964285714285715,8,1,8,0,0,0,0,0,0,0,1,2025,10,15,2,0.08073634859349145,10.857142857142858,0.0 +25926684,US,US,1,2.0,0,0,0,0,2025-10-15,65.0,801.0,Male,75.0,XELJANZ XR,covid-19,0,0,0.0,MidAge,US,0.0,9,0,8,0,0,0,0,0,0,0,1,2025,10,15,2,0.08073634859349145,0.0,0.0 +25927399,CN,CN,2,1.0,0,0,1,0,2025-10-15,53.0,801.0,Female,54.0,DARATUMUMAB,pyrexia,1,3,0.21428571428571427,MidAge,CN,0.14285714285714285,3,1,7,0,0,0,0,0,0,0,1,2025,10,15,2,0.08936301793444651,7.571428571428571,0.14285714285714285 +25928103,US,US,1,2.0,0,0,0,0,2025-10-16,24.0,801.0,Female,75.0,DUPIXENT,urticaria,0,0,0.0,Young,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,10,16,3,0.08073634859349145,0.372333548804137,0.015513897866839042 +25928385,US,US,1,2.0,0,0,0,0,2025-10-16,69.0,801.0,Female,75.0,TRELEGY ELLIPTA,muscle spasms,0,0,0.0,Senior,US,0.0,4,0,13,0,0,0,0,0,0,0,2,2025,10,16,3,0.08073634859349145,0.0,0.0 +25929438,EU,EU,1,1.0,0,0,1,0,2025-10-16,8.0,801.0,Male,30.0,XOLAIR,scrotal oedema,1,3,0.21428571428571427,Child,EU,0.14285714285714285,4,1,14,0,0,0,0,0,0,0,2,2025,10,16,3,0.08073634859349145,1.1428571428571428,0.0 +25930142,US,US,1,1.0,0,0,1,0,2025-10-16,54.0,801.0,Female,61.0,FLUOROURACIL,colitis,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,7,0,0,0,0,0,0,0,1,2025,10,16,3,0.08073634859349145,11.571428571428571,0.21428571428571427 +25930748,US,US,1,2.0,0,0,0,0,2025-10-16,45.0,801.0,Female,75.0,ORENCIA,loss of therapeutic response,0,0,0.0,Adult,US,0.10204081632653061,14,0,28,0,0,0,0,0,0,0,4,2025,10,16,3,0.08073634859349145,4.591836734693878,0.10204081632653061 +25930829,EU,EU,1,1.0,0,0,0,0,2025-10-16,13.0,801.0,Male,75.0,DUPILUMAB,ocular surface disease,1,0,0.0,Child,EU,0.04285714285714286,5,0,22,0,0,0,0,0,0,0,3,2025,10,16,3,0.08073634859349145,0.5571428571428572,0.0 +25931910,US,US,1,1.0,0,0,1,0,2025-10-16,57.0,801.0,Male,85.45,DUPIXENT,pneumonia,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,9,0,0,0,0,0,1,0,1,2025,10,16,3,0.08073634859349145,0.8842921784098254,0.0 +25932234,EU,EU,1,1.0,0,0,1,0,2025-10-16,68.0,801.0,Female,84.0,FUROSEMIDE,orthostatic hypotension,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,23,0,0,0,0,0,0,0,2,2025,10,16,3,0.08073634859349145,14.571428571428571,0.21428571428571427 +25934784,US,Unknown,1,2.0,0,0,0,0,2025-10-17,73.0,801.0,Female,59.864,JAKAFI,pruritus,0,0,0.0,Senior,US,0.0,3,0,8,0,0,0,0,0,0,0,1,2025,10,17,4,0.08073634859349145,0.0,0.0 +25934999,US,US,2,2.0,0,0,0,0,2025-10-17,14.0,801.0,Male,75.0,OMNITROPE,injection site erythema,0,0,0.0,Child,US,0.0,5,0,23,0,0,0,0,0,0,0,3,2025,10,17,4,0.08936301793444651,0.0,0.0 +22969302,CA,CA,1,1.0,0,0,1,0,2023-09-22,61.0,801.0,Female,86.0,CISPLATIN,fluid intake reduced,1,3,0.21428571428571427,MidAge,CA,0.10714285714285714,2,0,20,0,0,0,0,0,0,0,3,2023,9,22,4,0.08073634859349145,6.535714285714286,0.10714285714285714 +23150136,US,US,2,1.0,0,0,1,0,2023-11-06,64.0,801.0,Female,86.168,LANADELUMAB,faecaloma,1,3,0.21428571428571427,MidAge,US,0.12857142857142856,5,1,9,0,0,0,0,0,0,0,1,2023,11,6,0,0.08936301793444651,8.228571428571428,0.12857142857142856 +23244501,CA,Unknown,2,1.0,0,0,0,0,2023-11-30,66.0,801.0,Female,75.0,CERTOLIZUMAB PEGOL,bladder operation,1,0,0.0,Senior,CA,0.04285714285714286,5,0,17,0,0,0,0,0,0,0,2,2023,11,30,3,0.08936301793444651,2.8285714285714287,0.04285714285714286 +23245445,US,US,1,2.0,0,0,0,0,2023-11-30,57.0,801.0,Female,75.0,TERIPARATIDE,device use error,0,0,0.0,MidAge,US,0.0,1,0,16,0,0,0,0,0,0,0,3,2023,11,30,3,0.08073634859349145,0.0,0.0 +23318507,JP,JP,1,1.0,1,0,0,0,2023-12-20,57.0,801.0,Female,75.0,VENCLEXTA,death,1,5,0.35714285714285715,MidAge,JP,0.18571428571428572,5,1,5,0,0,1,0,0,0,0,1,2023,12,20,2,0.08073634859349145,10.585714285714285,0.18571428571428572 +23662905,EU,EU,1,1.0,0,0,0,0,2024-03-22,41.0,801.0,Male,75.0,PREGABALIN,condition aggravated,1,0,0.0,Adult,EU,0.10714285714285714,6,0,20,0,0,0,0,0,0,0,2,2024,3,22,4,0.08073634859349145,4.392857142857142,0.0 +23763116,CA,CA,1,1.0,0,0,0,0,2024-04-19,69.0,801.0,Female,75.0,PANTOPRAZOLE,blood magnesium decreased,1,0,0.0,Senior,CA,0.0,1,0,25,0,0,0,0,0,0,0,3,2024,4,19,4,0.08073634859349145,0.0,0.0 +26007676,US,US,1,1.0,0,0,1,0,2025-11-06,57.0,801.0,Female,75.0,DUPIXENT,hospitalisation,1,3,0.21428571428571427,MidAge,US,0.015513897866839042,221,0,15,0,0,0,0,0,0,0,1,2025,11,6,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26008271,US,US,1,2.0,0,0,0,0,2025-11-06,54.0,801.0,Female,75.0,DUPIXENT,injection site pain,0,0,0.0,MidAge,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,11,6,3,0.08073634859349145,0.8377504848093082,0.015513897866839042 +26009067,US,US,1,2.0,0,0,0,0,2025-11-07,35.0,801.0,Male,75.0,DUPIXENT,wisdom teeth removal,0,0,0.0,Young,US,0.015513897866839042,221,0,20,0,0,0,0,0,0,0,3,2025,11,7,4,0.08073634859349145,0.5429864253393665,0.0 +26009081,US,US,1,2.0,0,0,0,0,2025-11-07,33.0,801.0,Female,75.0,DUPIXENT,injection site pain,0,0,0.0,Young,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,11,7,4,0.08073634859349145,0.5119586296056884,0.015513897866839042 +26010997,US,US,2,1.0,0,0,0,0,2025-11-07,63.0,801.0,Male,75.0,SKYRIZI,surgery,1,0,0.0,MidAge,US,0.051587301587301584,36,0,7,0,0,0,0,0,0,0,1,2025,11,7,4,0.08936301793444651,3.25,0.0 +26057644,US,Unknown,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,LACOSAMIDE,hypersensitivity,0,0,0.0,MidAge,US,0.16666666666666666,3,1,16,0,0,0,0,0,0,0,1,2025,11,18,1,0.08073634859349145,9.5,0.16666666666666666 +26058049,US,US,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Male,75.0,OTEZLA,dry skin,0,0,0.0,MidAge,US,0.0,4,0,8,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,0.0,0.0 +26058454,EU,EU,1,1.0,0,0,1,0,2025-11-18,52.0,801.0,Female,75.0,GABAPENTIN,hepatic cytolysis,1,3,0.21428571428571427,MidAge,EU,0.061224489795918366,7,0,17,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,3.183673469387755,0.061224489795918366 +26059507,JP,JP,1,1.0,0,0,0,0,2025-11-18,35.0,801.0,Male,75.0,MOUNJARO,retinal haemorrhage,1,0,0.0,Young,JP,0.2142857142857143,4,1,19,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,7.500000000000001,0.0 +26011835,CA,CA,3,1.0,0,0,1,0,2025-11-07,57.0,801.0,Female,75.0,DOXORUBICIN HYDROCHLORIDE,acute hepatic failure,1,3,0.21428571428571427,MidAge,CA,0.21428571428571427,1,1,21,0,0,0,0,1,0,0,3,2025,11,7,4,0.17857142857142855,12.214285714285714,0.21428571428571427 +26014980,US,US,1,2.0,0,0,0,0,2025-11-09,69.0,801.0,Male,75.0,DUPIXENT,vision blurred,0,0,0.0,Senior,US,0.015513897866839042,221,0,14,0,0,0,0,0,0,0,2,2025,11,9,6,0.08073634859349145,1.070458952811894,0.0 +26015075,US,US,1,2.0,0,0,0,0,2025-11-09,42.0,801.0,Female,75.0,DUPIXENT,injection site pain,0,0,0.0,Adult,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,11,9,6,0.08073634859349145,0.6515837104072397,0.015513897866839042 +26015251,US,US,1,2.0,0,0,0,0,2025-11-09,7.0,801.0,Female,75.0,DUPIXENT,injection site erythema,0,0,0.0,Child,US,0.015513897866839042,221,0,23,0,0,0,0,0,0,0,3,2025,11,9,6,0.08073634859349145,0.10859728506787329,0.015513897866839042 +26062127,US,US,2,1.0,0,0,0,0,2025-11-19,52.0,801.0,Female,75.0,NUPLAZID,mental impairment,1,0,0.0,MidAge,US,0.09523809523809523,6,0,17,0,0,0,0,0,0,0,2,2025,11,19,2,0.08936301793444651,4.9523809523809526,0.09523809523809523 +26063328,BR,BR,1,1.0,0,0,0,0,2025-11-19,57.0,801.0,Female,56.0,CLONAZEPAM,diabetes mellitus,1,0,0.0,MidAge,BR,0.07142857142857142,3,0,17,0,0,0,0,0,0,0,2,2025,11,19,2,0.08073634859349145,4.071428571428571,0.07142857142857142 +26019178,US,US,1,2.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,LENALIDOMIDE,product dose omission issue,0,0,0.0,MidAge,US,0.15413533834586465,19,1,27,0,0,0,0,0,0,0,4,2025,11,10,0,0.08073634859349145,8.785714285714285,0.15413533834586465 +26020125,US,US,1,2.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,POLYETHYLENE GLYCOL 3350,therapeutic product effect delayed,0,0,0.0,MidAge,US,0.0,4,0,34,0,0,0,0,0,0,0,4,2025,11,10,0,0.08073634859349145,0.0,0.0 +26020435,US,US,1,2.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,POLYETHYLENE GLYCOL 3350,drug ineffective,0,0,0.0,MidAge,US,0.0,4,0,16,0,0,0,0,0,0,0,2,2025,11,10,0,0.08073634859349145,0.0,0.0 +25936027,US,US,2,1.0,0,0,0,0,2025-10-17,67.0,801.0,Male,75.0,AUSTEDO XR,aspiration,1,0,0.0,Senior,US,0.0,1,0,10,0,0,0,0,0,0,0,1,2025,10,17,4,0.08936301793444651,0.0,0.0 +25936351,CA,CA,2,1.0,0,0,0,0,2025-10-17,32.0,801.0,Female,75.0,VEDOLIZUMAB,rectal haemorrhage,1,0,0.0,Young,CA,0.057692307692307696,26,0,18,0,0,0,0,0,0,0,2,2025,10,17,4,0.08936301793444651,1.8461538461538463,0.057692307692307696 +25936823,JP,JP,1,1.0,0,0,1,0,2025-10-17,73.0,801.0,Male,75.0,VYXEOS,pneumonia,1,3,0.21428571428571427,Senior,JP,0.21428571428571427,1,1,9,0,0,0,0,0,1,0,1,2025,10,17,4,0.08073634859349145,15.642857142857142,0.0 +25937309,US,US,2,1.0,0,0,0,0,2025-10-17,55.0,801.0,Female,75.0,SKYRIZI,drug-induced liver injury,1,0,0.0,MidAge,US,0.051587301587301584,36,0,25,0,0,0,0,0,0,0,3,2025,10,17,4,0.08936301793444651,2.837301587301587,0.051587301587301584 +25937457,US,US,2,2.0,0,0,0,0,2025-10-18,66.0,801.0,Male,75.0,SKYRIZI,cough,0,0,0.0,Senior,US,0.051587301587301584,36,0,5,0,0,0,0,0,0,0,1,2025,10,18,5,0.08936301793444651,3.4047619047619047,0.0 +25937714,CN,CN,1,1.0,0,0,0,0,2025-10-18,67.0,801.0,Male,75.0,TADALAFIL,drug ineffective,1,0,0.0,Senior,CN,0.0,2,0,16,0,0,0,0,0,0,0,2,2025,10,18,5,0.08073634859349145,0.0,0.0 +26021326,US,US,1,1.0,0,0,0,0,2025-11-10,31.0,801.0,Female,75.0,METHOTREXATE,drug ineffective,1,0,0.0,Young,US,0.17346938775510204,7,1,16,0,0,0,0,0,0,0,2,2025,11,10,0,0.08073634859349145,5.377551020408164,0.17346938775510204 +26022499,US,US,1,1.0,0,0,1,0,2025-11-10,79.0,801.0,Female,82.55,REVLIMID,blood calcium abnormal,1,3,0.21428571428571427,Senior,US,0.05357142857142857,4,0,22,0,0,0,0,0,0,0,3,2025,11,10,0,0.08073634859349145,4.232142857142857,0.05357142857142857 +26022703,US,US,1,2.0,0,0,0,0,2025-11-10,57.0,801.0,Female,75.0,LEVOTHYROXINE SODIUM,alopecia,0,0,0.0,MidAge,US,0.0,3,0,8,0,0,0,0,0,0,0,1,2025,11,10,0,0.08073634859349145,0.0,0.0 +26064596,US,US,1,2.0,0,0,0,0,2025-11-19,4.0,801.0,Male,75.0,DUPIXENT,eczema,0,0,0.0,Child,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,11,19,2,0.08073634859349145,0.06205559146735617,0.0 +26064624,US,US,1,2.0,0,0,0,0,2025-11-19,23.0,801.0,Male,75.0,DUPIXENT,feeling abnormal,0,0,0.0,Young,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,11,19,2,0.08073634859349145,0.35681965093729795,0.0 +26064691,US,US,1,2.0,0,0,0,0,2025-11-19,57.0,801.0,Female,75.0,DUPIXENT,illness,0,0,0.0,MidAge,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,1,2025,11,19,2,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26065649,US,Unknown,1,1.0,0,0,1,0,2025-11-19,56.0,801.0,Female,75.0,AMJEVITA,abdominal operation,1,3,0.21428571428571427,MidAge,US,0.21428571428571427,1,1,19,0,0,0,0,0,0,0,2,2025,11,19,2,0.08073634859349145,12.0,0.21428571428571427 +26066811,CA,CA,1,1.0,0,0,0,0,2025-11-19,57.0,801.0,Female,75.0,TRIAMCINOLONE ACETONIDE,irritable bowel syndrome,1,0,0.0,MidAge,CA,0.19047619047619047,3,1,24,0,0,0,0,0,0,0,3,2025,11,19,2,0.08073634859349145,10.857142857142856,0.19047619047619047 +26067188,US,US,2,1.0,0,0,0,0,2025-11-19,61.0,801.0,Female,75.0,SKYRIZI,rotator cuff syndrome,1,0,0.0,MidAge,US,0.051587301587301584,36,0,21,0,0,0,0,0,0,0,3,2025,11,19,2,0.08936301793444651,3.1468253968253967,0.051587301587301584 +26067889,EU,EU,1,1.0,0,0,1,0,2025-11-20,57.0,801.0,Male,75.0,PEMETREXED,acute kidney injury,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,3,1,19,0,0,0,0,0,0,0,3,2025,11,20,3,0.08073634859349145,12.214285714285714,0.0 +26068202,US,US,1,2.0,0,0,0,0,2025-11-20,43.0,801.0,Female,109.0,NEULASTA,device malfunction,0,0,0.0,Adult,US,0.0,5,0,18,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,0.0,0.0 +25939859,GB,Unknown,1,1.0,0,0,0,1,2025-10-20,57.0,801.0,Female,66.0,EZETIMIBE AND SIMVASTATIN,dizziness postural,1,2,0.14285714285714285,MidAge,GB,0.14285714285714285,1,1,18,0,0,0,0,0,0,0,2,2025,10,20,0,0.08073634859349145,8.142857142857142,0.14285714285714285 +25940334,US,US,1,1.0,0,0,0,0,2025-10-20,57.0,801.0,Female,75.0,JAYPIRCA,malignant neoplasm progression,1,0,0.0,MidAge,US,0.0,1,0,30,0,0,0,0,0,0,0,3,2025,10,20,0,0.08073634859349145,0.0,0.0 +25941010,US,US,2,2.0,0,0,0,0,2025-10-20,57.0,801.0,Male,75.0,CORTICOTROPIN,skin irritation,0,0,0.0,MidAge,US,0.0,3,0,15,0,0,0,0,0,0,0,2,2025,10,20,0,0.08936301793444651,0.0,0.0 +25942884,US,US,1,2.0,0,0,0,0,2025-10-21,57.0,801.0,Female,75.0,DUPIXENT,weight increased,0,0,0.0,MidAge,US,0.015513897866839042,221,0,16,0,0,0,0,0,0,0,2,2025,10,21,1,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26026387,US,US,1,2.0,0,0,0,0,2025-11-11,57.0,801.0,Female,75.0,DUPIXENT,injection site scar,0,0,0.0,MidAge,US,0.015513897866839042,221,0,19,0,0,0,0,0,0,0,3,2025,11,11,1,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26026644,US,US,1,2.0,0,0,0,0,2025-11-11,81.0,801.0,Female,75.0,DUPIXENT,urticaria,0,0,0.0,Senior,US,0.015513897866839042,221,0,9,0,0,0,0,0,0,0,1,2025,11,11,1,0.08073634859349145,1.2566257272139625,0.015513897866839042 +26026725,US,US,1,2.0,0,0,0,0,2025-11-11,72.0,801.0,Male,75.0,DUPIXENT,incorrect dose administered,0,0,0.0,Senior,US,0.015513897866839042,221,0,27,0,0,0,0,0,0,0,3,2025,11,11,1,0.08073634859349145,1.117000646412411,0.0 +26069713,CA,CA,1,1.0,0,0,0,0,2025-11-20,34.0,801.0,Male,75.0,GABAPENTIN,crohn^s disease,1,0,0.0,Young,CA,0.061224489795918366,7,0,15,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,2.0816326530612246,0.0 +26069766,US,US,2,1.0,0,0,0,0,2025-11-20,53.0,801.0,Male,75.0,CREON,gallbladder operation,1,0,0.0,MidAge,US,0.03296703296703297,13,0,21,0,0,0,0,0,0,0,2,2025,11,20,3,0.08936301793444651,1.7472527472527473,0.0 +26070065,CA,CA,2,1.0,0,0,0,0,2025-11-20,57.0,801.0,Female,75.0,RITUXIMAB,abdominal operation,1,0,0.0,MidAge,CA,0.12406015037593986,19,0,19,0,0,0,0,0,0,0,2,2025,11,20,3,0.08936301793444651,7.071428571428572,0.12406015037593986 +26070146,US,US,1,1.0,0,0,1,0,2025-11-20,15.0,801.0,Female,75.0,PREDNISONE,immune-mediated myositis,1,3,0.21428571428571427,Child,US,0.1607142857142857,8,1,24,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,2.4107142857142856,0.1607142857142857 +26070470,US,US,1,1.0,0,0,0,0,2025-11-20,57.0,801.0,Female,75.0,DUPIXENT,crohn^s disease,1,0,0.0,MidAge,US,0.015513897866839042,221,0,15,0,0,0,0,0,0,0,2,2025,11,20,3,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26070995,US,US,1,2.0,0,0,0,0,2025-11-20,15.0,801.0,Female,75.0,DUPIXENT,injection site pain,0,0,0.0,Child,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,11,20,3,0.08073634859349145,0.23270846800258563,0.015513897866839042 +26033677,EU,EU,1,1.0,1,0,1,0,2025-11-12,73.0,801.0,Male,75.0,CARBIDOPA\LEVODOPA,pneumonia,1,8,0.5714285714285714,Senior,EU,0.3333333333333333,3,1,9,0,0,0,0,0,1,0,1,2025,11,12,2,0.08073634859349145,24.333333333333332,0.0 +26034663,US,US,1,1.0,0,0,1,0,2025-11-12,15.0,801.0,Female,75.0,MYCOPHENOLATE MOFETIL,gastrointestinal disorder,1,3,0.21428571428571427,Child,US,0.10150375939849625,19,0,25,0,0,0,0,0,0,0,2,2025,11,12,2,0.08073634859349145,1.5225563909774438,0.10150375939849625 +26035068,US,US,1,2.0,0,0,0,0,2025-11-12,16.0,801.0,Female,75.0,DUPIXENT,injection site swelling,0,0,0.0,Child,US,0.015513897866839042,221,0,23,0,0,0,0,0,0,0,3,2025,11,12,2,0.08073634859349145,0.24822236586942467,0.015513897866839042 +26035730,US,US,1,1.0,0,0,0,0,2025-11-12,57.0,801.0,Male,75.0,CARVYKTI,immunodeficiency,1,0,0.0,MidAge,US,0.0,1,0,16,0,0,0,0,0,0,0,1,2025,11,12,2,0.08073634859349145,0.0,0.0 +26036311,EU,EU,1,1.0,0,0,0,0,2025-11-12,59.0,801.0,Male,75.0,BINIMETINIB,autoimmune colitis,1,0,0.0,MidAge,EU,0.0,1,0,18,0,0,0,0,0,0,0,2,2025,11,12,2,0.08073634859349145,0.0,0.0 +26037107,EU,EU,1,1.0,0,0,0,0,2025-11-12,57.0,801.0,Female,75.0,METHOTREXATE,cerebral infarction,1,0,0.0,MidAge,EU,0.17346938775510204,7,1,19,0,0,0,0,0,0,0,2,2025,11,12,2,0.08073634859349145,9.887755102040817,0.17346938775510204 +25945180,US,US,1,2.0,0,0,0,0,2025-10-21,57.0,801.0,Female,75.0,XEOMIN,urticaria,0,0,0.0,MidAge,US,0.08928571428571429,4,0,9,0,0,0,0,0,0,0,1,2025,10,21,1,0.08073634859349145,5.089285714285714,0.08928571428571429 +25946758,US,US,1,1.0,0,0,0,0,2025-10-22,57.0,801.0,Female,75.0,COBENFY,serotonin syndrome,1,0,0.0,MidAge,US,0.0,1,0,18,0,0,0,0,0,0,0,2,2025,10,22,2,0.08073634859349145,0.0,0.0 +25946987,GB,GB,1,1.0,0,0,0,0,2025-10-22,57.0,801.0,Female,75.0,PREGABALIN,decreased appetite,1,0,0.0,MidAge,GB,0.10714285714285714,6,0,18,0,0,0,0,0,0,0,2,2025,10,22,2,0.08073634859349145,6.107142857142857,0.10714285714285714 +25947177,EU,EU,1,1.0,0,0,1,0,2025-10-22,37.0,801.0,Male,75.0,OLANZAPINE,intentional overdose,1,3,0.21428571428571427,Adult,EU,0.11904761904761905,6,0,20,0,0,0,0,0,0,0,2,2025,10,22,2,0.08073634859349145,4.404761904761905,0.0 +26037822,US,US,1,1.0,0,0,0,0,2025-11-12,57.0,801.0,Male,75.0,LUMASON,hypersensitivity,1,0,0.0,MidAge,US,0.25,2,1,16,0,0,0,0,0,0,0,1,2025,11,12,2,0.08073634859349145,14.25,0.0 +26038199,US,US,1,1.0,0,0,1,0,2025-11-13,63.0,801.0,Female,69.85,OPSUMIT,dyspnoea,1,3,0.21428571428571427,MidAge,US,0.10714285714285714,2,0,8,0,0,0,0,0,0,0,1,2025,11,13,3,0.08073634859349145,6.75,0.10714285714285714 +26038847,GB,GB,1,1.0,0,0,0,0,2025-11-13,49.0,801.0,Female,70.0,LEVETIRACETAM,dyspnoea,1,0,0.0,Adult,GB,0.05714285714285714,5,0,8,0,0,0,0,0,0,0,1,2025,11,13,3,0.08073634859349145,2.8,0.05714285714285714 +26039442,US,US,1,2.0,0,0,0,0,2025-11-13,20.0,801.0,Female,75.0,AMOXICILLIN,maternal exposure during pregnancy,0,0,0.0,Young,US,0.0,1,0,34,0,0,0,0,0,0,0,4,2025,11,13,3,0.08073634859349145,0.0,0.0 +26039914,EU,EU,2,1.0,0,0,0,0,2025-11-13,57.0,801.0,Male,94.0,UPTRAVI,renal impairment,1,0,0.0,MidAge,EU,0.0,1,0,16,0,0,0,0,0,0,0,2,2025,11,13,3,0.08936301793444651,0.0,0.0 +26040833,US,Unknown,1,1.0,0,0,1,0,2025-11-13,22.0,801.0,Male,70.3,DEXAMETHASONE,pancreatitis,1,3,0.21428571428571427,Young,US,0.1857142857142857,5,1,12,0,0,0,0,0,0,0,1,2025,11,13,3,0.08073634859349145,4.085714285714285,0.0 +26041333,US,US,1,1.0,0,0,0,0,2025-11-13,53.0,801.0,Female,75.0,AYVAKIT,toe operation,1,0,0.0,MidAge,US,0.0,2,0,13,0,0,0,0,0,0,0,2,2025,11,13,3,0.08073634859349145,0.0,0.0 +24422928,JP,JP,1,2.0,0,0,0,0,2024-10-10,57.0,801.0,Male,75.0,NGENLA,patient-device incompatibility,0,0,0.0,MidAge,JP,0.0,1,0,30,0,0,0,0,0,0,0,2,2024,10,10,3,0.08073634859349145,0.0,0.0 +24533750,US,US,1,2.0,0,0,0,0,2024-10-22,57.0,801.0,Female,75.0,ILUVIEN,device difficult to use,0,0,0.0,MidAge,US,0.0,3,0,23,0,0,0,0,0,0,0,4,2024,10,22,1,0.08073634859349145,0.0,0.0 +24533789,US,US,1,2.0,0,0,0,0,2024-10-22,69.0,801.0,Female,75.0,ILUVIEN,device malfunction,0,0,0.0,Senior,US,0.0,3,0,18,0,0,0,0,0,0,0,2,2024,10,22,1,0.08073634859349145,0.0,0.0 +24598913,US,US,1,1.0,0,0,1,0,2024-11-10,71.0,801.0,Female,75.0,DUPIXENT,infection,1,3,0.21428571428571427,Senior,US,0.015513897866839042,221,0,9,0,1,0,0,0,0,0,1,2024,11,10,6,0.08073634859349145,1.101486748545572,0.015513897866839042 +24607675,EU,EU,1,1.0,0,0,1,0,2024-11-12,50.0,801.0,Female,75.0,LORAZEPAM,suicide attempt,1,3,0.21428571428571427,Adult,EU,0.21428571428571427,1,1,15,0,0,0,0,0,0,0,2,2024,11,12,1,0.08073634859349145,10.714285714285714,0.21428571428571427 +24610147,US,US,1,2.0,0,0,0,0,2024-11-12,52.0,801.0,Male,75.0,DUPIXENT,bone pain,0,0,0.0,MidAge,US,0.015513897866839042,221,0,9,1,0,0,0,0,0,0,2,2024,11,12,1,0.08073634859349145,0.8067226890756302,0.0 +24632299,US,Unknown,1,2.0,0,0,0,0,2024-11-18,23.0,801.0,Female,83.9,REVCOVI,weight increased,0,0,0.0,Young,US,0.0,1,0,16,0,0,0,0,0,0,0,2,2024,11,18,0,0.08073634859349145,0.0,0.0 +24645921,US,US,1,2.0,0,0,0,0,2024-11-21,48.0,801.0,Female,75.0,VERZENIO,taste disorder,0,0,0.0,Adult,US,0.0,1,0,14,0,0,0,0,0,0,0,2,2024,11,21,3,0.08073634859349145,0.0,0.0 +25952456,CN,CN,1,1.0,0,0,0,0,2025-10-23,57.0,801.0,Female,75.0,CARBOPLATIN,neoplasm progression,1,0,0.0,MidAge,CN,0.12244897959183673,7,0,20,0,0,0,0,0,0,0,2,2025,10,23,3,0.08073634859349145,6.979591836734694,0.12244897959183673 +25953347,US,Unknown,1,1.0,1,0,0,0,2025-10-23,84.0,801.0,Male,75.0,LENALIDOMIDE,death,1,5,0.35714285714285715,Senior,US,0.15413533834586465,19,1,5,0,0,1,0,0,0,0,1,2025,10,23,3,0.08073634859349145,12.94736842105263,0.0 +25955224,US,US,1,2.0,0,0,0,0,2025-10-24,57.0,801.0,Female,75.0,SPRAVATO,drug monitoring procedure incorrectly performed,0,0,0.0,MidAge,US,0.026785714285714284,8,0,47,0,0,0,0,0,0,0,5,2025,10,24,4,0.08073634859349145,1.5267857142857142,0.026785714285714284 +25955534,US,US,2,1.0,0,0,0,0,2025-10-24,66.0,801.0,Male,75.0,IXAZOMIB,plasma cell myeloma,1,0,0.0,Senior,US,0.0,2,0,19,0,0,0,0,0,0,0,3,2025,10,24,4,0.08936301793444651,0.0,0.0 +26078137,EU,EU,3,1.0,0,0,1,0,2025-11-22,57.0,801.0,Female,75.0,ACETAMINOPHEN,depressed level of consciousness,1,3,0.21428571428571427,MidAge,EU,0.10267857142857142,16,0,32,0,0,0,0,0,0,0,4,2025,11,22,5,0.17857142857142855,5.852678571428571,0.10267857142857142 +26078313,US,US,1,2.0,0,0,0,0,2025-11-22,8.0,801.0,Male,75.0,DUPIXENT,eczema,0,0,0.0,Child,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,11,22,5,0.08073634859349145,0.12411118293471234,0.0 +26046651,EU,EU,1,1.0,0,0,1,0,2025-11-14,72.0,801.0,Male,65.0,NINTEDANIB,large granular lymphocytosis,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,1,1,28,0,0,0,0,0,0,0,3,2025,11,14,4,0.08073634859349145,15.428571428571427,0.0 +26048905,EU,EU,1,1.0,1,0,0,0,2025-11-15,57.0,801.0,Female,75.0,RITUXIMAB,multiple organ dysfunction syndrome,1,5,0.35714285714285715,MidAge,EU,0.12406015037593986,19,0,35,0,0,0,0,0,0,0,4,2025,11,15,5,0.08073634859349145,7.071428571428572,0.12406015037593986 +26048972,US,US,1,1.0,0,0,0,0,2025-11-15,57.0,801.0,Male,90.703,TYVASO DPI,pneumonia,1,0,0.0,MidAge,US,0.0,4,0,9,0,0,0,0,0,1,0,1,2025,11,15,5,0.08073634859349145,0.0,0.0 +26049500,US,US,1,2.0,0,0,0,0,2025-11-15,52.0,801.0,Male,75.0,TRULICITY,tremor,0,0,0.0,MidAge,US,0.04285714285714286,5,0,6,0,0,0,0,0,0,0,1,2025,11,15,5,0.08073634859349145,2.2285714285714286,0.0 +25957936,EU,EU,1,1.0,0,0,1,0,2025-10-24,41.0,801.0,Male,163.0,INFLIXIMAB,drug-induced liver injury,1,3,0.21428571428571427,Adult,EU,0.07142857142857142,9,0,25,0,0,0,0,0,0,0,3,2025,10,24,4,0.08073634859349145,2.9285714285714284,0.0 +25958665,CA,CA,1,1.0,0,0,1,0,2025-10-24,93.0,801.0,Male,75.0,SEMAGLUTIDE,incontinence,1,3,0.21428571428571427,Senior,CA,0.14285714285714285,3,1,12,0,0,0,0,0,0,0,1,2025,10,24,4,0.08073634859349145,13.285714285714285,0.0 +26049768,US,US,1,2.0,0,0,0,0,2025-11-15,10.0,801.0,Male,75.0,DUPIXENT,dry eye,0,0,0.0,Child,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,2,2025,11,15,5,0.08073634859349145,0.1551389786683904,0.0 +26050148,US,US,3,2.0,0,0,0,0,2025-11-16,57.0,801.0,Male,75.0,FILSPARI,fatigue,0,0,0.0,MidAge,US,0.0,4,0,7,0,0,0,0,0,0,0,1,2025,11,16,6,0.17857142857142855,0.0,0.0 +26050324,US,US,1,2.0,0,0,0,0,2025-11-16,57.0,801.0,Female,53.64,DUPIXENT,injection site pain,0,0,0.0,MidAge,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,11,16,6,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26051620,US,US,1,2.0,0,0,0,0,2025-11-17,43.0,801.0,Male,75.0,DUPIXENT,injection site bruising,0,0,0.0,Adult,US,0.015513897866839042,221,0,23,0,0,0,0,0,0,0,3,2025,11,17,0,0.08073634859349145,0.6670976082740788,0.0 +26052254,US,US,1,2.0,0,0,0,0,2025-11-17,76.0,801.0,Female,75.0,COSENTYX,injection site pain,0,0,0.0,Senior,US,0.05714285714285714,10,0,19,1,0,0,0,0,0,0,3,2025,11,17,0,0.08073634859349145,4.3428571428571425,0.05714285714285714 +26052807,US,Unknown,1,1.0,0,0,1,0,2025-11-14,79.0,801.0,Female,62.1,CABOMETYX,coronary arterial stent insertion,1,3,0.21428571428571427,Senior,US,0.10714285714285714,4,0,33,0,0,0,0,0,0,0,4,2025,11,14,4,0.08073634859349145,8.464285714285714,0.10714285714285714 +26053226,TH,TH,2,1.0,0,0,0,0,2025-11-17,57.0,801.0,Female,75.0,BEVACIZUMAB,sepsis,1,0,0.0,MidAge,Other,0.17857142857142858,2,1,6,0,0,0,0,0,0,0,1,2025,11,17,0,0.08936301793444651,10.178571428571429,0.17857142857142858 +26081458,AU,AU,1,1.0,0,0,0,0,2025-11-24,57.0,801.0,Female,75.0,LACOSAMIDE,cardiac septal defect,1,0,0.0,MidAge,AU,0.16666666666666666,3,1,21,0,0,0,0,0,0,0,3,2025,11,24,0,0.08073634859349145,9.5,0.16666666666666666 +26081500,US,US,1,2.0,0,0,0,0,2025-11-24,57.0,801.0,Female,79.09,DUPIXENT,injection site pain,0,0,0.0,MidAge,US,0.015513897866839042,221,0,19,1,0,0,0,0,0,0,3,2025,11,24,0,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26082349,US,US,1,2.0,0,0,0,0,2025-11-24,57.0,801.0,Male,75.0,METHYLPHENIDATE HYDROCHLORIDE,drug ineffective,0,0,0.0,MidAge,US,0.10714285714285714,2,0,16,0,0,0,0,0,0,0,2,2025,11,24,0,0.08073634859349145,6.107142857142857,0.0 +26082363,US,Unknown,1,1.0,0,0,0,1,2025-11-23,36.0,801.0,Female,49.05,CIPROFLOXACIN HYDROCHLORIDE,tendonitis,1,2,0.14285714285714285,Adult,US,0.14285714285714285,1,1,10,0,0,0,0,0,0,0,1,2025,11,23,6,0.08073634859349145,5.142857142857142,0.14285714285714285 +26082659,US,US,1,2.0,0,0,0,0,2025-11-24,57.0,801.0,Female,75.0,ESTRADIOL,device adhesion issue,0,0,0.0,MidAge,US,0.0,8,0,21,0,0,0,0,0,0,0,3,2025,11,24,0,0.08073634859349145,0.0,0.0 +26082673,US,Unknown,1,1.0,0,0,1,0,2025-11-22,57.0,801.0,Male,75.0,LENALIDOMIDE,pneumonia bacterial,1,3,0.21428571428571427,MidAge,US,0.15413533834586465,19,1,19,0,0,0,0,0,1,0,2,2025,11,22,5,0.08073634859349145,8.785714285714285,0.0 +26083511,US,Unknown,1,2.0,0,0,0,0,2025-11-24,57.0,801.0,Female,75.0,ADDERALL XR,heart rate increased,0,0,0.0,MidAge,US,0.0,2,0,20,0,0,0,0,0,0,0,3,2025,11,24,0,0.08073634859349145,0.0,0.0 +26053765,US,US,1,2.0,0,0,0,0,2025-11-17,65.0,801.0,Male,75.0,DUPIXENT,pyrexia,0,0,0.0,MidAge,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,1,2025,11,17,0,0.08073634859349145,1.0084033613445378,0.0 +26054117,US,US,2,2.0,0,0,0,0,2025-11-17,48.0,801.0,Female,130.0,NEULASTA,device adhesion issue,0,0,0.0,Adult,US,0.0,5,0,21,0,0,0,0,0,0,0,3,2025,11,17,0,0.08936301793444651,0.0,0.0 +26055480,GB,GB,1,1.0,0,0,0,0,2025-11-17,86.0,801.0,Female,99.0,XARELTO,ageusia,1,0,0.0,Senior,GB,0.0,1,0,7,0,0,0,0,0,0,0,1,2025,11,17,0,0.08073634859349145,0.0,0.0 +26056209,EU,EU,1,1.0,0,0,1,0,2025-11-18,55.0,801.0,Male,74.0,BACTRIM,rash morbilliform,1,3,0.21428571428571427,MidAge,EU,0.21428571428571427,1,1,17,0,0,0,0,0,0,0,2,2025,11,18,1,0.08073634859349145,11.785714285714285,0.0 +26057114,US,US,1,2.0,0,0,0,0,2025-11-18,57.0,801.0,Female,75.0,ISOTRETINOIN,adverse drug reaction,0,0,0.0,MidAge,US,0.023809523809523808,9,0,21,0,0,0,0,0,0,0,3,2025,11,18,1,0.08073634859349145,1.357142857142857,0.023809523809523808 +25959785,US,US,1,2.0,0,0,0,0,2025-10-26,2.0,801.0,Female,75.0,DUPIXENT,dry skin,0,0,0.0,Child,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,2,2025,10,26,6,0.08073634859349145,0.031027795733678084,0.015513897866839042 +25961704,CA,CA,2,1.0,0,0,0,0,2025-10-27,57.0,801.0,Female,75.0,TEZEPELUMAB,swollen tongue,1,0,0.0,MidAge,CA,0.10714285714285714,2,0,14,0,0,0,0,0,0,0,2,2025,10,27,0,0.08936301793444651,6.107142857142857,0.10714285714285714 +25961919,CN,CN,1,1.0,0,0,0,0,2025-10-27,35.0,801.0,Female,75.0,ETANERCEPT,carotid artery stenosis,1,0,0.0,Young,CN,0.0,1,0,23,0,0,0,0,0,0,0,3,2025,10,27,0,0.08073634859349145,0.0,0.0 +25962514,US,Unknown,1,1.0,1,0,0,0,2025-10-24,53.0,801.0,Male,75.0,CABENUVA,sepsis,1,5,0.35714285714285715,MidAge,US,0.35714285714285715,1,1,6,0,0,0,0,0,0,0,1,2025,10,24,4,0.08073634859349145,18.92857142857143,0.0 +25963229,US,US,1,2.0,0,0,0,0,2025-10-27,57.0,801.0,Female,75.0,ATENOLOL,heart rate decreased,0,0,0.0,MidAge,US,0.0,1,0,20,0,0,0,0,0,0,0,3,2025,10,27,0,0.08073634859349145,0.0,0.0 +26084617,US,US,1,2.0,0,0,0,0,2025-11-24,66.0,801.0,Female,75.0,DUPIXENT,pruritus,0,0,0.0,Senior,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,11,24,0,0.08073634859349145,1.0239172592113768,0.015513897866839042 +26085913,EU,EU,1,2.0,0,0,0,0,2025-11-25,68.0,801.0,Female,75.0,METFORMIN HYDROCHLORIDE,potentiating drug interaction,0,0,0.0,Senior,EU,0.0,1,0,29,0,0,0,0,0,0,0,3,2025,11,25,1,0.08073634859349145,0.0,0.0 +26086466,EU,EU,1,1.0,0,0,0,0,2025-11-25,77.0,801.0,Female,75.0,PACLITAXEL,pneumonitis,1,0,0.0,Senior,EU,0.07142857142857142,3,0,11,0,0,0,0,0,0,0,1,2025,11,25,1,0.08073634859349145,5.5,0.07142857142857142 +24700004,US,US,1,2.0,0,0,0,0,2024-12-05,57.0,801.0,Female,75.0,YUTIQ,circumstance or information capable of leading to medication error,0,0,0.0,MidAge,US,0.0,1,0,66,0,0,0,0,0,0,0,9,2024,12,5,3,0.08073634859349145,0.0,0.0 +24701744,US,US,1,2.0,0,0,0,0,2024-12-05,40.0,801.0,Female,75.0,DUPIXENT,stress,0,0,0.0,Adult,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2024,12,5,3,0.08073634859349145,0.6205559146735616,0.015513897866839042 +24757888,US,Unknown,1,2.0,0,0,0,0,2024-12-20,57.0,801.0,Female,75.0,BIMZELX,pain,0,0,0.0,MidAge,US,0.0,22,0,4,1,0,0,0,0,0,0,1,2024,12,20,4,0.08073634859349145,0.0,0.0 +24798092,JP,JP,1,1.0,0,0,0,0,2025-01-02,57.0,801.0,Male,56.9,ACTEMRA,blood immunoglobulin e abnormal,1,0,0.0,MidAge,JP,0.17857142857142858,6,1,31,0,0,0,0,0,0,0,4,2025,1,2,3,0.08073634859349145,10.178571428571429,0.0 +24836905,US,US,2,1.0,0,0,0,0,2025-01-13,36.0,801.0,Female,75.0,VEDOLIZUMAB,colitis ulcerative,1,0,0.0,Adult,US,0.057692307692307696,26,0,18,0,0,0,0,0,0,0,2,2025,1,13,0,0.08936301793444651,2.076923076923077,0.057692307692307696 +24839201,US,US,2,1.0,0,0,0,0,2025-01-14,53.0,801.0,Female,93.44,LANADELUMAB,spinal fracture,1,0,0.0,MidAge,US,0.12857142857142856,5,1,15,0,0,0,0,0,0,0,2,2025,1,14,1,0.08936301793444651,6.814285714285713,0.12857142857142856 +24855454,GB,GB,1,1.0,0,0,0,1,2025-01-17,59.0,801.0,Male,100.0,LOSARTAN,pain in extremity,1,2,0.14285714285714285,MidAge,GB,0.2857142857142857,2,1,17,1,0,0,0,0,0,0,3,2025,1,17,4,0.08073634859349145,16.857142857142858,0.0 +26089368,US,US,1,2.0,0,0,0,0,2025-11-25,64.0,801.0,Female,75.0,DUPIXENT,rhinorrhoea,0,0,0.0,MidAge,US,0.015513897866839042,221,0,11,0,0,0,0,0,0,0,1,2025,11,25,1,0.08073634859349145,0.9928894634776987,0.015513897866839042 +26089463,US,US,1,2.0,0,0,0,0,2025-11-25,66.0,801.0,Male,75.0,DUPIXENT,arthralgia,0,0,0.0,Senior,US,0.015513897866839042,221,0,10,0,0,0,0,0,0,0,1,2025,11,25,1,0.08073634859349145,1.0239172592113768,0.0 +26090100,US,US,1,2.0,0,0,0,0,2025-11-26,35.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,11,26,2,0.08073634859349145,0.5429864253393665,0.015513897866839042 +26090382,GB,GB,1,1.0,0,0,0,0,2025-11-26,67.0,801.0,Female,75.0,CYPROTERONE ACETATE,meningioma,1,0,0.0,Senior,GB,0.0,1,0,10,0,0,0,0,0,0,0,1,2025,11,26,2,0.08073634859349145,0.0,0.0 +26090706,US,US,2,1.0,0,0,1,0,2025-11-26,54.0,801.0,Female,89.811,CREON,trigeminal neuralgia,1,3,0.21428571428571427,MidAge,US,0.03296703296703297,13,0,20,0,0,0,0,0,0,0,2,2025,11,26,2,0.08936301793444651,1.7802197802197803,0.03296703296703297 +26091893,CN,CN,1,1.0,0,1,0,0,2025-11-26,57.0,801.0,Female,75.0,PREDNISONE,febrile neutropenia,1,4,0.2857142857142857,MidAge,CN,0.1607142857142857,8,1,19,0,0,0,0,0,0,0,2,2025,11,26,2,0.08073634859349145,9.160714285714285,0.1607142857142857 +26091907,US,Unknown,1,1.0,0,0,1,0,2025-11-25,57.0,801.0,Female,75.0,MYCOPHENOLATE MOFETIL,pneumonia aspiration,1,3,0.21428571428571427,MidAge,US,0.10150375939849625,19,0,20,0,0,0,0,0,1,0,2,2025,11,25,1,0.08073634859349145,5.7857142857142865,0.10150375939849625 +26093284,US,US,1,2.0,0,0,0,0,2025-11-26,42.0,801.0,Female,75.0,DUPIXENT,arthralgia,0,0,0.0,Adult,US,0.015513897866839042,221,0,10,0,0,0,0,0,0,0,1,2025,11,26,2,0.08073634859349145,0.6515837104072397,0.015513897866839042 +26093756,US,US,1,2.0,0,0,0,0,2025-11-26,45.0,801.0,Female,148.0,NEULASTA,unintentional medical device removal,0,0,0.0,Adult,US,0.0,5,0,36,0,0,0,0,0,0,0,4,2025,11,26,2,0.08073634859349145,0.0,0.0 +26093985,JP,JP,2,1.0,0,0,0,0,2025-11-26,51.0,801.0,Male,60.0,LEUPROLIDE ACETATE,erectile dysfunction,1,0,0.0,MidAge,JP,0.38095238095238093,3,1,20,0,0,0,0,0,0,0,2,2025,11,26,2,0.08936301793444651,19.428571428571427,0.0 +26094108,GB,GB,1,1.0,0,0,0,0,2025-11-26,68.0,801.0,Female,75.0,MYCOPHENOLATE MOFETIL,diffuse large b-cell lymphoma,1,0,0.0,Senior,GB,0.10150375939849625,19,0,29,0,0,0,0,0,0,0,4,2025,11,26,2,0.08073634859349145,6.902255639097745,0.10150375939849625 +26095686,US,US,1,1.0,0,0,0,0,2025-11-27,58.0,801.0,Female,75.0,TACROLIMUS,delirium,1,0,0.0,MidAge,US,0.09183673469387754,7,0,8,0,0,0,0,0,0,0,1,2025,11,27,3,0.08073634859349145,5.326530612244897,0.09183673469387754 +26096281,US,US,1,1.0,0,0,0,0,2025-11-27,57.0,801.0,Male,97.506,TYVASO DPI,insomnia,1,0,0.0,MidAge,US,0.0,4,0,8,0,0,0,0,0,0,0,1,2025,11,27,3,0.08073634859349145,0.0,0.0 +26096524,EU,EU,1,1.0,0,0,1,0,2025-11-27,72.0,801.0,Male,75.0,RIVAROXABAN,haematoma,1,3,0.21428571428571427,Senior,EU,0.21428571428571427,2,1,9,0,0,0,0,0,0,0,1,2025,11,27,3,0.08073634859349145,15.428571428571427,0.0 +24911143,KR,KR,2,1.0,0,0,0,0,2025-01-31,75.0,801.0,Female,60.0,LAZERTINIB,embolism,1,0,0.0,Senior,Other,0.0,1,0,8,0,0,0,0,0,0,0,1,2025,1,31,4,0.08936301793444651,0.0,0.0 +24942367,US,Unknown,1,1.0,0,0,0,0,2025-02-07,61.0,801.0,Female,75.0,JAKAFI,bone pain,1,0,0.0,MidAge,US,0.0,3,0,9,1,0,0,0,0,0,0,2,2025,2,7,4,0.08073634859349145,0.0,0.0 +24966491,US,US,2,1.0,0,0,0,0,2025-02-13,72.0,801.0,Female,76.0,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,diabetes mellitus,1,0,0.0,Senior,US,0.0,1,0,17,0,0,0,0,0,0,0,2,2025,2,13,3,0.08936301793444651,0.0,0.0 +24979923,US,US,2,1.0,0,0,0,0,2025-02-18,57.0,801.0,Male,75.0,RAVULIZUMAB,diabetes mellitus,1,0,0.0,MidAge,US,0.0,1,0,17,0,0,0,0,0,0,0,2,2025,2,18,1,0.08936301793444651,0.0,0.0 +24987065,JP,JP,2,1.0,1,1,1,0,2025-02-19,73.0,801.0,Female,45.6,ELRANATAMAB,plasma cell myeloma,1,12,0.8571428571428571,Senior,JP,0.8571428571428571,1,1,19,0,0,0,0,0,0,0,3,2025,2,19,2,0.08936301793444651,62.57142857142857,0.8571428571428571 +25967441,US,US,1,1.0,1,0,1,0,2025-10-28,57.0,801.0,Female,75.0,WINREVAIR,death,1,8,0.5714285714285714,MidAge,US,0.2619047619047619,3,1,5,0,0,1,0,0,0,0,1,2025,10,28,1,0.08073634859349145,14.928571428571429,0.2619047619047619 +25967670,GB,GB,1,1.0,0,0,1,0,2025-10-28,74.0,801.0,Female,75.0,AMLODIPINE,gastroenteritis salmonella,1,3,0.21428571428571427,Senior,GB,0.16964285714285715,8,1,26,0,0,0,0,0,0,0,2,2025,10,28,1,0.08073634859349145,12.553571428571429,0.16964285714285715 +25002592,US,US,1,2.0,0,0,0,0,2025-02-24,57.0,801.0,Female,85.714,TYVASO,flushing,0,0,0.0,MidAge,US,0.0,2,0,8,0,0,0,0,0,0,0,1,2025,2,24,0,0.08073634859349145,0.0,0.0 +25046871,GB,GB,2,1.0,0,0,0,0,2025-03-06,36.0,801.0,Male,75.0,COPAXONE,confusional state,1,0,0.0,Adult,GB,0.0,2,0,17,0,0,0,0,0,0,0,2,2025,3,6,3,0.08936301793444651,0.0,0.0 +25048167,US,US,2,2.0,0,0,0,0,2025-03-06,66.0,801.0,Female,75.0,RINVOQ,aphonia,0,0,0.0,Senior,US,0.0,3,0,7,0,0,0,0,0,0,0,1,2025,3,6,3,0.08936301793444651,0.0,0.0 +25068970,US,US,1,2.0,0,0,0,0,2025-03-12,34.0,801.0,Female,75.0,DUPIXENT,rash erythematous,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,3,12,2,0.08073634859349145,0.5274725274725274,0.015513897866839042 +25070241,US,US,1,2.0,0,0,0,0,2025-03-12,61.0,801.0,Female,75.0,OPZELURA,product dose omission issue,0,0,0.0,MidAge,US,0.0,2,0,27,0,0,0,0,0,0,0,4,2025,3,12,2,0.08073634859349145,0.0,0.0 +25071886,EU,EU,1,1.0,0,0,0,0,2025-03-13,11.0,801.0,Male,23.0,TACROLIMUS,hypogammaglobulinaemia,1,0,0.0,Child,EU,0.09183673469387754,7,0,22,0,0,0,0,0,0,0,1,2025,3,13,3,0.08073634859349145,1.010204081632653,0.0 +25074249,EU,EU,1,1.0,0,0,0,0,2025-03-13,8.0,801.0,Female,75.0,DORZOLAMIDE\TIMOLOL,dry eye,1,0,0.0,Child,EU,0.0,1,0,7,0,0,0,0,0,0,0,2,2025,3,13,3,0.08073634859349145,0.0,0.0 +26097105,EU,EU,1,1.0,0,0,0,0,2025-11-27,27.0,801.0,Male,75.0,DASATINIB,pulmonary hypertension,1,0,0.0,Young,EU,0.0,2,0,22,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,0.0,0.0 +26097334,US,US,1,2.0,0,0,0,0,2025-11-27,74.0,801.0,Female,75.0,DATROWAY,off label use,0,0,0.0,Senior,US,0.0,2,0,13,0,0,0,0,0,0,0,3,2025,11,27,3,0.08073634859349145,0.0,0.0 +26097873,US,US,1,2.0,0,0,0,0,2025-11-27,28.0,801.0,Female,75.0,DUPIXENT,eczema,0,0,0.0,Young,US,0.015513897866839042,221,0,6,0,0,0,0,0,0,0,1,2025,11,27,3,0.08073634859349145,0.43438914027149317,0.015513897866839042 +26098401,US,US,1,2.0,0,0,0,0,2025-11-27,29.0,801.0,Female,75.0,XELJANZ,drug ineffective,0,0,0.0,Young,US,0.0,3,0,16,0,0,0,0,0,0,0,2,2025,11,27,3,0.08073634859349145,0.0,0.0 +26099183,US,US,1,2.0,0,0,0,0,2025-11-28,13.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Child,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,11,28,4,0.08073634859349145,0.20168067226890754,0.015513897866839042 +26099345,US,US,1,2.0,0,0,0,0,2025-11-28,57.0,801.0,Female,75.0,AMLODIPINE,adverse drug reaction,0,0,0.0,MidAge,US,0.16964285714285715,8,1,21,0,0,0,0,0,0,0,3,2025,11,28,4,0.08073634859349145,9.669642857142858,0.16964285714285715 +25968385,CN,CN,1,1.0,0,0,0,0,2025-10-28,9.0,801.0,Male,75.0,DEXAMETHASONE,gene mutation,1,0,0.0,Child,CN,0.1857142857142857,5,1,13,0,0,0,0,0,0,0,2,2025,10,28,1,0.08073634859349145,1.6714285714285713,0.0 +25968466,GB,GB,2,1.0,0,0,0,0,2025-10-28,57.0,801.0,Female,75.0,COSENTYX,crohn^s disease,1,0,0.0,MidAge,GB,0.05714285714285714,10,0,15,0,0,0,0,0,0,0,2,2025,10,28,1,0.08936301793444651,3.257142857142857,0.05714285714285714 +25971963,CA,CA,1,1.0,1,0,0,0,2025-10-29,57.0,801.0,Female,75.0,TUMS ULTRA,hip arthroplasty,1,5,0.35714285714285715,MidAge,CA,0.35714285714285715,1,1,16,0,0,0,0,0,0,0,2,2025,10,29,2,0.08073634859349145,20.357142857142858,0.35714285714285715 +25102021,US,US,1,1.0,0,0,0,0,2025-03-20,27.0,801.0,Male,75.0,ALTUVIIIO,ankle operation,1,0,0.0,Young,US,0.0,1,0,15,0,0,0,0,0,0,0,2,2025,3,20,3,0.08073634859349145,0.0,0.0 +25110174,AU,AU,2,1.0,0,0,0,0,2025-03-24,38.0,801.0,Female,75.0,VEDOLIZUMAB,uveitis,1,0,0.0,Adult,AU,0.057692307692307696,26,0,7,0,0,0,0,0,0,0,1,2025,3,24,0,0.08936301793444651,2.1923076923076925,0.057692307692307696 +25112657,US,Unknown,1,2.0,0,0,0,0,2025-03-24,66.0,801.0,Female,75.0,BIMZELX,diarrhoea,0,0,0.0,Senior,US,0.0,22,0,9,0,0,0,0,0,0,0,1,2025,3,24,0,0.08073634859349145,0.0,0.0 +25112981,US,Unknown,1,2.0,0,0,0,0,2025-03-24,42.0,801.0,Female,75.0,BIMZELX,anxiety,0,0,0.0,Adult,US,0.0,22,0,7,0,0,0,0,0,0,0,1,2025,3,24,0,0.08073634859349145,0.0,0.0 +25114615,US,US,1,2.0,0,0,0,0,2025-03-24,23.0,801.0,Male,75.0,DUPIXENT,illness,0,0,0.0,Young,US,0.015513897866839042,221,0,7,0,0,0,0,0,0,0,1,2025,3,24,0,0.08073634859349145,0.35681965093729795,0.0 +25118165,US,US,1,1.0,0,0,0,0,2025-03-25,82.0,801.0,Female,54.0,REFRESH OPTIVE GEL DROPS,corneal scar,1,0,0.0,Senior,US,0.0,1,0,12,0,0,0,0,0,0,0,2,2025,3,25,1,0.08073634859349145,0.0,0.0 +25124335,US,US,1,2.0,0,0,0,0,2025-03-26,85.0,801.0,Female,75.0,IBRANCE,fatigue,0,0,0.0,Senior,US,0.07142857142857142,3,0,7,0,0,0,0,0,0,0,1,2025,3,26,2,0.08073634859349145,6.071428571428571,0.07142857142857142 +25138387,US,US,1,1.0,0,0,1,0,2025-03-30,72.0,801.0,Female,75.0,TYMLOS,depression suicidal,1,3,0.21428571428571427,Senior,US,0.21428571428571427,1,1,19,0,0,0,0,0,0,0,2,2025,3,30,6,0.08073634859349145,15.428571428571427,0.21428571428571427 +25138482,US,US,1,1.0,0,0,0,0,2025-03-30,4.0,801.0,Male,75.0,IDELVION,haemorrhage,1,0,0.0,Child,US,0.10714285714285714,2,0,11,0,0,0,0,0,0,0,1,2025,3,30,6,0.08073634859349145,0.42857142857142855,0.0 +25142074,EU,EU,1,1.0,0,0,0,0,2025-03-31,39.0,801.0,Female,75.0,CEFIDEROCOL,encephalitis,1,0,0.0,Adult,EU,0.0,1,0,12,0,0,0,0,0,0,0,1,2025,3,31,0,0.08073634859349145,0.0,0.0 +25144328,BR,BR,2,1.0,0,0,1,0,2025-04-01,15.0,801.0,Male,45.0,INFLIXIMAB,disseminated tuberculosis,1,3,0.21428571428571427,Child,BR,0.07142857142857142,9,0,25,0,0,0,0,0,0,0,2,2025,4,1,1,0.08936301793444651,1.0714285714285714,0.0 +25148850,US,US,2,2.0,0,0,0,0,2025-04-02,71.0,801.0,Male,75.0,ORGOVYX,hypersomnia,0,0,0.0,Senior,US,0.0,4,0,11,0,0,0,0,0,0,0,1,2025,4,2,2,0.08936301793444651,0.0,0.0 +25152132,US,US,2,1.0,0,0,0,0,2025-04-02,68.0,801.0,Female,75.0,TREMFYA,liver function test increased,1,0,0.0,Senior,US,0.10714285714285714,2,0,29,0,0,0,0,0,0,0,4,2025,4,2,2,0.08936301793444651,7.285714285714286,0.10714285714285714 +25170949,EU,EU,1,1.0,0,0,0,0,2025-04-08,44.0,801.0,Female,65.0,LYNPARZA,haemoglobin decreased,1,0,0.0,Adult,EU,0.0,1,0,21,0,0,0,0,0,0,0,2,2025,4,8,1,0.08073634859349145,0.0,0.0 +26101211,US,US,2,1.0,0,0,0,0,2025-11-28,57.0,801.0,Male,75.0,SKYRIZI,skin cancer,1,0,0.0,MidAge,US,0.051587301587301584,36,0,11,0,0,0,1,0,0,0,2,2025,11,28,4,0.08936301793444651,2.9404761904761902,0.0 +26101493,CN,CN,1,1.0,0,0,0,0,2025-11-28,35.0,801.0,Female,70.0,PALIPERIDONE,blood prolactin increased,1,0,0.0,Young,CN,0.0,1,0,25,0,0,0,0,0,0,0,3,2025,11,28,4,0.08073634859349145,0.0,0.0 +26101912,US,US,2,1.0,0,0,0,0,2025-11-28,57.0,801.0,Female,75.0,SKYRIZI,skin disorder,1,0,0.0,MidAge,US,0.051587301587301584,36,0,13,0,0,0,0,0,0,0,2,2025,11,28,4,0.08936301793444651,2.9404761904761902,0.051587301587301584 +26102102,CA,CA,1,1.0,0,0,0,0,2025-11-28,58.0,801.0,Female,75.0,APIXABAN,deep vein thrombosis,1,0,0.0,MidAge,CA,0.07142857142857142,3,0,20,0,0,0,0,0,0,0,3,2025,11,28,4,0.08073634859349145,4.142857142857142,0.07142857142857142 +26102627,US,US,1,2.0,0,0,0,0,2025-11-28,57.0,801.0,Female,75.0,DUPIXENT,injection site exfoliation,0,0,0.0,MidAge,US,0.015513897866839042,221,0,26,0,0,0,0,0,0,0,3,2025,11,28,4,0.08073634859349145,0.8842921784098254,0.015513897866839042 +26102722,GB,GB,1,1.0,0,0,0,0,2025-11-28,57.0,801.0,Female,75.0,DOXYCYCLINE,depression,1,0,0.0,MidAge,GB,0.19642857142857142,4,1,10,0,0,0,0,0,0,0,1,2025,11,28,4,0.08073634859349145,11.196428571428571,0.19642857142857142 +26103127,US,US,1,2.0,0,0,0,0,2025-11-29,57.0,801.0,Female,75.0,LEVOTHYROXINE SODIUM,abdominal discomfort,0,0,0.0,MidAge,US,0.0,3,0,20,0,0,0,0,0,0,0,2,2025,11,29,5,0.08073634859349145,0.0,0.0 +26104652,JP,JP,1,1.0,0,0,0,0,2025-11-30,57.0,801.0,Female,75.0,DUPIXENT,breast cancer,1,0,0.0,MidAge,JP,0.015513897866839042,221,0,13,0,0,0,1,0,0,0,2,2025,11,30,6,0.08073634859349145,0.8842921784098254,0.015513897866839042 +25973192,JP,JP,1,1.0,0,0,1,0,2025-10-29,62.0,801.0,Female,75.0,DOCETAXEL,hemiparesis,1,3,0.21428571428571427,MidAge,JP,0.061224489795918366,7,0,11,0,0,0,0,0,0,0,1,2025,10,29,2,0.08073634859349145,3.7959183673469385,0.061224489795918366 +25975499,EU,EU,1,1.0,0,0,0,0,2025-10-29,62.0,801.0,Male,54.0,MYCOPHENOLATE MOFETIL,deep vein thrombosis,1,0,0.0,MidAge,EU,0.10150375939849625,19,0,20,0,0,0,0,0,0,0,3,2025,10,29,2,0.08073634859349145,6.2932330827067675,0.0 +25176848,US,US,1,1.0,0,0,0,0,2025-04-09,57.0,801.0,Female,75.0,CREXONT,cholelithiasis,1,0,0.0,MidAge,US,0.0,1,0,14,0,0,0,0,0,0,0,1,2025,4,9,2,0.08073634859349145,0.0,0.0 +25179010,US,US,1,2.0,0,0,0,0,2025-04-09,13.0,801.0,Male,75.0,DUPIXENT,rash,0,0,0.0,Child,US,0.015513897866839042,221,0,4,0,0,0,0,0,0,0,1,2025,4,9,2,0.08073634859349145,0.20168067226890754,0.0 +25183842,US,US,1,2.0,0,0,0,0,2025-04-10,33.0,801.0,Female,75.0,DUPIXENT,dermatitis atopic,0,0,0.0,Young,US,0.015513897866839042,221,0,17,0,0,0,0,0,0,0,2,2025,4,10,3,0.08073634859349145,0.5119586296056884,0.015513897866839042 +25199838,CL,CL,2,1.0,0,0,0,0,2025-04-15,35.0,801.0,Female,75.0,SIMPONI,pneumonia,1,0,0.0,Young,Other,0.0,2,0,9,0,0,0,0,0,1,0,1,2025,4,15,1,0.08936301793444651,0.0,0.0 +25203687,US,US,1,2.0,0,0,0,0,2025-04-16,77.0,801.0,Male,75.0,DUPIXENT,erythema,0,0,0.0,Senior,US,0.015513897866839042,221,0,8,0,0,0,0,0,0,0,1,2025,4,16,2,0.08073634859349145,1.1945701357466063,0.0 +25210748,US,US,1,2.0,0,0,0,0,2025-04-17,80.0,801.0,Female,75.0,OLANZAPINE,sedation,0,0,0.0,Senior,US,0.11904761904761905,6,0,8,0,0,0,0,0,0,0,1,2025,4,17,3,0.08073634859349145,9.523809523809524,0.11904761904761905 +25211653,US,US,2,1.0,0,0,1,0,2025-04-18,57.0,801.0,Male,75.0,EPIDIOLEX,hospitalisation,1,3,0.21428571428571427,MidAge,US,0.14285714285714285,3,1,15,0,0,0,0,0,0,0,1,2025,4,18,4,0.08936301793444651,8.142857142857142,0.0 +25213301,CA,CA,1,1.0,0,0,0,0,2025-04-18,3.0,801.0,Male,75.0,RITUXIMAB,abdominal discomfort,1,0,0.0,Child,CA,0.12406015037593986,19,0,20,0,0,0,0,0,0,0,2,2025,4,18,4,0.08073634859349145,0.37218045112781956,0.0 +25226934,EU,EU,1,1.0,0,0,0,1,2025-04-22,21.0,801.0,Male,75.0,CLOZAPINE,general physical health deterioration,1,2,0.14285714285714285,Young,EU,0.23214285714285715,4,1,37,0,0,0,0,0,0,0,4,2025,4,22,1,0.08073634859349145,4.875,0.0 +25237383,EU,EU,1,1.0,0,0,0,0,2025-04-25,57.0,801.0,Male,2.49,GENTAMICIN,neonatal respiratory distress syndrome,1,0,0.0,MidAge,EU,0.0,1,0,38,0,0,0,0,0,0,0,4,2025,4,25,4,0.08073634859349145,0.0,0.0 diff --git a/requirements.txt b/requirements.txt new file mode 100644 index 0000000..01ce974 Binary files /dev/null and b/requirements.txt differ diff --git a/week2_analysis.ipynb b/week2_analysis.ipynb new file mode 100644 index 0000000..7d10f48 --- /dev/null +++ b/week2_analysis.ipynb @@ -0,0 +1,776 @@ +{ + "cells": [ + { + "cell_type": "markdown", + "id": "d25254ef-77e8-414a-a4c8-f367e48a4eff", + "metadata": {}, + "source": [ + "# Анализ данных FDA Drug Adverse Events\n", + "\n", + "В данной работе проводится анализ данных о побочных эффектах лекарственных препаратов. \n", + "Цель работы — загрузить датасет, изучить его структуру, провести базовый анализ и построить визуализации с использованием библиотек `pandas`, `numpy`, `matplotlib`, `seaborn` и `tqdm`." + ] + }, + { + "cell_type": "code", + "execution_count": 1, + "id": "f9f3cdba-7699-400d-941d-b6aa79357639", + "metadata": { + "jp-MarkdownHeadingCollapsed": true + }, + "outputs": [], + "source": [ + "import pandas as pd\n", + "import numpy as np\n", + "import matplotlib.pyplot as plt\n", + "import seaborn as sns\n", + "from tqdm import tqdm" + ] + }, + { + "cell_type": "code", + "execution_count": 2, + "id": "1665af01-f42a-48f3-aa29-2e9c8b823f96", + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
report_idcountryoccur_countryreport_typeseriousdeathlife_threateninghospitalizationdisablingreceive_date...reaction_pneumoniareaction_bleedingreaction_complexityyearmonthdayweekdayreport_type_riskage_drug_riskgender_drug_risk
026016170USUS12.000002025-11-10...0022025111000.0807360.6515840.000000
126017452NPNP11.010102025-11-10...0042025111000.0807368.8469390.000000
226017586USUS12.000002025-11-10...0032025111000.0807360.0000000.000000
326018910SGSG11.000002025-11-10...0022025111000.0807364.4285710.071429
426018949EUEU31.000002025-11-10...0022025111000.1785710.0000000.000000
\n", + "

5 rows × 40 columns

\n", + "
" + ], + "text/plain": [ + " report_id country occur_country report_type serious death \\\n", + "0 26016170 US US 1 2.0 0 \n", + "1 26017452 NP NP 1 1.0 1 \n", + "2 26017586 US US 1 2.0 0 \n", + "3 26018910 SG SG 1 1.0 0 \n", + "4 26018949 EU EU 3 1.0 0 \n", + "\n", + " life_threatening hospitalization disabling receive_date ... \\\n", + "0 0 0 0 2025-11-10 ... \n", + "1 0 1 0 2025-11-10 ... \n", + "2 0 0 0 2025-11-10 ... \n", + "3 0 0 0 2025-11-10 ... \n", + "4 0 0 0 2025-11-10 ... \n", + "\n", + " reaction_pneumonia reaction_bleeding reaction_complexity year month day \\\n", + "0 0 0 2 2025 11 10 \n", + "1 0 0 4 2025 11 10 \n", + "2 0 0 3 2025 11 10 \n", + "3 0 0 2 2025 11 10 \n", + "4 0 0 2 2025 11 10 \n", + "\n", + " weekday report_type_risk age_drug_risk gender_drug_risk \n", + "0 0 0.080736 0.651584 0.000000 \n", + "1 0 0.080736 8.846939 0.000000 \n", + "2 0 0.080736 0.000000 0.000000 \n", + "3 0 0.080736 4.428571 0.071429 \n", + "4 0 0.178571 0.000000 0.000000 \n", + "\n", + "[5 rows x 40 columns]" + ] + }, + "execution_count": 2, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df = pd.read_csv(\"data/gm_feature_engineered_fda.csv\")\n", + "\n", + "df.head()" + ] + }, + { + "cell_type": "code", + "execution_count": 3, + "id": "b2c52280-a63e-415f-9174-3ddeeb0e9092", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "Index(['report_id', 'country', 'occur_country', 'report_type', 'serious',\n", + " 'death', 'life_threatening', 'hospitalization', 'disabling',\n", + " 'receive_date', 'age', 'age_unit', 'gender', 'weight', 'drug',\n", + " 'reaction', 'is_serious', 'severity_score', 'severity_norm',\n", + " 'age_group', 'country_group', 'drug_risk', 'drug_freq',\n", + " 'high_risk_drug', 'reaction_length', 'reaction_pain',\n", + " 'reaction_infection', 'reaction_death', 'reaction_cancer',\n", + " 'reaction_failure', 'reaction_pneumonia', 'reaction_bleeding',\n", + " 'reaction_complexity', 'year', 'month', 'day', 'weekday',\n", + " 'report_type_risk', 'age_drug_risk', 'gender_drug_risk'],\n", + " dtype='str')" + ] + }, + "execution_count": 3, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.columns" + ] + }, + { + "cell_type": "markdown", + "id": "c7e87bc6-bbbb-45c1-a51c-f1483111eb56", + "metadata": {}, + "source": [ + "## 1. Первичный анализ данных\n", + "\n", + "На этом этапе рассматривается структура таблицы: количество строк и столбцов, типы данных, наличие пропусков, а также основные статистические характеристики числовых признаков." + ] + }, + { + "cell_type": "code", + "execution_count": 4, + "id": "a17b1b49-7d0d-4f70-a1c2-57dfc056a1d9", + "metadata": {}, + "outputs": [ + { + "name": "stdout", + "output_type": "stream", + "text": [ + "\n", + "RangeIndex: 1287 entries, 0 to 1286\n", + "Data columns (total 40 columns):\n", + " # Column Non-Null Count Dtype \n", + "--- ------ -------------- ----- \n", + " 0 report_id 1287 non-null int64 \n", + " 1 country 1287 non-null str \n", + " 2 occur_country 1287 non-null str \n", + " 3 report_type 1287 non-null int64 \n", + " 4 serious 1287 non-null float64\n", + " 5 death 1287 non-null int64 \n", + " 6 life_threatening 1287 non-null int64 \n", + " 7 hospitalization 1287 non-null int64 \n", + " 8 disabling 1287 non-null int64 \n", + " 9 receive_date 1287 non-null str \n", + " 10 age 1287 non-null float64\n", + " 11 age_unit 1287 non-null float64\n", + " 12 gender 1287 non-null str \n", + " 13 weight 1287 non-null float64\n", + " 14 drug 1287 non-null str \n", + " 15 reaction 1287 non-null str \n", + " 16 is_serious 1287 non-null int64 \n", + " 17 severity_score 1287 non-null int64 \n", + " 18 severity_norm 1287 non-null float64\n", + " 19 age_group 1286 non-null str \n", + " 20 country_group 1287 non-null str \n", + " 21 drug_risk 1287 non-null float64\n", + " 22 drug_freq 1287 non-null int64 \n", + " 23 high_risk_drug 1287 non-null int64 \n", + " 24 reaction_length 1287 non-null int64 \n", + " 25 reaction_pain 1287 non-null int64 \n", + " 26 reaction_infection 1287 non-null int64 \n", + " 27 reaction_death 1287 non-null int64 \n", + " 28 reaction_cancer 1287 non-null int64 \n", + " 29 reaction_failure 1287 non-null int64 \n", + " 30 reaction_pneumonia 1287 non-null int64 \n", + " 31 reaction_bleeding 1287 non-null int64 \n", + " 32 reaction_complexity 1287 non-null int64 \n", + " 33 year 1287 non-null int64 \n", + " 34 month 1287 non-null int64 \n", + " 35 day 1287 non-null int64 \n", + " 36 weekday 1287 non-null int64 \n", + " 37 report_type_risk 1287 non-null float64\n", + " 38 age_drug_risk 1287 non-null float64\n", + " 39 gender_drug_risk 1287 non-null float64\n", + "dtypes: float64(9), int64(23), str(8)\n", + "memory usage: 402.3 KB\n" + ] + }, + { + "data": { + "text/plain": [ + "report_id 0\n", + "country 0\n", + "occur_country 0\n", + "report_type 0\n", + "serious 0\n", + "death 0\n", + "life_threatening 0\n", + "hospitalization 0\n", + "disabling 0\n", + "receive_date 0\n", + "age 0\n", + "age_unit 0\n", + "gender 0\n", + "weight 0\n", + "drug 0\n", + "reaction 0\n", + "is_serious 0\n", + "severity_score 0\n", + "severity_norm 0\n", + "age_group 1\n", + "country_group 0\n", + "drug_risk 0\n", + "drug_freq 0\n", + "high_risk_drug 0\n", + "reaction_length 0\n", + "reaction_pain 0\n", + "reaction_infection 0\n", + "reaction_death 0\n", + "reaction_cancer 0\n", + "reaction_failure 0\n", + "reaction_pneumonia 0\n", + "reaction_bleeding 0\n", + "reaction_complexity 0\n", + "year 0\n", + "month 0\n", + "day 0\n", + "weekday 0\n", + "report_type_risk 0\n", + "age_drug_risk 0\n", + "gender_drug_risk 0\n", + "dtype: int64" + ] + }, + "execution_count": 4, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.info()\n", + "df.describe()\n", + "df.isnull().sum()" + ] + }, + { + "cell_type": "markdown", + "id": "676c57bf-d2c3-4cba-b333-bf9f2990135a", + "metadata": {}, + "source": [ + "## 2. Группировка и анализ признаков\n", + "\n", + "Для более подробного анализа используются группировки данных. \n", + "Это позволяет сравнить показатели по полу, странам и лекарственным препаратам." + ] + }, + { + "cell_type": "code", + "execution_count": 5, + "id": "124f939b-cc53-4b0d-a7b4-5101cbda0645", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "serious\n", + "1.0 808\n", + "2.0 479\n", + "Name: count, dtype: int64" + ] + }, + "execution_count": 5, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df[\"serious\"].value_counts()" + ] + }, + { + "cell_type": "code", + "execution_count": 6, + "id": "a1fb32cc-b1ff-4585-b7b1-661824bcea9d", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "death\n", + "0 1215\n", + "1 72\n", + "Name: count, dtype: int64" + ] + }, + "execution_count": 6, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df[\"death\"].value_counts()" + ] + }, + { + "cell_type": "code", + "execution_count": 7, + "id": "20a5a103-b2e5-416a-8f90-0e4fc05d8d8b", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "np.float64(53.92307692307692)" + ] + }, + "execution_count": 7, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df[\"age\"].mean()" + ] + }, + { + "cell_type": "code", + "execution_count": 8, + "id": "8965b8d8-db80-4d18-a86c-70446756e7c7", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "gender\n", + "Female 54.161939\n", + "Male 53.464853\n", + "Name: age, dtype: float64" + ] + }, + "execution_count": 8, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.groupby(\"gender\")[\"age\"].mean()" + ] + }, + { + "cell_type": "code", + "execution_count": 9, + "id": "7c4ae568-ebae-4675-90e0-6f6bea52e4a5", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "country\n", + "US 1252.0\n", + "EU 184.0\n", + "CA 110.0\n", + "JP 62.0\n", + "GB 55.0\n", + "CN 34.0\n", + "AU 20.0\n", + "BR 7.0\n", + "IN 6.0\n", + "PR 3.0\n", + "Name: serious, dtype: float64" + ] + }, + "execution_count": 9, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.groupby(\"country\")[\"serious\"].sum().sort_values(ascending=False).head(10)" + ] + }, + { + "cell_type": "code", + "execution_count": 10, + "id": "ab8f72ba-d2d4-4c50-a0a0-d233fc0ab9b9", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "drug\n", + "APREMILAST 14.0\n", + "ELRANATAMAB 12.0\n", + "SILDENAFIL 9.0\n", + "DOLUTEGRAVIR 8.0\n", + "DEFITELIO 8.0\n", + "MELPHALAN 8.0\n", + "GLIVEC 8.0\n", + "HEMLIBRA 8.0\n", + "YUTREPIA 8.0\n", + "TUKYSA 7.0\n", + "Name: severity_score, dtype: float64" + ] + }, + "execution_count": 10, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df.groupby(\"drug\")[\"severity_score\"].mean().sort_values(ascending=False).head(10)" + ] + }, + { + "cell_type": "markdown", + "id": "f4994af1-aaa7-4c2b-90a7-70c16fca4b12", + "metadata": {}, + "source": [ + "## 3. Визуализация данных\n", + "\n", + "В этом разделе построены графики для наглядного анализа данных: распределение возраста пациентов, сравнение серьёзности случаев по полу и количество случаев по странам." + ] + }, + { + "cell_type": "code", + "execution_count": 11, + "id": "122f15cd-3374-4148-a201-9c105329e160", + "metadata": {}, + "outputs": [ + { + "data": { + "image/png": "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", + "text/plain": [ + "
" + ] + }, + "metadata": {}, + "output_type": "display_data" + } + ], + "source": [ + "df[\"age\"].hist()\n", + "plt.title(\"Распределение возраста пациентов\")\n", + "plt.xlabel(\"Возраст\")\n", + "plt.ylabel(\"Количество\")\n", + "plt.show()" + ] + }, + { + "cell_type": "code", + "execution_count": 12, + "id": "a313c60d-5e66-485b-8d4b-bf0ade4de2da", + "metadata": {}, + "outputs": [ + { + "data": { + "image/png": "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", + "text/plain": [ + "
" + ] + }, + "metadata": {}, + "output_type": "display_data" + } + ], + "source": [ + "sns.boxplot(x=\"gender\", y=\"severity_score\", data=df)\n", + "plt.title(\"Серьёзность случаев по полу\")\n", + "plt.show()" + ] + }, + { + "cell_type": "code", + "execution_count": 13, + "id": "be1b82e2-6630-4332-9292-1fba6c6bef27", + "metadata": {}, + "outputs": [ + { + "data": { + "image/png": "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", + "text/plain": [ + "
" + ] + }, + "metadata": {}, + "output_type": "display_data" + } + ], + "source": [ + "top_countries = df[\"country\"].value_counts().head(10)\n", + "\n", + "top_countries.plot(kind=\"bar\")\n", + "plt.title(\"Топ стран по количеству случаев\")\n", + "plt.show()" + ] + }, + { + "cell_type": "markdown", + "id": "2abe77de-739a-4768-8b64-4381480bd2e1", + "metadata": {}, + "source": [ + "## 4. Использование tqdm\n", + "\n", + "Библиотека `tqdm` используется для отображения прогресс-бара при обработке данных. \n", + "В данной работе она применена для демонстрации прохода по строкам датасета." + ] + }, + { + "cell_type": "code", + "execution_count": 14, + "id": "8aa34e5c-26c8-4b35-b920-f427700dd8bd", + "metadata": {}, + "outputs": [ + { + "name": "stderr", + "output_type": "stream", + "text": [ + "100%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████| 1287/1287 [00:00<00:00, 1789217.52it/s]\n" + ] + } + ], + "source": [ + "from tqdm import tqdm\n", + "\n", + "count = 0\n", + "for i in tqdm(range(len(df))):\n", + " count += 1" + ] + }, + { + "cell_type": "markdown", + "id": "9cb10000-fa7b-4809-9f95-017e28d20f49", + "metadata": {}, + "source": [ + "## 5. Создание нового признака\n", + "\n", + "Для дополнительного анализа был создан новый столбец `risk_flag`. \n", + "Он показывает, относится ли случай к группе повышенного риска на основе значения `severity_score`." + ] + }, + { + "cell_type": "code", + "execution_count": 15, + "id": "d675d16a-2e41-4051-94f4-37a01ff4bb2f", + "metadata": {}, + "outputs": [], + "source": [ + "df[\"risk_flag\"] = df[\"severity_score\"] > 7" + ] + }, + { + "cell_type": "code", + "execution_count": 16, + "id": "f8ac6ccd-fd69-4472-8840-aeeb2daa1e26", + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "risk_flag\n", + "False 1258\n", + "True 29\n", + "Name: count, dtype: int64" + ] + }, + "execution_count": 16, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "df[\"risk_flag\"].value_counts()" + ] + }, + { + "cell_type": "markdown", + "id": "f1d00383-7ac0-4548-bea7-b961c53e7506", + "metadata": {}, + "source": [ + "## Вывод\n", + "\n", + "В ходе работы был загружен и проанализирован датасет FDA Drug Adverse Events. \n", + "Были изучены основные признаки, выполнена проверка структуры данных и построены визуализации.\n", + "\n", + "В работе были использованы:\n", + "- `pandas` для загрузки и обработки данных;\n", + "- `numpy` для работы с числовыми значениями;\n", + "- `matplotlib` и `seaborn` для построения графиков;\n", + "- `tqdm` для отображения прогресса обработки.\n", + "\n", + "Полученные графики помогают наглядно оценить распределение возраста пациентов, различия по полу и страны с наибольшим количеством зарегистрированных случаев." + ] + } + ], + "metadata": { + "kernelspec": { + "display_name": "Python 3 (ipykernel)", + "language": "python", + "name": "python3" + }, + "language_info": { + "codemirror_mode": { + "name": "ipython", + "version": 3 + }, + "file_extension": ".py", + "mimetype": "text/x-python", + "name": "python", + "nbconvert_exporter": "python", + "pygments_lexer": "ipython3", + "version": "3.14.4" + } + }, + "nbformat": 4, + "nbformat_minor": 5 +}